insulin glargine profile

Insulin Glargine: A recombinant LONG ACTING INSULIN and HYPOGLYCEMIC AGENT that is used to manage BLOOD GLUCOSE in patients with DIABETES MELLITUS. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	118984454
MeSH ID	M0361589

Synonym
160337-95-1
insulin glargine
lantus r
hoe 901
mk-1293
hoe 71gt
glargine
insulin (human), 21(sup a)-glycine-30(sup b)a-l-arginine-30(sup b)b-l-arginine-
2zm8cx04rz ,
ly 2963016
lantus solostar
optisulin
lusduna nexvue
toujeo solostar
basaglar
toujeo
insulin glargine [usan:inn:ban]
21(sup a)-glycine-30(supp b)a-l-arginine-30(supp b)b-l-arginineinsulin (human)
a21-gly-b31-arg-b32-arg-insulin
21(sup a)-glycine-30(sup b)a-l-arginine-30(sup b)b-l-arginine insulin (human)
solostar [insulin delivery pen]
solostar
insulin, glycyl(a21)-arginyl(b31,b32)-
unii-2zm8cx04rz

Excerpt	Reference	Relevance
"Insulin glargine (IGla) is a synthetic human-recombinant insulin analog that is used routinely in people as a q24h basal insulin. "	( Comparison of pharmacodynamics between insulin glargine 100 U/mL and insulin glargine 300 U/mL in healthy cats. Culp, WTN; Gilor, C; Johnson, AE; Leale, DM; Owens, JG; Pires, J; Quach, N; Saini, NK; Samms, RJ; Wasik, B, 2021)	2.33
"Insulin glargine is a long-acting analogue of human insulin that has been used to manage hyperglycemia in patients with diabetes mellitus (DM) for nearly 20 years. "	( Physicochemical and functional characterization of MYL-1501D, a proposed biosimilar to insulin glargine. Almeida, F; Annegowda, S; Barve, A; Bhattacharya, A; Gouda, S; Goyal, P; Jyothirmai, K; Karudumpa, UR; Khyade, SG; Kodali, P; Mane, K; Melarkode, R; Mohan, S; Moole, PR; More, DC; Nair, PS; Pai, HV; Palande, M; Ranayhossaini, DJ; Saxena, S; Smith, JP; Ullanat, R; Vajpai, N; Vats, B; Veerabhadraia, AB, 2021)	2.29
"Insulin glargine is a clinically superior and cost-effective alternative to sitagliptin in patients with type 2 diabetes who are inadequately controlled with metformin."	( Cost-effectiveness of insulin glargine versus sitagliptin in insulin-naïve patients with type 2 diabetes mellitus. Brown, ST; Grima, DG; Sauriol, L, 2014)	2.16
"Insulin glargine is a slow acting analog of insulin used in diabetes therapy. "	( Disruption of KEX1 gene reduces the proteolytic degradation of secreted two-chain Insulin glargine in Pichia pastoris. Chatterjee, A; Govindappa, N; Krishnaiah, SM; Mallikarjun, N; Sastry, KN; Shyam Mohan, AH; Sreenivas, S, 2016)	2.1
"Insulin glargine is a long-acting human insulin analog often administered at bedtime to patients with type 2 diabetes. "	( Nocturnal glucose metabolism after bedtime injection of insulin glargine or neutral protamine hagedorn insulin in patients with type 2 diabetes. Bretzel, RG; Eckhard, M; Ehl, J; Fischer, B; Kunz, C; Linn, T; Soydan, N, 2008)	2.03
"Insulin glargine is a once-daily basal insulin analog with prolonged duration of action and absence of an evident peak. "	( Use of glargine in pregnant women with type 1 diabetes mellitus: a case-control study. Accidenti, M; Amato, MC; Criscimanna, A; Galluzzo, A; Gambina, M; Giordano, C; Imbergamo, MP; Sciortino, G, 2008)	1.79
"Insulin glargine appears to be an effective insulin analogue for use in women whose pregnancies are complicated by diabetes."	( Insulin glargine versus neutral protamine Hagedorn insulin for treatment of diabetes in pregnancy. Manuck, TA; Merrill, DC; Smith, JG; White, J, 2009)	2.52
"Insulin glargine (Lantus) is an extended-action insulin analog with greater stability and duration of action than regular human insulin. "	( Insulin glargine safety in pregnancy: a transplacental transfer study. Feig, DS; Koren, G; Lubetsky, A; Pollex, EK; Yip, PM, 2010)	3.25
"Insulin glargine (Lantus) is a long-acting basal insulin analog that demonstrates effective day-long glycemic control and a lower incidence of hypoglycemia than NPH insulin. "	( In vitro metabolic and mitogenic signaling of insulin glargine and its metabolites. Habermann, P; Kurrle, R; Müller, G; Seipke, G; Sommerfeld, MR; Tennagels, N; Tschank, G, 2010)	2.06
"Insulin glargine is a relatively new medication in the treatment of diabetes mellitus, and there have only been six case reports of overdoses in the literature with this specific insulin."	( Lantus insulin overdose: a case report. Inboriboon, PC; Lu, M, 2011)	1.81
"Insulin glargine is a long-acting insulin that can cause prolonged hypoglycemia when misdosed or overdosed subcutaneously. "	( Intravenous overdose of insulin glargine without prolonged hypoglycemic effects. Gutovitz, S; Thornton, S, 2012)	2.13
"Insulin glargine (Lantus) is a long-acting, human insulin analogue that has been specifically designed to overcome the deficiencies of traditionally available 'intermediate-acting' insulins that are currently used for basal insulin supplementation. "	( Insulin glargine (Lantus). Griffiths, S; Owens, DR, )	3.02
"Insulin glargine is an innovative, long-acting human insulin analogue, whose prolonged mean activity profile has no pronounced peak. "	( An overview of insulin glargine. Ashwell, SG; Home, PD, )	1.93
"Insulin glargine is a novel, long-acting human insulin analog that is indicated in type 1 diabetic patients aged >or=6, or in type 2 diabetic patients who require basal insulin for glycemic control."	( Insulin glargine: a new once-daily basal insulin for the management of type 1 and type 2 diabetes mellitus. Lam, S, )	2.3
"Insulin glargine is a human insulin analogue prepared by recombinant DNA technology. "	( Insulin glargine: an updated review of its use in the management of diabetes mellitus. Dunn, CJ; Keating, GM; McKeage, K; Plosker, GL; Scott, LJ, 2003)	3.2
"Insulin glargine (Lantus) is a human insulin analogue produced by recombinant DNA technology and recently launched by Aventis. "	( [Medication of the month. Insulin glargine (Lantus)]. Scheen, AJ, 2004)	2.07
"Insulin glargine is a long-acting insulin analogue, with a longer duration of action and a flatter time-action profile compared with NPH insulin. "	( Insulin therapy in type 2 diabetes: role of the long-acting insulin glargine analogue. Yki-Järvinen, H, 2004)	2.01
"Insulin glargine is a new extended-action recombinant insulin analog, which is absorbed slowly into the bloodstream, reaching peak action in about 4 h and maintaining this concentration profil for 24-30 h."	( [New methods in insulin treatment]. Neuwirth, G, 2005)	1.05
"Insulin glargine is a recombinant human insulin analog produced by DNA technology using a nonpathogenic strain of Escherichia coli. "	( Spotlight on insulin glargine in type 1 and 2 diabetes mellitus. Goa, KL; McKeage, K, 2002)	2.13
"Insulin glargine (LANTUS) is a once-daily basal insulin analog with a smooth 24-h time-action profile that provides effective glycemic control with reduced hypoglycemia risk (particularly nocturnal) compared with NPH insulin in patients with type 2 diabetes. "	( Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Dailey, G; Fritsche, A; Lin, Z; Massi-Benedetti, M; Rosenstock, J; Salzman, A, 2005)	2.06
"Insulin glargine is an efficacious treatment to improve metabolic control in children and adolescents with type 1 diabetes. "	( Therapy with insulin glargine (Lantus) in toddlers, children and adolescents with type 1 diabetes. Alonso, M; Alvarez, MA; Barrio, R; Colino, E; Golmayo, L; López-Capapé, M, 2005)	2.14
"Insulin glargine is a long-acting insulin analogue providing a more predictable and reproducible circulating insulin profile than other available basal insulin products. "	( PHARMAC and long-acting insulin analogues: a poor man's insulin pump--but not available to the poor man. Krebs, J, 2005)	1.77
"Insulin glargine is a long-acting insulin analogue with favourable clinical characteristics. "	( Early hypoglycaemia after accidental intramuscular injection of insulin glargine. Boehm, BO; Karges, B; Karges, W, 2005)	2.01
"Insulin glargine is a new long-acting insulin analog with a duration of action of 24 hours and can be given once a day as the only basal insulin combined with short or rapid-acting insulin as bolus insulin for each meal. "	( Preliminary data of insulin glargine use among Thai adolescents and young adults with type 1 diabetes mellitus treated at Siriraj Hospital. Kiattisakthavee, P; Likitmaskul, S; Santiprabhob, J; Sawathiparnich, P, 2005)	2.09
"Insulin glargine is a long-acting (up to 24-hour duration of effect), parenteral blood glucose-lowering agent."	( Injection of acidic or neutral insulin and pain: a single-center, prospective, controlled, noninterventional study in pediatric patients with type 1 diabetes mellitus. Debatin, KM; Heinze, E; Karges, B; Karges, W; Moritz, M; Muche, R; Riegger, I; Wabitsch, M, 2006)	1.06
"Insulin glargine is an analogue of human insulin that is modified to provide a consistent level of plasma insulin over a long duration. "	( Insulin glargine in the treatment of type 1 and type 2 diabetes. Barnett, AH, 2006)	3.22
"Insulin glargine is a long-acting insulin analog that mimics normal basal insulin secretion without pronounced peaks. "	( [Comparison between basal insulin glargine and NPH insulin in patients with diabetes type 1 on conventional intensive insulin therapy]. Antić, S; Dimić, D; Pesić, M; Radenković, S; Velojić, M; Zivić, S, 2007)	2.08
"Insulin glargine is a long-acting insulin analogue increasingly used instead of neutral protamine Hagedorn (NPH) insulin in young subjects with type 1 diabetes."	( Basal insulin switch from NPH to glargine in children and adolescents with type 1 diabetes. Päivärinta, M; Tapanainen, P; Veijola, R, 2008)	1.79
"Insulin glargine is an extended-action biosynthetic human insulin. "	( Insulin glargine. Figgitt, DP; Gillies, PS; Lamb, HM, 2000)	3.19
"Insulin glargine is a recombinant human insulin analogue produced by DNA technology using a nonpathogenic strain of Escherichia coli. "	( Insulin glargine: a review of its therapeutic use as a long-acting agent for the management of type 1 and 2 diabetes mellitus. Goa, KL; McKeage, K, 2001)	3.2
"Insulin glargine is a new extended-action insulin analogue, created by recombinant DNA modification of human insulin. "	( Insulin glargine: the first clinically useful extended-action insulin analogue. Ashwell, SG; Home, PD, 2001)	3.2
"Insulin glargine is a new long-acting formulation that can provide prolonged basal glucose control in patients with diabetes mellitus."	( Insulin glargine: a new long-acting insulin product. Panning, CA; Reinhart, L, 2002)	2.48
"Insulin glargine is a long-acting, recombinant human insulin analog that is given once daily as a basal source of insulin in patients with type 1 or type 2 diabetes mellitus. "	( Insulin glargine: a new basal insulin. Baker, DE; Campbell, RK; Levien, TL; White, JR, 2002)	3.2
"Insulin glargine is a long-acting insulin analog capable of providing 24-hour basal insulin coverage when administered once daily at bedtime. "	( Insulin glargine: a new basal insulin. Baker, DE; Campbell, RK; Levien, TL; White, JR, 2002)	3.2
"Insulin glargine (LANTUS) is a new, long-acting insulin analogue with a stable profile of action. "	( Evaluation of the carcinogenic potential of insulin glargine (LANTUS) in rats and mice. Bube, A; Donaubauer, H; Durchfeld-Meyer, B; Stammberger, I; Troschau, G, )	1.84
"Insulin glargine (LANTUS) is a new insulin analog that has a prolonged duration of action with no pronounced peak of activity, rendering it an ideal basal insulin for the treatment of diabetes. "	( Evaluation of the reproductive toxicity and embryotoxicity of insulin glargine (LANTUS) in rats and rabbits. Hofmann, T; Horstmann, G; Stammberger, I, )	1.81
"Insulin glargine is a long-acting insulin analogue that is metabolically active for at least 24 h. "	( No evidence for accumulation of insulin glargine (LANTUS): a multiple injection study in patients with Type 1 diabetes. Bott, S; Dressler, A; Heinemann, L; Heise, T; Rave, K; Rosskamp, R, 2002)	2.04

Excerpt	Reference	Relevance
"Insulin glargine has a relatively constant concentration-time profile that mimics basal levels of insulin and allows for once-daily administration."	( Physicochemical and functional characterization of MYL-1501D, a proposed biosimilar to insulin glargine. Almeida, F; Annegowda, S; Barve, A; Bhattacharya, A; Gouda, S; Goyal, P; Jyothirmai, K; Karudumpa, UR; Khyade, SG; Kodali, P; Mane, K; Melarkode, R; Mohan, S; Moole, PR; More, DC; Nair, PS; Pai, HV; Palande, M; Ranayhossaini, DJ; Saxena, S; Smith, JP; Ullanat, R; Vajpai, N; Vats, B; Veerabhadraia, AB, 2021)	1.57
"Insulin glargine 300 U/mL has a more stable and prolonged pharmacokinetic/pharmacodynamic profile than insulin glargine 100 U/mL (Lantus(®)), with a duration of glucose-lowering activity exceeding 24 h."	( Insulin Glargine 300 U/mL: A Review in Diabetes Mellitus. Blair, HA; Keating, GM, 2016)	2.6
"Insulin glargine U-300 has a similar efficacy profile to insulin glargine U-100 for glycemic control, yet with lower rates of nocturnal and severe hypoglycemia."	( Clinical Pharmacokinetics and Pharmacodynamics of Insulin Glargine 300 U/mL. Clements, JN; Shealy, KM; Threatt, T; Ward, E, 2017)	1.43
"Insulin glargine has a long duration of action and has demonstrated its usefulness in diabetes type 2, specifically a lower incidence of (nocturnal) hypoglycaemia compared to isophane insulin, in clinical practice."	( [Long-acting insulin analogs: progressing slowly]. Hoekstra, JB; Holleman, F, 2004)	1.04
"Insulin glargine has a slower onset of action than human neutral protamine Hagedorn (NPH) insulin, a longer duration of action (up to 24 hours), and no pronounced peak. "	( Insulin glargine. Baker, D; Campbell, RK; Levien, T; White, JR, 2001)	3.2
"Insulin glargine has a slower onset of action than NPH insulin and a longer duration of action with no peak activity."	( Insulin glargine: a new basal insulin. Baker, DE; Campbell, RK; Levien, TL; White, JR, 2002)	2.48
"Insulin glargine has been associated with less nocturnal hypoglycemia and improved treatment satisfaction in several clinical trials with durations of < 52 weeks."	( Insulin glargine: a new once-daily basal insulin for the management of type 1 and type 2 diabetes mellitus. Lam, S, )	2.3
"Insulin glargine has been registered for use in New Zealand since June 2001, but currently remains unsubsidised by PHARMAC."	( PHARMAC and long-acting insulin analogues: a poor man's insulin pump--but not available to the poor man. Krebs, J, 2005)	1.05

Excerpt	Reference	Relevance
"Insulin glargine could inhibit the proliferation of omental preadipocytes, and enhance the differentiation of subcutaneous and omental preadipocytes."	( [Primary culturing and effects of insulin glargine on proliferation, differentiation of human preadipocytes from subcutaneous and omental adipose tissue]. Jiang, W; Li, XF; Lu, HY; Mu, PW; Zeng, LY, 2013)	2.11
"Insulin glargine use did not increase the risk of overall cancer incidence as compared with HI. "	( Cancer risk associated with insulin glargine among adult type 2 diabetes patients--a nationwide cohort study. Chang, CH; Chen, ST; Chuang, LM; Kuo, CW; Lai, MS; Lin, JW; Toh, S, 2011)	2.11
"Insulin glargine did not cause severe hypoglycemia in this study."	( Preliminary data of insulin glargine use among Thai adolescents and young adults with type 1 diabetes mellitus treated at Siriraj Hospital. Kiattisakthavee, P; Likitmaskul, S; Santiprabhob, J; Sawathiparnich, P, 2005)	1.37
"Insulin glargine has a slower onset of action than human neutral protamine Hagedorn (NPH) insulin, a longer duration of action (up to 24 hours), and no pronounced peak. "	( Insulin glargine. Baker, D; Campbell, RK; Levien, T; White, JR, 2001)	3.2
"Insulin glargine has a slower onset of action than NPH insulin and a longer duration of action with no peak activity."	( Insulin glargine: a new basal insulin. Baker, DE; Campbell, RK; Levien, TL; White, JR, 2002)	2.48

Excerpt	Reference	Relevance
"Insulin glargine treatment did not result in significantly different epithelial colonic proliferation compared to NPH insulin (G, 137 ± 22; NPH, 136 ± 15; NaCl, 100 ± 20 (relative proliferation index)), but both insulin-treated groups of mice had a higher proliferation index compared to the NaCl control group (p<0.001)."	( Insulin glargine and NPH insulin increase to a similar degree epithelial cell proliferation and aberrant crypt foci formation in colons of diabetic mice. Göke, B; Hoeflich, A; Horst, D; Kolligs, FT; Langkamp, M; Mantzoros, CS; Nagel, JM; Renner-Müller, I; Staffa, J; Vogeser, M, 2010)	2.52
"Insulin glargine treatment decreased urinary energetic loss, leading to a body weight gain of approximately 3 g/day."	( Energy loss via urine and faeces--a combustive analysis in diabetic rats and the impact of antidiabetic treatment on body weight. Elvert, R; Glombik, H; Herling, AW; Wandschneider, J; Werner, U; Wille, A, 2013)	1.11
"Insulin glargine treatment was also associated with a significant decrease in the variability of fasting blood glucose values (P = 0.0124)."	( A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes. Bergenstal, R; Donley, D; Hallé, JP; Klaff, L; Mecca, T; Raskin, P, 2000)	1.28
"Treatment with insulin glargine reduced the incidence of confirmed hypoglycaemia and confirmed nocturnal hypoglycaemia."	( (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus. Berghold, A; Engler, J; Horvath, K; Jeitler, K; Semlitsch, T; Siebenhofer, A, 2020)	0.9
"Treatment with insulin glargine compared with standard care early in the course of dysglycemia in the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial provides information on the frequency and predictors of hypoglycemia in this setting."	( Predictors of nonsevere and severe hypoglycemia during glucose-lowering treatment with insulin glargine or standard drugs in the ORIGIN trial. , 2015)	0.98
"Treatment with insulin glargine resulted in significant reductions in glucose variability as measured by the SD of glucose values (adjusted mean change from baseline to week 24: -13.4 mg/dl [-0.74 mmol/l]; P	( Comparison of glycemic variability associated with insulin glargine and intermediate-acting insulin when used as the basal component of multiple daily injections for adolescents with type 1 diabetes. Arslanian, S; Chase, HP; Tamborlane, WV; White, NH, 2009)	0.96
"Treatment with insulin glargine resulted in a lower daily basal insulin dose and a lower number of injection site reactions.There was no significant difference in the variability of FPG or glucose values in 24-hour profiles between treatment groups."	( Insulin detemir versus insulin glargine for type 2 diabetes mellitus. Devries, JH; Hoekstra, JB; Holleman, F; Simon, AC; Swinnen, SG, 2011)	1.02
"Treatment with insulin glargine and glulisine resulted in significant improvement in glycemic control compared with that achieved with the use of SSI alone. "	( Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes (RABBIT 2 trial). Ceron, M; Mejia, R; Palacio, A; Prieto, LM; Puig, A; Smiley, D; Umpierrez, GE; Zisman, A, 2007)	0.69

Excerpt	Reference	Relevance
" The pattern of adverse events and injection site reactions with HOE 901 was similar to that with NPH."	( Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes. The European Study Group of HOE 901 in type 1 diabetes. Derobert, E; Eugène-Jolchine, I; Pieber, TR, 2000)	0.31
" Insulin glargine was safe and effective in improving glycaemic control both in severe "T2DM" and in "secondary DM" patients."	( Effectiveness and safety of insulin glargine in the therapy of complicated or secondary diabetes: clinical audit. Bacchelli, M; Carapezzi, C; Ciardullo, AV; Daghio, MM, 2006)	1.54
" The primary endpoint was serious adverse drug reactions (SADRs), including major hypoglycaemia."	( Safety and efficacy of insulin detemir basal-bolus therapy in type 1 diabetes patients: 14-week data from the European cohort of the PREDICTIVE study. Ackermann, RW; Dornhorst, A; Gallwitz, B; Honka, M; Lüddeke, HJ; Meriläinen, M; Sreenan, S, 2008)	0.35
" plus single-dose insulin glargine regimen was safe for low-risk type 2 diabetic patients who insisted on fasting during Ramadan."	( Repaglinide plus single-dose insulin glargine: a safe regimen for low-risk type 2 diabetic patients who insist on fasting in Ramadan. Bakiner, O; Bozkirli, E; Demirag, NG; Ertorer, ME; Tutuncu, NB, 2009)	0.98
"Intensive insulin treatment with MDI is feasible, safe and efficacious in general medicine wards."	( Feasibility and safety of multiple daily insulin injections in general medicine wards. Aminov, S; Bloemers, R; Buchs, AE; Horowitz, M; Ramot, Y; Rapoport, MJ; Shiloah, E, 2009)	0.35
" In conclusion, intensive blood glucose control is safe and effective in diabetic cats using home monitoring and treatment with glargine."	( Intensive blood glucose control is safe and effective in diabetic cats using home monitoring and treatment with glargine. Rand, J; Roomp, K, 2009)	0.35
" The primary outcome was to maintain safe fasting glucose and random glucose levels of <350 and <500 mg/dL up to 4 weeks and <300 and <400 mg/dL, respectively, thereafter and to have no return ED visits (responders)."	( Safe and simple emergency department discharge therapy for patients with type 2 diabetes mellitus and severe hyperglycemia. Babu, A; Chen, Z; Fogelfeld, L; Guerrero, P; Koh, CK; Mehta, A; Meyer, PM; Roberts, R; Schaider, J, )	0.13
" Use of sulfonylurea alone once daily can be considered a safe discharge regimen for such patients and an effective bridge between ED intervention and subsequent follow-up."	( Safe and simple emergency department discharge therapy for patients with type 2 diabetes mellitus and severe hyperglycemia. Babu, A; Chen, Z; Fogelfeld, L; Guerrero, P; Koh, CK; Mehta, A; Meyer, PM; Roberts, R; Schaider, J, )	0.13
", Cambridge, MA) may be an efficacious and safe alternative to subcutaneously injected (SC) mealtime insulin."	( Two-year efficacy and safety of AIR inhaled insulin in patients with type 1 diabetes: An open-label randomized controlled trial. Berclaz, PY; Ferguson, JA; Gao, H; Garg, SK; Gates, JR; Mathieu, C; Rais, N; Tobian, JA; Webb, DM, 2009)	0.35
" Safety assessments included hypoglycemic events, pulmonary function tests, adverse events, and insulin antibody levels."	( Two-year efficacy and safety of AIR inhaled insulin in patients with type 1 diabetes: An open-label randomized controlled trial. Berclaz, PY; Ferguson, JA; Gao, H; Garg, SK; Gates, JR; Mathieu, C; Rais, N; Tobian, JA; Webb, DM, 2009)	0.35
" Some 62 participants reported 77 adverse events; none were related to a PTC."	( Usability, participant acceptance, and safety of a prefilled insulin injection device in a 3-month observational survey in everyday clinical practice in Australia. Beilin, J; Carter, J; De Luise, M; Morton, A, 2009)	0.35
" Data on patient satisfaction, product technical complaints, and adverse effects were reported."	( An analysis of patient acceptance and safety of a prefilled insulin injection device. Kroon, L, 2009)	0.35
" Metformin plus glargine or plus neutral protamine Hagedorn is a safe and effective therapeutic choice for type 2 diabetes mellitus cases with poor glycaemic control; moreover, metformin plus neutral protamine is a cheaper and effective choice."	( [Comparison on efficacy and safety of two regimens for treatment of type 2 diabetes mellitus: glargine plus metformin versus neutral protamine hagedorn plus metformin]. Hu, M; Luo, Y; Yang, X; Zhang, H; Zhang, L, 2010)	0.36
"No evidence has been documented for increased adverse fetal outcomes with the use of insulin glargine in pregnancy compared to the use of NPH insulin."	( Safety of insulin glargine use in pregnancy: a systematic review and meta-analysis. Feig, DS; Koren, G; Moretti, ME; Pollex, E, 2011)	1
"Both insulin glargine and detemir improved HbA(1c) at short-term and proved to be safe and well tolerated in children and adolescents with type 1 DM."	( Comparison of the efficacy and safety of insulin glargine and insulin detemir with NPH insulin in children and adolescents with type 1 diabetes mellitus receiving intensive insulin therapy. Dündar, BN; Dündar, N; Eren, E, 2009)	1.13
" Adverse event profiles were similar across groups."	( The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in individ Atkin, SL; Bain, S; Begtrup, K; Birkeland, KI; Blonde, L; Gough, SC; Johansen, T; Meneghini, L; Raz, I; Shestakova, M, 2013)	0.6
"This analysis suggests that insulin glargine may represent a safe option to improve glycemic control in older patients with T2DM."	( Efficacy and safety of insulin glargine compared to other interventions in younger and older adults: a pooled analysis of nine open-label, randomized controlled trials in patients with type 2 diabetes. DiGenio, A; Gao, L; Pandya, N; Patel, M, 2013)	0.99
"Results of this pilot indicate that treatment with sitagliptin alone or in combination with basal insulin is safe and effective for the management of hyperglycemia in general medicine and surgery patients with T2D."	( Safety and efficacy of sitagliptin therapy for the inpatient management of general medicine and surgery patients with type 2 diabetes: a pilot, randomized, controlled study. Farrokhi, F; Gianchandani, R; Jacobs, S; Lathkar-Pradhan, S; Newton, C; Pasquel, F; Peng, L; Reyes, D; Smiley, D; Umpierrez, GE; Wesorick, DH, 2013)	0.39
" No serious adverse drug reactions were reported."	( Safety and effectiveness of biphasic insulin aspart 30 in people with type 2 diabetes switching from basal-bolus insulin regimens in the A1chieve study. Almaghamsi, A; Chen, JW; Chuang, LM; Dieuzeide, G; Lavalle-González, FJ; Zilov, A, 2014)	0.4
" We conclude that this treatment intensification approach may be useful, efficient, and safe in daily clinical practice for patients with type 2 diabetes."	( Efficacy and safety of insulin glargine added to a fixed-dose combination of metformin and a dipeptidyl peptidase-4 inhibitor: results of the GOLD observational study. Bramlage, P; Pegelow, K; Seufert, J, 2013)	0.7
"Aspart, glargine, and detemir are safe treatment options for diabetes during pregnancy; these insulin analogs did not increase complications for the mothers or fetuses in our study."	( Safety of insulin analogs during pregnancy: a meta-analysis. Lv, S; Wang, J; Xu, Y, 2015)	0.42
" Changes from baseline in gastric emptying, 24-h plasma glucose profile, HbA1c, fasting plasma glucose (FPG), 24-h ambulatory heart rate and blood pressure, amylase and lipase levels, and adverse events (AEs) were also assessed."	( Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes on Optimized Insulin Glargine With or Without Metformin: A Randomized, Open-Label Trial. Coester, HV; Delfolie, A; Forst, T; Hincelin-Méry, A; Kapitza, C; Meier, JJ; Menge, BA; Rosenstock, J; Roy-Duval, C, 2015)	0.61
" Adverse events, allergic reactions, weight change, hypoglycaemia and insulin antibodies were similar between treatment groups."	( Similar efficacy and safety of LY2963016 insulin glargine and insulin glargine (Lantus®) in patients with type 2 diabetes who were insulin-naïve or previously treated with insulin glargine: a randomized, double-blind controlled trial (the ELEMENT 2 study) Bhargava, A; Hollander, P; Huster, WJ; Ilag, LL; Pollom, RK; Prince, MJ; Rosenstock, J; Zielonka, JS, 2015)	0.68
" At 52 weeks, similar findings were observed between LY IGlar and IGlar for safety outcomes, including adverse events, allergic reactions, hypoglycaemia, weight change and insulin antibodies."	( Efficacy and safety of LY2963016 insulin glargine compared with insulin glargine (Lantus®) in patients with type 1 diabetes in a randomized controlled trial: the ELEMENT 1 study. Blevins, TC; Dahl, D; Huster, WJ; Ilag, LL; Pollom, RK; Prince, MJ; Rosenstock, J; Zielonka, JS, 2015)	0.7
"5 mg, compared with daily insulin glargine without forced titration, demonstrated greater HbA1c reduction and weight loss, with a higher incidence of gastrointestinal adverse events and a lower risk of hypoglycemia."	( Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2). Benroubi, M; Giorgino, F; Pechtner, V; Sun, JH; Zimmermann, AG, 2015)	0.97
" The most frequent adverse events with dulaglutide treatment were nasopharyngitis and gastrointestinal symptoms."	( Efficacy and safety of once-weekly dulaglutide in combination with sulphonylurea and/or biguanide compared with once-daily insulin glargine in Japanese patients with type 2 diabetes: a randomized, open-label, phase III, non-inferiority study. Araki, E; Imaoka, T; Inagaki, N; Oura, T; Takeuchi, M; Tanizawa, Y, 2015)	0.62
" (5) No significant differences were observed in hypoglycemic episodes and adverse events between two groups."	( [The efficacy and safety of human glucagon-like peptide-1 analogue liraglutide in newly diagnosed type 2 diabetes with glycosylated hemoglobin A1c > 9]. Chen, C; Chen, P; Huang, Q; Shao, Z; Wang, S; Xu, X; Yan, L, 2015)	0.42
" The prevalence of adverse events and the risk of hypoglycemia were similar for both groups."	( A prospective, randomized, multicenter trial comparing the efficacy and safety of the concurrent use of long-acting insulin with mitiglinide or voglibose in patients with type 2 diabetes. Baik, SH; Cha, BS; Jang, HC; Lee, IK; Lee, KW; Park, TS; Son, JW; Sung, YA; Woo, JT; Yoo, SJ; Yoon, KH, 2015)	0.42
" This meta-analysis revealed the use of dulaglutide as a monotherapy or an add-on to OAM and lispro appeared to be effective and safe for adults with T2DM."	( Efficacy and safety of dulaglutide in patients with type 2 diabetes: a meta-analysis and systematic review. Tong, N; Zhang, L; Zhang, M; Zhang, Y, 2016)	0.43
" No statistically significant treatment differences were identified for efficacy and safety outcomes except for weight change (T1D), overall incidence of detectable insulin antibodies (T2D), and serious adverse events (T2D)."	( Efficacy and safety of LY2963016 insulin glargine in patients with type 1 and type 2 diabetes previously treated with insulin glargine. Chang, CL; Dahl, D; Hadjiyianni, I; Ilag, LL; Lacaya, LB; Pollom, RK, 2016)	0.72
" Frequencies of hypoglycemia and adverse events did not differ between groups."	( Efficacy and Safety of Flexible Versus Fixed Dosing Intervals of Insulin Glargine 300 U/mL in People with Type 2 Diabetes. Bergenstal, RM; Bolli, GB; Home, PD; Jeandidier, N; Muehlen-Bartmer, I; Riddle, MC; Vinet, L; Wardecki, M; Yki-Järvinen, H; Ziemen, M, 2016)	0.67
"LixiLan achieved statistically significant reductions to near-normal HbA1c levels with weight loss and no increased hypoglycemic risk, compared with insulin glargine alone, and a low incidence of gastrointestinal adverse events in type 2 diabetes inadequately controlled on metformin."	( Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Lixisenatide and Insulin Glargine, Versus Insulin Glargine in Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy: The LixiLan Proof-of-Concept Randomized Trial. Aroda, VR; Diamant, M; Fonseca, V; Perfetti, R; Rosenstock, J; Silvestre, L; Souhami, E; Zhou, T, 2016)	0.86
" There was no significant difference in the incidence rate of adverse events in two groups (OR=0."	( [Efficacy and safety of insulin degludec for diabetes mellitus: a meta-analysis]. Deng, XR; Ding, L; Jing, CB; Liu, HX; Sun, SM; Wang, YF; Zheng, RZ, 2016)	0.43
" Adverse events were reported in 18."	( Glycemic control and safety in Chinese patients with type 2 diabetes mellitus who switched from premixed insulin to insulin glargine plus oral antidiabetics: a large, prospective, observational study. Yang, W; Zhang, B; Zhao, J, 2017)	0.66
" We hypothesize that co-administration of glargine, a subcutaneous long-acting insulin analog, during insulin infusion may facilitate a flexible and safe transition from intravenous to subcutaneous therapy."	( Glargine co-administration with intravenous insulin in pediatric diabetic ketoacidosis is safe and facilitates transition to a subcutaneous regimen. Ferrara, C; Harrison, VS; Hawkes, CP; Palladino, AA; Rustico, S, 2017)	0.46
"Treatment with GesTIO protocol allows a safe and effective treatment even in very old and vulnerable inpatients with a faster management insulin therapy."	( The GesTIO protocol experience: safety of a standardized order set for subcutaneous insulin regimen in elderly hospitalized patients. Barbato, GM; Bruttomesso, D; Corradin, ML; Franchin, A; Manzato, E; Maran, A; Rossi, F; Sicolo, N; Zanatta, F, 2017)	0.46
" Most discontinuations were due to adverse events-mostly gastrointestinal with semaglutide, and others such as skin and subcutaneous tissue disorders (eg, rash, pruritus, and urticaria) with insulin glargine."	( Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, mul Aroda, VR; Axelsen, M; Bain, SC; Cariou, B; DeVries, JH; Piletič, M; Rose, L; Rowe, E, 2017)	0.88
" In all treatment groups, the incidences of treatment-emergent adverse events tended to be greater among females than among males."	( Analysis of efficacy and safety of dulaglutide 0.75 mg stratified by sex in patients with type 2 diabetes in 2 randomized, controlled phase 3 studies in Japan. Iwamoto, N; Matsui, A; Matsuura, J; Onishi, Y; Oura, T, 2017)	0.46
" Rates of adverse events did not differ between the two groups."	( Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes. Brown-Frandsen, K; Buse, JB; Emerson, SS; Haahr, PM; Kvist, K; Lange, M; Marso, SP; McGuire, DK; Moses, A; Pieber, TR; Poulter, NR; Pratley, RE; Skibsted, S; Zinman, B, 2017)	0.46
" Although dulaglutide increased gastrointestinal adverse events compared with glargine in both subgroups, all gastrointestinal events of diarrhea, nausea, constipation, and vomiting in dulaglutide-treated patients were mild in intensity and well tolerated."	( Efficacy and safety of subgroup analysis stratified by baseline HbA1c in a Japanese phase 3 study of dulaglutide 0.75 mg compared with insulin glargine in patients with type 2 diabetes. Kaneko, S; Matsui, A; Oura, T; Shingaki, T; Takeuchi, M, 2017)	0.66
" Serious adverse events (SAEs) were recorded at 3 and 6 months."	( Observational Registry of Basal Insulin Treatment in Patients with Type 2 Diabetes in China: Safety and Hypoglycemia Predictors. Gao, Y; Guo, X; Ji, J; Ji, L; Li, X; Zhang, H; Zhang, P; Zhang, T; Zhao, F; Zhu, D, 2017)	0.46
" The rates of adverse events including total mortality and cardiovascular events were not significantly different between two treatment strategies."	( Comparative safety and efficacy of insulin degludec with insulin glargine in type 2 and type 1 diabetes: a meta-analysis of randomized controlled trials. Kang, LN; Xu, B; Zhang, XL; Zhang, XW, 2018)	0.73
" Basal insulin/glucagon-like peptide-1 (GLP-1) agonist combination products have the benefit of being highly efficacious while having favorable effects on weight, reduced gastrointestinal adverse effects, and low hypoglycemic risks compared to the individual agents used alone."	( Efficacy and Safety of Basal Insulin/GLP-1 Receptor Agonist Used in Combination for Type 2 Diabetes Management. McCarty, BP; McCarty, D; Olenik, A, 2019)	0.51
" Secondary endpoints were changes in fasting plasma glucose, insulin dose, self-monitored blood glucose and immunogenicity from baseline, and occurrences of hypoglycaemic, nocturnal hypoglycaemic and adverse events up to week 52."	( Efficacy and safety of MYL-1501D vs insulin glargine in patients with type 1 diabetes after 52 weeks: Results of the INSTRIDE 1 phase III study. Ankersen, M; Barve, A; Blevins, TC; Sun, B, 2018)	0.76
" The rates of hypoglycemia and adverse events did not change during the follow-up period."	( Efficacy and Safety of Switching from Insulin Glargine 100 U/mL to the Same Dose of Glargine 300 U/mL in Japanese Type 1 and 2 Diabetes Patients: A Retrospective Analysis. Fushimi, Y; Hirukawa, H; Irie, S; Iwamoto, M; Kaku, K; Kamei, S; Kameyama, M; Kaneto, H; Kimura, T; Kinoshita, T; Kohara, K; Mizoguchi, A; Mune, T; Nakanishi, S; Nishioka, M; Obata, A; Sanada, J; Shimoda, M; Tatsumi, F, 2018)	0.75
" Safety and tolerability, including anti-insulin antibody responses, hypoglycaemia, adverse events and body weight, were similar between insulins."	( Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 2 diabetes: A randomized, open-label clinical trial. Carofano, WL; Crutchlow, MF; Eldor, R; Gallwitz, B; Golm, GT; Hollander, PA; Home, PD; Lam, RLH; Marcos, MC; Rendell, MS; Rosenstock, J, 2018)	0.77
" Safety and tolerability, including anti-insulin antibody responses, hypoglycaemia, adverse events and body weight, were similar between insulins over the 52-week study duration."	( Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 1 diabetes: A randomized, open-label clinical trial. Carofano, WL; Crutchlow, MF; Eldor, R; Gallwitz, B; Golm, GT; Hollander, PA; Home, PD; Lam, RLH; Marcos, MC; Rosenstock, J, 2018)	0.77
"A total of 150 first major adverse cardiovascular events were recorded at cut-off for the interim analysis."	( Developing, Planning and Conducting an Interim Analysis: Lessons From the DEVOTE Cardiovascular Outcomes Trial (Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Patients With Type 2 Diabetes at High Risk of Cardiovascul Amby, LK; Endahl, L; Helmark, IC; Hoskin, S; Hvelplund, A; Mollerup, I; Moses, AC; Theilgaard, H, 2019)	0.71
"This post hoc analysis of gastrointestinal (GI) adverse events (AEs) from the phase 3 LixiLan-L (NCT02058160) and LixiLan-O (NCT02058147) trials aimed to determine the frequency and timing of nausea, vomiting, and diarrhoea for iGlarLixi, a titratable, fixed-ratio combination of insulin glargine 100 units/mL (iGlar) and lixisenatide, versus iGlar alone or iGlar and lixisenatide alone, in patients with type 2 diabetes uncontrolled with oral antidiabetes drugs (OADs) or basal insulin ± OADs."	( Low incidence of gastrointestinal adverse events over time with a fixed-ratio combination of insulin glargine and lixisenatide versus lixisenatide alone. Chao, J; Dex, T; LaSalle, J; Roberts, M; Trujillo, JM; White, J, 2018)	0.88
" Hypoglycaemic adverse events were significantly higher in the INS group compared to the EMPA group (P = 0."	( Effectiveness and safety of empagliflozin-based quadruple therapy compared with insulin glargine-based therapy in patients with inadequately controlled type 2 diabetes: An observational study in clinical practice. Jeon, HJ; Ku, EJ; Lee, DH; Oh, TK, 2019)	0.74
" Secondary endpoints included metabolic readouts (eg, changes in fasting plasma glucose, insulin dosage, self-monitored blood glucose), immunogenicity and adverse events, including hypoglycaemia and nocturnal hypoglycaemic events."	( Efficacy and safety of MYL-1501D versus insulin glargine in patients with type 2 diabetes after 24 weeks: Results of the phase III INSTRIDE 2 study. Ankersen, M; Athalye, S; Aubonnet, P; Barve, A; Blevins, TC; Muniz, R; Raiter, Y; Sun, B, 2019)	0.78
" Gastrointestinal adverse events, including diarrhoea and nausea, were the most frequently reported for patients taking dulaglutide."	( Efficacy and safety of once-weekly dulaglutide versus insulin glargine in mainly Asian patients with type 2 diabetes mellitus on metformin and/or a sulphonylurea: A 52-week open-label, randomized phase III trial. Filippova, E; Gu, L; Li, P; Nevárez, L; Song, KH; Tao, B; Wang, F; Wang, W; Yang, J, 2019)	0.76
"A1C = hemoglobin A1C; AE = adverse event; CI = confidence interval; Degludec = insulin degludec; EOT = end of trial; ETD = estimated treatment difference; FPG = fasting plasma glucose; GLP-1RA = glucagon-like peptide 1 receptor agonist; IDegLira = insulin degludec/liraglutide; IGlar U100 = insulin glargine 100 U/mL; SU = sulfonylurea; T2D = type 2 diabetes."	( EFFICACY AND SAFETY OF IDEGLIRA IN OLDER PATIENTS WITH TYPE 2 DIABETES. Halladin, N; Handelsman, Y; Liebl, A; Lingvay, I; Linjawi, S; Ranc, K; Vilsbøll, T, 2019)	0.69
" Adverse events overall and changes from baseline in body weight were similar between the two treatment groups."	( Double-blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase-4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: The CompoSIT-I Study. Darmiento, C; Duran-García, S; Engel, SS; Gantz, I; Golm, GT; Kaufman, KD; Lam, RLH; O'Neill, EA; Roussel, R; Shah, S; Shankar, RR; Zhang, Y, 2019)	0.71
"1 mmol/L), daily linagliptin is a safe and effective alternative to multi-dose insulin therapy, resulting in similar glucose control with lower hypoglycaemia."	( Glycaemic efficacy and safety of linagliptin compared to a basal-bolus insulin regimen in patients with type 2 diabetes undergoing non-cardiac surgery: A multicentre randomized clinical trial. Alexanian, S; Anzola, I; Baldwin, D; Cardona, S; Pasquel, FJ; Peng, L; Rasouli, N; Umpierrez, GE; Urrutia, M; Vellanki, P, 2019)	0.51
"9 mmol/L]), severe hypoglycemia (requiring assistance of another person), and incidence of gastrointestinal adverse events."	( Efficacy and safety of insulin glargine/lixisenatide (iGlarLixi) fixed-ratio combination in older adults with type 2 diabetes. Chovanes, C; Dex, T; Frias, JP; Giorgino, F; Handelsman, Y; Niemoeller, E; Skolnik, N; Souhami, E; Stager, W, 2019)	0.82
" Safety endpoints included hypoglycemia and adverse events."	( A Randomized Controlled, Treat-to-Target Study Evaluating the Efficacy and Safety of Insulin Glargine 300 U/mL (Gla-300) Administered Using Either Device-Supported or Routine Titration in People With Type 2 Diabetes. Bain, S; Charpentier, G; Davies, M; Edelman, S; Flacke, F; Goyeau, H; Hasslacher, C; Vespasiani, G; Woloschak, M, 2019)	0.74
" Outcomes by overall age group and randomized treatment differences were analysed for major adverse cardiovascular events (MACE), all-cause mortality, severe hypoglycaemia and serious adverse events (SAEs)."	( Cardiovascular safety and lower severe hypoglycaemia of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes aged 65 years or older: Results from DEVOTE (DEVOTE 7). Buse, JB; Emerson, SS; Franek, E; Gilbert, MP; Hansen, CT; Hansen, MV; Mark, T; Marso, SP; McGuire, DK; Moses, AC; Pieber, TR; Pratley, RE; Zinman, B, 2019)	0.74
" Secondary outcomes included SMPG target achievement without hypoglycaemia, hypoglycaemia incidence, adverse events and participant-reported outcomes (PROs)."	( Take Control: A randomized trial evaluating the efficacy and safety of self- versus physician-managed titration of insulin glargine 300 U/mL in patients with uncontrolled type 2 diabetes. Bonnemaire, M; Dauchy, A; Davies, M; Delgado, E; Dimitriadis, G; Frandsen, HA; Popescu, L; Roborel de Climens, A; Russell-Jones, D; Schultes, B; Strojek, K, 2019)	0.72
" Safety outcomes included the incidence of documented symptomatic hypoglycemia (plasma glucose <60 mg/dL) and gastrointestinal treatment-emergent adverse events (TEAEs)."	( Efficacy and safety of lixisenatide as add-on therapy to basal insulin in older adults with type 2 diabetes in the GetGoal-O Study. Dailey, GE; Dex, TA; Liu, M; Meneilly, GS; Roberts, M, 2019)	0.51
"5%的患者比例以及复合终点相对于基线的变化。安全性结局包括记录的症状性低血糖(血糖<60 mg/dl)及治疗期间胃肠道不良事件(treatment-emergent adverse events, TEAEs)的发生率。还通过中度肾功能不全的发生对结果进行了分析。结果: 与安慰剂组相比, 利西那肽治疗组的HbA1c、餐后2小时血糖、平均7点SMPG以及体重下降均更显著。安慰剂组中记录的症状性低血糖发生率大约是利西那肽治疗组患者的2倍(分别为12."	( Efficacy and safety of lixisenatide as add-on therapy to basal insulin in older adults with type 2 diabetes in the GetGoal-O Study. Dailey, GE; Dex, TA; Liu, M; Meneilly, GS; Roberts, M, 2019)	0.51
" Safety endpoints included incidence of documented symptomatic hypoglycemia and gastrointestinal (GI) adverse events."	( Post hoc efficacy and safety analysis of insulin glargine/lixisenatide fixed- ratio combination in North American patients compared with the rest of world. Bajaj, HS; Dailey, G; Dex, T; Groleau, M; Stager, W; Vinik, A, 2019)	0.78
" iGlarLixi treatment responses, hypoglycemia risk and GI adverse events in NA patients were comparable with patients in the RoW."	( Post hoc efficacy and safety analysis of insulin glargine/lixisenatide fixed- ratio combination in North American patients compared with the rest of world. Bajaj, HS; Dailey, G; Dex, T; Groleau, M; Stager, W; Vinik, A, 2019)	0.78
" Secondary endpoints included: change in fasting plasma glucose (FPG), self-monitored blood glucose (SMBG) and insulin dose; immunogenicity; and adverse events, including hypoglycaemia."	( Efficacy and safety of MYL-1501D versus insulin glargine in people with type 1 diabetes mellitus: Results of the INSTRIDE 3 phase 3 switch study. Athalye, S; Aubonnet, P; Barve, A; Blevins, TC; Muniz, R; Raiter, Y; Sun, B, 2020)	0.83
" Adverse events (AEs) were reported in similar proportions of subjects across trials."	( Efficacy and Safety of Semaglutide for Type 2 Diabetes by Race and Ethnicity: A Post Hoc Analysis of the SUSTAIN Trials. Cariou, B; DeSouza, C; Fonseca, V; Garg, S; Lausvig, N; Navarria, A, 2020)	0.56
" Rates of adverse events were similar between groups and low for serious adverse events."	( Efficacy and safety of insulin glargine 300 U/mL versus insulin glargine 100 U/mL in Asia Pacific insulin-naïve people with type 2 diabetes: The EDITION AP randomized controlled trial. Dong, X; Ji, L; Kang, ES; Li, L; Niemoeller, E; Shang, S; Yuan, G, 2020)	0.87
" iGlarLixi patients had more gastrointestinal-related adverse events than iGlar patients (33."	( Efficacy and safety of insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) in Japanese patients with type 2 diabetes mellitus inadequately controlled on basal insulin and oral antidiabetic drugs: The LixiLan JP-L randomized clinical trial. Amano, A; Kaneto, H; Niemoeller, E; Spranger, R; Takami, A; Watanabe, D, 2020)	0.87
" Data on glycemic endpoints (hemoglobin A1c (HbA1c), fasting plasma glucose (FPG), hypoglycemia) and other outcomes (insulin dose, body weight, patient-reported outcomes, adverse events, rescue medication, discontinuation) were extracted."	( Efficacy and safety of patient-led versus physician-led titration of basal insulin in patients with uncontrolled type 2 diabetes: a meta-analysis of randomized controlled trials. Castellana, M; Giannelli, G; Procino, F; Sardone, R; Trimboli, P, 2020)	0.56
"Gla-300, in clinical practice, provides an effective and safe therapy as HbA1c was reduced/maintained in insulin-naïve/experienced Japanese T2DM patients without new safety signal."	( Effectiveness and safety of insulin glargine 300 unit/mL in Japanese type 2 diabetes mellitus patients: a 12-month post-marketing surveillance study (X-STAR study). Hirose, T; Koshida, R; Matsuhisa, M; Odawara, M; Senda, M; Tanaka, Y; Terauchi, Y, 2020)	0.85
" We compared gastrointestinal adverse event (AE) rates for iGlarLixi versus GLP-1 RAs during the first 12 weeks of therapy, including a sensitivity analysis with IDegLira."	( Gastrointestinal adverse events with insulin glargine/lixisenatide fixed-ratio combination versus glucagon-like peptide-1 receptor agonists in people with type 2 diabetes mellitus: A network meta-analysis. Aroda, VR; Guyot, P; Horowitz, M; Kanters, S; Rayner, CK; Shaunik, A; Whittington, C; Wu, T, 2021)	0.89
"This study aimed to compare the rate of hypoglycemic events from all spontaneously reported adverse events (AEs) between insulin detemir and insulin degludec using the Korea Adverse Event Reporting System (KAERS) database."	( Disproportionality analysis of spontaneously reported hypoglycemia events due to insulin use: A comparison between insulin detemir and insulin degludec using the Korea Adverse Event Reporting System. Jeong, D; Kim, W; Shin, JY, 2021)	0.62
"We analyzed data on the reported hypoglycemia events retrieved from adverse drug reactions (ADR) on the use of different insulin types from 2016 to 2017 in the Korea Institute of Drug Safety & Risk Management-Korea Adverse Event Reporting System Database (KIDS-KD)."	( Disproportionality analysis of spontaneously reported hypoglycemia events due to insulin use: A comparison between insulin detemir and insulin degludec using the Korea Adverse Event Reporting System. Jeong, D; Kim, W; Shin, JY, 2021)	0.62
" The incidence of gastrointestinal adverse events was higher with liraglutide than with insulin glargine (P < 0."	( Liraglutide hospital discharge trial: A randomized controlled trial comparing the safety and efficacy of liraglutide versus insulin glargine for the management of patients with type 2 diabetes after hospital discharge. Albury, B; Anzola, I; Cardona, S; Chaudhuri, A; Coronado, KWZ; Davis, GM; Farias, JM; Fayfman, M; Galindo, RJ; Gomez, P; Iacobellis, G; Migdal, AL; Palacios, J; Pasquel, FJ; Peng, L; Perez-Guzman, MC; Umpierrez, GE; Urrutia, MA; Vellanki, P, 2021)	1.05
"Compared to insulin glargine, treatment with liraglutide at hospital discharge resulted in better glycaemic control and greater weight loss, but increased gastrointestinal adverse events."	( Liraglutide hospital discharge trial: A randomized controlled trial comparing the safety and efficacy of liraglutide versus insulin glargine for the management of patients with type 2 diabetes after hospital discharge. Albury, B; Anzola, I; Cardona, S; Chaudhuri, A; Coronado, KWZ; Davis, GM; Farias, JM; Fayfman, M; Galindo, RJ; Gomez, P; Iacobellis, G; Migdal, AL; Palacios, J; Pasquel, FJ; Peng, L; Perez-Guzman, MC; Umpierrez, GE; Urrutia, MA; Vellanki, P, 2021)	1.21
" But it is also associated with adverse outcomes such as hypoglycaemia."	( Efficacy and safety of dulaglutide compared with glargine in patients with type 2 diabetes: A systematic review and meta-analysis. Xia, J; Xu, J; Yao, D, 2021)	0.62
"5 mg groups than in insulin glargine group,whereas dulaglutide had a statistically higher gastrointestinal adverse events incidence than insulin glargine."	( Efficacy and safety of dulaglutide compared with glargine in patients with type 2 diabetes: A systematic review and meta-analysis. Xia, J; Xu, J; Yao, D, 2021)	0.94
" Adverse events, allergic reactions, hypoglycaemia and insulin antibodies were similar in the two groups."	( Efficacy and safety of LY2963016 insulin glargine versus insulin glargine (Lantus) in Chinese adults with type 2 diabetes: A phase III, randomized, open-label, controlled trial. Chen, W; Du, L; Feng, W; Jiang, S; Zhu, D, 2021)	0.9
" In conclusion, IG is safe and equally effective as an NPH-based basal-bolus regimen for acute stroke patients with hyperglycemia receiving intensive care."	( A randomized trial to investigate the efficacy and safety of insulin glargine in hyperglycemic acute stroke patients receiving intensive care. Chen, CH; Jeng, JS; Lin, SY; Shih, SR; Tang, SC; Tsai, LK; Yang, WS; Yeh, SJ, 2021)	0.86
" Weight change, insulin antibodies and all adverse events including allergic reactions and hypoglycaemia, were also similar between the two treatment groups (all p > ."	( Comparable efficacy and safety between LY2963016 insulin glargine and insulin glargine (Lantus®) in Chinese patients with type 1 diabetes: A phase III, randomized, controlled trial. Jiang, S; Lou, Y; Yan, X; Zhou, Z, 2021)	0.88
"The self-titration of Gla-300 using the INSIGHT algorithm was effective and safe compared with that using the EDITION algorithm in Korean individuals with uncontrolled T2DM (ClinicalTrials."	( Efficacy and Safety of Self-Titration Algorithms of Insulin Glargine 300 units/mL in Individuals with Uncontrolled Type 2 Diabetes Mellitus (The Korean TITRATION Study): A Randomized Controlled Trial. Ahn, CH; Bae, JH; Cho, YM; Jung, HS; Kwak, SH; Moon, SJ; Park, KS; Yang, YS, 2022)	0.97
" Adverse events were more frequent with iGlarLixi because of gastrointestinal intolerance."	( Efficacy and safety of iGlarLixi versus IDegAsp: Results of a systematic literature review and indirect treatment comparison. Alvarez, A; Gurova, OY; Hafidh, KAS; Home, PD; Mehta, R; Pourrahmat, MM; Serafini, P, 2021)	0.62
"iGlarLixi + insulin glulisine combination therapy is safe and equally efficacious as multiple daily injection therapy for glycemic control, while avoiding hypoglycemia risk and reducing the number of injections are required."	( Comparisons of efficacy and safety in insulin glargine and lixisenatide plus glulisine combination therapy with multiple daily injection therapy in Japanese patients with type 2 diabetes. Ashida, N; Hajika, Y; Hamazaki, K; Kawaguchi, Y; Kumeda, Y; Masumoto, K; Miyamoto, S; Sawa, J, 2022)	0.99
" Their excellent glucose-lowering efficacy is complemented with lower risk of hypoglycemia in comparison to basal insulin, neutral effect on body weight and the lower risk of gastrointestinal adverse effects in comparison to GLP-1 receptor agonists."	( An update on the safety of insulin-GLP-1 receptor agonist combinations in type 2 diabetes mellitus. Haluzík, M; Novodvorský, P, 2022)	0.72
" The results showed that IDeg/Asp significantly decreased the mean hemoglobin A1c (HbA1c) level but was prone to serious adverse events, and IGlar increased the nocturnal confirmed hypoglycemia events."	( Comparative efficiency and safety of insulin degludec/aspart with insulin glargine in type 2 diabetes: a meta-analysis of randomized controlled trials. Huang, JS; Lai, JM; Lai, YM; Li, SZ; Lin, JT; Lin, MH; Long, T; Wu, QL; Zeng, CP; Zeng, JY; Zhou, ZC, 2022)	0.96
"iGlarLixi achieved significant HbA1c reductions, to near-normoglycaemic levels, compared with iGlar or Lixi, with no meaningful additional risk of hypoglycaemia and mitigated body weight gain versus iGlar, with fewer gastrointestinal adverse events versus Lixi."	( Efficacy and safety benefits of iGlarLixi versus insulin glargine 100 U/mL or lixisenatide in Asian Pacific people with suboptimally controlled type 2 diabetes on oral agents: The LixiLan-O-AP randomized controlled trial. Chen, L; Cheng, Z; Dong, X; Gu, S; Li, Q; Liu, M; Niemoeller, E; Ping, L; Souhami, E; Xiao, J; Yang, W; Yuan, G, 2022)	0.98
" Rates of adverse events were similar for both hypoglycaemia and vascular events."	( Effectiveness, safety and treatment adherence of biosimilar follow-on insulin in diabetes management. Abarca, J; Barron, J; Chen, X; DeVries, A; Hart, R; Pham, TT, 2022)	0.72
"Treatment with degludec U100 is as effective and safe as glargine U300 for the early postoperative hospital management of patients with T2D undergoing CABG."	( Efficacy and safety of degludec U100 versus glargine U300 for the early postoperative management of patients with type 2 diabetes mellitus undergoing coronary artery bypass graft surgery: A non-inferiority randomized trial. Gagneja, S; Gill, HK; Jain, R; Kaur, P; Kohli, C; Kuchay, MS; Kumari, P; Mathew, A; Mishra, M; Mishra, SK; Singh, MK; Surendran, P; Wasir, JS, 2023)	0.91
"Titrating basal insulin first is an effective and safe method of SIIT in individuals with T2D, rapidly achieving target glucose levels with a relatively low rate of hypoglycaemia."	( Efficacy and safety of basal-first titration order in individuals with type 2 diabetes receiving short-term intensive insulin therapy: An exploratory analysis of BEYOND V. Cui, N; Guo, L; Jiang, C; Li, Y; Liang, L; Liu, J; Mu, Y; Wan, H; Wang, G; Wang, J; Xu, B; Yu, D; Zhang, J; Zhang, M, 2023)	0.91
" Occurrence of serious adverse events was similar between the BIF and degludec groups."	( Novel Once-Weekly Basal Insulin Fc Achieved Similar Glycemic Control With a Safety Profile Comparable to Insulin Degludec in Patients With Type 1 Diabetes. Bue-Valleskey, JM; Chien, J; Chigutsa, E; Dahl, D; Haupt, A; Kazda, CM; Landschulz, W; Wullenweber, P; Zhang, Q, 2023)	0.91
" Outcomes of interest were change in HbA1c, blood glucose, weight and insulin dose, as well as incidence and event rate of hypoglycaemia and other adverse events."	( Comparative efficacy and safety of Gla-300 versus IDegAsp in insulin-naïve people with type 2 diabetes mellitus uncontrolled on oral anti-diabetics. Emral, R; Ghosh, S; Guyot, P; Landgraf, W; Mabunay, MA; Malek, R; Malik, RA; Pushkarna, D; Ritzel, R; Serafini, P; Zeng, L, 2023)	0.91
" No significant differences were observed for insulin dose and adverse events."	( Comparative efficacy and safety of Gla-300 versus IDegAsp in insulin-naïve people with type 2 diabetes mellitus uncontrolled on oral anti-diabetics. Emral, R; Ghosh, S; Guyot, P; Landgraf, W; Mabunay, MA; Malek, R; Malik, RA; Pushkarna, D; Ritzel, R; Serafini, P; Zeng, L, 2023)	0.91
" The most common treatment-emergent adverse events with dulaglutide/glargine were decreased appetite (22."	( Efficacy and safety of adding once-weekly dulaglutide to basal insulin for inadequately controlled type 2 diabetes in Chinese patients (AWARD-CHN3): A randomized, double-blind, placebo-controlled, phase III trial. Cheng, Z; Deng, Y; Ma, J; Wang, R; Wang, W; Yan, X; Zhang, Q; Zhu, D, 2023)	0.91
"Based on the currently available data, tirzepatide appears to be safe regarding the risk of pancreatitis."	( Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis. Fan, H; Li, S; Mu, X; Shi, Y; Xu, J; Zeng, Q, 2023)	0.91

Excerpt	Reference	Relevance
"In this paper, a comprehensive pharmacokinetic model for different insulin formulations including insulin Glargine is developed based on the model proposed by Trajanoski et al."	( Comprehensive pharmacokinetic model of insulin Glargine and other insulin formulations. Bondia, J; Pfleiderer, HJ; Picó, J; Tarín, C; Teufel, E, 2005)	0.81
"The pharmacokinetic and pharmacodynamic properties of biphasic insulin aspart (BIAsp 30) (30% soluble, 70% protaminated insulin aspart [IAsp]) and insulin glargine (IGlarg) were compared."	( Comparison of the pharmacokinetics and pharmacodynamics of biphasic insulin aspart and insulin glargine in people with type 2 diabetes. Dunseath, G; Luzio, S; Owens, DR; Pauvaday, V; Peter, R, 2006)	0.76
"The pharmacodynamic and pharmacokinetic profiles were 34 and 28%, respectively, higher following equivalent doses (0."	( Comparison of the pharmacokinetics and pharmacodynamics of biphasic insulin aspart and insulin glargine in people with type 2 diabetes. Dunseath, G; Luzio, S; Owens, DR; Pauvaday, V; Peter, R, 2006)	0.56
" The two analogues are popularly perceived to differ from each other in their pharmacodynamic (PD) profiles, in particular with regard to 'flatness' and duration of action."	( Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies. Heise, T; Pieber, TR, 2007)	0.34
" Insulin aspart and insulin lispro have nearly identical pharmacokinetic and pharmacodynamic profiles and provide better postprandial glucose control and less hypoglycaemia (primarily nocturnal and severe hypoglycaemia in type 1 diabetes mellitus) than regular insulin."	( New insulin analogues and routes of delivery: pharmacodynamic and clinical considerations. Roach, P, 2008)	0.35
" This randomized, double-blind, crossover trial compared the within-subject variability of detemir and insulin glargine (glargine) in pharmacokinetic properties in children and adolescents with T1DM."	( Insulin detemir is characterized by a more reproducible pharmacokinetic profile than insulin glargine in children and adolescents with type 1 diabetes: results from a randomized, double-blind, controlled trial. Danne, T; Datz, N; Endahl, L; Fjording, MS; Haahr, H; Kordonouri, O; Nestoris, C; Westergaard, L, 2008)	0.78
"8 U/kg) and evaluate pharmacokinetic (PK) and pharmacodynamic (PD) dose responses of ILPS."	( Pharmacokinetics and pharmacodynamics of insulin lispro protamine suspension compared with insulin glargine and insulin detemir in type 2 diabetes. Campaigne, BN; Hompesch, M; Jacober, SJ; Kollmeier, AP; Morrow, LA; Ocheltree, SM; Wondmagegnehu, ET, 2009)	0.57
" However, no formal glucose clamp studies have been performed to determine whether mixing with glargine has an adverse effect on the early pharmacodynamic action of rapid-acting insulin in humans."	( Early pharmacokinetic and pharmacodynamic effects of mixing lispro with glargine insulin: results of glucose clamp studies in youth with type 1 diabetes. Cengiz, E; Dziura, J; Martin-Fredericksen, M; Tamborlane, WV; Weinzimer, SA, 2010)	0.36
"This pedagogical review illustrates the differences between pharmacokinetic (PK) and pharmacodynamic (PD) measures, using insulin therapy as the primary example."	( How pharmacokinetic and pharmacodynamic principles pave the way for optimal basal insulin therapy in type 2 diabetes. Arnolds, S; Heise, T; Kapitza, C; Kuglin, B, 2010)	0.36
" The aim was to directly compare the pharmacodynamic properties of the long-acting insulin analogues and NPH insulin after a single subcutaneous injection."	( Similarity of pharmacodynamic effects of a single injection of insulin glargine, insulin detemir and NPH insulin on glucose metabolism assessed by 24-h euglycaemic clamp studies in healthy humans. Brock, B; Mengel, A; Moller, N; Nielsen, S; Rungby, J; Schmitz, O; Sørensen, LP; Vølund, A, 2010)	0.6
"In this experimental design, only minor pharmacodynamic differences were demonstrated between insulin detemir, insulin glargine and NPH insulin."	( Similarity of pharmacodynamic effects of a single injection of insulin glargine, insulin detemir and NPH insulin on glucose metabolism assessed by 24-h euglycaemic clamp studies in healthy humans. Brock, B; Mengel, A; Moller, N; Nielsen, S; Rungby, J; Schmitz, O; Sørensen, LP; Vølund, A, 2010)	0.81
" We compared the pharmacodynamic (PD) variability of IDeg and insulin glargine (IGlar) under steady-state conditions."	( Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Feldman, A; Haahr, H; Heise, T; Hermanski, L; Nosek, L; Rasmussen, S, 2012)	0.85
"The pharmacodynamic characteristics of the basal insulin analogues insulin detemir (IDet) and insulin glargine (IGlar) have been examined extensively via euglycaemic clamp studies."	( Pharmacodynamics of the long-acting insulin analogues detemir and glargine following single-doses and under steady-state conditions in patients with type 1 diabetes. Koehler, G; Korsatko, S; Mader, JK; Pieber, TR; Semlitsch, B; Treiber, G; Wutte, A, 2014)	0.62
"Insulin degludec (IDeg) is a basal insulin with an ultra-long pharmacokinetic profile in adults that at steady-state produces remarkably flat and stable insulin levels; however, no studies have yet reported on the pharmacokinetic properties of IDeg in subjects younger than 18 years of age."	( Insulin degludec's ultra-long pharmacokinetic properties observed in adults are retained in children and adolescents with type 1 diabetes. Aschemeier, B; Biester, T; Blaesig, S; Danne, T; Granhall, C; Haahr, H; Kordonouri, O; Kristensen, NR; Remus, K; Søndergaard, F, 2014)	0.4
" Time-to-maximum plasma concentration (medians) and geometric means for half-life (t½ ) and apparent clearance, respectively, ranged from 18."	( Single-dose pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 in healthy subjects. Choi, SL; Howey, DC; Lim, ST; Mace, KF; Sinha, VP; Soon, DK; Yeo, KP, 2014)	0.4
" Glucose infusion rate (GIR), distribution of GIR and half-life were assessed."	( Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine. Bøttcher, SG; Haahr, H; Heise, T; Hermanski, L; Hövelmann, U; Nosek, L, 2015)	0.64
" At SS, the half-life was 25."	( Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine. Bøttcher, SG; Haahr, H; Heise, T; Hermanski, L; Hövelmann, U; Nosek, L, 2015)	0.64
"IDeg has a longer half-life (> 25 h) than IGlar."	( Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine. Bøttcher, SG; Haahr, H; Heise, T; Hermanski, L; Hövelmann, U; Nosek, L, 2015)	0.64
" Three studies evaluated the pharmacokinetic (PK) and pharmacodynamic (PD) similarity of LY IGlar and the European Union- and US-approved versions of IGlar."	( Comparison of the Pharmacokinetics and Pharmacodynamics of LY2963016 Insulin Glargine and EU- and US-Approved Versions of Lantus Insulin Glargine in Healthy Subjects: Three Randomized Euglycemic Clamp Studies. Chong, CL; Chua, L; Coutant, D; Ferreira, MM; Lam, EC; Linnebjerg, H; Seger, ME; Soon, D; Zhang, X, 2015)	0.65
" Expert opinion: Gla-300 has a flatter and more prolonged pharmacokinetic profile compared to glargine 100 units/ml (Gla-100), but is less potent on a unit per unit basis."	( Pharmacodynamic and pharmacokinetic evaluation of insulin glargine U300 for the treatment of type 1 diabetes. Hurren, KM; O'Neill, JL, 2016)	0.69
" Pharmacodynamic variables were assessed at steady-state from the glucose infusion rate profiles of three 24-hour euglycaemic glucose clamps (days 6, 9 and 12) during each treatment period."	( Insulin degludec: Lower day-to-day and within-day variability in pharmacodynamic response compared with insulin glargine 300 U/mL in type 1 diabetes. Famulla, S; Haahr, HL; Heise, T; Kaplan, K; Nosek, L; Nørskov, M, 2017)	0.67
" Two euglycaemic clamp studies, 1 in subjects with type 1 diabetes (T1D) and 1 in healthy subjects, were conducted to demonstrate pharmacokinetic (PK) and pharmacodynamic (PD) similarity between MK-1293 and Lantus commercially procured in both the European Union (EU-Lantus) and the USA (US-Lantus)."	( Single-dose euglycaemic clamp studies demonstrating pharmacokinetic and pharmacodynamic similarity between MK-1293 insulin glargine and originator insulin glargine (Lantus) in subjects with type 1 diabetes and healthy subjects. Barbour, AM; Crutchlow, MF; Hompesch, M; Mahon, CD; Marcos, MC; Morrow, L; Mostoller, KM; Palcza, JS; Watkins, E; Xu, Y, 2018)	0.69
" Pharmacokinetic assessment was based on LC-MS/MS-based measurement of the major insulin glargine metabolite (M1) and PD was characterized using the euglycaemic clamp platform."	( Single-dose euglycaemic clamp studies demonstrating pharmacokinetic and pharmacodynamic similarity between MK-1293 insulin glargine and originator insulin glargine (Lantus) in subjects with type 1 diabetes and healthy subjects. Barbour, AM; Crutchlow, MF; Hompesch, M; Mahon, CD; Marcos, MC; Morrow, L; Mostoller, KM; Palcza, JS; Watkins, E; Xu, Y, 2018)	0.92
"To compare steady state pharmacodynamic and pharmacokinetic profiles of insulin glargine 300U/mL (Gla-300) with insulin degludec 100U/mL (Deg-100) in people with type 1 diabetes."	( Morning administration of 0.4U/kg/day insulin glargine 300U/mL provides less fluctuating 24-hour pharmacodynamics and more even pharmacokinetic profiles compared with insulin degludec 100U/mL in type 1 diabetes. Bailey, TS; Bolli, GB; Dahmen, R; Klein, O; Maroccia, M; Nassr, N; Pettus, J; Roussel, R; Schmider, W, 2018)	0.98
"Gla-300 provides less fluctuating steady state pharmacodynamic profiles (i."	( Morning administration of 0.4U/kg/day insulin glargine 300U/mL provides less fluctuating 24-hour pharmacodynamics and more even pharmacokinetic profiles compared with insulin degludec 100U/mL in type 1 diabetes. Bailey, TS; Bolli, GB; Dahmen, R; Klein, O; Maroccia, M; Nassr, N; Pettus, J; Roussel, R; Schmider, W, 2018)	0.75
"Despite their widespread use in this population, data on the pharmacodynamic (PD) properties of the insulin analogs detemir and glargine in severely obese patients with type 2 diabetes are lacking."	( Comparison of the dose-response pharmacodynamic profiles of detemir and glargine in severely obese patients with type 2 diabetes: A single-blind, randomised cross-over trial. Bilz, S; Falconnier, C; Flückiger, M; Keller, U; Meienberg, F; Puder, JJ, 2018)	0.48
" Surface-area-dependent redissolution is introduced to established diffusion and absorption pathways, and pharmacokinetic (PK) profiles are simulated and subsequently validated using experimental data from euglycemic glucose clamp studies."	( Insulin depot absorption modeling and pharmacokinetic simulation with insulin glargine 300 U/mL . Becker, R; Lindauer, K, 2019)	0.75
"4 U/kg, morning) showed a more stable pharmacodynamic profile (20% lower within-day variability [P = 0."	( Clinical relevance of pharmacokinetic and pharmacodynamic profiles of insulin degludec (100, 200 U/mL) and insulin glargine (100, 300 U/mL) - a review of evidence and clinical interpretation. Bolli, GB; Fanelli, CG; Owens, DR; S Bailey, T; Yale, JF, 2019)	0.73
" Comparing the pharmacokinetic time curves of serum insulin levels on two insulin immunoassays with different insulin analog cross-reactivity allowed the likely diagnosis of surreptitious glargine overdose to be made rapidly."	( A Case of Surreptitious Glargine Overdose Confirmed by Insulin Pharmacokinetic Time Curves. Barmanray, R; Chiang, CY; Yates, CJ; Yeoh, K, 2019)	0.51
"The double-blind, randomized, three-way crossover study compared the pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of MYL-1501D, US IG and EU IG."	( Pharmacokinetic and pharmacodynamic bioequivalence of proposed biosimilar MYL-1501D with US and European insulin glargine formulations in patients with type 1 diabetes mellitus. Aubonnet, P; Barve, A; Donnelly, C; Heise, T, 2020)	0.77
" In this study, we aimed to compare its pharmacodynamic (PD) and pharmacokinetic (PK) with Lantus."	( Pharmacodynamics and pharmacokinetics of a new type of recombinant insulin Lisargine injection. Jiang, L; Li, J; Lu, J; Xiong, A; Yi, X; Zeng, Y; Zhang, H; Zhou, W; Zhu, H; Zhu, L, 2020)	0.56
"For the successful approval and clinical prescription of insulin biosimilars, it is essential to show pharmacokinetic (PK) and pharmacodynamic (PD) bioequivalence to the respective reference products sourced from the European Union and the United States."	( Pharmacokinetic and pharmacodynamic bioequivalence of Gan & Lee insulin analogues aspart (rapilin®), lispro (prandilin®) and glargine (basalin®) with EU- und US-sourced reference insulins. Andersen, G; Chen, W; Gan, Z; Hao, C; He, A; Heise, T; Li, L; Lu, J; Plum-Mörschel, L; Xie, T; Zijlstra, E, 2023)	0.91

Excerpt	Reference	Relevance
"To investigate the efficacy and safety of glimepiride combined with either morning or bedtime insulin glargine or bedtime neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes."	( Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Fritsche, A; Häring, HU; Schweitzer, MA, 2003)	0.82
"The risk for nocturnal hypoglycemia was lower with glimepiride in combination with morning and bedtime insulin glargine than with glimepiride in combination with bedtime NPH insulin in patients with type 2 diabetes."	( Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Fritsche, A; Häring, HU; Schweitzer, MA, 2003)	0.81
" The aim of this observational study was to evaluate the treatment costs of insulin glargine in combination with oral antidiabetic drugs (OADs) compared with conventional insulin therapy in T2DM in everyday clinical practice."	( Insulin glargine in combination with oral antidiabetic drugs as a cost-equivalent alternative to conventional insulin therapy in type 2 diabetes mellitus. Haehling, E; Lechleitner, M; Mueller, M; Roden, M, 2005)	2
"In type 2 diabetic patients we compared 9 months of combination therapy with insulin glargine and metformin with 9 months of NPH insulin combined with metformin."	( Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Hänninen, J; Hardy, K; Hulme, S; Kauppinen-Mäkelin, R; Lahdenperä, S; Lehtonen, R; Levänen, H; McNulty, S; Nikkilä, K; Ryysy, L; Tiikkainen, M; Tulokas, T; Vähätalo, M; Virtamo, H; Yki-Järvinen, H, 2006)	2.01
"Mitiglinide is novel class of rapid-acting insulin secretagogues, which have been widely used alone or in combination with other oral hypoglycemic drugs to improve postprandial hyperglycemia in early type 2 diabetes."	( Therapeutic efficacy of mitiglinide combined with once daily insulin glargine after switching from multiple daily insulin regimen of aspart insulin and glargine in patients with type 2 diabetes mellitus. Abe, M; Hara, K; Hirose, T; Kanazawa, A; Kanazawa, Y; Kanno, R; Kawai, J; Kawamori, R; Kumashiro, N; Mita, T; Miwa, S; Motojima, K; Sakai, K; Sakurai, Y; Sato, F; Shimizu, T; Tanaka, Y; Uchino, H; Watada, H; Yamazaki, Y; Yoshihara, T, 2006)	0.58
" This study compared the efficacy and safety of insulin glargine and NPH insulin, both in combination with a once-daily fixed dose of glimepiride, in terms of glycemic control and incidence of hypoglycemia."	( Therapy in type 2 diabetes: insulin glargine vs. NPH insulin both in combination with glimepiride. Aschner, P; Calvo, C; Eliaschewitz, FG; Jimenez, J; Ramirez, LA; Ruiz, M; Valbuena, H; Villena, J, 2006)	0.88
" In this study, the effects of insulin glargine (IG) in combination with repaglinide or acarbose on glycemic parameters were investigated."	( The investigation of the efficacy of insulin glargine on glycemic control when combined with either repaglinide or acarbose in obese Type 2 diabetic patients. Duran, C; Ercan, I; Ersoy, C; Erturk, E; Guclu, M; Imamoglu, S; Kiyici, S; Selimoglu, H; Tuncel, E, 2009)	0.91
"The aim of the study was to compare the efficacy and safety of liraglutide in type 2 diabetes mellitus vs placebo and insulin glargine (A21Gly,B31Arg,B32Arg human insulin), all in combination with metformin and glimepiride."	( Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Antic, S; Lalic, N; Ravn, GM; Russell-Jones, D; Schmitz, O; Sethi, BK; Simó, R; Vaag, A; Zdravkovic, M, 2009)	0.91
"8 mg once daily (n = 232), liraglutide placebo (n = 115) and open-label insulin glargine (n = 234), all in combination with metformin (1 g twice daily) and glimepiride (4 mg once daily)."	( Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Antic, S; Lalic, N; Ravn, GM; Russell-Jones, D; Schmitz, O; Sethi, BK; Simó, R; Vaag, A; Zdravkovic, M, 2009)	0.94
"A total of 180 hospitalized patients with type 2 diabetes received either glulisine (n = 88) or regular insulin (n = 92) before each meal in combination with insulin glargine at bedtime in a randomized double-blind fashion."	( Glulisine versus human regular insulin in combination with glargine in noncritically ill hospitalized patients with type 2 diabetes: a randomized double-blind study. Boron, A; Meyer, C; Plummer, E; Vedda, R; Voltchenok, M, 2010)	0.56
"To compare the treatment effects of Novolin® 30R(a), versus Lantus(®a) combined with acarbose (Glucobay®), in elderly patients with type 2 diabetes mellitus."	( Clinical effectiveness of Novolin® 30R versus Lantus® combined with Glucobay® treatment in elderly patients with type 2 diabetes mellitus controlled by oral hypoglycaemic agents: A randomized study. Ge, J; Jiang, H; Liu, Y; Niu, X; Shao, L; Sun, Y; Zhang, H, 2014)	0.4
"2 IU/kg) combined with 50 mg acarbose."	( Clinical effectiveness of Novolin® 30R versus Lantus® combined with Glucobay® treatment in elderly patients with type 2 diabetes mellitus controlled by oral hypoglycaemic agents: A randomized study. Ge, J; Jiang, H; Liu, Y; Niu, X; Shao, L; Sun, Y; Zhang, H, 2014)	0.4
" Although there were fewer hypoglycaemic events in the Lantus® combined with Glucobay® group compared with the Novolin® 30R group, the difference was not significant."	( Clinical effectiveness of Novolin® 30R versus Lantus® combined with Glucobay® treatment in elderly patients with type 2 diabetes mellitus controlled by oral hypoglycaemic agents: A randomized study. Ge, J; Jiang, H; Liu, Y; Niu, X; Shao, L; Sun, Y; Zhang, H, 2014)	0.4
"Novolin® 30R and Lantus® combined with acarbose both had beneficial effects on blood glucose control and blood lipid levels in elderly patients with type 2 diabetes mellitus."	( Clinical effectiveness of Novolin® 30R versus Lantus® combined with Glucobay® treatment in elderly patients with type 2 diabetes mellitus controlled by oral hypoglycaemic agents: A randomized study. Ge, J; Jiang, H; Liu, Y; Niu, X; Shao, L; Sun, Y; Zhang, H, 2014)	0.4
" We aimed to compare the efficacy and safety of long-acting glucagon-like peptide-1 receptor agonist dulaglutide with that of insulin glargine, both combined with prandial insulin lispro, in patients with type 2 diabetes."	( Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study. Blonde, L; Fahrbach, JL; Gross, J; Jendle, J; Jiang, H; Milicevic, Z; Woo, V, 2015)	0.89
"Dulaglutide in combination with lispro resulted in a significantly greater improvement in glycaemic control than did glargine and represents a new treatment option for patients unable to achieve glycaemic targets with conventional insulin treatment."	( Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study. Blonde, L; Fahrbach, JL; Gross, J; Jendle, J; Jiang, H; Milicevic, Z; Woo, V, 2015)	0.69
" From October 2013 to July 2014, a total of 166 T2DM outpatients who attended the Shanghai Changhai Hospital and the Yijishan Hospital of Wannan Medical College were randomly assigned into an experimental sitagliptin/metformin combined with low caloric diet group (n = 115) and an insulin glargine combined with metformin control group (n = 51)."	( Sitagliptin/Metformin Versus Insulin Glargine Combined With Metformin in Obese Subjects With Newly Diagnosed Type 2 Diabetes. Cao, J; Ji, M; Xia, L; Zou, D, 2016)	0.9
"To evaluate the efficacy and safety of basal insulin peglispro (BIL) with those of insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (T2D)."	( Randomized double-blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 2 diabetes: IMAGINE 4. Bastyr, EJ; Blevins, T; Chang, AM; Colón Vega, G; Pieber, TR; Zhang, S, 2016)	0.89
"In this phase III, multicentre, double-blind, 26-week study, we randomized patients with T2D [glycated haemoglobin (HbA1c) ≥7 and <12%, on ≥1 insulin injections daily) to BIL (n = 691) or glargine (n = 678), in combination with lispro."	( Randomized double-blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 2 diabetes: IMAGINE 4. Bastyr, EJ; Blevins, T; Chang, AM; Colón Vega, G; Pieber, TR; Zhang, S, 2016)	0.66
"75 mg and glargine, all in combination with prandial insulin lispro."	( Continuous glucose monitoring in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonist dulaglutide in combination with prandial insulin lispro: an AWARD-4 substudy. Jendle, J; Jiang, H; Martin, S; Milicevic, Z; Testa, MA, 2016)	0.43
"In combination with prandial lispro, treatment with dulaglutide and glargine resulted in similar proportions of glucose values in the normoglycaemic range, but dulaglutide provided an improved balance between the proportion of values within the near-normoglycaemia range and values within the hypoglycaemic range."	( Continuous glucose monitoring in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonist dulaglutide in combination with prandial insulin lispro: an AWARD-4 substudy. Jendle, J; Jiang, H; Martin, S; Milicevic, Z; Testa, MA, 2016)	0.43
" Adults with type 1 diabetes (n = 455) were randomized (2:1) to bedtime BIL or GL in combination with prandial insulin lispro for 78 weeks, with a primary endpoint of 26 weeks."	( A randomized clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: IMAGINE 1. Bastyr, EJ; Dreyer, M; Garg, S; Hartman, ML; Jacober, SJ; Jinnouchi, H; Mou, J; Qu, Y; Rosilio, M, 2016)	0.67
"This study aimed to examine the switch from glargine+once daily insulin aspart (1 + 1 regimen) to glargine+insulin aspart 30 before breakfast combined with exercise and in patients with type 2 diabetes mellitus (T2DM) with poorly controlled blood glucose levels."	( Switching from glargine+insulin aspart to glargine+insulin aspart 30 before breakfast combined with exercise after dinner and dividing meals for the treatment of type 2 diabetes patients with poor glucose control - a prospective cohort study. Chen, F; Li, J; Miao, L; Wang, L; Xia, D, 2018)	0.48
"Consecutive patients with poorly controlled T2DM (n = 182) were switched from the 1 + 1 regimen to glargine+insulin aspart 30 before breakfast in combination with exercise after dinner and dividing meals in two (same final calories intake)."	( Switching from glargine+insulin aspart to glargine+insulin aspart 30 before breakfast combined with exercise after dinner and dividing meals for the treatment of type 2 diabetes patients with poor glucose control - a prospective cohort study. Chen, F; Li, J; Miao, L; Wang, L; Xia, D, 2018)	0.48
"For patients with poorly controlled T2DM under the 1 + 1 regimen, switching to glargine+insulin aspart 30 before breakfast combined with exercise after dinner and dividing meals showed promising benefits."	( Switching from glargine+insulin aspart to glargine+insulin aspart 30 before breakfast combined with exercise after dinner and dividing meals for the treatment of type 2 diabetes patients with poor glucose control - a prospective cohort study. Chen, F; Li, J; Miao, L; Wang, L; Xia, D, 2018)	0.48
" In an open-label, multicenter, randomized controlled trial, 74 patients were randomly assigned to either the IDeg (36 patients) or IGla (38 patients) group and were administered with basal-bolus therapy during hospitalization."	( Efficacy and safety of insulin degludec U100 and insulin glargine U100 in combination with meal-time bolus insulin in hospitalized patients with type 2 diabetes: an open-label, randomized controlled study. Kadonosono, K; Nagakura, J; Oba, M; Okamoto, Y; Sakamoto, R; Shigematsu, E; Shinoda, M; Suzuki, J; Takahashi, K; Takano, T; Tamura, H; Terauchi, Y; Yamakawa, T, 2019)	0.77

Excerpt	Reference	Relevance
"[GlyA21,ArgB31,ArgB32]insulin (HOE 901) represents a biosynthetic human insulin analogue that, due to its isoelectric point, precipitates at neutral tissue pH leading to a retarded absorption rate and a corresponding longer duration of action."	( Growth promoting and metabolic activity of the human insulin analogue [GlyA21,ArgB31,ArgB32]insulin (HOE 901) in muscle cells. Bähr, M; Eckel, J; Kolter, T; Seipke, G, 1997)	0.3
"In study 1, the time in hours for 25% of the administered radioactivity to disappear after bolus subcutaneous injection (T75%) for NPH insulin indicated a significantly faster absorption rate compared with the 2 insulin glargine formulations (3."	( Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites. Coates, PA; Kurzhals, R; Luzio, SD; Owens, DR; Tinbergen, JP, 2000)	0.77
" There is little or no difference in the absorption rate of insulin glargine between the main subcutaneous injection sites."	( Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites. Coates, PA; Kurzhals, R; Luzio, SD; Owens, DR; Tinbergen, JP, 2000)	0.83
"Insulin glargine (HOE 901, 21(A)-Gly-30(B)a-L-Arg-30(B)b-L-Arg human insulin) is a novel recombinant analog of human insulin with a shift in the isoelectric point producing a retarded absorption rate and an increased duration of action that closely mimics normal basal insulin secretion."	( Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group. Park, G; Rosenstock, J; Zimmerman, J, 2000)	2.23
"An intense 30-min period of exercise does not increase the absorption rate of the subcutaneously injected basal long-acting insulin analog insulin glargine in patients with type 1 diabetes."	( Effects of exercise on the absorption of insulin glargine in patients with type 1 diabetes. Backx, K; Dunseath, G; Hare, B; Luzio, SD; Miles, A; Owens, DR; Pauvaday, V; Peter, R, 2005)	0.8
"Insulin-like growth factor binding protein-1 (IGFBP-1) is known to regulate the bioavailability of insulin-like growth factor (IGF) and the levels of IGFBP-1 are increased in the morning in patients with type 1 diabetes mellitus."	( Nocturnal blood glucose and IGFBP-1 changes in type 1 diabetes: Differences in the dawn phenomenon between insulin regimens. Amemiya, S; Cho, H; Kobayashi, K; Mitsui, Y; Mochizuki, M; Nagamine, K; Nakazawa, S; Ohyama, K; Saitou, T; Yagasaki, H, 2010)	0.36
" In Study 2, absolute bioavailability of SC LY2605541 was assessed in 8 subjects by comparing dose normalized area under concentration versus time curve of SC against IV administration."	( Single-dose pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 in healthy subjects. Choi, SL; Howey, DC; Lim, ST; Mace, KF; Sinha, VP; Soon, DK; Yeo, KP, 2014)	0.4
"Manufacturers of insulin products for diabetes therapy have long sought ways to modify the absorption rate of exogenously administered insulins in an effort to better reproduce the naturally occurring pharmacokinetics of endogenous insulin secretion."	( Impact of the mode of protraction of basal insulin therapies on their pharmacokinetic and pharmacodynamic properties and resulting clinical outcomes. Heise, T; Mathieu, C, 2017)	0.46
" Approximately 6% absolute bioavailability in the bloodstream was estimated for the same formulation through in vivo pharmacokinetic studies in rats."	( Lipid nanoparticles as vehicles for oral delivery of insulin and insulin analogs: preliminary ex vivo and in vivo studies. Ahmadi, N; Bargoni, A; Battaglia, L; Biasibetti, E; Capucchio, MT; Ghè, C; Marini, E; Milla, P; Muntoni, E, 2019)	0.51
" SC Gla-300 has lower M1 bioavailability with a reduced BG-lowering effect and need for greater doses versus Gla-100."	( Equipotency of insulin glargine 300 and 100 U/mL with intravenous dosing but differential bioavailability with subcutaneous dosing in dogs. Bolli, GB; Fanelli, CG; Tennagels, N; Werner, U, 2021)	0.97
" We conducted a randomized, open-label, 2-treatment, 2-period, crossover study in healthy Chinese subjects to evaluate the relative bioavailability of LY IGlar to IGlar and pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of LY IGlar."	( A Euglycemic Glucose Clamp Study to Evaluate the Bioavailability of LY2963016 Relative to Insulin Glargine in Healthy Chinese Subjects. Chua, L; Ji, Y; Li, H; Linnebjerg, H; Liu, H; Ma, T; Tham, LS; Wang, F; Yu, Y, 2021)	0.84

Excerpt	Relevance	Reference
"This article reviews the pharmacology, pharmacokinetics, dosing guidelines, adverse effects, and potential drug interactions of insulin glargine, a new long-acting recombinant human insulin analogue."	( Insulin glargine. Baker, D; Campbell, RK; Levien, T; White, JR, 2001)	1.96
"The pharmacodynamics, pharmacokinetics, clinical efficacy, adverse effects, and dosage and administration of insulin glargine are reviewed."	( Insulin glargine: a new long-acting insulin product. Panning, CA; Reinhart, L, 2002)	1.97
"To review the pharmacology, pharmacokinetics, dosing guidelines, adverse effects, drug interactions, and clinical efficacy of insulin glargine."	( Insulin glargine: a new basal insulin. Baker, DE; Campbell, RK; Levien, TL; White, JR, 2002)	1.96
" Other drawbacks include inter- and intra-patient variability that compromises dosing reproducibility and unsuitability for single daily dosing."	( A review of basal insulins. Barnett, AH, 2003)	0.32
"To determine the effect of insulin glargine on glycemic control in pediatric type 1 and 2 diabetes, a retrospective repeated-measure analysis of variance was performed of hemoglobin A1C (HbA1C), frequency of hypoglycemia and hyperglycemia, mean blood glucose, body mass index (BMI), and daily weight-adjusted insulin dosage before and after institution of glargine therapy in 72 children and adolescents with diabetes."	( Effect of therapy with insulin glargine (lantus) on glycemic control in toddlers, children, and adolescents with diabetes. Fujishige, L; Geach, J; Hathout, EH; Ischandar, M; Mace, JW; Maruo, S, 2003)	0.93
" The once-daily flexible dosing of insulin glargine and its smooth, flat profile, associated with fewer episodes of nocturnal hypoglycemia, make it among the safest and most practical tools to date for transforming the paradigm of type 2 diabetes management."	( Basal insulin supplementation in type 2 diabetes; refining the tactics. Rosenstock, J, 2004)	0.6
"To compare hemoglobin A1c (A1C) values at baseline with those after 1 year of insulin glargine therapy and, secondarily, to compare insulin dosage and patients' body weight at baseline and at 1 year."	( The utility of insulin glargine in the treatment of diabetes mellitus. Bakst, G; Busch, RS; Hamilton, RA; Kane, MP; Stroup, J, 2004)	0.9
" The A1C values improved significantly from baseline for the evening and the split dosage groups or when all groups were combined."	( Improved glycemic control without an increase in severe hypoglycemic episodes in intensively treated patients with type 1 diabetes receiving morning, evening, or split dose insulin glargine. Chase, HP; D'Souza, A; Garg, SK; Gottlieb, PA; Hisatomi, ME; Izuora, KE; Walker, AJ, 2004)	0.52
" Insufficient data are available to conclude whether insulin glargine is different from each of the commonly used NPH dosing regimens: once daily and more than once daily."	( Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine. Beverley, C; Chilcott, J; Warren, E; Weatherley-Jones, E, 2004)	0.8
" Insulin dosage was titrated to target FBG	( Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Janka, HU; Kliebe-Frisch, C; Plewe, G; Riddle, MC; Schweitzer, MA; Yki-Järvinen, H, 2005)	0.33
" The more pronounced effect of CSII was achieved with a lower daily dosage of insulin."	( Optimization of basal insulin delivery in Type 1 diabetes: a retrospective study on the use of continuous subcutaneous insulin infusion and insulin glargine. Eliasson, B; Fahlén, M; Odén, A, 2005)	0.53
" The data of body mass index, frequency of severe hypoglycaemia, daily mean blood glucose, fasting blood glucose, haemoglobin A1c and total daily insulin dosage before and after institution of glargine therapy were collected."	( Therapy with insulin glargine (Lantus) in toddlers, children and adolescents with type 1 diabetes. Alonso, M; Alvarez, MA; Barrio, R; Colino, E; Golmayo, L; López-Capapé, M, 2005)	0.7
" All were to be given subcutaneous insulin glargine at a dosage equal to the average of insulin/day administered in the preceding days spent receiving AN."	( Use of insulin glargine in patients with hyperglycaemia receiving artificial nutrition. Del Tosto, S; Fatati, G; Mattei, R; Mirri, E; Palazzi, M; Puxeddu, A; Vendetti, AL, 2005)	1.06
" Treatment and dosing decisions were made at the physician's discretion, reflecting everyday practice."	( Insulin glargine in combination with oral antidiabetic drugs as a cost-equivalent alternative to conventional insulin therapy in type 2 diabetes mellitus. Haehling, E; Lechleitner, M; Mueller, M; Roden, M, 2005)	1.77
"Using a hemoglobin A1c (A1c) value of 7% as a treatment goal based on evidence from interventional studies and a fasting plasma glucose level of 100 mg/dL as a target for titration of dosage of basal insulin, the Treat-to-Target Trial tested two hypotheses."	( The Treat-to-Target Trial and related studies. Riddle, MC, )	0.13
" Future trials should include hypoglycemia and weight gain as specific, objectively measured endpoints to assess their importance as adverse effects of titrating insulin dosage to target."	( The Treat-to-Target Trial and related studies. Riddle, MC, )	0.13
" The goals of this study were to evaluate short term result of treatment with insulin glargine compared to NPH and to determine the initial dosage of insulin glargine in Thai adolescents with type 1 diabetes."	( Preliminary data of insulin glargine use among Thai adolescents and young adults with type 1 diabetes mellitus treated at Siriraj Hospital. Kiattisakthavee, P; Likitmaskul, S; Santiprabhob, J; Sawathiparnich, P, 2005)	0.88
" We recommend the starting total daily insulin dosage to be decreased to 70-80% of previous dosage."	( Preliminary data of insulin glargine use among Thai adolescents and young adults with type 1 diabetes mellitus treated at Siriraj Hospital. Kiattisakthavee, P; Likitmaskul, S; Santiprabhob, J; Sawathiparnich, P, 2005)	0.65
" Mean daily insulin dosage was 12."	( Effectiveness and safety of insulin glargine in the therapy of complicated or secondary diabetes: clinical audit. Bacchelli, M; Carapezzi, C; Ciardullo, AV; Daghio, MM, 2006)	0.63
" All were to be given subcutaneous insulin glargine at a dosage equal to the average of insulin/day administered in the preceding days spent receiving PN."	( Insulin glargine in patients with severe hepato-gastroenterology diseases and hyperglycemia receiving parenteral nutrition. Coaccioli, S; Fatati, G; Mattei, R; Mirri, E; Palazzi, M; Parillo, M; Pierotti, F; Puxeddu, A; Vendetti, AL; Weber, P, )	1.85
" Prandial insulin aspart was added to the subcutaneous regimen when patients began oral intake, and the dosage was left to clinical judgment."	( Conversion of intravenous insulin infusions to subcutaneously administered insulin glargine in patients with hyperglycemia. Brandt, S; DeSantis, AJ; Molitch, ME; O'Shea-Mahler, E; Peterson, S; Rhee, C; Schmeltz, LR; Schmidt, K, )	0.36
" Insulin dosage in each group was titrated to target fasting blood glucose (FBG) of 100 mg/dL or less (	( Combination of oral antidiabetic agents with basal insulin versus premixed insulin alone in randomized elderly patients with type 2 diabetes mellitus. Busch, K; Janka, HU; Plewe, G, 2007)	0.34
"8 dosing units (DU) (1 DU corresponds to 6 nmol NN344) per kilogram of body weight."	( Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes. Damholt, B; Endahl, L; Heise, T; Klein, O; Lynge, J; Nosek, L, 2007)	0.55
" The aim was to assess prescription patterns and dosing for insulin glargine (market launch: 6/2000) in primary care patients."	( Prescription of insulin glargine in primary care practices in Germany. Giani, G; Haastert, B; Huppertz, E; Kostev, K; Rathmann, W; Riebel, P; Schroeder-Bernhardi, D, 2007)	0.93
" Attention was paid to dosing schedules and 24-h glycaemic profiles."	( Refining basal insulin therapy: what have we learned in the age of analogues? Devries, JH; Nattrass, M; Pieber, TR, 2007)	0.34
" Morning administration tends to require higher dosing than evening administration."	( Refining basal insulin therapy: what have we learned in the age of analogues? Devries, JH; Nattrass, M; Pieber, TR, 2007)	0.34
" Adequate insulin dosing is crucial to the achievement of good glycemic control with minimal hypoglycemia, and dose titration immediately following insulin initiation is needed to ensure its success."	( Dosing of insulin glargine in the treatment of type 2 diabetes. Barnett, A, 2007)	0.74
"Insulin glargine (Lantus, Aventis Pharmaceuticals, Bridgewater, NJ) is a long-acting once-daily dosed form of insulin intended to maintain a constant baseline insulin level."	( Lantus overdose: case presentation and management options. Fuller, ET; Janke, C; Kaylor, DW; Miller, MA, 2009)	1.8
" The mean therapeutic dosage of insulin glargine in group A was 14."	( Therapeutic options for elderly diabetic subjects: open label, randomized clinical trial of insulin glargine added to oral antidiabetic drugs versus increased dosage of oral antidiabetic drugs. Alagona, C; Chiavetta, A; Fedele, V; Leotta, C; Lorenti, I; Luca, S; Papa, G; Pezzino, V; Piro, S; Purrello, F; Rabuazzo, AM; Spadaro, L, 2008)	0.85
" With detemir, 45% of participants completed the study on once daily dosing and 55% on twice daily dosing, with no difference in HbA(1c)."	( A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Davies, M; Home, PD; Koenen, C; Larsen, J; Rosenstock, J; Schernthaner, G, 2008)	0.58
" This study in healthy cats demonstrates that glargine has a long duration of action with carry-over effects to the next day likely, regardless of dosing regimen."	( Insulin glargine has a long duration of effect following administration either once daily or twice daily in divided doses in healthy cats. Marshall, RD; Morton, JM; Rand, JS, 2008)	1.79
" Thresholds for dosing accuracy were calculated according to the 2000 International Organization for Standardization (ISO) recommendations (Guideline 11608-1)."	( Dosing accuracy with a novel pen device (SoloSTAR) as performed by patients with diabetes in a clinical setting. Haak, T; Hermanns, N; Kulzer, B, 2008)	0.35
"The SoloSTAR pen allows people with diabetes to achieve a dosing accuracy with glargine and glulisine similar to that achieved in laboratory conditions."	( Dosing accuracy with a novel pen device (SoloSTAR) as performed by patients with diabetes in a clinical setting. Haak, T; Hermanns, N; Kulzer, B, 2008)	0.35
" This study compared the dosing accuracy of two commonly available insulin pens, the SoloSTAR (sanofi-aventis Deutschland GmbH, Frankfurt, Germany) and FlexPen (Novo Nordisk A/S, Bagsvaerd, Denmark) devices."	( Dose accuracy comparison between SoloSTAR and FlexPen at three different dose levels. Horvat, K; Penfornis, A, 2008)	0.35
"4 U/kg of detemir and glargine was injected subcutaneously 24 h apart at each of two dosing visits."	( Insulin detemir is characterized by a more reproducible pharmacokinetic profile than insulin glargine in children and adolescents with type 1 diabetes: results from a randomized, double-blind, controlled trial. Danne, T; Datz, N; Endahl, L; Fjording, MS; Haahr, H; Kordonouri, O; Nestoris, C; Westergaard, L, 2008)	0.57
" We propose a method and a number of indicators to measure patients' conformance to these insulin dosing guidelines."	( A novel method for measuring patients' adherence to insulin dosing guidelines: introducing indicators of adherence. Bar-Hen, A; Cahané, M; Choleau, C; Reach, G; Toussi, M; Venot, A, 2008)	0.35
"Once-daily dosing with insulin detemir and insulin glargine were compared in a double-blind, randomised, crossover study in type 2 diabetes subjects previously treated with other antihyperglycaemic medications."	( Once-daily insulin detemir is comparable to once-daily insulin glargine in providing glycaemic control over 24 h in patients with type 2 diabetes: a double-blind, randomized, crossover study. King, AB, 2009)	0.86
"Total insulin dosage on the last treatment day was approximately 40."	( Glycemic exposure is affected favorably by inhaled human insulin (Exubera) as compared with subcutaneous insulin glargine (Lantus) in patients with type 2 diabetes. Davies, S; Heinemann, L; Hompesch, M; Kollmeier, A; Mitnick, M; Rave, K; Strack, T, 2009)	0.57
" We found no dose-response relationship between end-of-study insulin dose and hypoglycaemia or weight gain."	( Contact frequency determines outcome of basal insulin initiation trials in type 2 diabetes. DeVries, JH; Swinnen, SGHA, 2009)	0.35
" These results potentially support once-daily dosing of ILPS in T2DM."	( Pharmacokinetics and pharmacodynamics of insulin lispro protamine suspension compared with insulin glargine and insulin detemir in type 2 diabetes. Campaigne, BN; Hompesch, M; Jacober, SJ; Kollmeier, AP; Morrow, LA; Ocheltree, SM; Wondmagegnehu, ET, 2009)	0.57
" Efficacy was likely reduced because of the upper limit of insulin glargine dosage imposed by some providers as a safety consideration."	( Cleveland Clinic cardiovascular intensive care unit insulin conversion protocol. Hoogwerf, B; Lober, C; Olansky, L; Sam, S; Yared, JP, 2009)	0.6
" Prefilled insulin pens are preferred by healthcare providers and patients because of ease-of-use, dosage flexibility, disposability, and widespread availability."	( The broken pen penalty. Ayyappan, S; Jain, A; Konezny, M; Lakshmanadoss, U; Rajamani, K, 2010)	0.36
" Further, the mean dosage to achieve this glucose goal was the same with both insulins."	( No higher dose requirements with insulin detemir than glargine in type 2 diabetes: a crossover, double-blind, and randomized study using continuous glucose monitoring. King, AB, 2010)	0.36
" Previous studies have demonstrated noninferiority of insulin detemir, dosed once or twice daily, and insulin glargine, dosed once daily."	( An analysis of dosing equivalence of insulin detemir and insulin glargine: more evidence? True, MW, 2010)	0.82
"To determine the pharmacokinetic and pharmacodynamic dose-response effects of insulin glargine administered subcutaneously in individuals with type 2 diabetes."	( Dose-response effects of insulin glargine in type 2 diabetes. Briscoe, VJ; Davis, SN; Gogitidze Joy, N; Hedrington, MS; Nicholson, W; Richardson, MA; Tate, DB; Wang, Z; Younk, L, 2010)	0.89
" After reduction of the metformin dosage (500 mg twice daily) and discontinuance of exenatide as well as a reduction of his physical activity (because of joint pain) for six months, the glucose control worsened."	( [Sequential treatment with insulin glargine and metformin, and exenatide in a patient with newly diagnosed type-2 diabetes]. Kress, S, 2010)	0.66
" The key information for the synthesis of the control algorithm is the subject insulin sensitivity that is calculated for two cases: (a) when the subject's glycemia and insulin dosing information is known (sensitivity response) and (b) when there is no previous information about the subject's response to the insulin protocol."	( An advisory protocol for rapid- and slow-acting insulin therapy based on a run-to-run methodology. Campos-Cornejo, F; Campos-Delgado, DU; Dassau, E; Doyle, FJ; Espinoza-Trejo, D; Jovanovic, L; Zisser, H, 2010)	0.36
" Our study results suggest that premixed therapy, dosed 2 times per day (LM75/25) or 3 times per day (LM50/50), was noninferior to BBT (4 injections/d) in this population of adult patients with type 2 DM previously uncontrolled with OADs plus basal insulin or twice-daily premixed insulin."	( Randomized, open-label, parallel-group evaluations of basal-bolus therapy versus insulin lispro premixed therapy in patients with type 2 diabetes mellitus failing to achieve control with starter insulin treatment and continuing oral antihyperglycemic drug Anderson, PW; Arakaki, R; Fahrbach, JL; Jiang, H; Miser, WF; Scism-Bacon, J, 2010)	0.36
" Furthermore, intensive glycemic control was achieved with insulin detemir in insulin dependent diabetic dogs, using a lower dosage than NPH insulin and insulin glargine therapeutic doses."	( Time-action profiles of insulin detemir in normal and diabetic dogs. Arai, T; Ishioka, K; Kurishima, M; Lee, P; Makino, Y; Miki, Y; Mimura, K; Mizutani, H; Mori, A; Nozawa, S; Oda, H; Saeki, K; Sako, T, 2011)	0.57
"Since their introduction, insulin analogues are the preferred choice for short-acting insulin due to their superior pharmacologic profiles, leading to greater flexibility and convenience of dosing and, thus, greater patient satisfaction and improved quality of life."	( Insulin analogues in the management of the pregnancy complicated by diabetes mellitus. Durnwald, CP; Landon, MB, 2011)	0.37
"A pooled analysis of randomized controlled trials of individuals with type 2 diabetes mellitus (T2DM) was conducted to compare dosing and impact of two basal insulin analogs, insulin glargine (glargine) and insulin detemir (detemir), on weight and hemoglobin A1c (A1c)."	( Relationship of insulin dose, A1c lowering, and weight in type 2 diabetes: comparing insulin glargine and insulin detemir. Admane, K; Dailey, G; Mercier, F; Owens, D, 2010)	0.78
" Average increases in insulin dosage with exenatide and placebo were 13 U/d and 20 U/d."	( Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Bergenstal, RM; Buse, JB; Glass, LC; Heilmann, CR; Hoogwerf, BJ; Kwan, AY; Lewis, MS; Rosenstock, J, 2011)	0.37
"Insulin degludec provides comparable glycaemic control to insulin glargine without additional adverse events and might reduce dosing frequency due to its ultra-long action profile."	( Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial. Endahl, LA; Fulcher, G; Johansen, T; Lewin, A; Lindh, R; Mathieu, C; Pinget, M; Rao, PV; Rosenstock, J; Thomas, N; Zinman, B, 2011)	0.83
" Insulin glargine was dosed once-daily in the evening."	( Insulin detemir versus insulin glargine for type 2 diabetes mellitus. Devries, JH; Hoekstra, JB; Holleman, F; Simon, AC; Swinnen, SG, 2011)	1.59
" Dose-response relationships could not be identified."	( Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study. Coebergh, JW; Geelhoed-Duijvestijn, PH; Haak, HR; Herings, RM; Ruiter, R; Straus, SM; Stricker, BH; van Herk-Sukel, MP; Visser, LE, 2012)	0.67
" Further studies are necessary to test glargine at higher dosage and for a longer follow-up period."	( Slow-release insulin in cystic fibrosis patients with glucose intolerance: a randomized clinical trial. Bagnasco, F; Bertasi, S; Casciaro, R; Cialdella, P; De Alessandri, A; Haupt, M; Haupt, R; Lorini, R; Lucidi, V; Minicucci, L; Notarnicola, S; Raia, V, 2012)	0.38
"Development of protected graft copolymer (PGC) excipients that bind native human insulin non-covalently and testing blood glucose control obtained with these formulations in streptozotocin-induced diabetic Sprague Dawley rats compared to equally dosed insulin glargine."	( Protected graft copolymer (PGC) basal formulation of insulin as potentially safer alternative to Lantus® (insulin-glargine): a streptozotocin-induced, diabetic Sprague Dawley rats study. Banerjee, A; Bogdanov, A; Bolotin, EM; Castillo, GM; Lai, M; Lyubimov, AV; Nishimoto-Ashfield, A; Reichstetter, S, 2012)	0.56
" Insulin glargine was replaced with the same dosage of NPH insulin."	( Insulin glargine or neutral protamine Hagedorn in patients with severe insulin resistance: Is there a benefit? Bota, VM; Hirsch, IB, )	2.48
" An expected reduction in dosing frequency, as well as in the basal insulin dose was reported for glargine vs."	( Outcomes with insulin glargine in patients with type 2 diabetes previously on NPH insulin: evidence from clinical practice in Spain. Delgado, E, 2012)	0.74
"To evaluate the mathematical relationships between dosing factors in type 1 diabetic patients using multiple daily injections."	( How much do I give? Dose estimation formulas for once-nightly insulin glargine and premeal insulin lispro in type 1 diabetes mellitus. Clark, D; King, AB; Wolfe, GS, )	0.37
" For determining dosing formulas, the slope of the linear regression line comparing the variables of weight, total daily dose (TDD), total basal dose (TBD), insulin-to-carbohydrate ratio (ICR), and correction factor (CF) was determined."	( How much do I give? Dose estimation formulas for once-nightly insulin glargine and premeal insulin lispro in type 1 diabetes mellitus. Clark, D; King, AB; Wolfe, GS, )	0.37
"Our results suggest that appropriate starting dosage and subsequent dose adjustment are essential to achieve target HbA1c (<7%) and that the FPG level should be decreased to be 110 mg/dL or below for this achievement."	( Dosing of insulin glargine to achieve the treatment target in Japanese type 2 diabetes on a basal supported oral therapy regimen in real life: ALOHA study subanalysis. Kadowaki, T; Odawara, M; Ohtani, T, 2012)	0.78
" Targeting insulin titration to this glucose level may result in excessive basal insulin dosing for the non-dawn phenomenon periods of the day."	( Contribution of the dawn phenomenon to the fasting and postbreakfast hyperglycemia in type 1 diabetes treated with once-nightly insulin glargine. Clark, D; King, AB; Wolfe, GS, )	0.34
"Reduction of initial glargine/glulisine insulin weight-based dosing in hospitalized patients with diabetes and renal insufficiency reduced the frequency of hypoglycemia by 50% without compromising the control of hyperglycemia."	( A randomized trial of two weight-based doses of insulin glargine and glulisine in hospitalized subjects with type 2 diabetes and renal insufficiency. Baldwin, D; DeLange-Hudec, S; Emanuele, MA; Glossop, V; Lee, H; Molitch, M; Munoz, C; Raghu, P; Smallwood, K; Zander, J, 2012)	0.63
" However, high dosage of NPH insulin often occurs nocturnal hypoglycemia."	( Efficacy of long-acting insulin analog insulin glargine at high dosage for basal-bolus insulin therapy in patients with type 2 diabetes. Fukagawa, M; Kimura, M; Kondo, M; Kuriyama, Y; Miyatake, H; Miyauchi, M; Sato, H; Suzuki, D; Tanaka, E; Toyoda, M; Umezono, T; Yamamoto, N, 2012)	0.65
" After the switching, the basal insulin was increased with reference to the self-monitoring of blood glucose results, with the aim of maintaining fasting blood sugar (FBS) level at 110 mg/dL, and simultaneously reducing the bolus insulin dosage to maintain the total daily insulin dosage."	( Efficacy of long-acting insulin analog insulin glargine at high dosage for basal-bolus insulin therapy in patients with type 2 diabetes. Fukagawa, M; Kimura, M; Kondo, M; Kuriyama, Y; Miyatake, H; Miyauchi, M; Sato, H; Suzuki, D; Tanaka, E; Toyoda, M; Umezono, T; Yamamoto, N, 2012)	0.65
" While insulin Glu is usually injected just before meals, postprandial injection may help to avoid unexpected postprandial hypoglycemia or hyperglycemia by adjusting the insulin dosage according to food intake."	( Comparison of daily glucose excursion by continuous glucose monitoring between type 2 diabetic patients receiving preprandial insulin aspart or postprandial insulin glulisine. Arai, K; Asai, S; Fukuda, H; Katabami, T; Kato, H; Nagai, Y; Nishine, A; Ohta, A; Sada, Y; Tanaka, Y, 2013)	0.39
"To investigate concentration of plasma insulin glargine after its subcutaneous dosing compared with concentration of its metabolites 1 (M1) and 2 (M2) in subjects with type 2 diabetes."	( Metabolism of insulin glargine after repeated daily subcutaneous injections in subjects with type 2 diabetes. Andreoli, AM; Bolli, GB; Candeloro, P; Cioli, P; Fanelli, CG; Hahn, A; Lucidi, P; Porcellati, F; Rossetti, P; Schmidt, R, 2012)	1.01
" Subjects were then randomized to three evening insulin glargine dosing strategies: (a) take 80% of usual dose, (b) call physician for dose, or (c) refer to dosing table, based on self-reported usual FBG and insulin regimen."	( Insulin glargine dosing before next-day surgery: comparing three strategies. Arndt-Mutz, M; Balasubramaniam, M; Dukatz, T; Henry, M; Jahn, R; Miller, V; Ramsdell, C; Rogers, K; Rosenblatt, SI; Sakharova, A, 2012)	2.08
" In the insulin glargine plus bolus group, fewer subjects following the dosing table had FBG > 249 mg/dL (> 13."	( Insulin glargine dosing before next-day surgery: comparing three strategies. Arndt-Mutz, M; Balasubramaniam, M; Dukatz, T; Henry, M; Jahn, R; Miller, V; Ramsdell, C; Rogers, K; Rosenblatt, SI; Sakharova, A, 2012)	2.26
"To compare the efficacy and safety of dosing insulin glargine by weight versus percentage of TDI in cardiac surgery patients transitioning from continuous insulin infusion to subcutaneous insulin."	( Converting continuous insulin infusion to subcutaneous insulin glargine after cardiac surgery using percentage-based versus weight-based dosing: a pilot trial. Hite, MS; Kirshner, R; Silinskie, KM, 2013)	0.9
"In this small cohort, dosing insulin glargine by weight proved to be safe, but larger scale studies are needed before adopting weight-based dosing in this patient population."	( Converting continuous insulin infusion to subcutaneous insulin glargine after cardiac surgery using percentage-based versus weight-based dosing: a pilot trial. Hite, MS; Kirshner, R; Silinskie, KM, 2013)	0.93
" Participants were randomized to 1) once-daily (OD) IDeg in a prespecified dosing schedule, creating 8-40-h intervals between injections (IDeg OD Flex; n = 229); 2) once-daily IDeg at the main evening meal (IDeg OD; n = 228); or 3) once-daily insulin glargine at the same time each day (IGlar OD; n = 230)."	( The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in individ Atkin, SL; Bain, S; Begtrup, K; Birkeland, KI; Blonde, L; Gough, SC; Johansen, T; Meneghini, L; Raz, I; Shestakova, M, 2013)	0.79
"The use of extreme dosing intervals of 8-40 h demonstrates that the daily injection time of IDeg can be varied without compromising glycemic control or safety."	( The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in individ Atkin, SL; Bain, S; Begtrup, K; Birkeland, KI; Blonde, L; Gough, SC; Johansen, T; Meneghini, L; Raz, I; Shestakova, M, 2013)	0.6
"0% are attained with glargine dosage ≤0."	( Clinical predictors of risk of hypoglycaemia during addition and titration of insulin glargine for type 2 diabetes mellitus. Gill, J; Karl, DM; Riddle, MC; Zhou, R, 2013)	0.62
" IDegAsp was given before the largest meal at the discretion of each subject (and maintained throughout the trial); IGlar was dosed according to label."	( Superior glycaemic control with once-daily insulin degludec/insulin aspart versus insulin glargine in Japanese adults with type 2 diabetes inadequately controlled with oral drugs: a randomized, controlled phase 3 trial. Endahl, L; Nakamura, S; Onishi, Y; Ono, Y; Rabøl, R, 2013)	0.62
"8 kg/m(2), and daily glargine dosage of 44 units."	( Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1). Aronson, R; Forst, T; Ping, L; Riddle, MC; Rosenstock, J; Sauque-Reyna, L; Silvestre, L; Souhami, E, 2013)	0.6
" Insulin dosage or duration of use and tumor stage did not change the results."	( Risk of breast cancer by individual insulin use: an international multicenter study. Abenhaim, L; Alpérovitch, A; Barnett, AH; Bénichou, J; Boivin, JF; Cameron, D; Charbonnel, B; Grimaldi-Bensouda, L; Khachatryan, A; Marty, M; Mignot, L; Penault-Llorca, F; Pollak, M; Riddle, M; Rossignol, M, 2014)	0.4
" The importance of patient education in overcoming barriers to insulin is discussed, as well as the choice of available basal insulins and the necessity to optimize basal insulin dosage by self-titration."	( Initiating basal insulin therapy in type 2 diabetes: practical steps to optimize glycemic control. Philis-Tsimikas, A, 2013)	0.39
"Using the weighing procedure recommended by DIN EN ISO 11608-1:2000, dose accuracy was evaluated based on nonrandomized delivery of low (5 U), mid (30 U), and high (60 U) dosage levels."	( Dose accuracy and injection force of different insulin glargine pens. Abdel-Tawab, M; Adler, S; Bohnet, J; Friedrichs, A; Korger, V; Schubert-Zsilavecz, M, 2013)	0.65
"All tested pens delivered comparable average doses within the DIN EN ISO 11608-1:2000 limits at all dosage levels."	( Dose accuracy and injection force of different insulin glargine pens. Abdel-Tawab, M; Adler, S; Bohnet, J; Friedrichs, A; Korger, V; Schubert-Zsilavecz, M, 2013)	0.65
"All pens fulfilled the dose accuracy requirements defined by DIN EN ISO 11608-1:2000 standards at all three dosage levels, with the WR, WD, and GL showing higher dosage variability and injection force compared with the SS and CS."	( Dose accuracy and injection force of different insulin glargine pens. Abdel-Tawab, M; Adler, S; Bohnet, J; Friedrichs, A; Korger, V; Schubert-Zsilavecz, M, 2013)	0.65
"To review the available evidence regarding dosing conversion between glargine and detemir in an effort to assist clinicians in performing dosing conversion."	( Comparing dosing of basal insulin analogues detemir and glargine: is it really unit-per-unit and dose-per-dose? McFarland, MS; Wallace, JL; Wallace, JP, 2014)	0.4
"All English-language clinical trials were reviewed for inclusion of dosing and/or pharmacokinetic data."	( Comparing dosing of basal insulin analogues detemir and glargine: is it really unit-per-unit and dose-per-dose? McFarland, MS; Wallace, JL; Wallace, JP, 2014)	0.4
"A total of 7 large (n ≥ 258) randomized controlled trials (RCTs) comparing glargine and detemir in patients with type 1 and 2 diabetes had dosing equivalency data available."	( Comparing dosing of basal insulin analogues detemir and glargine: is it really unit-per-unit and dose-per-dose? McFarland, MS; Wallace, JL; Wallace, JP, 2014)	0.4
"4 U/kg IDeg or insulin glargine (IGlar), respectively, on two separate dosing visits, with pharmacokinetic blood sampling up to 72-h postdose."	( Insulin degludec's ultra-long pharmacokinetic properties observed in adults are retained in children and adolescents with type 1 diabetes. Aschemeier, B; Biester, T; Blaesig, S; Danne, T; Granhall, C; Haahr, H; Kordonouri, O; Kristensen, NR; Remus, K; Søndergaard, F, 2014)	0.76
"The inferior glycaemic control and increased risk of hypoglycaemia with IDeg 3TW compared with IGlar OD do not support a three-times-weekly dosing regimen."	( Efficacy and safety of insulin degludec three times a week versus insulin glargine once a day in insulin-naive patients with type 2 diabetes: results of two phase 3, 26 week, randomised, open-label, treat-to-target, non-inferiority trials. Bode, B; DeVries, JH; Johansen, T; Leiter, LA; Moses, A; Ratner, R; Russell-Jones, D; Zinman, B, 2013)	0.63
"Because insulin dosing requires optimization of glycemic control, it is important to use a single metric of benefit and risk to determine best insulin dosing practices."	( A clinical utility index for selecting an optimal insulin dosing algorithm for LY2605541 in patients with type 2 diabetes pretreated with basal insulin. Berry, S; Gaydos, BL; Jacober, SJ; Luo, J; Manner, DH; Qu, Y, 2014)	0.4
"A CUI was developed to transform the multidimensional problem of assessing benefit/risk of multiple dosing algorithms into a single decision-making metric to evaluate two LY2605541 dosing algorithms relative to the insulin glargine (GL) dosing algorithm."	( A clinical utility index for selecting an optimal insulin dosing algorithm for LY2605541 in patients with type 2 diabetes pretreated with basal insulin. Berry, S; Gaydos, BL; Jacober, SJ; Luo, J; Manner, DH; Qu, Y, 2014)	0.59
"CUI methodology, and in particular this CUI, is a useful tool for comparing dosing algorithms."	( A clinical utility index for selecting an optimal insulin dosing algorithm for LY2605541 in patients with type 2 diabetes pretreated with basal insulin. Berry, S; Gaydos, BL; Jacober, SJ; Luo, J; Manner, DH; Qu, Y, 2014)	0.4
" After proper education, patients titrated the insulin dosage under self-monitoring with the help of their attending physicians."	( [Evaluation of the DIABOBHU Observational Study]. Bakó, B; Gaál, Z; Papp, Z, 2014)	0.4
"1 mU/min) in three dosing periods and insulin glargine (20 or 30 mU/m(2)/min) in a fourth period, targeted to achieve 50-100% suppression of EGP."	( Basal insulin peglispro demonstrates preferential hepatic versus peripheral action relative to insulin glargine in healthy subjects. Armstrong, DA; Bose, N; Burke, P; Choi, SL; Ciaraldi, TP; Garhyan, P; Henry, RR; Jacober, SJ; Knadler, MP; Lam, EC; Linnebjerg, H; Mudaliar, S; Pettus, J; Porksen, N; Prince, MJ; Sinha, VP, 2014)	0.89
" The insulin dosing algorithm was not sufficient to equalize nocturnal hypoglycaemia between the two insulins."	( Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-naïve people with type 2 diabetes. Bolli, GB; Candelas, C; Dain, MP; Deerochanawong, C; Home, PD; Landgraf, W; Mathieu, C; Pilorget, V; Riddle, MC, 2015)	0.64
"Optimal dosing of basal insulin is needed to achieve target fasting blood glucose and to avoid hypoglycaemia on the other hand in patients of type 2 diabetes on bedtime basal insulin and daytime sulfonylureas."	( Study of optimal basal insulin glargine dose requirement in Indian population as an add on therapy to oral hypoglycaemic agents to achieve target fasting blood glucose levels. Agarwal, SK; Singh, BK; Wadhwa, R, 2013)	0.7
"The strategies that aim at preventing diabetic retinopathy by treating T2DM patients with long-acting insulin analogues remain further prospective studies with longer follow-up period to validate our observations within an appropriate dosage range and to further evaluate the safety of long-acting insulin analogues on reducing the progression of diabetic retinopathy."	( Long-acting insulin analogues and diabetic retinopathy: a retrospective cohort study. Lai, MS; Lin, JC; Shau, WY, 2014)	0.4
" Significant differences were observed between the basal insulin groups for glycated hemoglobin level and dosing frequency."	( Use of basal insulin and the associated clinical outcomes among elderly nursing home residents with type 2 diabetes mellitus: a retrospective chart review study. Davis, KL; Kilpatrick, BS; Meyers, JL; Pandya, N; Wei, W, 2014)	0.4
" Differences in glycated hemoglobin and dosing frequencies between types of basal insulin warrant further comparative effectiveness studies."	( Use of basal insulin and the associated clinical outcomes among elderly nursing home residents with type 2 diabetes mellitus: a retrospective chart review study. Davis, KL; Kilpatrick, BS; Meyers, JL; Pandya, N; Wei, W, 2014)	0.4
"This may enable for a more flexible daytime dosing versus up to now available basal insulins."	( [Daytime flexible application of Insulin degludec in patients with type 1 diabetes or type 2 diabetes]. Jaeckel, E; Lüdemann, J; Milek, K; Segner, A; Wilhelm, B, 2014)	0.4
" Both phase 3 studies compared a daytime flexible dosing of IDeg (IDeg-flex) with IDeg at the evening meal (IDeg-evening) and IDler at a fixed daytime."	( [Daytime flexible application of Insulin degludec in patients with type 1 diabetes or type 2 diabetes]. Jaeckel, E; Lüdemann, J; Milek, K; Segner, A; Wilhelm, B, 2014)	0.4
" Data regarding blood glucose control, insulin dosage adjustment and recording of hypoglycemia episodes were obtained through telephone calls; office visits were conducted to measure weight, glycated hemoglobin, fasting plasma glucose and blood glucose profile."	( Replacing Insulin Glargine with Neutral Protamine Hagedorn (NPH) Insulin in a Subpopulation of Study Subjects in the Action to Control Cardiovascular Risk in Diabetes (ACCORD): Effects on Blood Glucose Levels, Hypoglycemia and Patient Satisfaction. Berard, L; Cameron, B; Stewart, J; Woo, V, 2015)	0.82
"The limitations of current basal insulin preparations include concerns related to their pharmacokinetic and pharmacodynamic properties, hypoglycaemia, weight gain, and perception of management complexity, including rigid dosing schedules."	( Clinical use of insulin degludec. Cariou, B; Evans, M; Gross, JL; Harris, S; Landstedt-Hallin, L; Meneghini, L; Mithal, A; Rodriguez, MR; Vora, J, 2015)	0.42
" The evenly distributed glucose-lowering effect of IDeg was confirmed by the AUCGIR across one dosing interval, as each of the four 6-h intervals across one dosing interval contributed ∼ 25% of the AUCGIR,τ,SS."	( Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine. Bøttcher, SG; Haahr, H; Heise, T; Hermanski, L; Hövelmann, U; Nosek, L, 2015)	0.64
" Exposure and glucose-lowering effects are more stable and evenly distributed across one dosing interval for IDeg versus IGlar (Clinical trials."	( Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine. Bøttcher, SG; Haahr, H; Heise, T; Hermanski, L; Hövelmann, U; Nosek, L, 2015)	0.64
" The biggest disadvantage of this product is the slightly higher insulin dosage that is required to improve and/or maintain patients' HbA1c."	( The role of Toujeo®, insulin glargine U-300, in the treatment of diabetes mellitus. Brown, MA; Davis, CS; Fleming, JW; Fleming, LW, 2016)	0.75
" IDegAsp once daily was administered with the main evening meal or the largest meal of the day (agreed at baseline); dosing time was maintained throughout the trial."	( Efficacy and safety of once-daily insulin degludec/insulin aspart compared with once-daily insulin glargine in participants with Type 2 diabetes: a randomized, treat-to-target study. Bode, B; Demirağ, NG; Endahl, L; Jang, HC; Kumar, S; Skjøth, TV, 2017)	0.68
" Single dosing of the long-acting insulin analogue glargine was able to dose-dependently reduce blood glucose over 4 h towards normoglycemia in STZ-treated rats."	( Short- and Longterm Glycemic Control of Streptozotocin-Induced Diabetic Rats Using Different Insulin Preparations. Bedenik, J; Grempler, R; Luippold, G; Voigt, A, 2016)	0.43
" Reasons for TA-overruling dosing decisions were hypoglycemic events (14 mild/4 moderate) in 9 patients."	( Real-World Data Collection Regarding Titration Algorithms for Insulin Glargine in Patients With Type 2 Diabetes Mellitus. Flacke, F; Funke, K; Pfützner, A; Pohlmeier, H; Rose, L; Sieber, J; Stratmann, B; Tschoepe, D, 2016)	0.67
" An electronic diary facilitated data capture and insulin dosing calculations for intensive insulin management."	( A randomized clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: IMAGINE 1. Bastyr, EJ; Dreyer, M; Garg, S; Hartman, ML; Jacober, SJ; Jinnouchi, H; Mou, J; Qu, Y; Rosilio, M, 2016)	0.67
" Compared to Gla-100, Gla-300 achieves lower and delayed peak concentrations with a PK exposure that is more stable and evenly distributed across a 24-h dosing interval."	( Pharmacokinetics and pharmacodynamics of insulin glargine 300 U/mL in the treatment of diabetes and their clinical relevance. Owens, DR, 2016)	0.7
" The aim of this study was to compare the impacts of two modes of insulin administration (single injections of long-acting insulin or pump delivery of rapid-acting insulin) at the same dosage (4 IU/200 g/day) on rat metabolism and tissues."	( Impact of the Type of Continuous Insulin Administration on Metabolism in a Diabetic Rat Model. Bietiger, W; Dal, S; Jeandidier, N; Langlois, A; Maillard, E; Mura, C; Peronet, C; Pinget, M; Schaschkow, A; Seyfritz, E; Sigrist, S; Sookhareea, C, 2016)	0.43
" Indeed, NPH insulin remains widely used today despite a frequent need for a twice-daily dosing and a relatively high incidence of hypoglycaemia."	( Impact of the mode of protraction of basal insulin therapies on their pharmacokinetic and pharmacodynamic properties and resulting clinical outcomes. Heise, T; Mathieu, C, 2017)	0.46
" Gla-300 is available in an insulin pen to mitigate potential dosing errors with different glargine concentrations; the maximum dose per injection is 80 units."	( Pharmacodynamic and pharmacokinetic evaluation of insulin glargine U300 for the treatment of type 1 diabetes. Hurren, KM; O'Neill, JL, 2016)	0.69
"Nocturnal-confirmed hypoglycemia was higher with IGlar whereas overall and diurnal hypoglycemia were higher with IDegAsp dosed at breakfast."	( Efficacy and Safety of Once-Daily Insulin Degludec/Insulin Aspart versus Insulin Glargine (U100) for 52 Weeks in Insulin-Naïve Patients with Type 2 Diabetes: A Randomized Controlled Trial. Franek, E; Kumar, A; Mersebach, H; Niemeyer, M; Simó, R; Wise, J, 2016)	0.67
" Our objective was to compare preoperative glargine dosing regimens on perioperative glycemic control in patients undergoing ambulatory surgery."	( Effect of basal insulin dosage on blood glucose concentration in ambulatory surgery patients with type 2 diabetes. Carlson, KT; Demma, LJ; Duggan, EW; Morrow, JG; Umpierrez, G, 2017)	0.46
" The day-to-day variability in glucose-lowering effect assessed in 2-hour intervals was consistently low with IDeg over 24 hours, but steadily increased with IGlar-U300 to a maximum at 10 to 12 hours and 12 to 14 hours after dosing (variance ratios 12."	( Insulin degludec: Lower day-to-day and within-day variability in pharmacodynamic response compared with insulin glargine 300 U/mL in type 1 diabetes. Famulla, S; Haahr, HL; Heise, T; Kaplan, K; Nosek, L; Nørskov, M, 2017)	0.67
" Despite glycated haemoglobin concentrations being lower with IDegLira at end of treatment, confirmed and nocturnal-confirmed hypoglycaemia rates were lower for IDegLira vs IDeg and IGlar U100, irrespective of dosing time."	( Rates of hypoglycaemia are lower in patients treated with insulin degludec/liraglutide (IDegLira) than with IDeg or insulin glargine, regardless of the hypoglycaemia definition used. Chen, R; Heller, S; Jaeckel, E; Jarlov, H; Lehmann, L; Lingvay, I; Norwood, P, 2017)	0.66
"Treatment with IDegLira, vs IDeg and IGlar U100, resulted in lower rates of hypoglycaemia regardless of dosing time and definition of hypoglycaemia used."	( Rates of hypoglycaemia are lower in patients treated with insulin degludec/liraglutide (IDegLira) than with IDeg or insulin glargine, regardless of the hypoglycaemia definition used. Chen, R; Heller, S; Jaeckel, E; Jarlov, H; Lehmann, L; Lingvay, I; Norwood, P, 2017)	0.66
"Patients were randomized 1:1 to receive once-daily insulin degludec followed by insulin glargine U100 (n = 249) or to receive insulin glargine U100 followed by insulin degludec (n = 252) and randomized 1:1 to morning or evening dosing within each treatment sequence."	( Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 1 Diabetes: The SWITCH 1 Randomized Clinical Trial. Bailey, TS; Gerety, G; Gumprecht, J; Hansen, CT; Lane, W; Nielsen, TSS; Philis-Tsimikas, A; Warren, M, 2017)	0.97
"Patients were randomized 1:1 to receive once-daily insulin degludec followed by insulin glargine U100 (n = 361) or to receive insulin glargine U100 followed by insulin degludec (n = 360) and randomized 1:1 to morning or evening dosing within each treatment sequence."	( Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes: The SWITCH 2 Randomized Clinical Trial. Bhargava, A; Chaykin, L; de la Rosa, R; Handelsman, Y; Kvist, K; Norwood, P; Troelsen, LN; Wysham, C, 2017)	0.97
" Two control dosing algorithms were included for comparison: no insulin lispro (basal insulin+metformin only) or insulin lispro with fixed doses without titration."	( Simulation-Based Evaluation of Dose-Titration Algorithms for Rapid-Acting Insulin in Subjects with Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antihyperglycemic Medications. Chien, JY; Johnson, J; Ma, X; Malone, J; Sinha, V, 2017)	0.46
"Of the seven dosing algorithms assessed, daily adjustment of insulin lispro dose, when glucose targets were met at pre-breakfast, pre-lunch, and pre-dinner, sequentially, demonstrated greater HbA1c reduction at 24 weeks, compared with the other dosing algorithms."	( Simulation-Based Evaluation of Dose-Titration Algorithms for Rapid-Acting Insulin in Subjects with Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antihyperglycemic Medications. Chien, JY; Johnson, J; Ma, X; Malone, J; Sinha, V, 2017)	0.46
"Our model-based simulations support a simplified dosing algorithm that does not include carbohydrate counting, but that includes glucose targets for daily dose adjustment to maintain glycemic control with a low risk of hypoglycemia."	( Simulation-Based Evaluation of Dose-Titration Algorithms for Rapid-Acting Insulin in Subjects with Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antihyperglycemic Medications. Chien, JY; Johnson, J; Ma, X; Malone, J; Sinha, V, 2017)	0.46
" In the US, iGlarLixi is available in a 3:1 ratio of iGlar and lixisenatide, respectively, across the dosage range of 15-60 U of iGlar and 5-20 µg of lixisenatide."	( iGlarLixi, a titratable once-daily fixed-ratio combination of basal insulin and lixisenatide for intensifying type 2 diabetes management for patients inadequately controlled on basal insulin with or without oral agents. Dupree, RS; Johnson, EL; Skolnik, N, 2017)	0.46
" Participants were randomly assigned to 1 of 2 algorithms: they either increased their dosage by 1 unit/day (INSIGHT, n=108) or the dose was adjusted by the investigator at least once weekly, but no more often than every 3 days (EDITION, n=104)."	( TITRATION: A Randomized Study to Assess 2 Treatment Algorithms with New Insulin Glargine 300 units/mL. Berard, L; Groleau, M; Harris, SB; Javadi, P; Stewart, J; Yale, JF, 2017)	0.69
"Both studies were single-dose, randomized, double-blind, single-centre, crossover studies with ≥7 days between dosing periods."	( Single-dose euglycaemic clamp studies demonstrating pharmacokinetic and pharmacodynamic similarity between MK-1293 insulin glargine and originator insulin glargine (Lantus) in subjects with type 1 diabetes and healthy subjects. Barbour, AM; Crutchlow, MF; Hompesch, M; Mahon, CD; Marcos, MC; Morrow, L; Mostoller, KM; Palcza, JS; Watkins, E; Xu, Y, 2018)	0.69
"001), and dosing of glargine (r2=0."	( Predictors of Glycemic Response and Change in HbA1c Following Newly Initiated Basal Insulin Among Insulin Naïve Adults With Type 2 Diabetes. Aghili, R; Ebrahim Valojerdi, A; Khamseh, ME; Malek, M, 2017)	0.46
" This study evaluated differences in dosing and clinical outcomes before and after Gla-300 treatment initiation in patients with type 2 diabetes starting or switching to treatment with Gla-300 to assess whether the benefits observed in clinical trials translate into real-world settings."	( Treatment Dosing Patterns and Clinical Outcomes for Patients with Type 2 Diabetes Starting or Switching to Treatment with Insulin Glargine (300 Units per Milliliter) in a Real-World Setting: A Retrospective Observational Study. Cali, A; Gupta, S; Lee, LK; Liebert, RM; Preblick, R; Skolnik, N; Stella, P; Tong, L; Wang, H, 2018)	0.69
" Differences in dosing and clinical outcomes before versus after treatment initiation or switching were examined by generalized linear mixed-effects models."	( Treatment Dosing Patterns and Clinical Outcomes for Patients with Type 2 Diabetes Starting or Switching to Treatment with Insulin Glargine (300 Units per Milliliter) in a Real-World Setting: A Retrospective Observational Study. Cali, A; Gupta, S; Lee, LK; Liebert, RM; Preblick, R; Skolnik, N; Stella, P; Tong, L; Wang, H, 2018)	0.69
" The new glargine-300 formulation was developed to have a flatter and more extended time-action profile than the original glargine-100, and these characteristics may translate into more stable and sustained glycemic control over a 24 h dosing interval."	( Efficacy and Safety of Insulin Glargine 300 U/mL versus 100 U/mL in Diabetes Mellitus: A Comprehensive Review of the Literature. Vargas-Uricoechea, H, 2018)	0.79
" Titration of insulin was guided by a fasting plasma glucose (FPG)-based dosing algorithm."	( Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 2 diabetes: A randomized, open-label clinical trial. Carofano, WL; Crutchlow, MF; Eldor, R; Gallwitz, B; Golm, GT; Hollander, PA; Home, PD; Lam, RLH; Marcos, MC; Rendell, MS; Rosenstock, J, 2018)	0.77
" Dose titration of basal insulin was by a pre-breakfast plasma glucose dosing algorithm."	( Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 1 diabetes: A randomized, open-label clinical trial. Carofano, WL; Crutchlow, MF; Eldor, R; Gallwitz, B; Golm, GT; Hollander, PA; Home, PD; Lam, RLH; Marcos, MC; Rosenstock, J, 2018)	0.77
"A clear dose-response relationship can be demonstrated for both insulin analogs, even at very high doses in severely obese patients with type 2 diabetes."	( Comparison of the dose-response pharmacodynamic profiles of detemir and glargine in severely obese patients with type 2 diabetes: A single-blind, randomised cross-over trial. Bilz, S; Falconnier, C; Flückiger, M; Keller, U; Meienberg, F; Puder, JJ, 2018)	0.48
"7 U/d, the Gla-100 dosage was 22."	( Titration and optimization trial for the initiation of insulin glargine 100 U/mL in patients with inadequately controlled type 2 diabetes on oral antidiabetic drugs. Anderten, H; Borck, A; Bramlage, P; Fritsche, A; Pegelow, K; Pfohl, M; Pscherer, S; Seufert, J, 2019)	0.76
"In this open, non-controlled single-arm pilot study, glycaemic control at the general ward of a tertiary care hospital was guided by a mobile decision support system (GlucoTab) for basal-bolus insulin dosing using the novel basal insulin analogue insulin glargine U300 for the first time."	( GlucoTab-guided insulin therapy using insulin glargine U300 enables glycaemic control with low risk of hypoglycaemia in hospitalized patients with type 2 diabetes. Aberer, F; Beck, P; Donsa, K; Höll, B; Lichtenegger, KM; Mader, JK; Malle, O; Pieber, TR; Plank, J; Samonigg, J; Smajic, E, 2019)	0.97
" Glycaemic efficacy, hypoglycaemia, changes in body weight and insulin dosage and adverse events were examined over 6 months' treatment with Gla-300 versus Gla-100 for participants aged ≥ 65 and < 65 years."	( Glycaemic control and hypoglycaemia risk with insulin glargine 300 U/mL versus glargine 100 U/mL: A patient-level meta-analysis examining older and younger adults with type 2 diabetes. Aroda, VR; Bigot, G; Bolli, GB; Brulle-Wohlhueter, C; Cahn, A; Charbonnel, B; Merino-Trigo, A; Ritzel, R; Sinclair, AJ; Trescoli, C; Yale, JF, 2020)	0.82
"0001), and more even dosing over each 6-h quartile, with insulin degludec 200 U/mL versus insulin glargine 300 U/mL (0."	( Clinical relevance of pharmacokinetic and pharmacodynamic profiles of insulin degludec (100, 200 U/mL) and insulin glargine (100, 300 U/mL) - a review of evidence and clinical interpretation. Bolli, GB; Fanelli, CG; Owens, DR; S Bailey, T; Yale, JF, 2019)	0.95
"Medical records were retrospectively analyzed to investigate the effect of a hospital formulary change at a semi-urban underserved hospital that substituted detemir for glargine on a 1:1 dosing basis."	( Detemir vs Glargine: Comparison of Inpatient Glycemic Control. Avanesyan, A; Cade, K; Capson, J, 2019)	0.51
" Multiple randomized control trials and real-world evidence studies have demonstrated that the newer second-generation basal insulin analogs, insulin glargine 300 units/mL and insulin degludec 100 or 200 units/mL, provide stable glycemic control with once-daily dosing and are associated with a reduced risk of hypoglycemia compared with previous-generation basal insulin analogs insulin glargine 100 units/mL and insulin detemir."	( Differentiating Basal Insulin Preparations: Understanding How They Work Explains Why They Are Different. Cheng, AYY; Patel, DK; Reid, TS; Wyne, K, 2019)	0.72
" Study objectives were to determine if, across weight categories, admission body weight (ABW)-based initial insulin glargine dosing resulted in similar fasting blood glucose responses on day of discharge, how initial ABW-based doses differed from doses at outpatient follow-up, and whether an ideal body weight (IBW) would provide a better estimate of body weight after discharge."	( Insulin Glargine Dose and Weight Changes in Underweight, Normal Weight, and Overweight Children Newly Diagnosed with Type 1 Diabetes Mellitus. Chalk, BS; Crane, J; Lee, CKK; Pineda, EM; Yenokyan, G, 2019)	2.17
" Further investigation of the role of IBW- or ABW-based dosing methods in underweight pediatric patients with T1D may assist in optimal dosing."	( Insulin Glargine Dose and Weight Changes in Underweight, Normal Weight, and Overweight Children Newly Diagnosed with Type 1 Diabetes Mellitus. Chalk, BS; Crane, J; Lee, CKK; Pineda, EM; Yenokyan, G, 2019)	1.96
" Currently, there is no real-world data published on the implications of conversion to Basaglar on dosing or glycemic control."	( Impact of Dosing Conversion From Basal Insulin to Follow-On Insulin Glargine. Ashjian, EJ; Kippes, KA; Maes, ML; Marshall, V; Rida, N; Thompson, AN, 2021)	0.86
"To identify differences in basal insulin dosing requirements, hemoglobin A1c (HbA1c), and incidence of hypoglycemia or weight gain when converting a patient to Basaglar from another basal insulin."	( Impact of Dosing Conversion From Basal Insulin to Follow-On Insulin Glargine. Ashjian, EJ; Kippes, KA; Maes, ML; Marshall, V; Rida, N; Thompson, AN, 2021)	0.86
"Twice/day dosing of insulin glargine has been used to treat hyperglycemia in clinical practice; however, data supporting its use in the critically ill population are lacking."	( Insulin Glargine in Critically ill Patients: Once/Day versus Twice/Day Dosing. Fox, MA; Liu-DeRyke, X; Perry, MC, 2020)	2.32
" We determined dosage of 1 basal and 3 bolus "treat" insulin based on "target" blood glucose level and changed each insulin dose by small units (2 units) every day for 2 weeks."	( Practical application of short-term intensive insulin therapy based on the concept of "treat to target" to reduce hypoglycaemia in routine clinical site. Kaneto, H; Nakashima, K; Okamura, N; Sanefuji, H, 2020)	0.56
"In this experimental study, glargine insulin-loaded nanostructured lipid carriers have been converted into solid oral dosage forms (tablets, capsules), that are more suitable for administration in humans and have prolonged shelf-life."	( Glargine insulin loaded lipid nanoparticles: Oral delivery of liquid and solid oral dosage forms. Anfossi, L; Battaglia, L; Capucchio, MT; Colombino, E; Ferraris, C; Marini, E; Milla, P; Muntoni, E; Porta, M; Segale, L, 2021)	0.62
" Goals were to assess how to rapidly and safely initiate TI intensification, determine dosing requirements, and establish an effective dose range in uncontrolled T2DM."	( Ultra Rapid-Acting Inhaled Insulin Improves Glucose Control in Patients With Type 2 Diabetes Mellitus. Bromberger, L; Hoogwerf, BJ; Levin, P; Pyle, L; Snell-Bergeon, J; Vigers, T, 2021)	0.62
"Treatment with inhaled TI dosed using a simple algorithm improved glycemic control measured by both HbA1c and time in range, with low rates of hypoglycemia."	( Ultra Rapid-Acting Inhaled Insulin Improves Glucose Control in Patients With Type 2 Diabetes Mellitus. Bromberger, L; Hoogwerf, BJ; Levin, P; Pyle, L; Snell-Bergeon, J; Vigers, T, 2021)	0.62
"We aimed to investigate the effect of dosage reduction of four hypoglycemic multidrug regimens on the incidences of acute glycemic complications in people with type 2 diabetes who fast during Ramaḍān."	( Effect of Dosage Reduction of Hypoglycemic Multidrug Regimens on the Incidences of Acute Glycemic Complications in People With Type 2 Diabetes Who Fast During Ramaḍān: A Randomized Controlled Trial. Amarin, JZ; Beirat, AF; Hasan, YY; Hassoun Al Najar, AM; Qtaishat, A; Tierney, ME; Zaghlol, LY; Zaghlol, RY; Zayed, AA, 2021)	0.62
" Serum was collected before and up to 24 hours after dosing to assess PK characteristics."	( A Euglycemic Glucose Clamp Study to Evaluate the Bioavailability of LY2963016 Relative to Insulin Glargine in Healthy Chinese Subjects. Chua, L; Ji, Y; Li, H; Linnebjerg, H; Liu, H; Ma, T; Tham, LS; Wang, F; Yu, Y, 2021)	0.84
"Patients with inadequate glycemic control or who find their basal insulin dosing inconvenient may benefit from switching to Ideg, with the potential for small improvementa in A1C at lower basal insulin doses."	( Clinical Utility of Switching to Insulin Degludec From Other Basal Insulins in Adult Patients With Type 1 or Type 2 Diabetes. Bakal, JA; Baran, O; Dersch-Mills, D; Hnatiuk, M; Huyghebaert, T; Roedler, RL, 2022)	0.72
" The app uses patient-logged fasting blood glucose (FBG) values and a titration plan defined by the treating physician to provide basal insulin dosing recommendations."	( A Smartphone-Based Application to Assist Insulin Titration in Patients Undergoing Basal Insulin-Supported Oral Antidiabetic Treatment. Gouveri, E; Marck, C; Simon, J; Tews, D, 2023)	0.91
"At 90 days postrandomization, total insulin dosing was increased by ~7% in both cohorts."	( Reduced hypoglycaemia using liver-targeted insulin in individuals with type 1 diabetes. Bode, BW; El Sanadi, C; Garg, SK; Geho, WB; Klonoff, DC; Muchmore, DB; Penn, MS; Weinstock, RS, 2022)	0.72
" Gla-300 provides a stable and sustained time-action profile, which is associated with glycaemic control and flexible dosing schedule."	( Insulin Glargine 300 U/mL Therapy in Children and Adolescents with Type 1 Diabetes. Maffeis, C; Rabbone, I, 2022)	2.16
"The smooth and prolonged activity of insulin glargine 300 Units/mL (Gla-300), a second-generation basal insulin, results in a stable and sustained glycaemic control while allowing flexible dosing times."	( Insulin Glargine 300 U/mL Therapy in Children and Adolescents with Type 1 Diabetes. Maffeis, C; Rabbone, I, 2022)	2.44
" In the 6-week multiple ascending dose study, people with T2D, previously treated with basal insulin, received insulin glargine daily or a one-time loading dose of BIF followed by 5 weeks of once-weekly dosing (1-10 mg)."	( Pharmacokinetic and pharmacodynamic properties of the novel basal insulin Fc (insulin efsitora alfa), an insulin fusion protein in development for once-weekly dosing for the treatment of patients with diabetes. Beals, JM; Benson, C; Chien, J; Haupt, A; Heise, T; Klein, O; Moyers, JS; Pratt, EJ, 2023)	1.12
"BIF was well tolerated and the PK/PD profile enabled once-weekly dosing with minimal variation in exposure in a treatment interval of 1 week."	( Pharmacokinetic and pharmacodynamic properties of the novel basal insulin Fc (insulin efsitora alfa), an insulin fusion protein in development for once-weekly dosing for the treatment of patients with diabetes. Beals, JM; Benson, C; Chien, J; Haupt, A; Heise, T; Klein, O; Moyers, JS; Pratt, EJ, 2023)	0.91
" Attempts to reduce the gap with closed-loop therapies using advanced dosing advisors have so far failed, mainly because they require too much human intervention."	( Intermittent closed-loop blood glucose control for people with type 1 diabetes on multiple daily injections. Beneyto, A; Cabrera, A; Contreras, I; Estremera, E; Vehí, J, 2023)	0.91
"To compare the effectiveness and safety of icodec titrated with a dosing guide app (icodec with app) versus once-daily basal insulin analogues (OD analogues) dosed per standard practice."	( Once-Weekly Insulin Icodec With Dosing Guide App Versus Once-Daily Basal Insulin Analogues in Insulin-Naive Type 2 Diabetes (ONWARDS 5) : A Randomized Trial. Aberle, J; Bajaj, HS; Bode, B; Davies, M; Donatsky, AM; Frederiksen, M; Gowda, A; Lingvay, I; Yavuz, DG, 2023)	0.91
"Inability to differentiate the effects of icodec and the dosing guide app."	( Once-Weekly Insulin Icodec With Dosing Guide App Versus Once-Daily Basal Insulin Analogues in Insulin-Naive Type 2 Diabetes (ONWARDS 5) : A Randomized Trial. Aberle, J; Bajaj, HS; Bode, B; Davies, M; Donatsky, AM; Frederiksen, M; Gowda, A; Lingvay, I; Yavuz, DG, 2023)	0.91

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	4 (0.19)	18.7374
1990's	7 (0.34)	18.2507
2000's	611 (29.36)	29.6817
2010's	1094 (52.57)	24.3611
2020's	365 (17.54)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	772 (35.35%)	5.53%
Reviews	361 (16.53%)	6.00%
Case Studies	112 (5.13%)	4.05%
Observational	67 (3.07%)	0.25%
Other	872 (39.93%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (511)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Two-Part Clinical Trial to Assess Pharmacodynamic and Pharmacokinetic Variability of a Basal Insulin [NCT01152242]	Phase 1	36 participants (Actual)	Interventional	2010-08-31	Completed
Effectiveness of a Subcutaneously Administered Long-acting Insulin Added to Insulin Drip Therapy as Compared With Standard Insulin Drip Treatment [NCT01153100]	Phase 1	60 participants (Actual)	Interventional	2010-04-30	Completed
[NCT01195454]	Phase 1	24 participants (Actual)	Interventional	2010-08-31	Completed
A Study of Effectiveness and Safety of Apidra in Combination With Lantus Therapy in Basal-bolus Insulin Regimen in Inadequately Controlled Children and Adolescents With Type 1 Diabetes in the Russian Federation. [NCT01202474]	Phase 4	100 participants (Actual)	Interventional	2011-05-31	Completed
Six-month, Randomized, Open-label, Parallel-group Comparison of SAR341402 to NovoLog®/NovoRapid® in Adult Patients With Diabetes Mellitus Also Using Insulin Glargine, With a 6-month Safety Extension Period [NCT03211858]	Phase 3	597 participants (Actual)	Interventional	2017-08-02	Completed
Safety and Efficacy of Insulin Glargine Injection [rDNA Origin] Treatment in Place of the TZD or the Sulfonylurea or Metformin in Triple Agent Therapy for T2DM Adult Subjects With Unsatisfactory Control [NCT00283049]	Phase 4	390 participants (Actual)	Interventional	2006-02-28	Terminated(stopped due to Due to technical issues relating to the Electronic diary data.)
A Trial Comparing the Efficacy and Safety of Insulin Degludec and Insulin Glargine 300 Units/mL in Subjects With Type 2 Diabetes Mellitus Inadequately Treated With Basal Insulin With or Without Oral Antidiabetic Drugs [NCT03078478]	Phase 3	1,609 participants (Actual)	Interventional	2017-03-13	Completed
A Trial Evaluating the Pharmacodynamic Response of NN1250 at Steady State Conditions in Subjects With Type 1 Diabetes [NCT01114542]	Phase 1	66 participants (Actual)	Interventional	2010-05-03	Completed
A Randomized, Cross-over, Open, Euglycemic Clamp Study on the Relative Bioavailability and Activity of 0.6 U/kg Insulin Glargine and 20 μg Lixisenatide, Given as On-site Mix Compared to Separate Simultaneous Injections in Subjects With Type 1 Diabetes Mel [NCT01146678]	Phase 1	22 participants (Anticipated)	Interventional	2010-06-30	Completed
A Trial Comparing NNC0148-0287 C (Insulin 287) Versus Insulin Glargine U100, Both in Combination With Metformin, With or Without DPP4 Inhibitors and With or Without SGLT2 Inhibitors, in Basal Insulin Treated Subjects With Type 2 Diabetes Mellitus [NCT03922750]	Phase 2	154 participants (Actual)	Interventional	2019-05-09	Completed
Comparison of Glycaemic Fluctuation and Oxidative Stress Between Two Short-term Therapies for Type 2 Diabetes [NCT02526810]	Phase 4	70 participants (Anticipated)	Interventional	2015-07-31	Recruiting
Comparison of Insulin Degludec With Insulin Glargine U100 for Adults With Type 1 Diabetes Travelling Across Multiple Time Zones. A Pilot Study. [NCT03668808]	Phase 4	25 participants (Actual)	Interventional	2018-11-16	Completed
A Multiple-dose Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0148-0287 C (Insulin 287) for Subcutaneous Administration in Japanese Subjects With Type 1 Diabetes [NCT03766854]	Phase 1	24 participants (Actual)	Interventional	2018-12-07	Completed
Comparison of a Basal Plus (Insulin Glargine/Insulin Glulisine) Regimen to Biphasic Insulin (InsulinAspart/Insulin Aspart Protamine 30/70) in T2DM Patients Who Require Insulin Intensification After Basal Insulin Optimization. [NCT01212913]	Phase 4	161 participants (Actual)	Interventional	2010-08-31	Completed
A Phase 3, Parallel-Design, Open-Label, Randomized Control Study to Evaluate the Efficacy and Safety of LY3209590 Administered Weekly Using a Fixed Dose Escalation Compared to Insulin Glargine in Insulin-Naïve Adults With Type 2 Diabetes [NCT05662332]	Phase 3	796 participants (Actual)	Interventional	2023-01-14	Active, not recruiting
A 24-week, Open, Multicenter, Comparative Study of 2 Strategies (Including Insulin Glargine Versus Premixed Insulin) for the Therapeutic Management of Patients With Type 2 Diabetes Failing Oral Agents [NCT01121835]	Phase 4	934 participants (Actual)	Interventional	2010-02-28	Completed
Effect of Normalization of Fasting Glucose by Intensified Insulin Therapy on the Incidence of Restenosis After Peripheral Angioplasty in Patients With Type 2 Diabetes. [NCT01150617]	Phase 4	46 participants (Actual)	Interventional	2008-12-31	Terminated(stopped due to end-point reached)
Early Administration of Insulin Glargine in Patients With Diabetic Ketoacidosis [NCT06007508]	Phase 2	150 participants (Anticipated)	Interventional	2022-05-31	Recruiting
Phase IV, Multicenter, International, Non-comparative, Open Label Study of Efficacy and Safety of Basal Bolus Therapy (Insulin Glargine + Insulin Glulisine) in Patients With T1 Diabetes Previously Uncontrolled on Any Insulin Regimen. [NCT01204593]	Phase 4	206 participants (Actual)	Interventional	2010-11-30	Completed
Efficacy and Safety of Intensive Insulin Therapy With Insulin Glulisine in Patients With Type 2 Diabetes Inadequately Controlled With Basal Insulin and Oral Glucose-lowering Drugs [NCT01203111]	Phase 4	207 participants (Actual)	Interventional	2010-12-31	Completed
Relative Bioavailability of LY2963016 to LANTUS® After Single Dose Subcutaneous Administration to Healthy Subjects [NCT01374178]	Phase 1	16 participants (Actual)	Interventional	2011-06-30	Completed
Relative Bioavailability of LY2963016 to LANTUS® After Single-Dose Subcutaneous Administration in Healthy Chinese Subjects [NCT03555305]	Phase 1	58 participants (Actual)	Interventional	2018-09-26	Completed
A Prospective, Randomized, Double-Blind Comparison of LY900014 to Insulin Lispro With an Open-Label Postprandial LY900014 Treatment Group, in Combination With Insulin Glargine or Insulin Degludec, in Adults With Type 1 Diabetes PRONTO-T1D [NCT03214367]	Phase 3	1,392 participants (Actual)	Interventional	2017-07-17	Completed
A Trial Comparing Efficacy and Safety of NN1250 and Insulin Glargine in Subjects With Type 2 Diabetes (BEGIN™: EASY AM) [NCT01068678]	Phase 3	460 participants (Actual)	Interventional	2010-02-28	Completed
A Prospective, Randomized, Double-Blind Comparison of LY900014 to Humalog With an Open-Label Postprandial LY900014 Treatment Group in Children and Adolescents With Type 1 Diabetes [NCT03740919]	Phase 3	751 participants (Actual)	Interventional	2019-04-07	Completed
Pharmacist Intervention for Glycemic Control in The Community (The RxING Study) [NCT01335763]		100 participants (Actual)	Interventional	2011-04-30	Completed
A Comparison of LY2605541 Versus Insulin Glargine as Basal Insulin Treatment in Combination With Oral Anti-Hyperglycemia Medications in Insulin-Naïve Patients With Type 2 Diabetes Mellitus: An Open-Label, Randomized, 52-week Study [NCT02106364]	Phase 3	0 participants (Actual)	Interventional	2015-02-28	Withdrawn(stopped due to Lilly's decision to cancel this trial is due to regulatory uncertainty in China.)
Remission Through Early Monitored Insulin Therapy - Duration Month [NCT03670641]	Phase 4	10 participants (Actual)	Interventional	2019-03-26	Completed
A Randomized, Double-blind, Two Period, Cross Over Glucose Clamp Study to Test for Bioeqivalence Between Two Long Acting Insulin Analogs-Wockhardt's Glaritus™ (Insulin Glargine) and Lantus (Insulin Glargine) in Subjects With Type 1 Diabetes [NCT01357603]	Phase 1	111 participants (Actual)	Interventional	2011-06-30	Completed
Lantus® (Insulin Glargine[rDNA Origin] Injection) vs Humalog® Mix 75/25 (75% Insulin Lispro Protamine Suspension and 25% Insulin Lispro Injection) as add-on Therapy in Type 2 Diabetes Patients Failing Sulfonylurea and Glucophage (Metformin) Combination Tr [NCT01336751]	Phase 3	212 participants (Actual)	Interventional	2001-07-31	Completed
An Open Label, Randomized Comparison of Wockhardt's Recombinant Insulin Analogue With Innovator's Glargine in Type 1 Diabetic Patients. [NCT01352663]	Phase 3	0 participants (Actual)	Interventional		Withdrawn(stopped due to Business strategy decision)
A Randomized, Double-blind, 2x2 Cross-over Euglycemic Clamp Study in Two Parallel Cohorts to Assess the Safety and Tolerability of Two Dose Levels of a New Formulation of Insulin Glargine and to Compare Its Pharmacodynamic and Pharmacokinetic Properties W [NCT01349855]	Phase 1	30 participants (Anticipated)	Interventional	2011-03-31	Completed
Central Effects of Endogenous Glucagon Like Peptide-1 (GLP-1) and the GLP-1 Analog Liraglutide on Brain Satiety and Reward Circuits and Feeding Behavior in Diabetes [NCT01363609]		50 participants (Actual)	Interventional	2011-10-31	Completed
Metformin and Sitagliptin Therapy for Adult Patients With Type 2 Diabetes Admitted to the General Medical Unit [NCT02250794]	Phase 4	0 participants (Actual)	Interventional	2014-10-31	Withdrawn(stopped due to No subjects enrolled.)
Multicentre Phase IV Single Arm Clinical Trial to evaluAte the saFety and Efficacy of Gla-300 in insUlin-naïve Patients With Type 2 DiAbetes uncontRolled on Oral Antihyperglycemic Drugs [NCT04980027]	Phase 4	228 participants (Actual)	Interventional	2021-06-07	Completed
A Study to Assess the Safety, Pharmacokinetics and Pharmacodynamic Effect of MK-5160 in Subjects With Type 1 and Type 2 Diabetes Mellitus [NCT03095651]	Phase 1	33 participants (Actual)	Interventional	2017-04-12	Completed
Effects of Replacing Lantus With Basalin on the Glycemic Variation in Patients [NCT03631121]	Phase 4	100 participants (Anticipated)	Interventional	2018-08-15	Recruiting
Asian Treat to Target Lantus Study: A Randomized, Multicentre, Multinational, Open-Label, Parallel-Group, 24-Week Phase IV Study Evaluating the Effectiveness and Safety of Physician Versus Patient-led Initiation and Titration of Insulin Glargine in Type 2 [NCT01169818]	Phase 4	555 participants (Actual)	Interventional	2010-08-31	Completed
Variability of Glucose Assessed in a Randomized Trial Comparing the Initiation of A Treatment Approach With Biosimilar Basal Insulin Analog Or a Titratable iGlarLixi combinatioN in Type 2 Diabetes Among South Asian Subjects (VARIATION 2 SA Trial) [NCT03819790]	Phase 4	119 participants (Actual)	Interventional	2018-10-02	Completed
National, Phase IV, Multicentric, Open Label, Comparative Study to Evaluate the Efficacy and Safety of Insulin Glargine Plus Glulisine and Sliding Scale Plus Glulisine in Hospitalized Patients With Diabetes Metabolism Type II Under Enteral Nutrition. [NCT01081938]	Phase 4	15 participants (Actual)	Interventional	2010-02-28	Terminated(stopped due to Recruitment challenges)
Better Acceptance of a Single Injection Apidra (Insulin Glulisine) Added to Once Daily Lantus (Insulin Glargine) Versus Twice Daily Premixed Insulin in a Real Life Use Setting [NCT01079364]	Phase 4	52 participants (Actual)	Interventional	2010-01-31	Terminated(stopped due to Slow recruitment)
A Phase 3, Randomized, Open Label, Comparator-Controlled, Parallel Group, Multicenter Study to Compare the Effects of Exenatide and Insulin Glargine on Beta Cell Function and Cardiovascular Risk Markers in Subjects With Type 2 Diabetes Treated With Metfor [NCT00097500]	Phase 3	69 participants (Actual)	Interventional	2004-09-30	Completed
Effect of Semaglutide Once-weekly Versus Insulin Aspart Three Times Daily, Both as Add on to Metformin and Optimised Insulin Glargine (U100) in Subjects With Type 2 Diabetes A 52-week, Multi-centre, Multinational, Open-label, Active-controlled, Two Armed, [NCT03689374]	Phase 3	2,274 participants (Actual)	Interventional	2018-10-01	Completed
A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0268-0965 in Healthy Subjects and in Subjects With Type 1 Diabetes Mellitus [NCT03965013]	Phase 1	78 participants (Actual)	Interventional	2019-06-05	Completed
A 78-week Trial Comparing the Effect and Safety of Once Weekly Insulin Icodec and Once Daily Insulin Glargine 100 Units/mL, Both in Combination With Non-insulin Anti-diabetic Treatment, in Insulin naïve Subjects With Type 2 Diabetes [NCT04460885]	Phase 3	984 participants (Actual)	Interventional	2020-11-25	Completed
Efficacy and Safety of Human Insulin Versus Analog Insulin in Hospitalized Acute Stroke Patients With Hyperglycemia: a Randomized, Open-label, Single Center Trial [NCT04834362]	Phase 4	452 participants (Actual)	Interventional	2021-04-05	Completed
A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Insulin 320 in Healthy Subjects [NCT02479022]	Phase 1	84 participants (Actual)	Interventional	2015-06-30	Completed
A Single-Center, Randomized, Double-Blind, 3-Treatment, 3-Period, 6-Sequence Cross-Over Study To Compare The Pharmacokinetic And Pharmacodynamic Effects of Single Doses of Insulin Glargine Given As U200 And U500 To Lantus® In A Euglycemic Clamp Setting In [NCT02201199]	Phase 1	36 participants (Actual)	Interventional	2014-08-31	Completed
A Comparison of Exenatide and Insulin Glargine on Glycemic Variability in T2DM Patients Inadequately Controlled With Metformin Monotherapy [NCT02325960]	Phase 4	44 participants (Actual)	Interventional	2015-01-31	Completed
A Randomized, 30-week, Active-controlled, Open-label, 2 Treatment-arm, Parallel Group, Multicenter Study Comparing Efficacy and Safety of iGlarLixi to Insulin Glargine With or Without Metformin in Patients With Type 2 Diabetes Mellitus Insufficiently Cont [NCT03798080]	Phase 3	426 participants (Actual)	Interventional	2019-02-19	Completed
A Phase3, Multi-Center, Open-Label, Randomized, Clinical Trial Evaluating the Efficacy and Safety of Technosphere® Insulin Inhalation Powder in Combination With Lantus® Versus Humalog® in Combination With Lantus® in Subjects With Type 1 Diabetes Mellitus [NCT00700622]	Phase 3	130 participants (Actual)	Interventional	2008-05-31	Terminated(stopped due to Sponsor stopped development of the MedTone inhaler in favor of an improved device (Gen2 inhaler))
A Phase 3, Open-Label, Parallel-Group Study to Evaluate the Efficacy of Preprandial Human Insulin Inhalation Powder (HIIP) Compared to Preprandial Injectable Insulin in Patients With Type 1 Diabetes Mellitus [NCT00356109]	Phase 3	494 participants (Actual)	Interventional	2006-08-31	Completed
Evaluation of Glycemic Control and Quality of Life in Adults With Type 1 Diabetes During Continuous Glucose Monitoring When Switching to Insulin Glargine 300 U/mL: A FUTURE Substudy [NCT05109520]		867 participants (Actual)	Observational	2021-09-08	Completed
A 24-week, Multicenter, Randomized, Open-Label, Parallel-group StudyComparing the Efficacy and Safety of Toujeo® and Tresiba® in Insulin-NaivePatients With Type 2 Diabetes Mellitus Not Adequately Controlled With OralAntihyperglycemic Drug(s) ± GLP-1 Recep [NCT02738151]	Phase 4	929 participants (Actual)	Interventional	2016-05-19	Completed
A Randomized Controlled Trial Comparing Glargine U300 and Glargine U100 for the Inpatient and Post-Hospital Discharge Management of Medicine and Surgery Patients With Type 2 Diabetes [NCT03013985]	Phase 4	247 participants (Actual)	Interventional	2017-05-17	Completed
This Trial is Conducted Globally. The Aim of This Trial is to Compare the Effect and Safety of Insulin Degludec/Insulin Aspart vs. Insulin Glargine Plus Insulin Aspart in Subjects With Type 2 Diabetes Treated With Basal Insulin With or Without Oral Antidi [NCT02906917]	Phase 3	532 participants (Actual)	Interventional	2016-09-20	Completed
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3209590 Following Multiple Weekly Doses in Patients With Type 2 Diabetes Mellitus [NCT03367377]	Phase 1	70 participants (Actual)	Interventional	2018-01-03	Completed
A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0123-0338 in Healthy Subjects and in Subjects With Type 1 Diabetes Mellitus [NCT02220296]	Phase 1	62 participants (Actual)	Interventional	2014-08-20	Completed
A Phase 3, Open-Label Study of Once Daily LY3502970 Compared With Insulin Glargine in Adult Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk [NCT05803421]	Phase 3	2,620 participants (Anticipated)	Interventional	2023-04-03	Recruiting
Insulin Degludec Versus Glargine U300 for the Management of Hospitalized Patients With Type 2 Diabetes: Randomized Controlled Trial [NCT05036876]		220 participants (Actual)	Interventional	2021-10-10	Completed
A Single Center, Randomized, Open-Label, Crossover Study, Comparing the Pharmacodynamic Properties of Insulin VIAJECT™, Regular Human Insulin, and Insulin Lispro Either in Combination With a Basal Insulin Infusion or With Insulin Glargine Relative to a St [NCT01000922]	Phase 2	24 participants (Actual)	Interventional	2006-06-30	Completed
A Pivotal Long-Term, Open-Label, Parallel Study of the Efficacy and Safety of Human Insulin Inhalation Powder in Patients With Type 1 Diabetes Mellitus [NCT00127634]	Phase 3	385 participants (Actual)	Interventional	2005-07-31	Completed
Insulin Scheme for Glycemic Control in Non-critical Hospitalized Patients With Type 2 Diabetes in the Context of a Health System in Mexico. [NCT03350984]	Phase 4	75 participants (Actual)	Interventional	2017-11-02	Completed
A Clinical Trial Comparing Glycaemic Control and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine (IGlar) as add-on Therapy to SGLT2i in Subjects With Type 2 Diabetes Mellitus. DUALTM IX - Add-on to SGLT2i [NCT02773368]	Phase 3	420 participants (Actual)	Interventional	2016-05-23	Completed
A 6-month, Multicenter, Prospective, Single-arm, Open-label, Phase IV Study Evaluating the Clinical Efficacy and Safety of Insulin Glargine U300 in Chinese Adult Patients With Uncontrolled Type 2 Diabetes Mellitus With a 3-month Extension Period [NCT05002933]	Phase 4	570 participants (Actual)	Interventional	2021-05-20	Completed
The Durability of Twice-Daily Insulin Lispro Low Mixture Compared to Once-Daily Insulin Glargine When Added to Existing Oral Therapy in Patients With Type 2 Diabetes and Inadequate Glycemic Control [NCT00279201]	Phase 4	2,091 participants (Actual)	Interventional	2005-12-31	Completed
A Randomized Controlled Trial to Evaluate Early Intermittent Intensive Insulin Therapy as an Effective Treatment of Type 2 Diabetes: REmission Studies Evaluating Type 2 DM - Intermittent Insulin Therapy (RESET-IT) [NCT02192424]	Phase 3	109 participants (Actual)	Interventional	2014-07-31	Completed
A Multi-Center,Open-Label, Single-Arm, Multiple Dose Study With HOE901-U300 to Assess The Ease of Use And Safety of a New U300 Pen Injector in Insulin-Naïve Patients With T2DM [NCT02227212]	Phase 3	40 participants (Actual)	Interventional	2014-08-31	Completed
Randomized, Open Label, Parallel-group Study Comparing the Pharmacokinetics and Immunogenicity of Alternating Use of SAR341402 and NovoLog® Versus Continuous Use of NovoLog in Participants With Type 1 Diabetes Mellitus Also Using Insulin Glargine [NCT03874715]	Phase 3	210 participants (Actual)	Interventional	2019-03-11	Completed
AN OPEN-LABEL, RANDOMIZED, MULTICENTER, PHASE 3 STUDY TO COMPARE THE IMMUNOGENICITY, EFFICACY, AND SAFETY OF GAN & LEE PHARMACEUTICALS INSULIN GLARGINE INJECTION TO LANTUS® IN ADULT SUBJECTS WITH TYPE 1 DIABETES MELLITUS [NCT03371082]	Phase 3	550 participants (Actual)	Interventional	2017-10-31	Completed
Benefits of Insulin Supplementation for Correction of Hyperglycemia in Patients With Type 2 Diabetes Treated With Basal Bolus Insulin Regimen [NCT02408120]	Phase 4	226 participants (Actual)	Interventional	2015-10-31	Completed
A Phase 3, Open-Label, Crossover Study to Evaluate the Efficacy and Safety of Human Insulin Inhalation Powder (HIIP) Compared With Once-Daily Insulin Glargine in Insulin-Naive Patients With Type 2 Diabetes Mellitus on Oral Agents [NCT00437112]	Phase 3	142 participants (Actual)	Interventional	2007-02-28	Completed
Efficacy of Liraglutide vs. Sitagliptin vs. Insulin Glargine Per Day on Liver Fat When Combined With Metformin in T2DM Subjects With Non-alcoholic Fatty-liver Disease [NCT02147925]	Phase 4	75 participants (Actual)	Interventional	2014-08-31	Completed
Exenatide BID Compared With Insulin Glargine to Change Liver Fat Content in Non-alcoholic Fatty-liver Disease Patients With Type 2 Diabetes [NCT02303730]	Phase 4	76 participants (Actual)	Interventional	2015-03-31	Completed
A 16-week, Multicenter, Prospective, Open-label, Single-arm, Phase 4 Study to Evaluate the Effect of Soliqua™ 100/33 on the Percentage of Time in Range (TIR) From Continuous Glucose Monitoring (CGM) in Insulin-naïve Patients With Very Uncontrolled Type 2 [NCT05114590]	Phase 4	72 participants (Actual)	Interventional	2022-01-27	Completed
Conversion of Hyperglycemic Patients Being Treated With Intravenous Insulin Infusions to Lantus Insulin [NCT00338104]	Phase 4	75 participants (Actual)	Interventional	2004-07-31	Completed
National (Brazil), Phase IV, Multicentric, Open Label, Parallel, Comparative Study of the Use of Insulin Glargine + Glulisine or Insulin Regular + NPH Insulin (Isophane Insulin) in Type 2 Diabetes Mellitus Patients With Moderate Renal Failure. [NCT01122979]	Phase 4	72 participants (Actual)	Interventional	2010-07-31	Completed
A 24-week, Randomized, Open-label, Parallel Group, Multicenter Comparison of Lantus® (Insulin Glargine) Given Once Daily Versus Neutral Protamine Hagedorn (NPH) Insulin in Children With Type 1 Diabetes Mellitus Aged at Least 6 Years to Less Than 18 Years [NCT01223131]	Phase 3	162 participants (Actual)	Interventional	2011-02-28	Completed
Practical Implementation of ADA/EASD Consensus Algorithm in Patients With Type 2 Diabetes: Timely Insulin Initiation and Titration [NCT01127269]	Phase 4	178 participants (Actual)	Interventional	2010-05-31	Completed
A Comparative Study to Evaluate the Prandial Treatment Adjustment Effect Via Continuous Glucose Monitoring on Type 2 DM Patients Uncontrolled With a Basal Insulin or Premix Once a Day [NCT01234597]	Phase 4	219 participants (Actual)	Interventional	2012-12-31	Completed
Effect of Insulin Glargine and Lixisenatide Versus Insulin Glargine on Brain Insulin Sensitivity in Patients With Type 2 Diabetes [NCT03881995]	Phase 4	1 participants (Actual)	Interventional	2019-03-18	Terminated(stopped due to insufficient recruitment)
An Investigational Trial Comparing the Efficacy and Safety of Once Weekly NNC0148-0287 C (Insulin 287) Versus Once Daily Insulin Glargine, Both in Combination With Metformin, With or Without DPP-4 Inhibitors, in Insulin naïve Subjects With Type 2 Diabetes [NCT03751657]	Phase 2	247 participants (Actual)	Interventional	2018-11-29	Completed
A Randomized Controlled Trial Comparing Insulin Degludec and Glargine U100 for the Inpatient and Post-Hospital Discharge Management of Medicine and Surgery Patients With Type 2 Diabetes [NCT03336528]	Phase 4	180 participants (Actual)	Interventional	2018-01-02	Completed
Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IGlarLixi [NCT03130426]	Phase 3	161 participants (Actual)	Interventional	2017-06-27	Completed
A Prospective, Randomized, Open-Label Comparison of a Long-Acting Basal Insulin Analog LY2963016 to Lantus® in Adult Chinese Patients With Type 2 Diabetes Mellitus [NCT03338010]	Phase 3	536 participants (Actual)	Interventional	2018-03-22	Completed
A Comparative Study of the Effects of QS-M Needle Free Injector and Glargine Pen Subcutaneous Injection of Insulin Glargine on Insulin Use [NCT03420040]		65 participants (Anticipated)	Interventional	2017-11-27	Enrolling by invitation
A 12-week Randomized, Controlled Trial to Compare TOUJEO® and TRESIBA® in Terms of Glucose Values in Target Range and Variability During Continuous Glucose Monitoring in Patients With Type 1 Diabetes Mellitus [NCT04075513]	Phase 4	343 participants (Actual)	Interventional	2019-10-09	Completed
Evaluation of Virtual Versus Traditional Study Conduct in a 6-month, Multicenter, Randomized, Open-label, Two-parallel Group Pilot Study in Adult Patients With Type 1 Diabetes Mellitus [NCT03260868]	Phase 4	15 participants (Actual)	Interventional	2017-09-19	Terminated(stopped due to "Due to prolonged low participant recruitment")
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Basal Insulin Alone or in Addition to O [NCT03285594]	Phase 3	571 participants (Actual)	Interventional	2017-09-15	Completed
Randomised Open Label Study of Insulin Degludec Versus Insulin Glargine U100 in Ramadan [NCT03349840]	Phase 4	273 participants (Actual)	Interventional	2018-01-07	Terminated(stopped due to The study was terminated by the IRB and the Institutional Official after the MOPH and WCMQ audits)
A Prospective, Randomized, Double-Blind Comparison of LY900014 to Insulin Lispro, Both in Combination With Insulin Glargine or Insulin Degludec in Adults With Type 2 Diabetes PRONTO-T2D [NCT03214380]	Phase 3	933 participants (Actual)	Interventional	2017-07-14	Completed
A Single Ascending Dose Clinical Trial to Study the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-1092 in Healthy Subjects, Subjects With Type 1 Diabetes Mellitus, and Subjects With Type 2 Diabetes Mellitus. [NCT03170544]	Phase 1	69 participants (Actual)	Interventional	2017-08-16	Completed
A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC 0123-0000-0338 in Healthy Subjects [NCT01334034]	Phase 1	70 participants (Actual)	Interventional	2011-04-11	Completed
A 26-week Randomized, Open-label, Active-controlled, 2-treatment Arm, Parallel Group Multi-center Study, Comparing the Efficacy and Safety of Soliqua™100/33 Versus Lantus® in Ethnically/Racially Diverse Patients With Type 2 Diabetes Mellitus Inadequately [NCT03434119]	Phase 3	241 participants (Actual)	Interventional	2018-02-20	Terminated(stopped due to "(Trial terminated (recruitment delays))")
Biphasic Insulin Aspart 70/30 + Metformin Compared to Insulin Glargine + Metformin in Type 2 Diabetes Failing OAD Therapy [NCT00598793]	Phase 3	242 participants (Actual)	Interventional	2002-11-30	Completed
A Trial Comparing Efficacy and Safety of NN5401 With Insulin Glargine, Both in Combination With Oral Antidiabetic Drugs in Subjects With Type 2 Diabetes (BOOST™ : INTENSIFY BASAL) [NCT01045447]	Phase 3	465 participants (Actual)	Interventional	2010-01-31	Completed
A Pan Asian Trial Comparing Efficacy and Safety of Insulin NN1250 and Insulin Glargine as Add on to OAD(s) in Subjects With Type 2 Diabetes (BEGIN™: ONCE ASIA) [NCT01059799]	Phase 3	435 participants (Actual)	Interventional	2010-02-01	Completed
A 26 Week Randomised, Controlled, Open Label, Multicentre, Multinational, Three-arm, Treat to Target Trial Comparing Efficacy and Safety of Three Different Dosing Regimens of Either Soluble Insulin Basal Analogue (SIBA) or Insulin Glargine With or Without [NCT01006291]	Phase 3	687 participants (Actual)	Interventional	2009-11-30	Completed
A Randomized, Open-Label, Parallel-Arm, Noninferiority Comparison of the Effects of Two Doses of LY2189265 and Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes on Stable Doses of Metformin and Glimepiride [NCT01075282]	Phase 3	810 participants (Actual)	Interventional	2010-02-28	Completed
An Open Label Randomized Multicenter Study to Assess Patient Preference for and Evaluate Clinical Benefit of Insulin Glargine (Lantus®) SoloSTAR® Pen Versus Conventional Vial/Syringe Method of Insulin Glargine (Lantus®) Injection Therapy in Patients With [NCT01226043]	Phase 4	405 participants (Actual)	Interventional	2010-10-31	Completed
NN1250-3582: A 52-week Randomised, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing Efficacy and Safety of SIBA and Insulin Glargine Both Administered Once Daily in a Basal-bolus Regimen With Insulin Aspart as Mealtime In [NCT00972283]	Phase 3	1,006 participants (Actual)	Interventional	2009-09-01	Completed
A Phase 2 Study of LY2605541 Compared With Insulin Glargine in the Treatment of Type 2 Diabetes Mellitus [NCT01027871]	Phase 2	289 participants (Actual)	Interventional	2010-01-31	Completed
Basal Bolus Versus Basal Insulin Regimen for the Treatment of Hospitalized Patients With Type 2 Diabetes Mellitus [NCT00979628]	Phase 4	375 participants (Actual)	Interventional	2010-01-31	Completed
Superiority Study of Insulin Glargine Over Sitagliptin in Insulin-naïve Patients With Type 2 Diabetes Treated With Metformin and Not Adequately Controlled [NCT00751114]	Phase 4	515 participants (Actual)	Interventional	2008-11-30	Completed
6-Month, Multicenter, Randomized, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® in Insulin-Naïve Patients With Type 2 Diabetes Mellitus Not Adequately Controlled With Non-Insulin Antihyperglyce [NCT02855684]	Phase 3	604 participants (Actual)	Interventional	2016-08-24	Completed
A 21-Week, Open-label, Randomized, Controlled, Parallel-group, Multi-center Study Evaluating the Efficacy and Safety of HOE901-U300 Administered According to a Device-Supported Treat-to-target Regimen Versus Routine Titration in Patients With Type 2 Diabe [NCT02585674]	Phase 3	151 participants (Actual)	Interventional	2015-12-31	Completed
A 24-week, Randomized, Open-label, Parallel Group Multinational Comparison of Lantus® (Insulin Glargine) Given in the Morning as Once-a-day Basal Insulin Versus Neutral Protamine Hagedorn (NPH) Insulin, in Children With Type 1 Diabetes Mellitus Aged at Le [NCT00993473]	Phase 3	125 participants (Actual)	Interventional	2009-10-31	Completed
A Randomized, Open-Label, Active-Controlled, Parallel-Group, Multicenter Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin Glargine as Compared With the Combination of Insulin Glargine and Preprandial Lispr [NCT00976391]	Phase 3	586 participants (Actual)	Interventional	2009-09-30	Completed
Comparison of Efficacy and Safety of Standard vs Higher Starting Dose of Insulin Glargine in Overweight and Obese Chinese Patients With Type 2 Diabetes [NCT02836704]	Phase 4	892 participants (Actual)	Interventional	2016-09-09	Completed
Effect of Simplified Insulin Regimen on Glycemic Control and Quality of Life in an Elderly Population With Type 2 Diabetes [NCT03660553]	Phase 4	7 participants (Actual)	Interventional	2018-10-10	Terminated(stopped due to PI left University of Miami)
The Metabolic and Glycaemic Effects of a Combined Basal-Bolus Insulin Reduction And Carbohydrate Feeding Strategy For Evening Exercise in Type 1 Diabetes Mellitus [NCT02204839]		10 participants (Actual)	Interventional	2014-01-31	Completed
Proof-of-concept Trial of Clinician-supported Patient Self-management of Hospital Insulin Therapy [NCT02144441]		0 participants (Actual)	Interventional	2014-06-30	Withdrawn(stopped due to Very few patients met eligibility criteria, none of whom elected to enroll.)
A Randomized, Active-controlled, Parallel Group, 16-Week Open Label Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo (Insulin Glargine-U300) Versus Lantus in Patients With Type 1 Diabetes Mellitus [NCT02688933]	Phase 4	638 participants (Actual)	Interventional	2016-05-05	Completed
A 24-week International, Multicenter, Randomized, Open-Label, Active-Controlled, Parallel Group, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in [NCT02551874]	Phase 3	650 participants (Actual)	Interventional	2015-10-20	Completed
A Multicenter, Randomized, Open-label, Active-controlled Study to Compare the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Insulin Glargine in Insulin-naïve Type 2 Diabetic Patients Inadequately Controlled With Metformin and [NCT00755287]	Phase 3	1,072 participants (Actual)	Interventional	2008-11-30	Completed
A Phase 3, Open-Label, Three-Group Parallel Study to Evaluate the Efficacy and Safety of Human Insulin Inhalation Powder (HIIP) in Patients With Type 2 Diabetes Treated With Once-Daily Insulin Glargine [NCT00355849]	Phase 3	555 participants (Actual)	Interventional	2006-08-31	Completed
A Randomized, Open-Label, Controlled, Parallel-group, Multicenter Trial Comparing the Efficacy and Safety of INS068 and Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Not Adequately Controlled With Basal Insulin [NCT05702073]	Phase 3	400 participants (Anticipated)	Interventional	2023-03-31	Recruiting
A Phase 1, Exploratory, Randomized, Double-Blind, Two-Way Cross Over Study to Assess Pharmacokinetic and Pharmacodynamic Effects of Gan & Lee's Insulin Glargine Injection in Comparison to Lantus in Subjects With Type 1 Diabetes Mellitus [NCT02506647]	Phase 1	41 participants (Actual)	Interventional	2015-12-31	Completed
Sitagliptin for the Prevention and Treatment of Stress Hyperglycemia in Non-Diabetic Patients Undergoing Cardiac Surgery [NCT02443402]	Phase 4	68 participants (Actual)	Interventional	2016-01-31	Completed
The Effect of Short-term Insulin Intensive Therapy Based on the Application of Insulin Pump and Real-time Dynamic Glucose Monitoring Technology on Reversing the Newly Diagnosed Type 2 Diabetes [NCT06127433]	Phase 4	210 participants (Anticipated)	Interventional	2023-03-07	Recruiting
A Pilot Study of the Effect of Continuous Subcutaneous Insulin Infusion in Adolescents With Newly-diagnosed Type 1 Diabetes on Insulin Resistance, Beta-cell Function and the Honeymoon Period. [NCT00357890]		12 participants (Actual)	Interventional	2005-12-31	Completed
The Efficacy and Safety of Once-Weekly, Subcutaneous Dulaglutide Compared to Once-Daily Insulin Glargine in Patients With Type 2 Diabetes Mellitus on Metformin and/or a Sulfonylurea [NCT01648582]	Phase 3	774 participants (Actual)	Interventional	2012-07-31	Completed
Effects of Degludec/Liraglutide on Time in Range, Markers of Inflammation and Endothelial Dysfunction Compared to Scheme Insulin Basal Bolus, in a Population of Diabetic Inpatients and Possible Correlation With Intra-hospital Mortality Rates [NCT05360537]	Phase 4	100 participants (Actual)	Interventional	2021-04-01	Completed
Effect of Short-term Basal Insulin Initiation in Newly Diagnosed Type 2 Diabetes on 1-year Glycemic Control [NCT06107153]		200 participants (Anticipated)	Interventional	2023-11-01	Not yet recruiting
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3209590 Following Multiple Weekly Doses in Chinese Patients With Type 2 Diabetes Mellitus [NCT05596747]	Phase 1	30 participants (Anticipated)	Interventional	2022-11-30	Active, not recruiting
Intravenous Insulin Protocol in Diabetes and Renal Transplantation Study [NCT00609986]		104 participants (Actual)	Interventional	2007-07-31	Completed
A Canadian, Phase IV, Multicenter, Comparative, Open-label Study Evaluating 2 Approaches of Blood Glucose Monitoring and Insulin Titration (Patient-managed vs Health Care Professional) in T2DM Patients While Receiving the Addition of 1 Injection of Insuli [NCT01013571]	Phase 4	493 participants (Actual)	Interventional	2009-10-31	Completed
A Randomised, Multicentre, Open-Label, Parallel-Group, 24-Week Phase IV Study Comparing the Effectiveness and Safety of Two Approaches to the Management of Type 2 Diabetes Mellitus in Australian Primary Care: General Practitioner Initiation of Insulin Gla [NCT00950534]	Phase 4	25 participants (Actual)	Interventional	2009-07-31	Terminated(stopped due to due to poor recruitment)
Comparison of Insulin Lispro Low Mixture With Insulin Glargine When Initiating and Intensifying Insulin Therapy As Required in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Oral Antihyperglycemic Medication [NCT00548808]	Phase 4	426 participants (Actual)	Interventional	2007-11-30	Completed
Insulin Dose Titration System in Diabetic Patients Using a Short Messaging Service Automatically Produced by a Knowledge Matrix [NCT00948584]		100 participants (Actual)	Interventional	2007-11-30	Completed
Superiority of Insulin Glargine Lantus vs. NPH: Treat to Normoglycemia Concept.Effect of Insulin Glargine in Comparison to Insulin NPH in Insulin-nave People With Type 2 Diabetes Mellitus Treated With at Least One OAD and Not Adequately Controlled [NCT00949442]	Phase 4	708 participants (Actual)	Interventional	2009-07-31	Completed
Effect of AC2993 (Synthetic Exendin-4) Compared With Insulin Glargine in Patients With Type 2 Diabetes Also Using Combination Therapy With Sulfonylurea and Metformin [NCT00082381]	Phase 3	551 participants (Actual)	Interventional	2003-06-30	Completed
A Trial Investigating the Pharmacodynamic and Pharmacokinetic Properties of NN1250 in Young and Geriatric Subjects With Type 1 Diabetes [NCT00964418]	Phase 1	27 participants (Actual)	Interventional	2009-08-31	Completed
Multicentre, Open, Non-randomised Controlled Phase IV Clinical Trial of Efficacy and Safety for Insulin Glulisine Injected Subcutaneously in Patients With Type 1 Diabetes Mellitus Using Also Insulin Glargine [NCT00964574]	Phase 4	68 participants (Actual)	Interventional	2009-07-31	Completed
A Six Month, Open Label, Randomized Parallel Group Trial Assessing The Impact Of Dry Powder Inhaled Insulin (Exubera) On Glycemic Control Compared To Insulin Glargine (Lantus) In Patients With Type 2 Diabetes Mellitus Who Are Poorly Controlled On A Combin [NCT00418522]	Phase 4	413 participants (Actual)	Interventional	2007-03-31	Completed
Outcome of Using Long Acting Glargine Insulin With Low Dose Regular Insulin Infusion in Diabetic Ketoacidosis Patients :A Comparative Study [NCT05219942]		52 participants (Anticipated)	Interventional	2020-12-01	Recruiting
A Study of the Rules for Insulin Dosing in Patients Using Multiple Daily Injections [NCT01045954]		50 participants (Anticipated)	Interventional	2010-01-31	Recruiting
Pathogenesis of the Impaired Incretin Effect in Type 2 Diabetes [NCT00469833]		17 participants (Actual)	Interventional	2008-04-30	Completed
A Phase 4, Randomized, Open Label, Parallel Group, Multicenter Study to Characterize Regimens of Basal Insulin Intensified With Either Symlin® or Rapid Acting Insulin in Patients With Type 2 Diabetes [NCT00467649]	Phase 4	112 participants (Actual)	Interventional	2007-05-31	Completed
A Trial Investigating the Hypoglycaemic Response to NN1250 in Subjects With Type 1 Diabetes [NCT01002768]	Phase 1	28 participants (Actual)	Interventional	2009-10-31	Completed
A Randomized, Active-controlled, Open Label, 2-treatment Arm, and Multicenter Study Comparing the Efficacy and Safety of Insulin Glargine/Lixisenatide Combination to Lixisenatide on Top of OADs in Japanese Patients With Type 2 DM With an Extension Period [NCT02749890]	Phase 3	321 participants (Actual)	Interventional	2016-05-09	Completed
A 24 Week, Open-Label, Single Arm, Multi-Center Clinical Study to Document the Benefits of the Combination of Lantus and Amaryl in Ethnic Japanese Type 2 Diabetic Patients Living Outside of Japan (in US or Brazil), Who Failed Good Metabolic Control With O [NCT00642915]	Phase 4	100 participants (Actual)	Interventional	2003-06-30	Completed
Titration Target for Chinese Type 2 Diabetes Mellitus Patients Using Insulin Glargine to Achieve Glycaemic Goals: An Assessment of Three Different Fasting Plasma Glucose Targets - BEYOND III/FPG GOAL Study [NCT02545842]	Phase 4	947 participants (Actual)	Interventional	2015-09-07	Completed
A Randomized, Active-controlled, Open Label, 2-treatment Arm, and Multicenter Study Comparing the Efficacy and Safety of the Insulin Glargine/Lixisenatide Combination to Insulin Glargine With Metformin in Japanese Patients With Type 2 Diabetes Mellitus In [NCT02752412]	Phase 3	513 participants (Actual)	Interventional	2016-05-17	Completed
Effect of Dosage Reduction of Glucose-Lowering Multidrug Regimens on the Incidence of Acute Glycemic Complications in People With Type 2 Diabetes Who Fast During Ramadan: An Open-Label, Parallel-Group, Randomized, Controlled Trial [NCT04237493]	Phase 4	687 participants (Actual)	Interventional	2017-02-14	Completed
A Trial Comparing NNC0148-0287 C (Insulin 287) Versus Insulin Glargine U100, Both in Combination With Metformin, With or Without DPP4 Inhibitors and With or Without SGLT2 Inhibitors, in Insulin-naïve Subjects With Type 2 Diabetes Mellitus [NCT03951805]	Phase 2	205 participants (Actual)	Interventional	2019-05-09	Completed
A Prospective Study to Optimize Insulin Treatment by Basal Regimen With Insulin Glargine in Type-2-Diabetic Patients Previously Uncontrolled on Premixed Insulin [NCT00693771]	Phase 4	313 participants (Actual)	Interventional	2008-04-30	Completed
Acute Effect of a GLP-1-Analogue (Exenatide) and of a DPP-4-Inhibitor (Sitagliptin) in Subjects With Type 2 Diabetes Treated With Insulin Glargine Once Daily [NCT00971659]	Phase 1	48 participants (Actual)	Interventional	2008-01-31	Completed
An Open Label Study Comparing Exenatide With Basal Insulin in Achieving an HbA1c of ≤ 7.4% With Minimum Weight Gain, in Type 2 Diabetes Patients Who Are Not Achieving Adequate HbA1c Control on Oral Anti Diabetic Therapies Alone [NCT00360334]	Phase 3	235 participants (Actual)	Interventional	2006-06-30	Completed
Basal/Bolus Insulin Therapy in the Hospital Ward Comparison of Two Protocols: Feasibility Study [NCT00841919]	Phase 4	60 participants (Anticipated)	Interventional	2006-12-31	Completed
A Multicenter, 2-Part, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-0941 on Postprandial Plasma Glucose Concentrations After Daily Administration MK-0941 [NCT00511472]	Phase 1	70 participants (Actual)	Interventional	2007-07-31	Completed
A Multi-national, Open-labelled, Randomised, Parallel Group, 4 Week run-in and 26 Weeks Treat-to-target Comparison of Biphasic Insulin Aspart 30 Once Daily Versus Insulin Glargine Once Daily Both in Combination With Metformin and Glimepiride in Insulin na [NCT00469092]	Phase 4	480 participants (Actual)	Interventional	2007-05-31	Completed
Health Assessment, Patient Treatment Satisfaction and Quality-of-Life in Insulin-naive Type 2 Diabetes Patients Uncontrolled on Oral Hypoglycemic Agent Treatment Initiating Basal Insulin Therapy With Either Insulin Glargine or NPH Insulin [NCT00941369]	Phase 4	345 participants (Actual)	Interventional	2009-06-30	Completed
A Randomized Trial Comparing Insulin Lispro Protamine Suspension With Insulin Glargine in Subjects With Type 2 Diabetes on Oral Antihyperglycemic Medications and Exenatide [NCT00560417]	Phase 3	339 participants (Actual)	Interventional	2007-11-30	Completed
Effects of Intensive Glycemic Control on Infectious Morbidity In Patients With Acute Leukemia [NCT00943709]	Phase 3	0 participants (Actual)	Interventional	2009-05-31	Withdrawn(stopped due to lack of accrual)
Comparison of a Basal Plus One Insulin Regimen (Insulin Glargine/Insulin Glulisine) With a Biphasic Insulin Regimen (Insulin Aspart/Insulin Aspart Protamine 30/70) in Type 2 Diabetes Patients Following Basal Insulin Optimisation [NCT00965549]	Phase 4	463 participants (Actual)	Interventional	2009-07-31	Completed
A Multi-center, Randomized, Open-label, Active-controlled Study to Compare the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Insulin Glargine in Insulin-naive Type 2 Diabetic Patients Inadequately Controlled With Metformin and [NCT01051011]	Phase 3	370 participants (Actual)	Interventional	2010-01-31	Terminated(stopped due to high discontinuation rates mainly due to GI tolerability and implementation of risk mitigation plan to address hypersensitivity reactions)
A Trial Investigating the Pharmacokinetic Properties of NN1250 in Children, Adolescents and Adults With Type 1 Diabetes [NCT01030926]	Phase 1	39 participants (Actual)	Interventional	2009-12-31	Completed
Comparison of Efficacy and Safety of Biphasic Insulin Aspart 30 Plus Metformin With Insulin Glargine Plus Glimepiride in Type 2 Diabetes [NCT00619697]	Phase 4	260 participants (Actual)	Interventional	2003-12-31	Completed
A Randomised, Open-labelled, 2-period Crossover Trial Investigating Pharmacodynamics and Pharmacokinetics of Biphasic Insulin Aspart 30 Thrice Daily and Basal-bolus Therapy With Insulin Glargine & Insulin Glulisine in Subjects With Type 2 Diabetes [NCT00824668]	Phase 1	24 participants (Actual)	Interventional	2007-08-31	Completed
Assessment of Forced Titration to Reach the Effective Dose for Good Glycemic Control in Lantus Treated Type 2 Patients [NCT00701831]	Phase 4	241 participants (Actual)	Interventional	2008-05-31	Completed
Combination Therapy of Insulin Glargine and Sitagliptin in Patients With Type 2 Diabetes Not Adequately Controlled by a Previous Treatment With Metformin and Either Insulin Glargine or Sitagliptin [NCT00851903]	Phase 3	112 participants (Actual)	Interventional	2009-06-30	Completed
Effects of Optimized Glycemic Control Achieved With add-on Basal Insulin Therapy on Indexes of Endothelial Damage and Regeneration in Type 2 Diabetic Patients With Macroangiopathy. A Randomized Cross-over Trial Comparing Detemir vs Glargine [NCT00699686]	Phase 4	50 participants (Anticipated)	Interventional	2008-05-31	Completed
An International Multicentre Randomized Controlled Trial of Intensive Insulin Therapy Targeting Normoglycemia In Acute Myocardial Infarction: the RECREATE (REsearching Coronary REduction by Appropriately Targeting Euglycemia) Pilot Study [NCT00640991]	Phase 3	500 participants (Anticipated)	Interventional	2008-04-30	Completed
A Multi-center, Open, Randomized, Parallel-group, 2 Arm Study to Compare the Efficacy and Safety of Amaryl®M 1/500mg Twice Daily Versus Amaryl® 4mg Both in Combination With Lantus® Once-daily Regimen in Type 2 Diabetes Mellitus Patients With Inadequate Gl [NCT00913367]	Phase 4	110 participants (Anticipated)	Interventional	2009-05-31	Completed
A Randomised, Single-centre, Double-blind, Two-period Cross-over, Multiple Dose Trial Comparing Pharmacodynamic and Pharmacokinetic Properties of Insulin Degludec and Insulin Glargine 300 U/mL at Steady-state Conditions in Subjects With Type 1 Diabetes Me [NCT02536859]	Phase 1	60 participants (Actual)	Interventional	2015-08-31	Completed
Comparison Safety and Efficacy of Basal Insulin Lantus® (Insulin Glargine) vs NPH Insulin in Combination With OADs in Patients With DMT2, Assessed by Continuous Glucose Monitoring System (CGMS). Multicentre, Prospective, Open- Label, Single Arm, Comparati [NCT00659477]	Phase 4	117 participants (Actual)	Interventional	2008-03-31	Completed
RAndomized Study of Basal Bolus Insulin Therapy in the Inpatient Management of Patients With Type 2 Diabetes Undergoing General Surgery (RABBIT 2 Surgery) [NCT00596687]	Phase 4	234 participants (Actual)	Interventional	2007-12-31	Completed
A Comparison of PK/PD Dose Response Characteristics of Glargine in Type 2 Diabetics [NCT00574912]	Phase 1	20 participants (Actual)	Interventional	2007-03-31	Completed
A Multi-center, Phase 3b, Stratified, Randomized, Open-label Clinical Trial to Evaluate the Efficacy of Intensive Apidra®/Lantus® Therapy vs Sliding Scale Insulin on Infarct Size in Hyperglycemic Subjects With Anterior STEMI (ST Elevation Myocardial Infar [NCT00670228]	Phase 3	34 participants (Actual)	Interventional	2008-04-30	Terminated(stopped due to Due to Negative feasibility assessment of recruiting the planned number of subjects within the study timelines)
A Prospective Randomized Trial to Compare Basal Bolus Therapies That Use Either Insulin Lispro Protamine Suspension or Insulin Glargine Together With Lispro Insulin in Patients With Type 2 Diabetes [NCT00666718]	Phase 3	374 participants (Actual)	Interventional	2008-04-30	Completed
Treatment Initiation With Basal Insulin in Uncontrolled Type 2 Diabetes Patients on Oral Anti-Diabetic Agent (OAD) in Jordan [NCT02606357]	Phase 4	242 participants (Actual)	Interventional	2015-11-22	Completed
A Phase IIb, Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Range Finding Clinical Trial of MK0941 in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin [NCT00767000]	Phase 2	813 participants (Actual)	Interventional	2008-10-31	Terminated
Comparison of Premixed Insulin Lispro Low-Mixture and Mid-Mixture Regimens With Separate Basal and Bolus Insulin Injections in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Oral Therapy Who Consume Light Breakfast [NCT00664534]	Phase 4	344 participants (Actual)	Interventional	2008-04-30	Completed
Insulin Glargine Combined With Sulfonylurea Versus Metformin in Patients With Type 2 Diabetes: A Randomized, Controlled Trial. [NCT00708578]	Phase 4	99 participants (Actual)	Interventional	2008-05-31	Completed
A Randomized, Open-label, Parallel-group, Multicenter Study to Determine the Efficacy and Long-term Safety of Albiglutide Compared With Insulin in Subjects With Type 2 Diabetes Mellitus. [NCT00838916]	Phase 3	779 participants (Actual)	Interventional	2009-02-28	Completed
Phase 4 Study of Comparison of Combination Therapy of Gliclazide MR and Basal Insulin With Pre-mix Insulin Monotherapy for the Patients With Type 2 Diabetes Mellitus [NCT00736515]	Phase 4	160 participants (Actual)	Interventional	2008-10-31	Completed
Efficacy of Once-Weekly Exenatide Long-Acting Release and Once-Daily Insulin Glargine in Patients With Type 2 Diabetes Treated With Metformin Alone or in Combination With Sulfonylurea [NCT00641056]	Phase 3	467 participants (Actual)	Interventional	2008-04-30	Completed
A Randomized, Open Label, Placebo-controlled, 4-sequence, 4-period, 4-treatment Crossover Study to Investigate the Postprandial Glucodynamic Response to Single Dose of Insulin Glargine/Lixisenatide Fixed Ratio Combination in Japanese Patients With Type 2 [NCT02713477]	Phase 1	20 participants (Actual)	Interventional	2016-04-30	Completed
The Effect of Exenatide Compared to Insulin Glargine on Cardiac Function and Metabolism in Type 2 Diabetic Patients With Congestive Heart Failure: a Randomized Comparator-controlled Trial [NCT00766857]	Phase 4	27 participants (Actual)	Interventional	2009-05-31	Completed
A Phase II, Randomized, Double Blind, 2-Way Crossover Safety and Efficacy Study of Subcutaneously Injected Prandial Insulins: Lispro-PH20 or Aspart-PH20 Compared to Insulin Lispro (Humalog®) in Patients With Type 1 Diabetes [NCT01194245]	Phase 2	135 participants (Actual)	Interventional	2010-08-31	Completed
"A Randomized Double Blinded Two-way Crossover Single-dose Pharmacokinetics and Pharmacodynamics Study of RinGlar® (LLC GEROPHARM, Russia) Versus Lantus® (Sanofi-Aventis) in Type 1 Diabetes Mellitus Patients Using the Euglycemic Clamp Technique" [NCT04101383]		42 participants (Actual)	Interventional	2017-10-16	Completed
An Open-labelled, Randomised, Parallel Group, 3 Week run-in and 24 Week Treat-to-target Comparison of Biphasic Insulin Aspart 30 Once Daily Versus Insulin Glargine Once Daily Both in Combination With Metformin and Glimepiride in Chinese and Japanese Insul [NCT01123980]	Phase 4	521 participants (Actual)	Interventional	2010-05-31	Completed
A Trial Assessing the Implications of Switching From Insulin Glargine to Insulin Degludec in Subjects With Type 2 Diabetes Mellitus (BEGIN™: SIMPLIFY) [NCT01135992]	Phase 3	143 participants (Actual)	Interventional	2010-06-30	Completed
A 24-week, Multicenter, International, Randomized (1:1), Parallel-group, Open-label, Comparative Study of Insulin Glargine Versus Liraglutide in Insulin-naïve Patients With Type 2 Diabetes Treated With Oral Agents and Not Adequately Controlled, Followed b [NCT01117350]	Phase 4	978 participants (Actual)	Interventional	2010-07-31	Completed
A 16 Week Randomised, Open Labelled, 3-armed, Treat-to-target, Parallel Group Trial Comparing SIBA (D) Once Daily + NovoRapid®, SIBA (E) Once Daily + NovoRapid® and Insulin Glargine Once Daily + NovoRapid®, All in a Basal/Bolus Regimen in Subjects With Ty [NCT00612040]	Phase 2	178 participants (Actual)	Interventional	2008-01-31	Completed
A 16 Week Randomised, Open-labelled, Four-armed, Treat-to-target, Parallel-group Trial Comparing SIBA D Once Daily, SIBA E Once Daily, SIBA D Monday, Wednesday and Friday and Insulin Glargine Once Daily, All in Combination With Metformin in Subjects With [NCT00611884]	Phase 2	245 participants (Actual)	Interventional	2008-01-31	Completed
Effects of Local Insulin on Wound Angiogenesis and Fibroplasia in Varicose Ulcers [NCT04310280]	Phase 3	13 participants (Actual)	Interventional	2019-06-01	Completed
Comparison of Lantus and NPH Insulin in the Dawn Phenomenon [NCT00694122]	Phase 3	27 participants (Actual)	Interventional	2005-06-30	Completed
A Randomized, Active-controlled, Open Label, 2-treatment Arm, and Multicenter Study Comparing the Efficacy and Safety of the Insulin Glargine/Lixisenatide Combination to Insulin Glargine on Top of OADs in Japanese Patients With Type 2 Diabetes Mellitus (T [NCT02752828]	Phase 3	521 participants (Actual)	Interventional	2016-05-23	Completed
The LANCET Trial: A Randomized Clinical Trial of Lantus for C-reactive Protein Reduction in Early Treatment of Type 2 Diabetes [NCT00366301]	Phase 4	500 participants (Actual)	Interventional	2006-08-31	Terminated(stopped due to Interim analyses demonstrated futility. Thus, recruitment curtailed 10/08.)
A Six Month, Open-Label Outpatient, Randomized Parallel Group Trial Assessing The Impact Of Dry Powder Inhaled Insulin (Exubera®) On Glycemic Control Compared To Insulin Glargine (Lantus®) In Patients With Type 2 Diabetes Mellitus Who Are Poorly Controlle [NCT00391027]	Phase 4	261 participants (Actual)	Interventional	2006-12-31	Completed
A 28-week, Prospective, Single-arm, Phase 4 Study to Evaluate Treatment Optimization With Once-daily Insulin Glargine 300 U/mL in Combination With Prandial Rapid-acting Insulin Analogue in Patients With Type 1 Diabetes Previously Uncontrolled on Twice-dai [NCT03406000]	Phase 4	170 participants (Actual)	Interventional	2018-01-22	Completed
A Phase 2 Study of LY2605541 Compared With Insulin Glargine in the Treatment of Type 1 Diabetes Mellitus [NCT01049412]	Phase 2	138 participants (Actual)	Interventional	2010-01-31	Completed
The Utility of Insulin Glargine (Lantus) Compared to NPH in Ethnic Minority Type 2 Diabetic Subjects Starting Insulin Therapy [NCT00686712]	Phase 4	108 participants (Actual)	Interventional	2003-02-28	Completed
Assessment of the Phenotype of the Type 2 Diabetic Responders to the First Insulinisation Using Lantus (Insulin Glargine) Plus Glucophage (Metformin) Combination After Failure in OADs Treatment [NCT00653302]	Phase 4	280 participants (Actual)	Interventional	2003-04-30	Completed
All to Target Trial Lantus® (Insulin Glargine) With Stepwise Addition of APIDRA® (Insulin Glulisine) or Lantus With One Injection of Apidra vs a Twice-Daily Premixed Insulin Regimen (Novolog® Mix 70/30) in Adult Subjects With Type 2 Diabetes Failing Dual [NCT00384085]	Phase 4	588 participants (Actual)	Interventional	2006-05-31	Completed
A 16 Week Randomised, Open Labelled, 3 Armed, Parallel Group, Treat-to-target Trial Comparing Once Daily Injection of SIAC 30 (B), SIAC 45 (B) and Insulin Glargine, All in Combination With Metformin in Subjects With Type 2 Diabetes Failing on OAD Treatmen [NCT00614055]	Phase 2	178 participants (Actual)	Interventional	2008-01-31	Completed
A 52 Week Study Comparing the Efficacy and Safety of Once Weekly IcoSema and Daily Insulin Glargine 100 Units/mL Combined With Insulin Aspart, Both Treatment Arms With or Without Oral Anti Diabetic Drugs, in Participants With Type 2 Diabetes Inadequately [NCT05013229]	Phase 3	680 participants (Anticipated)	Interventional	2021-11-30	Active, not recruiting
Randomized Trial of Liraglutide and Insulin Therapy on Hepatic Steatosis as Measured by MRI and MRS in Metformin-treated Patients With Type 2 Diabetes: an Open Pilot Study [NCT01399645]	Phase 2	35 participants (Actual)	Interventional	2011-05-31	Completed
An Open, Single-centre, Controlled Trial to Investigate the Efficacy and Usability of Published Best Practice to Control Glycaemia in Hospitalised Patients With Type 2 Diabetes [NCT01407289]	Phase 4	74 participants (Actual)	Interventional	2011-06-30	Completed
A Randomised, Single-centre, Double-blind, Parallelgroup, Multiple Dose Trial Comparing the Within-subject Variability of SIBA and Insulin Glargine With Respect to Pharmacodynamic Response at Steady State Conditions in Subjects With Type 1 Diabetes [NCT00961324]	Phase 1	54 participants (Actual)	Interventional	2009-07-27	Completed
A 26-week Trial Investigating the Dosing Flexibility, Efficacy and Safety of NN1250 in Subjects With Type 1 Diabetes With a 26-week Extension (Begin™: Flex T1) [NCT01079234]	Phase 3	493 participants (Actual)	Interventional	2010-03-31	Completed
Treatment Satisfaction of Insulin Glargine Plus Insulin Apidra Compared With NPH Insulin Plus Insulin Apidra in Recently Diagnosed Type 1 Diabetes Children and Adolescents [NCT00925977]		44 participants (Actual)	Interventional	2009-07-31	Terminated
28-week, Open, Randomized, Multinational, Multicenter Clinical Trial to Compare Efficacy and Safety of Combination Therapy of Glimepiride Plus Metformin Plus HOE901 Insulin Analogue Versus a Two-injection Conventional Therapy With Premixed Insulin NPH 30/ [NCT00783744]	Phase 3	375 participants (Actual)	Interventional	2001-12-31	Completed
A 26 Week Randomised, Multinational, Open Labelled, 2 Armed, Parallel Group, Treat-to-target Once Daily Treatment Trial With Insulin Detemir Versus Insulin Glargine, Both in Combination With Metformin in Subjects With Type 2 Diabetes [NCT00909480]	Phase 4	457 participants (Actual)	Interventional	2009-05-31	Completed
Insulin Degludec vs Insulin Glargine for Glycemic Control in Critical Illness Hyperglycemia [NCT06178874]		90 participants (Anticipated)	Interventional	2023-12-31	Not yet recruiting
Basal Insulin in the Management of Patients With Diabetic Ketoacidosis [NCT00590044]	Phase 4	74 participants (Actual)	Interventional	2007-12-31	Completed
A 12-month Prospective Observational Study Assessing the Real-world Clinical Effectiveness, Safety and Health-economic Benefits of Toujeo® Initiation After Oral Antidiabetic Drug Failure in Insulin-naïve Patients With Type 2 Diabetes Mellitus [NCT03703869]		4,589 participants (Actual)	Observational	2018-03-06	Completed
A Study of LY900014 in Participants With Type 2 Diabetes Using Continuous Glucose Monitoring [NCT04605991]	Phase 3	187 participants (Actual)	Interventional	2020-11-04	Completed
A Randomised, Single Centre, Double-blind, Two-Period Cross-over, Multiple Dose Trial Comparing the Pharmacodynamic Response of Insulin 454 With Insulin Glargine at Steady-State Conditions in Subjects With Type 1 Diabetes Mellitus [NCT01868529]	Phase 1	63 participants (Actual)	Interventional	2008-01-31	Completed
Early Administration of Long-acting Insulin Glargine for the Treatment of Diabetic Ketoacidosis in Pediatric Type 1 Diabetes: A Randomized Double Blind Trial [NCT02548494]		17 participants (Actual)	Interventional	2015-11-30	Terminated(stopped due to Project terminated due to insufficient resources for recruitment.)
A Prospective, Randomized, Double-Blind Comparison of LY900014 to Insulin Lispro, Both in Combination With Insulin Glargine or Insulin Degludec in Adults With Type 2 Diabetes [NCT03952143]	Phase 3	628 participants (Actual)	Interventional	2019-05-27	Completed
The PERSISTENT Trial: A Prospective Randomized Trial Comparing Insulin Lispro Protamine Suspension to Insulin Glargine in Patients With Type 2 Diabetes on Anti-hyperglycemic Medications [NCT00510952]	Phase 3	471 participants (Actual)	Interventional	2007-08-31	Completed
A Randomized, Phase 3, Open-label Trial Comparing the Effect of Tirzepatide Once Weekly Versus Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes on Metformin With or Without a Sulfonylurea [NCT04093752]	Phase 3	917 participants (Actual)	Interventional	2019-12-09	Completed
The Differences Between Insulin Glargine U300 and Insulin Degludec U100 in Impact on the Glycaemic Variability, Oxidative Stress, Arterial Stiffness and the Lipid Profiles in Insulin naïve Patients Suffering From Type Two Diabetes Mellitus [NCT04692415]	Phase 4	25 participants (Actual)	Interventional	2018-12-15	Completed
Comparison of Three Therapeutic Strategies for Treating Type 2 Diabetes Mellitus Patients Poorly Controlled With Basal Insulin Associated With Oral Antidiabetic Drugs [NCT00174642]	Phase 3	811 participants (Actual)	Interventional	2004-12-31	Completed
Efficacy and Safety of iGlarLixi Versus Insulin Glargine Plus Dulaglutide in Patients With Type 2 Diabetes Insufficiently Controlled by Insulin Glargine and Metformin Combination Therapy [NCT04893148]	Phase 4	40 participants (Anticipated)	Interventional	2020-05-26	Active, not recruiting
[NCT00540709]	Phase 4	58 participants (Actual)	Interventional	2002-11-30	Completed
Effects of Colesevelam on Insulin Sensitivity in Type 2 Diabetes Mellitus [NCT00147745]	Phase 2	36 participants (Actual)	Interventional	2005-06-30	Completed
A Randomised, Cross-over, Open-label, Multi-centre Trial Comparing the Effect of Insulin Degludec and Insulin Glargine 100U/mL, With or Without OADs in Subjects With Type 2 Diabetes Using Flash Glucose Monitoring [NCT03687827]	Phase 4	498 participants (Actual)	Interventional	2018-10-02	Completed
Healthy Heart Study: Can Insulin Glargine Improve Myocardial Function in Patients With Type 2 Diabetes and Coronary Artery Disease? A Prospective, Randomized, Controlled Clinical Study With Blinded Analysis of Ultrasound Data [NCT01035528]	Phase 4	32 participants (Anticipated)	Interventional	2005-04-30	Active, not recruiting
INHALE-1: A 26-week Primary Treatment Phase, With 26-week Extension, Open-label, Randomized Clinical Trial Evaluating the Efficacy and Safety of Afrezza® Versus Rapid-acting Insulin Analog Injections, Both in Combination With a Basal Insulin, in Pediatric [NCT04974528]	Phase 3	264 participants (Anticipated)	Interventional	2021-09-29	Recruiting
Comparison of Two Therapeutic Strategies for Treating Type 2 Diabetic Patients Poorly Controlled With Basal Insulin Associated With Oral Antidiabetic Drugs : 6-month Proof of Concept Study. [NCT00360698]	Phase 4	106 participants (Actual)	Interventional	2006-07-31	Completed
Randomized, Double-blind, Euglycemic Glucose Clamp Study of Four Formulations of SAR161271, in Single Doses in Healthy Subjects and Single Ascending Doses in Patients With Type 1 Diabetes Mellitus [NCT01053728]	Phase 1/Phase 2	46 participants (Actual)	Interventional	2010-02-28	Completed
Comparison of Two Approaches to Basal-Bolus Insulin Therapy in Patients With Type 2 Diabetes and Inadequate Glycemic Control on Oral Therapy: Comparison of Premixed Insulin Lispro Mid Mixture With Separate Basal and Bolus Insulin Injections [NCT00377858]	Phase 4	484 participants (Actual)	Interventional	2006-08-31	Completed
A Multicenter, International Randomized, 2x2 Factorial Design Study to Evaluate the Effects of Lantus (Insulin Glargine) Versus Standard Care, and of Omega-3 Fatty Acids Versus Placebo, in Reducing Cardiovascular Morbidity and Mortality in High Risk Peopl [NCT00069784]	Phase 3	12,537 participants (Actual)	Interventional	2003-08-31	Completed
A Randomized, Multicenter, Open-Label, Parallel-Group, 28 Days Phase IV Study Comparing The Postprandial Plasma Glucose Profile of Lixisenatide With That of Sitagliptin Add-On to Insulin Glargine in Type 2 Diabetes Mellitus [NCT02200991]	Phase 4	136 participants (Actual)	Interventional	2014-08-31	Completed
A Bicentric Open-label, Randomized, Two-parallel-group Study Investigating the Impact of Combined Lantus Insulin Glargine) and Lyxumia(Lixisenatide) on Insulin Secretion and Gastric Emptying in Subjects With Type 2 Diabetes Mellitus Not Adequately Control [NCT01910194]	Phase 2	39 participants (Actual)	Interventional	2013-12-31	Completed
Comparison of Insulin Glargine Vs Standard Insulin Therapy in CFRD Without Fasting Hyperglycemia [NCT00222521]	Phase 3	20 participants	Interventional	2003-04-30	Completed
A Multicentre, Multinational, Randomised, Open Study to Establish the Optimal Method for Initiating Lantus(Insulin Glargine) Therapy to Determine Metabolic and Economic Outcomes, Safety, and Satisfaction in Subjects With Type 2 Diabetes Mellitus [NCT00565162]	Phase 4	124 participants (Actual)	Interventional	2003-11-30	Completed
A Comparison of Premixed and Basal-Bolus Insulin Intensification Therapies in Patients With Type 2 Diabetes Mellitus With Inadequate Glycaemic Control on Twice-daily Premixed Insulin [NCT01175811]	Phase 4	402 participants (Actual)	Interventional	2011-02-28	Completed
Validation of Insulin Protocol for Prevention and Management of Hyperglycemia in Oncology Patients With Diabetes Receiving High Dose Glucocorticoid Therapy [NCT02012465]	Early Phase 1	15 participants (Actual)	Interventional	2013-09-30	Completed
Efficacy and Safety of TrEating Type 2 Diabetic Patients With Inadequate Response to Metformin and DPP-4 Inhibitors by Adding Basal Insulin Therapy (Insulin Glargine) [NCT02027753]	Phase 4	109 participants (Actual)	Interventional	2013-12-31	Completed
A Multiple Dose, Randomised, Double Blinded, Double Dummy Trial Investigating Efficacy and Safety of NNC0268-0965 Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus [NCT04575181]	Phase 1	86 participants (Actual)	Interventional	2020-10-21	Completed
FLAT-SUGAR: FLuctuATion Reduction With inSULin and Glp-1 Added togetheR [NCT01524705]	Phase 4	102 participants (Actual)	Interventional	2012-08-31	Completed
No Evidence for Essential Differences Between the Effects of Insulin Glargine, Insulin Detemir and NPH Insulin on Glucose Metabolism After a Single Injection as Assessed by 24-h Euglycemic Clamp Studies in Healthy Humans [NCT00566124]	Phase 4	10 participants (Actual)	Interventional	2005-01-31	Completed
Lantus vs Sulfonylurea as add-on Therapy in Type 2 Diabetic Patients Failing Metformin Monotherapy: Comparison of Effects on Beta Cell Function and Metabolic Profile. [NCT00562172]	Phase 4	75 participants (Actual)	Interventional	2007-09-30	Completed
A Multicenter, Non-Comparative, Open, Phase III Study to Evaluate the Efficacy and Safety of Insulin Glargine on Subjects With Type 2 Diabetes Mellitus [NCT00563225]	Phase 3	90 participants (Actual)	Interventional	2002-10-31	Completed
The Efficacy, Safety, and Immunogenicity Study Comparing an Insulin Glargine Biosimilar Sansulin® Log-G With Its Reference Lantus® in Patients With Type 2 Diabetes Mellitus [NCT04591457]	Phase 2	120 participants (Anticipated)	Interventional	2020-10-31	Not yet recruiting
Randomized Clinical Trial of Subcutaneous Analog Basal Bolus Therapy Versus Sliding Scale Human Regular Insulin in the Hospital Management of Hyperglycemia in Non-Critically Ill Patients Without Known History of Diabetes: The HMH Trial [NCT01136746]	Phase 3	16 participants (Actual)	Interventional	2011-03-31	Terminated(stopped due to Low enrollment)
Hyperglycemia and Its Effect After Acute Myocardial Infarction on Cardiovascular Outcomes in Patients With Type 2 Diabetes (HEART2D) [NCT00191282]	Phase 4	1,116 participants (Actual)	Interventional	2002-10-31	Completed
An Open Therapeutic Project to Confirm the Efficacy Tolerability and Safety Profile of Lantus in Everyday Medical Practice [NCT00576368]	Phase 4	4,464 participants (Actual)	Interventional	2003-06-30	Completed
Basal Bolus Regimen With Insulin Analogs Versus Human Insulin in Medical Patients With Type 2 Diabetes: A Randomized Controlled Trial in Paraguay [NCT02278913]	Phase 4	134 participants (Actual)	Interventional	2009-04-30	Completed
A Phase 3b, Multicenter, Open-label, Randomized, Forced-titration Clinical Trial Evaluating the Efficacy and Safety of Technosphere® Insulin Inhalation Powder, Using the Gen2 Inhaler, in Combination With Insulin Glargine Versus Insulin Aspart in Combinati [NCT01196104]	Phase 3	39 participants (Actual)	Interventional	2010-09-30	Terminated(stopped due to For Business Reasons)
Glargine Insulin Versus Continous Regular Insulin in Diabetic Surgical Patients Receiving Parenteral Nutrition (GLUCOSE-in-PN) [NCT02216799]	Phase 4	61 participants (Actual)	Interventional	2013-03-31	Completed
A 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® in Japanese Patients With Type 1 Diabetes Mellitus With a 6-month Safety Extension Period [NCT01689129]	Phase 3	243 participants (Actual)	Interventional	2012-09-30	Completed
Comparison of Twice-Daily Insulin Lispro Low Mixture Versus Once-Daily Basal Insulin Glargine and Once-Daily Prandial Insulin Lispro as Insulin Intensification Strategies in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Basal Insul [NCT01175824]	Phase 4	478 participants (Actual)	Interventional	2011-04-30	Completed
A 26-week Randomised, Confirmatory, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA 200 U/ml Three Times Weekly Injected in the Evening and Insulin Glargine Once Daily in a Population of I [NCT01076647]	Phase 3	467 participants (Actual)	Interventional	2010-03-31	Completed
A Randomized, 26-week, Open-label, 2-treatment Arm, Parallel Group Multicenter Study Comparing the Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed-ratio Combination (Soliqua™) Titrated Using a Simple Titration Algorithm (One Unit Daily Adjustme [NCT03767543]	Phase 3	265 participants (Actual)	Interventional	2019-03-11	Completed
A Multicenter, Multinational, Prospective, Interventional, Single-arm, Phase IV Study Evaluating the Clinical Efficacy and Safety of 26 Weeks of Treatment With Insulin Glargine 300 U/mL (Gla-300) in Patients With Type 2 Diabetes Mellitus Uncontrolled on B [NCT03760991]	Phase 4	372 participants (Actual)	Interventional	2018-12-18	Completed
Subcutaneous Versus Intravenous Basal Insulin in Non-critical Hospitalized Diabetic Patients That Receive Total Parenteral Nutrition [NCT02706119]	Phase 4	163 participants (Actual)	Interventional	2016-07-01	Completed
NN1250-3583: A 52 Week Randomised, Controlled, Open Label, Multicentre, Multinational, Parallel, Treat-to-target Trial Comparing Efficacy and Safety of SIBA and Insulin Glargine Both Administered Once Daily in a Basal-bolus Regimen With Insulin Aspart as [NCT00982228]	Phase 3	629 participants (Actual)	Interventional	2009-09-01	Completed
Differences in Metabolic and Cardiovascular Effects of Pioglitazone vs. Insulin Glargine in the Treatment of Secondary Drug Failure in Type 2 Diabetes [NCT00609856]	Phase 4	36 participants (Actual)	Interventional	2004-04-30	Completed
A Randomized, 24-week, Controlled, Open Label, Parallel Arm, Multicenter Study Comparing the Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine in Type 2 Diabetes Patients, Inadequately Controlled on Basal [NCT03529123]	Phase 3	247 participants (Actual)	Interventional	2018-06-19	Completed
Bedtime Insulin Glargine or Bedtime Neutral Protamine Lispro Combined With Sulfonylurea and Metformin in Type 2 Diabetes. A Randomized, Controlled Trial [NCT00641407]	Phase 4	100 participants (Actual)	Interventional	2007-01-31	Completed
Efficacy and Durability of Glucagon Like Peptide 1 Receptor Agonists (GLP-1 RA)/Thiazolidinedione Versus Basal Bolus Insulin Therapy in Poorly Controlled Type 2 Diabetic Patients (T2DM) Patients on Sulfonylurea Plus Metformin [NCT02887625]		410 participants (Anticipated)	Interventional	2015-02-28	Recruiting
Target Glycemic Control and the Incidence of Symptomatic Nocturnal Hypoglycemia in Insulin Naïve Subjects With Type 2 Diabetes on Oral Hypoglycemic Agent(s) and Treated With Insulin Glargine or NPH Human Insulin. [NCT00653341]	Phase 3	764 participants (Actual)	Interventional	2000-01-31	Completed
A Multicenter, Open-Label, Single-Arm, Phase 4 Study to Assess the Safety of Basaglar in Subjects With Type 2 Diabetes Mellitus in India [NCT04153981]	Phase 4	260 participants (Actual)	Interventional	2019-12-16	Completed
NN1250-3579: A 52-week Randomised, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA and Insulin Glargine, Both Injected Once Daily in Combination With Oral Anti-diabetic Drugs (OAD), in Sub [NCT00982644]	Phase 3	1,030 participants (Actual)	Interventional	2009-09-30	Completed
Evaluation of Pharmacokinetic and Pharmacodynamic Properties of Rapid-Acting Insulin Analogs Given as a Bolus by Continuous Subcutaneous Insulin Infusion (CSII) and in MDI Basal-Bolus Therapy in Pediatric Subjects With Type 1 Diabetes (TID) [NCT00652288]	Phase 1	36 participants (Actual)	Interventional	2007-04-30	Completed
A Phase II, Randomized, Open Label, 2-Way Crossover, Safety Study of Subcutaneously Injected Prandial INSULIN-PH20 NP Compared to Insulin Analog Injection in Patients With Type 1 Diabetes [NCT00883558]	Phase 2	48 participants (Actual)	Interventional	2009-05-31	Completed
Pan-European Proof-of-concept Study Comparing Decentralised Clinical Trial (DCT) and Hybrid Approaches to Conventional Clinical Trial Approaches in Patients With Type 2 Diabetes Mellitus Treated With Toujeo® [NCT05780151]	Phase 4	600 participants (Anticipated)	Interventional	2023-06-30	Not yet recruiting
A Randomized, Placebo-controlled, 2-arm Parallel-group, Multicenter Study With a 24-week Double-blind Treatment Period Assessing the Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Insufficiently Controlled With Insulin Glargine and M [NCT00975286]	Phase 3	446 participants (Actual)	Interventional	2009-10-31	Completed
Glargine Dosing in Hospitalized Patients With Type 2 Diabetes and Renal Insufficiency [NCT00911625]	Phase 4	114 participants (Actual)	Interventional	2009-01-21	Completed
Insulin Glargine Versus Regular Insulin Based Regimens in Glycemic Control After Acute Stroke: A Multi-center, Randomized Control Study [NCT02607943]	Phase 3	120 participants (Anticipated)	Interventional	2015-12-31	Recruiting
NN5401-3590: A Trial Comparing Efficacy and Safety of NN5401 With Insulin Glargine in Insulin Naive Subjects With Type 2 Diabetes (BOOST™ : START 1) / NN5401-3726: An Extension Trial Comparing Safety and Efficacy of NN5401 With Insulin Glargine in Subject [NCT01045707]	Phase 3	530 participants (Actual)	Interventional	2010-01-31	Completed
A Glucose Clamp Trial Investigating the Biosimilarity of Gan & Lee Insulin Glargine Injection (Insulin Glargine 100 U/mL) With US and EU Lantus® Comparator Products in Patients With Type 1 Diabetes Mellitus [NCT04236895]	Phase 1	114 participants (Actual)	Interventional	2018-07-10	Completed
A 24 Weeks, Randomized, 2 Arms, Controlled, Multi-centre, National, Open-labeled, Parallel Study in Insulin naïve Patients With Type 2 Diabetes to Compare a Lantus Titration Algorithm vs. Physician's Standard Practice [NCT00627471]	Phase 4	9 participants (Actual)	Interventional	2008-01-31	Terminated(stopped due to Low recruitment in spite of strategies implemented)
A Phase II, Randomized, Double Blind, 2-Way Crossover Safety and Efficacy Study of Subcutaneously Injected Prandial Insulins: Lispro-PH20 or Aspart-PH20 Compared to Insulin Lispro (Humalog®) in Patients With Type 2 Diabetes [NCT01194258]	Phase 2	132 participants (Actual)	Interventional	2010-08-31	Completed
The Impact of LY2189265 Versus Insulin Glargine in Combination With Insulin Lispro for the Treatment to Target of Type 2 Diabetes Mellitus (AWARD-4: Assessment of Weekly AdministRation of LY2189265 in Diabetes - 4) [NCT01191268]	Phase 3	884 participants (Actual)	Interventional	2010-11-30	Completed
Concurrent Subcutaneous Basal Insulin and Intravenous Insulin Pump in Hyperglycemic Crisis Patients Under Critical Care [NCT05155917]	Phase 2	70 participants (Anticipated)	Interventional	2022-03-01	Recruiting
A Randomized, Open-Label, Parallel-Design Trial. Glycemia Optimization Treatment: Safety of Glucose Control Using Dosing Algorithms With Lantus®(Insulin Glargine [rDNA Origin[) in Adult Individuals With Type 2 Diabetes. [NCT00552370]	Phase 4	5,062 participants (Actual)	Interventional	2003-03-31	Completed
Evaluation of Differing Type 1 Diabetes Regimens in Youth in the Developing World [NCT01424046]		50 participants (Actual)	Interventional	2011-05-31	Completed
Efficacy and Safety Comparison of Insulin Detemir Plus Insulin Aspart Versus Insulin Glargine Plus Insulin Aspart in Type 2 Diabetes [NCT00097084]	Phase 3	324 participants (Actual)	Interventional	2004-09-30	Completed
Comparative Investigation of Efficacy and Safety of Insulin Glargine Versus Metformin as First Line Drug in Treatment of Early Type 2 Diabetes [NCT00857870]	Phase 4	96 participants (Actual)	Interventional	2009-03-31	Completed
A 12 Week, Parallel, Open-label, Randomized, Multi-center Study Evaluating Use, Safety and Effectiveness of a Web Based Tool vs. Enhanced Usual Therapy of Glargine Titration in T2DM Patients With a 4 Week Safety Extension [NCT02540486]		139 participants (Actual)	Interventional	2013-12-31	Completed
Parallel Group Study to Evaluate the Efficacy and Safety of Exenatide Once-Weekly Injection Compared to Once-Daily Insulin in Type 2 Diabetes Mellitus Treated With Oral Antidiabetic(s) [NCT00935532]	Phase 3	427 participants (Actual)	Interventional	2009-07-31	Completed
Evaluation of Diabetic Retinopathy Progression in Subjects With Type 2 Diabetes Mellitus Treated With Insulin [NCT00174824]	Phase 4	1,024 participants (Actual)	Interventional	2001-06-30	Completed
An 8-week Randomised, Double-blind, Parallel, Multiple Dose Trial Comparing NNC0123-0000-0338 in a Tablet Formulation and Insulin Glargine in Subjects With Type 2 Diabetes Currently Treated With Oral Antidiabetic Therapy [NCT02470039]	Phase 2	50 participants (Actual)	Interventional	2015-06-01	Completed
A Trial Comparing Efficacy and Safety of NN1250 and Insulin Glargine in Subjects With Type 2 Diabetes (BEGIN™: LOW VOLUME) [NCT01068665]	Phase 3	460 participants (Actual)	Interventional	2010-03-31	Completed
The Effect of Insulin Glargine on Glycemic Control, Morbidity, and Length of Stay in Hospitalized Subjects With Diabetes Receiving Enteral Nutrition [NCT00177398]	Phase 4	50 participants	Interventional	2005-02-28	Completed
Multicenter,Open,Uncontrolled,Clinical Extension Trial in Subjects With Type I Diabetes Previously Participating in Study HMR1964A/3011 in Belgium [NCT00576862]	Phase 4	32 participants (Actual)	Interventional	2002-11-30	Completed
44-week, Parallel, Open, Randomized, Multinational, Multi-center Clinical Trial to Compare Efficacy and Safety of the Combination Therapy of an Oral Anti-diabetic Drug Treatment With Either HOE901 Insulin Once Daily or Lispro Insulin Analogue at Mealtime [NCT00311818]	Phase 4	0 participants	Interventional	2003-06-30	Completed
Basal Insulin Therapy in Patients With Insulin Resistance: A 6 Month Comparison of Insulin Glargine and NPH Insulin [NCT01854723]	Phase 4	0 participants (Actual)	Interventional	2013-04-30	Withdrawn
A Randomised, Double-Blind, Single Dose, Six-Period Cross-over Dose Response Trial Comparing the Pharmacodynamics and Pharmacokinetics of Insulin 454 With Insulin Glargine in Subjects With Type 1 and Type 2 Diabetes [NCT01865292]	Phase 1	40 participants (Actual)	Interventional	2006-08-31	Completed
A 24-Week, Multicenter, Randomized, Open-Label, Parallel-Group Trial Comparing the Efficacy and Safety of Insulin Glargine 300 U/mL (Gla-300) and Insulin Degludec 100 U/mL (IDeg-100) in Insulin-Naïve People With Type 2 Diabetes Mellitus and Renal Impairme [NCT05552859]	Phase 4	62 participants (Actual)	Interventional	2022-12-05	Terminated(stopped due to Sponsor decision to cancel trial due to poor recruitment/ severe recruitment delay and not related to safety concern.)
32-Week, Open, Randomized, Cross-Over, Local, Multicenter Clinical Trial Comparing Insulin Glargine in Combination With Insulin Analogue (Insulin Lispro) to NPH Insulin in Combination With Regular Insulin in Type 1 Diabetes Mellitus Patients in an Intensi [NCT00537251]	Phase 3	80 participants (Actual)	Interventional	2001-11-30	Completed
Phase IV, Open Label, Non-comparative, Multi-center, Study of the Effects of Both Insulin Glargine & Insulin Glulisine in Type I Diabetes Mellitus Patients. [NCT00539448]	Phase 4	98 participants (Actual)	Interventional	2007-04-30	Completed
Assessment of Duration of Metabolic Effect of a Single Bolus of Subcutaneous Injected Lantus Compared to NPH-Insulin(Protaphan)in Patients With Type 2 Diabetes [NCT00553020]	Phase 4	16 participants (Actual)	Interventional	2004-04-30	Completed
A Prospective, Randomized, Double-Blind Comparison of a Long-Acting Basal Insulin Analog LY2963016 to Lantus in Adult Patients With Type 2 Diabetes Mellitus: The ELEMENT 2 Study [NCT01421459]	Phase 3	759 participants (Actual)	Interventional	2011-09-30	Completed
A Randomized, Double-blind, 3-sequence, 3-period Cross-over, Single-dose Study of a New Formulation of Insulin Glargine Compared to the Marketed Lantus® in Japanese Patients With Type 1 Diabetes Mellitus Using the Euglycemic Clamp Technique [NCT01493115]	Phase 1	18 participants (Actual)	Interventional	2011-11-30	Completed
A School Intervention: Lunch Time Insulin Injections in Children With Poorly Controlled Type 1 Diabetes [NCT00340613]	Phase 4	36 participants (Actual)	Interventional	2006-06-30	Completed
A Crossover Study to Evaluate the Efficacy and Safety of Preprandial Human Insulin Inhalation Powder (HIIP) Compared to Preprandial Injectable Insulin in Patients With Type 1 Diabetes Mellitus [NCT00447213]	Phase 2/Phase 3	70 participants (Actual)	Interventional	2007-04-30	Completed
12-week, Multicenter, Controlled, Open, 3:1 Randomized, Parallel Clinical Trial Comparing Insulin Glulisine With Regular Human Insulin (Insulin Lispro) Injected Subcutaneously in Subjects With Type 1 or 2 Diabetes Mellitus Also Using Lantus (Insulin Glarg [NCT00467376]	Phase 3	485 participants (Actual)	Interventional	2007-01-31	Completed
Chronic Reduction of Fasting Gylcaemia With Insulin Glargine Improves First and Second Phase Insulin Secretion in Patients With Type 2 Diabetes [NCT01249677]	Phase 4	14 participants (Actual)	Interventional	2009-01-31	Completed
Satisfaction of Treatment Among Elderly Patients With Insulin Therapy Using Pens for a Basal Insulin Treatment (STEP IT UP a BIT) [NCT01240200]	Phase 4	49 participants (Actual)	Interventional	2011-01-31	Completed
A Multicenter Clinical Trial to Evaluate Quality of Life in Patients With Type 2 Diabetes Before and After Changing Therapy to a Combination of Insulin Glargine and Oral Antidiabetic Drugs in a Real Life Situation [NCT00518427]	Phase 4	26 participants (Actual)	Interventional	2005-10-31	Completed
A Trial Investigating the Hypoglycaemic Response to Overdosing of NNC0148-0287 C (Insulin 287) in Subjects With Type 2 Diabetes [NCT03945656]	Phase 1	43 participants (Actual)	Interventional	2019-05-07	Completed
A Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart With Insulin Glargine in Insulin Naive Subjects With Type 2 Diabetes (BOOST™: JAPAN) [NCT01272193]	Phase 3	296 participants (Actual)	Interventional	2011-01-31	Completed
Twenty-Four-Hour Plasma Glucose Profiles Observed in Patients With Type 2 Diabetes During Therapy Consisting of Oral Agent(s) Plus Twice-Daily Insulin Lispro Low Mixture or Once-Daily Insulin Glargine [NCT00551538]	Phase 4	15 participants (Actual)	Interventional	2003-05-31	Completed
Effects of Modulators of Gluconeogenesis, Glycogenolysis and Glucokinase Activity on Endogenous Glucose Production in Type 2 Diabetes [NCT05098470]	Phase 3	100 participants (Anticipated)	Interventional	2022-03-07	Recruiting
Effects of LY3209590 on Frequency and Severity of Hypoglycaemia Under Conditions of Increased Hypoglycaemic Risk Compared to Insulin Glargine in Participants With Type 2 Diabetes Mellitus [NCT04957914]	Phase 1	54 participants (Actual)	Interventional	2021-07-14	Completed
"An Open-label, Randomized, Multi-center, Parallel-group Clinical Trial Comparing the Efficacy and Safety of Insulin RinGlar® (Geropharm, Russia) Compared to Lantus® SoloStar® (Sanofi-Aventis Deutschland GmbH, Germany) in Type 1 Diabetes Mellitus Patients [NCT04022993]	Phase 3	180 participants (Actual)	Interventional	2018-07-04	Completed
Italian Experience Trial for the Implementation of the Use of Lantus in Basal - Bolus Regimen in Type I Diabetes Mellitus Patients. [NCT00272090]	Phase 3	489 participants (Actual)	Interventional	2002-11-30	Completed
Can Hypoglycaemia Awareness Be Restored in Individuals With Type 1 Diabetes and Severe Hypoglycaemia Employing Optimised Subcutaneous Insulin Regime or Continuous Subcutaneous Insulin Infusion Pump [NCT00360984]	Phase 4	21 participants	Interventional	2003-05-31	Completed
AN OPEN-LABEL, RANDOMIZED, MULTICENTER, PHASE 3 STUDY TO COMPARE THE IMMUNOGENICITY, EFFICACY, AND SAFETY OF GAN & LEE PHARMACEUTICALS INSULIN GLARGINE INJECTION TO LANTUS® IN ADULT SUBJECTS WITH TYPE 2 DIABETES MELLITUS [NCT03371108]	Phase 3	567 participants (Actual)	Interventional	2017-10-31	Completed
Risk of Hypoglycemia in the Transition From Inpatient to Outpatient Setting. Comparative Study of Basal-bolus Insulin Versus Basal Insulin Plus GLP-1 Analogue [NCT05767255]	Phase 3	66 participants (Anticipated)	Interventional	2022-12-01	Recruiting
"A Twenty-six Week, Randomized, Open-label, 2-Arm Parallel Group Real World Pragmatic Trial to Assess the Clinical and Health Outcomes Benefit of Toujeo® Compared to Standard of Care Insulin for Initiating Basal Insulin in Insulin Naïve Patients With Unco [NCT02967224]	Phase 4	705 participants (Actual)	Interventional	2015-11-05	Completed
Open Trial of the Safety and Efficacy of Lantus for Insulin Naive Type 2 Diabetes Mellitus Patients or Patients Who Use Insulin Combined With 1 or More Oral Antidiabetic Drugs and Don't Have Good Glycemic Control. [NCT00268645]	Phase 4	534 participants	Interventional	2004-09-30	Completed
Pilot Study on Glycaemic Variability in Type 2 Diabetes Mellitus Patients With Basal Insulin and Fixed Combo Oral Antidiabetic Treatment. [NCT00272077]	Phase 4	0 participants	Interventional	2005-04-30	Completed
A Comparison of Prandial Insulin Lispro Mixtures Therapy to Glargine Basal-Bolus Therapy With Insulin Lispro on the Overall Glycemic Control of Patients With Type 2 Diabetes Previously Treated With Oral Agents Combined With Insulin Glargine [NCT00110370]	Phase 4	300 participants	Interventional	2004-04-30	Completed
Comparison of Glycaemic Fluctuations During 3 Days Subcutaneous Continuous Monitoring in Patients With Basal Substitution Human Insulin NPH vs Insuline Glargine [NCT00322075]	Phase 4	35 participants	Interventional	2006-04-30	Completed
Human Versus Analogue Insulin for Youth With Type 1 Diabetes in Low-Resource Settings: A Randomized Controlled Trial [NCT05614089]	Phase 4	400 participants (Anticipated)	Interventional	2023-03-15	Recruiting
Comparison of the Effect on Glycemic Control of Biphasic Insulin Aspart 70/30 Versus Insulin Glargine in Combination With Metformin in Subjects With Type 2 Diabetes [NCT00097877]	Phase 3	293 participants (Actual)	Interventional	2005-01-31	Completed
Insulin Glulisine Administered in a Fixed Bolus Regimen Versus Variable Bolus Regimen Based on Carbohydrate Counting in Adult Subjects With Type 2 Diabetes Receiving Insulin Glargine as Basal Insulin [NCT00135057]	Phase 3	281 participants	Interventional	2004-04-30	Completed
APIDRA® (Insulin Glulisine) Administered Premeal vs Postmeal in Adult Subjects With Type 2 Diabetes Mellitus Receiving LANTUS® (Insulin Glargine) as Basal Insulin: a Multicenter, Randomized, Parallel, Open Label Clinical Study [NCT00135096]	Phase 3	345 participants (Actual)	Interventional	2004-08-31	Completed
A Double Blind, Randomized, Parallel, Cross-Over Comparision of Glycemic Control Achieved With Once a Day Insulin Glargine Versus Detemir in Type 2 Diabetes [NCT00457093]		35 participants (Anticipated)	Interventional	2006-10-31	Completed
One-Year Glargine-Treatment Can Ameliorate Clinical Features in Cystic Fibrosis Children and Adolescents With Glucose Derangements [NCT00483769]	Phase 4	20 participants (Actual)	Interventional	2006-02-28	Completed
Multicentric, Open Label Clinical Trial. Use of Optimal Method to Initiate and Maintain Lantus Therapy (Insulin Glargine) in Combination With Hypoglycemic Agents, Assessing the Resulting Metabolic Control and the Safety in T2 Diabetes Mellitus Patients. [NCT00488527]	Phase 4	371 participants (Actual)	Interventional	2007-04-30	Completed
Insulin Glargine Plus Insulin Glulisine MDI Versus Premix Insulin Treatment in Subjects With Diabetes Mellitus (Type 1 or Type 2) Evaluating Differences in Patient Reported Outcomes [NCT00135941]	Phase 3	582 participants (Actual)	Interventional	2005-08-31	Completed
A National, Multicenter, Prospective, Interventional, Open-label, Single-arm, 24-Week Phase IV Study to Evaluate the Effectiveness and Safety of Initiation and Titration of Insulin Glargine U300 in Insulin-naïve Patients With T2DM Inadequately Controlled [NCT02954692]	Phase 4	112 participants (Actual)	Interventional	2016-11-30	Completed
Comparison of Carbohydrate Metabolism During the Night and at Hypoglycemia in Type-2 Diabetic Patients Either on Glargine or NPH Insulin [NCT00468364]		12 participants (Actual)	Observational	2003-07-31	Completed
A Randomized, Open-Label, Controlled, Parallel-group, Multicenter Trial Comparing the Efficacy and Safety of INS068 and Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Not Adequately Controlled With Oral Antidiabetic Drugs [NCT05699408]	Phase 3	513 participants (Actual)	Interventional	2023-03-31	Active, not recruiting
Efficacy and Safety of Once-weekly Semaglutide S.C. 2.0 mg as Add-on to Dose-reduced Insulin Glargine vs Titrated Insulin Glargine in Participants With Type 2 Diabetes and Overweight [NCT05514535]	Phase 3	568 participants (Anticipated)	Interventional	2022-08-29	Recruiting
Comparison of Postprandial Glycemic Control in Non-critically Ill Hospitalized Patients With Type 2 Diabetes Mellitus Using Novolog vs. Fiasp Insulin: a Randomized Controlled Open Label Trial [NCT04460326]	Phase 3	139 participants (Actual)	Interventional	2020-12-07	Completed
"Comparison of SoloSTAR With a Syringe-administered Glargine Insulin in Diabetic Patients Discharged From the Hospital" [NCT01203774]	Phase 4	43 participants (Actual)	Interventional	2010-09-30	Completed
The Utility of Insulin Glargine (Lantus) Compared to NPH in Ethnic Minority Type 2 Diabetic Subjects on Combination Insulin-Oral Agent Therapy [NCT00687453]	Phase 4	27 participants (Actual)	Interventional	2003-02-28	Terminated
An Assessment of the Impact of Performing Physical Exercise on the Maximum Plasma Glucose Decline in Subjects With Type 1 Diabetes Managed on a Basal Bolus Insulin Regimen: A Comparison of 3 Basal Insulin Treatments - Insulin Detemir, Insulin Glargine and [NCT00313742]	Phase 4	51 participants (Actual)	Interventional	2006-04-30	Completed
A First-in-Human, Ascending-Dose Study to Investigate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of a Single, Subcutaneous Dose of LY3209590 [NCT02942914]	Phase 1	80 participants (Actual)	Interventional	2016-12-20	Completed
Testing the Usefulness of Lantus When Initiated Prematurely In Patients With Type 2 Diabetes [NCT00174681]	Phase 4	390 participants	Interventional	2003-04-30	Completed
Pilot Study Investigating the Effects of Insulin Lispro Low Mixture Therapy Compared With Insulin Glargine on Perceived Mood Symptoms in Patients With Type 2 Diabetes Mellitus [NCT00191178]	Phase 4	60 participants	Interventional	2003-08-31	Completed
Safety and Efficacy of Insulin Glargine Versus Biphasic Insulin Aspart 30/70 or Biphasic Insulin Aspart 30/70 in Combination With Metformin in Subjects With Type 2 Diabetes. [NCT00184626]	Phase 4	97 participants (Actual)	Interventional	2004-09-10	Completed
52-week, Open, Randomized, Multinational, Multicenter Clinical Trial Comparing Insulin Glulisine in Combination With Insulin Glargine in an Intensified Insulin Regimen to a Two-injection Conventional Insulin Regimen in Type 2 Diabetes Mellitus Patients Wi [NCT00174668]	Phase 3	311 participants (Actual)	Interventional	2004-11-30	Completed
An Open-label, Randomised, In-patient, Cross Over PK/PD Trial Investigating the Pharmackinectic and Pharmacodynamic Profiles Following Continuous Subcutaneous Infusion of Insulin Aspart or Injection of Insulin Glargine in Subjects With Type 2 Diabetes Mel [NCT00184613]	Phase 1	22 participants (Actual)	Interventional	2005-05-31	Completed
The Incidence of Hypoglycemia in Insulin Glargine-Treated Subjects With Diabetes Mellitus Upon Switching Between Bedtime and Morning Dosing [NCT00609895]	Phase 4	22 participants (Actual)	Interventional	2004-01-31	Completed
Pilot Study for the Evaluation of the Effects of Insulin Treatment on Myocardial Function, Perfusion, and Glucose Metabolism in Patients With Primary Left Ventricular Dysfunction and Type 2 Diabetes. [NCT00335465]	Phase 4	15 participants (Actual)	Interventional	2005-09-30	Completed
Efficacy of Exenatide Compared With Insulin Glargine in Patients With Type 2 Diabetes Using Metformin or Sulfonylurea for Whom Insulin is the Next Appropriate Therapy [NCT00099619]	Phase 3	138 participants (Actual)	Interventional	2004-09-30	Completed
Efficacy and Safety Comparison of Insulin Detemir and Insulin Glargine Plus Insulin Aspart in Patients With Type 2 Diabetes [NCT00106366]	Phase 3	389 participants (Actual)	Interventional	2005-03-31	Completed
Efficacy and Safety of Insulin Glulisine Compared With Insulin Lispro in Children and Adolescents With Type 1 Diabetes Mellitus: A 26 Week, Multicenter, Open, Parallel Clinical Trial [NCT00115570]	Phase 3	572 participants (Actual)	Interventional	2005-04-30	Completed
Action to Control Cardiovascular Risk in Diabetes (ACCORD) [NCT00000620]	Phase 3	10,251 participants (Actual)	Interventional	1999-09-30	Completed
Substituting Lantus®(Insulin Glargine[rDNAorigin]Inj) for a Thiazolidinedione vs. a 3rd Oral Agent as add-on Therapy in Patients Failing a Thiazolidinedione & Sulfonylurea or Metformin Combination [NCT00046462]	Phase 3	240 participants	Interventional	2001-11-30	Completed
Morning LANTUS v. Intermediate-acting Insulin 2x/Day as Basal Insulin in a Multiple Daily Inj. w/ Humalog in Adolescents w/ Type 1 Diabetes Mellitus: an Active-controlled, Open, Randomized, Gender-stratified, Two-arm, Parallel-group Study [NCT00046501]	Phase 3	250 participants	Interventional	2002-11-30	Completed
"A Twenty-six Week, Randomized, Open-label, 2-arm Parallel Group Real World Pragmatic Trial to Assess the Clinical and Health Outcomes Benefit of Transition to Toujeo Compared to Standard of Care Insulin in Basal Insulin Treated Patients With Uncontrolled [NCT02967211]	Phase 4	609 participants (Actual)	Interventional	2015-12-21	Completed
A Multicentre, Multinational, Randomised, Open Study to Establish the Optimal Method for Initiating and Maintaining Lantus® (Insulin Glargine) Therapy Based on a Comparison of Two Treatment Algorithms to Determine Optimal Metabolic Outcomes, Safety, and S [NCT00399724]	Phase 4	7,376 participants	Interventional	2002-03-31	Completed
"A Phase IIIb/IV, Multinational, Multicentre, Randomised, Open Study to Establish the Optimal Method for Initiating and Maintaining Lantus® (Insulin Glargine) Therapy Based on a Comparison of Two Treatment Algorithms to Determine Optimal Metabolic Outcome [NCT00390728]	Phase 4	2,346 participants	Interventional	2002-04-30	Completed
Target Glycemic Control and the Incidence of Documented Symptomatic Hypoglycemia in Insulin naïve Subjects With Type 2 Diabetes Failing on Oral Hypoglycemic Agent(s) and Treated With Insulin Glargine or Insulin Detemir. [NCT00405418]	Phase 4	973 participants (Actual)	Interventional	2006-11-30	Completed
Efficacy and Safety of Liraglutide-bolus (Liraglutide Plus Prandial Insulin) Versus Glargine-bolus Therapy in Overweight / Obese Patients With Uncontrolled Type 2 Diabetes (LiraGooD)--A Multicenter Randomized Controlled Study [NCT03087032]	Phase 4	140 participants (Anticipated)	Interventional	2019-01-10	Recruiting
An Interventional, Open-label, Single-arm, Multicenter, 24 Weeks Phase 4 Study Assessing the Efficacy and Safety of Toujeo in Patients With Type 2 Diabetes Inadequately Controlled With Basal Insulin [NCT02967237]	Phase 4	136 participants (Actual)	Interventional	2016-01-04	Completed
Conventional Insulin Therapy Vs Intensive Insulin Management In Children With Type 1 Diabetes Mellitus [NCT00206401]	Phase 4	60 participants	Interventional	2004-11-30	Completed
A 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® Injected in the Morning or Evening in Patients With Type 1 Diabetes Mellitus With a 6-month Safety [NCT01683266]	Phase 3	549 participants (Actual)	Interventional	2012-09-30	Completed
Long-Term Effects of Insulin Plus Metformin Regimens on the Overall and Postprandial Glycemic Control of Patients With Type 2 Diabetes: A Comparison of Premeal Insulin Lispro Mixtures to Once-Daily Insulin Glargine [NCT00191464]	Phase 4	320 participants	Interventional	2003-12-31	Completed
Efficacy and Safety Comparison of Insulin Detemir Plus Insulin Aspart Versus Insulin Glargine Plus Insulin Aspart in Type 1 Diabetes [NCT00095082]	Phase 3	447 participants (Actual)	Interventional	2004-09-30	Completed
Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study [NCT05220917]		781,430 participants (Anticipated)	Observational	2021-08-01	Active, not recruiting
Exploration of the Weight Neutral Effects of Insulin Detemir Compared to Insulin Glargine: A Measure of Satiety and Calories Consumed in Type 1 Diabetes [NCT00659165]		10 participants (Actual)	Interventional	2008-04-30	Completed
A Randomized Controlled Study Comparing a DPP4 Inhibitor (Linagliptin) and Basal Insulin (Glargine) in Long-Term Care Residents With Type 2 Diabetes [NCT02061969]	Phase 4	140 participants (Actual)	Interventional	2014-04-25	Completed
10-week, Open, National, Multicenter Clinical Trial to Evaluate the Safety of Insulin Glargine in Type 2 Diabetes Mellitus Patients, on Intensified Conventional Therapy (ICT) [NCT00354939]	Phase 4	480 participants	Interventional	2003-10-31	Completed
Cost Effectiveness of Glargine Insulin Versus NPH Insulin in Diabetic Patients in Iran [NCT01832935]	Phase 4	200 participants (Actual)	Interventional	2011-07-31	Completed
A Double-blind, Randomized, Two-treatment Crossover Bioequivalence Study Comparing Two New Insulin Glargine Formulations Using the Euglycemic Clamp Technique in Subjects With Type 1 Diabetes Mellitus [NCT01838083]	Phase 1	50 participants (Actual)	Interventional	2013-04-30	Completed
A Randomized, 30-week, Active-controlled, Open Label, 2- Treatment Arm, Parallel-group, Multicenter Study Comparing the Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine With or Without Metformin in Patie [NCT02058160]	Phase 3	736 participants (Actual)	Interventional	2014-01-31	Completed
Pharmacodynamics of LY2963016 Compared to LANTUS® in Subjects With Type 1 Diabetes Mellitus [NCT01600950]	Phase 1	20 participants (Actual)	Interventional	2012-05-31	Completed
Linagliptin Inpatient Trial: A Randomized Controlled Trial on the Safety and Efficacy of Linagliptin (Tradjenta®) Therapy for the Inpatient Management of General Surgery Patients With Type 2 Diabetes [NCT02004366]	Phase 4	295 participants (Actual)	Interventional	2014-01-31	Completed
A Prospective, Multicentric, Randomized, Open-Label Comparison of a Long-Acting Basal Insulin Analog Glargine Plus Glulisine With Premixed Insulin in Adult Patients With Type 2 Diabetes Mellitus [NCT02987751]	Phase 4	200 participants (Actual)	Interventional	2016-12-29	Completed
Remission Evaluation of a Metabolic Intervention in Type 2 Diabetes With Forxiga [NCT02561130]	Phase 4	154 participants (Actual)	Interventional	2015-12-31	Completed
Empagliflozin Effect on Glucose Toxicity in Type 2 Diabetes Patients - a Randomized, Open-label, Controlled, Parallel Group, Exploratory Study [NCT03437330]	Phase 4	50 participants (Anticipated)	Interventional	2021-10-27	Active, not recruiting
Evaluation (Safety and Efficacy) of Treatment With Insulin Glargine and Glimepiride in Patients With Type 2 Diabetes Before, During and After the Period of Fasting in Ramadan [NCT00258804]	Phase 4	450 participants	Interventional	2005-05-31	Completed
Study on the Feasibility and Treatment Experience of Community Doctors in Shenzhen Guided by Specialists to Use Basic Insulin in the Treatment of Adult Type 2 Diabetes Mellitus [NCT04553380]		150 participants (Anticipated)	Interventional	2020-12-01	Not yet recruiting
A 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® Both in Combination With Oral Antihyperglycemic Drug(s) in Japanese Patients With Type 2 Diabetes M [NCT01689142]	Phase 3	240 participants (Actual)	Interventional	2012-09-30	Completed
A Crossover, Multicentre, Randomised Trial Comparing the Effect on the Control of Blood Glucose Concentration of Insulin Glargine and Insulin Detemir, Combined With Insulin Glulisine, Used as a Bolus, in Type 1 Diabetic Patients [NCT00271284]	Phase 3	88 participants (Actual)	Interventional	2005-10-31	Completed
Optimisation of Insulin Treatment of Type 2 Diabetes Mellitus by Telecare Assistance for Self Monitoring of Blood Glucose (SMBG). [NCT00272064]	Phase 3	352 participants (Actual)	Interventional	2005-10-31	Completed
Comparison of Efficacy and Safety of Insulin Detemir and Insulin Glargine as Add-on to Current Oral Antidiabetic Drugs in Subjects With Type 2 Diabetes [NCT00283751]	Phase 3	583 participants (Actual)	Interventional	2003-03-31	Completed
Comparison of Efficacy and Safety of Insulin Detemir and Insulin Glargine in Patients With Type 1 Diabetes. [NCT00312104]	Phase 3	325 participants (Actual)	Interventional	2002-04-30	Completed
Single Centre, Open, Controlled, Randomised (1:1), Parallel Group: Insulin Glargine vs. NPH: FPG (Fasting Plasma Glucose) in Patients With DM Type 1 Who Skip the Morning Meal During Treatment With MDI (Multiple Daily Injection) Basal/Bolus Insulin [NCT00313937]	Phase 4	91 participants (Actual)	Interventional	2001-11-30	Completed
Assessment of Safety and Tolerability of Lantus® (Insulin Glargine) in Subjects With Impaired Fasting Glucose (IFG) or Impaired Glucose Tolerance (IGT) [NCT00348972]	Phase 1	20 participants	Interventional	2002-02-28	Completed
A Single-centre, Parallel-group, Randomised, Double Blind Trial in Healthy Japanese Subjects Comparing the Within-subject Variability of Insulin Detemir and Insulin Glargine With Respect to Pharmacodynamic and Pharmacokinetic Properties [NCT01497535]	Phase 1	40 participants (Actual)	Interventional	2004-05-27	Completed
A Single-centre, Randomised, Double-blind, Cross-over Trial Comparing the Within-subject Variability of the Pharmacokinetic Profiles of Insulin Detemir and Insulin Glargine in Children and Adolescents With Type 1 Diabetes [NCT01497574]	Phase 1	32 participants (Actual)	Interventional	2005-05-31	Completed
Establishing Cardiovascular Biomarkers to Define Preferred Lantus® Use. [NCT01500850]	Phase 4	60 participants (Anticipated)	Interventional	2011-10-31	Recruiting
A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0268-0965 in Subjects With Type 2 Diabetes Mellitus [NCT04136067]	Phase 1	36 participants (Actual)	Interventional	2019-10-29	Completed
Insulin Therapy for Post-transplant Glucocorticoid Induced Hyperglycemia [NCT01648218]	Phase 4	5 participants (Actual)	Interventional	2012-08-31	Terminated(stopped due to Poor enrollment)
A 16-week, Randomized, Open-label, Controlled Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine Versus Lantus in Patients With Type 1 Diabetes Mellitus [NCT01658579]	Phase 2	59 participants (Actual)	Interventional	2012-08-31	Completed
A 26-Week Randomized, Open-label, Active Controlled, Parallel-group, Study Assessing the Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and [NCT02787551]	Phase 3	514 participants (Actual)	Interventional	2016-07-06	Completed
6-Month, Multicenter, Randomized, Open-label, 2-Arm, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® Injected Once Daily in Children and Adolescents Age 6 - 17 Years With Type 1 Diabetes Mellitus [NCT02735044]	Phase 3	463 participants (Actual)	Interventional	2016-04-14	Completed
An Open-label, Randomized, Parallel Design Trial to Compare the Efficacy of a Sitagliptin-based Metabolic Intervention Versus Standard Diabetes Therapy in Inducing Remission of Type 2 Diabetes [NCT02623998]	Phase 3	102 participants (Actual)	Interventional	2016-07-09	Completed
6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® Both in Combination With Oral Antihyperglycemic Drug(s) in Patients With Type 2 Diabetes Mellitus Wit [NCT01499095]	Phase 3	811 participants (Actual)	Interventional	2011-12-31	Completed
6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® Both Plus Mealtime Insulin in Patients With Type 2 Diabetes Mellitus With a 6-month Safety Extension [NCT01499082]	Phase 3	807 participants (Actual)	Interventional	2011-12-31	Completed
A Trial Comparing the Effect of Exercise on Blood Glucose Between Insulin Degludec and Insulin Glargine in Subjects With Type 1 Diabetes [NCT01704417]	Phase 1	40 participants (Actual)	Interventional	2012-10-31	Completed
Comparison of the Effects of LY2605541 and Insulin Glargine on Endogenous Glucose Output and Peripheral Glucose Disposal in Healthy Subjects and Patients With Type 1 Diabetes Mellitus [NCT01654380]	Phase 1	22 participants (Actual)	Interventional	2012-07-31	Completed
A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0148-0000-0287 in Healthy Subjects and in Subjects With Type 1 Diabetes [NCT01730014]	Phase 1	70 participants (Actual)	Interventional	2012-10-31	Completed
Early Basal Insulin Administration in Adult Diabetic Ketoacidosis Management [NCT04567225]	Phase 4	39 participants (Actual)	Interventional	2020-10-01	Terminated(stopped due to Stopped after internal review)
A Randomized Controlled Trial to Evaluate Early Intermittent Intensive Insulin Therapy as an Effective Treatment of Type 2 Diabetes: REmission Studies Evaluating Type 2 DM - Intermittent Insulin Therapy (RESET-IT Pilot Study) [NCT01755468]	Phase 3	24 participants (Actual)	Interventional	2013-04-30	Completed
Restoring Insulin Secretion Adult Medication Study [NCT01779362]	Phase 3	267 participants (Actual)	Interventional	2013-04-30	Completed
A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0148-0000-0287 in Healthy Subjects [NCT01809184]	Phase 1	84 participants (Actual)	Interventional	2013-03-04	Completed
A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus [NCT02420262]	Phase 3	506 participants (Actual)	Interventional	2015-07-26	Completed
The Management of Glucocorticoid-Induced Hyperglycemia in Hospitalized Patients [NCT01810952]	Phase 4	37 participants (Actual)	Interventional	2010-09-30	Completed
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Study the Safety and Insulin-Sparing Efficacy of the Addition of Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Insulin [NCT01462266]	Phase 3	660 participants (Actual)	Interventional	2012-01-13	Completed
Early Use of Insulin Glargine in Diabetic Ketoacidosis [NCT00179127]		75 participants (Actual)	Interventional	2004-08-31	Completed
A Multicenter, Randomized, Controlled Trial to Prevent Diabetes With Short-term Insulin Glargine Treatment or Lifestyle Intervention [NCT01276912]		2,420 participants (Anticipated)	Interventional	2011-01-31	Recruiting
Impact of Insulin Detemir Versus Insulin Glargine on Glycaemic Control and Metabolism During Exercise in Type 1 Diabetes [NCT01440439]	Phase 4	30 participants (Anticipated)	Interventional	2011-11-30	Recruiting
A Multicenter, Open-label, Single-arm, 24 Week Phase IV Study Evaluating the Effectiveness and Safety of Treatment of Insulin Glargine in Type 2 Diabetes Mellitus Following Glucagon-like Peptide-1 (GLP-1) Failure [NCT01461577]	Phase 4	89 participants (Actual)	Interventional	2011-11-30	Completed
Effect of NPH Insulin, Insulin Detemir and Insulin Glargine on IGFBP-1 Production and Serum IGF-I in Subjects With Type 1 Diabetes Mellitus: An Open-label, Randomised, Triple Cross-over Trial [NCT01461616]	Phase 3	19 participants (Actual)	Interventional	2012-02-29	Completed
New Onset Type 1 Diabetes: Role of Exenatide [NCT01269034]	Phase 4	13 participants (Actual)	Interventional	2010-12-31	Completed
Sitagliptin for the Prevention and Treatment of Hyperglycemia in Patients With Type 2 Diabetes Undergoing Cardiac Surgery [NCT02556918]	Phase 4	202 participants (Actual)	Interventional	2016-01-31	Completed
Randomized Controlled Study of Dipeptidyl Peptidase-4 (DPP4) Inhibitor (Sitagliptin) Therapy in the Inpatient Management of Patients With Type 2 Diabetes [NCT01378117]	Phase 4	90 participants (Actual)	Interventional	2011-08-31	Completed
A Randomized Comparison of Transitioning From Insulin GLargine to Insulin Degludec usING a Bridging Dose of Glargine Versus Direct Conversion, in Patients With Type 1 Diabetes Mellitus - a Pilot Study [NCT04623086]	Phase 4	40 participants (Actual)	Interventional	2020-02-14	Active, not recruiting
Evaluation of Insulin Glargine and Exenatide: A Randomized Clinical Trial With Continuous Glucose Monitoring and Ambulatory Glucose Profile Analysis [NCT01089569]		60 participants (Actual)	Interventional	2010-04-30	Completed
Resolution of Type 2 Diabetes Mellitus: Intensive vs. Conventional Glycaemic Control After Obesity Surgery. [NCT01257087]		35 participants (Actual)	Interventional	2010-12-31	Completed
A Randomized, Open-label, Controlled,Parallel-group Study for Beinaglutide Versus Glargine Therapy in Glycemic Variability of Type 2 Diabetes Mellitus [NCT03829891]		60 participants (Actual)	Interventional	2018-08-07	Completed
A 26-week Trial Comparing the Effect and Safety of Once Weekly Insulin Icodec and Once Daily Insulin Glargine 100 Units/mL, Both in Combination With Bolus Insulin With or Without Non-insulin Anti-diabetic Drugs, in Subjects With Type 2 Diabetes on a Basal [NCT04880850]	Phase 3	582 participants (Actual)	Interventional	2021-05-14	Completed
An Open-label, Randomized, Three-parallel-group Study on Pharmacodynamic Effects of 8-week QD Treatment With Lixisenatide Compared to Liraglutide in Patients With Type 2 Diabetes Not Adequately Controlled With Insulin Glargine With or Without Metformin [NCT01596504]	Phase 2	142 participants (Actual)	Interventional	2012-05-31	Completed
Bioequivalence Study Comparing the Pharmacokinetics and Pharmacodynamics of LY2963016 With Insulin Glargine in Healthy Volunteers [NCT01476345]	Phase 1	80 participants (Actual)	Interventional	2011-11-30	Completed
Efficacy and Safety Of Different Hypoglycemic Regimens Compared With Premixed Insulin In Patients With Type 2 Diabetes Receiving Short-term Intensive Insulin Therapy [NCT05545800]	Phase 3	78 participants (Anticipated)	Interventional	2022-09-01	Recruiting
Efficacy and Safety of LY3298176 Once Weekly Versus Insulin Glargine in Patients With Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4) [NCT03730662]	Phase 3	2,002 participants (Actual)	Interventional	2018-11-20	Completed
A Comparison of LY2605541 Versus Insulin Glargine as Basal Insulin Treatment in Combination With Oral Anti-Hyperglycemia Medications in Insulin-Naive Patients With Type 2 Diabetes Mellitus: A Double-Blind, Randomized Study [NCT01435616]	Phase 3	1,538 participants (Actual)	Interventional	2011-11-30	Completed
A Phase III, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of the Combination of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin Compared With Ertugliflozin Alone and Sitagliptin Alone, in the Treatment of Subjects W [NCT02099110]	Phase 3	1,233 participants (Actual)	Interventional	2014-04-22	Completed
A 32-week Randomised, Multinational, Treat-to-target, Open Label, Parallel Group Comparison of Stepwise Insulin Intensification of Biphasic Insulin Aspart (BIAsp) 30 and Basal-bolus Therapy With Insulin Glargine and Insulin Aspart in Insulin naïve Type 2 [NCT02453685]	Phase 4	335 participants (Actual)	Interventional	2015-08-31	Completed
A Randomized, Comparative Study of Basal-bolus Insulin Versus Conventional Sliding-scale Regular Insulin Therapy in Management of Non-critically Ill Patients Hospitalized in the Medical Ward. [NCT01594060]	Phase 4	36 participants (Actual)	Interventional	2012-06-30	Completed
Remission Evaluation of Metabolic Interventions in Type 2 Diabetes (REMIT): A Randomized Controlled Pilot Trial [NCT01181674]	Phase 4	83 participants (Actual)	Interventional	2011-01-31	Completed
Hospital Insulin Protocol Aims for Glucose Control in Corticosteroid-induced Hyperglycemia [NCT01184014]	Phase 4	72 participants (Actual)	Interventional	2010-08-31	Completed
A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0148-0000-0362 in Healthy Subjects [NCT01597713]	Phase 1	83 participants (Actual)	Interventional	2012-05-31	Completed
Prospective Comparison of Early Subcutaneous Insulin Glargine Plus Standard of Care Versus Standard of Care for Treatment of Diabetic Ketoacidosis in the Emergency Department [NCT02930044]		18 participants (Actual)	Interventional	2016-10-31	Completed
Diabetes Care in Nursing Home Residents: A Randomized Controlled Study [NCT01131052]	Phase 4	150 participants (Actual)	Interventional	2011-03-31	Completed
The Determination of the First Dose and the Optimal Time of Administration of Insulin Glargine Combined With Oral Antidiabetic Drug in Poorly Controlled Type II Diabetic Patients [NCT00349986]	Phase 4	4 participants (Actual)	Interventional	2006-09-30	Terminated(stopped due to prematurely terminated due to loss of interest)
Treatment of Early Insulinization With Glargine in Type 2 Diabetes Patients Uncontrolled on Sulfonylurea or Metformin Monotherapy [NCT00347100]	Phase 4	387 participants (Actual)	Interventional	2006-06-30	Completed
Liraglutide Effect and Action in Diabetes (LEAD-5): Effect on Glycaemic Control After Once Daily Administration of Liraglutide in Combination With Glimepiride and Metformin Versus Glimepiride and Metformin Combination Therapy, and Versus Insulin Glargine [NCT00331851]	Phase 3	584 participants (Actual)	Interventional	2006-05-31	Completed
A Study of the Relationship Between the Proportional Insulin Glargine Evening Dose and the Perioperative Serum Glucose Values in Patients With Diabetes Undergoing Surgery [NCT00309465]	Phase 4	402 participants (Actual)	Interventional	2005-10-31	Completed
A Trial Comparing Efficacy and Safety of Insulin Degludec and Insulin Glargine in Insulin naïve Subjects With Type 2 Diabetes (BEGIN™: ONCE) [NCT01849289]	Phase 3	833 participants (Actual)	Interventional	2013-06-02	Completed
A Pilot Study to Describe the Glycaemic Variability of Insulin Glargine 300U/ml Versus NPH (Neutral Protamine Hagedorn) in the Insulin-naïve Type 2 Diabetes Patients Following a Patient-adjusted Insulin Algorithm in Hong Kong [NCT03389490]	Phase 4	50 participants (Actual)	Interventional	2018-01-01	Completed
The Effect of Treatment With Basal Insulin Peglispro or Insulin Glargine on Insulin Sensitivity and the Effect of Prandial Insulin Lispro in Patients With Type 2 Diabetes Mellitus [NCT02197520]	Phase 1	24 participants (Actual)	Interventional	2014-07-31	Completed
A Comparison of Pharmacodynamics When Receiving a Double Dose of Insulin Peglispro or Insulin Glargine in Patients With Type 2 Diabetes Mellitus: A Double-Blind, Crossover Design Study [NCT02132637]	Phase 3	68 participants (Actual)	Interventional	2014-05-31	Completed
A Single Center, Single-dose, Double-blind, Randomized, Two-period, Two-treatment, Two-sequence, Crossover Study to Demonstrate Pharmacokinetic and Pharmacodynamic Similarity Between HEC-Glargine and US-Lantus® Using the Euglycemic Clamp Technique in Heal [NCT05248841]	Phase 1	104 participants (Actual)	Interventional	2022-03-08	Completed
A Randomized, 30 Week, Active-controlled, Open-label, 3-treatment Arm, Parallel-group Multicenter Study Comparing the Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination to Insulin Glargine Alone and to Lixisenatide Alone on Top [NCT02058147]	Phase 3	1,170 participants (Actual)	Interventional	2014-02-28	Completed
Subcutaneous Insulin Glargine Versus NPH Insulin in Patients With Chronic Kidney Disease Stages III and IV: Randomized Controlled Trial. [NCT02451917]	Phase 4	34 participants (Actual)	Interventional	2013-12-31	Completed
A Randomized, Open-label, Parallel Group Real World Pragmatic Trial to Assess the Clinical and Health Outcomes of Toujeo Compared to Commercially Available Basal Insulins for Initiation of Therapy in Insulin-naive Patients With Uncontrolled Type 2 Diabete [NCT02451137]	Phase 4	3,304 participants (Actual)	Interventional	2015-06-16	Completed
Comparison of Insulin Isophane (NPH) With Insulin Glargine in New Onset Diabetes After Transplant (NODAT) [NCT01963728]	Phase 4	2 participants (Actual)	Interventional	2013-11-27	Terminated(stopped due to Blood sugar status of the enrolled subjects wasn't evaluable)
A Randomised, Double Blind, Cross-over Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, Both With Insulin Aspart as Mealtime Insulin in Subjects With Type 1 Diabetes (SWITCH 1) [NCT02034513]	Phase 3	501 participants (Actual)	Interventional	2014-01-05	Completed
A 1 Month, Open-Label Inpatient, Randomized Cross-Over Trial Assessing The Impact Of Dry Powder Inhaled Insulin (Exubera) On 24-Hour Glycemic Control Compared To Insulin Glargine (Lantus) In Patients With Type 2 Diabetes Mellitus Who Are Poorly Controlled [NCT00367445]	Phase 4	30 participants	Interventional	2006-09-30	Completed
Effect of the Administration of Insulin Degludec Versus Insulin Glargine on Glycemic Variability in Patients With Type 2 Diabetes Mellitus Drug-naïve [NCT02680457]	Phase 4	12 participants (Actual)	Interventional	2013-11-30	Completed
Prevention of Stress Hyperglycemia With the Use of DPP-4 Inhibitors in Non-diabetic Patients Undergoing Non-cardiac Surgery, a Pilot Study [NCT02741687]	Phase 4	80 participants (Actual)	Interventional	2016-06-30	Completed
Effectiveness of Subcutaneous Glargine On The Time To Closure of The Anion Gap in Patients Presenting to the Emergency Department With Diabetic Keto-acidosis: A Pilot Study [NCT02006342]		40 participants (Actual)	Interventional	2012-11-30	Completed
Effectiveness and Safety of Once Weekly Insulin Icodec Used With DoseGuide Versus Once Daily Basal Insulin Analogues in an Insulin naïve Type 2 Diabetes Population in a Clinical Practice Setting [NCT04760626]	Phase 3	1,085 participants (Actual)	Interventional	2021-03-01	Completed
[NCT00358124]	Phase 4	220 participants	Interventional	2001-01-31	Completed
A Prospective, Randomized, Double-Blind Comparison of LY900014 to Insulin Lispro in Combination With Insulin Glargine or Insulin Degludec in Adults With Type 1 Diabetes [NCT03952130]	Phase 3	354 participants (Actual)	Interventional	2019-05-29	Completed
Comparison of Glycemic Response to Morning Only, Evening Only or Twice Daily Insulin Glargine in Patients With Type 1 Diabetes Using Continuous Glucose Monitoring [NCT00869414]		16 participants (Actual)	Interventional	2009-07-31	Terminated(stopped due to PI deceased)
An Open-label, Randomized, Multi-center, Parallel-Group Clinical Trial Comparing the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 1 Diabetes Mellitus Patients: An Extension Study [NCT02666430]	Phase 3	127 participants (Actual)	Interventional	2015-12-31	Completed
A Trial Comparing the Efficacy of Insulin Degludec With Insulin Glargine on Glycaemic Control Using Continuous Glucose Monitoring in Patients With Type 1 Diabetes [NCT01569841]	Phase 3	24 participants (Actual)	Interventional	2012-04-30	Completed
A Randomized, 24-week, Open-label, 2-arm Parallel-group, Multicenter Study Comparing the Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine on Top of Metformin in Type 2 Diabetic Patients [NCT01476475]	Phase 2	323 participants (Actual)	Interventional	2011-11-30	Completed
The Impact of LY2605541 Versus Insulin Glargine for Patients With Type 2 Diabetes Mellitus Advanced to Multiple Injection Bolus Insulin With Insulin Lispro: a Double-Blind, Randomized, 26-week Study - The IMAGINE 4 Study [NCT01468987]	Phase 3	1,369 participants (Actual)	Interventional	2011-12-31	Completed
User Experience and Daily Use Patterns With the Integrated Insulin Management (IIM) System [NCT04484779]		67 participants (Actual)	Interventional	2020-07-14	Completed
The Effect of Treatment With Basal Insulin Peglispro or Insulin Glargine on the Dose Response Effect of Prandial Insulin Lispro in Patients With Type 1 Diabetes Mellitus. [NCT02152384]	Phase 1	28 participants (Actual)	Interventional	2014-06-30	Completed
Nanjing First Hospital, Nanjing Medical University [NCT05553093]	Phase 4	150 participants (Anticipated)	Interventional	2022-03-15	Recruiting
A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0472-0147 in Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus [NCT04262661]	Phase 1	36 participants (Actual)	Interventional	2020-03-02	Completed
A Pilot Descriptive Canadian, Multicenter, Open-label, Randomized Study of Two Titration Algorithms With Insulin Glargine 300 Units/mL in Type 2 Diabetes Mellitus Patients [NCT02401243]	Phase 3	253 participants (Actual)	Interventional	2015-03-31	Completed
An Open Therapeutic Observational Evaluation of the Efficacy and Safety Profile of Lantus in Everyday Medical Practice in Type 2 Diabetes Mellitus Patients, Who Start Receiving Lantus - Treated With Any Other Insulin, With A1c>7% [NCT00423215]		1,007 participants (Actual)	Observational	2006-03-31	Completed
Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as Add on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes [NCT02128932]	Phase 3	1,089 participants (Actual)	Interventional	2014-08-04	Completed
A Trial Comparing the Efficacy, Patient-reported Outcomes and Safety of Insulin Degludec 200 U/mL vs Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Requiring High-dose Insulin [NCT01570751]	Phase 3	145 participants (Actual)	Interventional	2012-04-30	Completed
A Single-Site, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Glucodynamic Effects of LY3192767 in Healthy Subjects [NCT03025009]	Phase 1	57 participants (Actual)	Interventional	2017-03-06	Completed
Simplification of Diabetes Regimen in Elderly Patients Using Glargine [NCT01480843]	Phase 4	65 participants (Actual)	Interventional	2011-06-30	Completed
The Effect of Exenatide Compared to Lantus Insulin on Vascular Function Before and After a Meal Tolerance Test in Patients With Type 2 Diabetes [NCT00353834]	Phase 4	72 participants (Actual)	Interventional	2006-08-31	Completed
An Open-label, Randomized, Multi-center, Parallel Group Clinical Trial Comparing the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 2 Diabetes Mellitus Patients [NCT02227875]	Phase 3	560 participants (Actual)	Interventional	2014-08-31	Completed
Evaluation of the Counter-Regulatory Response to Hypoglycaemia Following LY2605541 Administration Compared to Insulin Glargine in Patients With Type 1 Diabetes Mellitus [NCT01769404]	Phase 1	25 participants (Actual)	Interventional	2013-02-28	Completed
Assessment of the Effects of LY2605541 on Triglyceride Metabolism, Compared to Insulin Glargine, in Patients With Type 1 Diabetes Mellitus [NCT01771250]	Phase 1	15 participants (Actual)	Interventional	2013-10-31	Completed
Arterial Stiffness and Endothelial Function Indexes, Relationships With Clinical and Laboratory Variables in a Group of Diabetic Patients in Treatment With Dulaglutide: a Case-control Study [NCT03824002]	Phase 4	92 participants (Actual)	Interventional	2017-04-01	Completed
Evaluation of the Effects of Insulin Peglispro (LY2605541) on Respiratory Quotient During Sleep and Response to Hyperinsulinemia Compared With That of Insulin Glargine in Patients With Type 1 Diabetes Mellitus [NCT01925989]	Phase 1	27 participants (Actual)	Interventional	2013-11-30	Completed
Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes [NCT01819129]	Phase 3	881 participants (Actual)	Interventional	2013-09-09	Completed
Comparative Pharmacokinetics and Pharmacodynamics of LY2963016 and US-Approved Lantus® After Single-Dose Subcutaneous Administration to Healthy Subjects [NCT01688635]	Phase 1	91 participants (Actual)	Interventional	2012-09-30	Completed
A Randomized Controlled Trial Comparing the Safety and Efficacy of Liraglutide Versus Glargine Insulin for the Management of Patients With Type 2 Diabetes After Hospital Discharge [NCT01919489]	Phase 4	273 participants (Actual)	Interventional	2014-03-31	Completed
Reducing the Risk of Metabolic Decompensation in Adolescents With Poorly Controlled Type 1 Diabetes by Supervised School Administration of Insulin Degludec [NCT03400501]	Early Phase 1	32 participants (Actual)	Interventional	2017-10-01	Completed
Insulin Glargine [rDNA Origin] Injection vs Pioglitazone as add-on Therapy in Patients Failing Monotherapy With Sulfonylurea or Metformin: a Randomized, Open, Parallel Study [NCT00384215]	Phase 4	352 participants	Interventional	2001-12-31	Completed
Effect of Tight Control of Blood Glucose During Hyper-CVAD Chemotherapy For Acute Lymphocytic Leukemia [NCT00500240]	Phase 3	52 participants (Actual)	Interventional	2004-04-30	Terminated(stopped due to Terminated early due to futility.)
A Multiple Dose Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0123-0000-0338 in Subjects With Type 2 Diabetes [NCT01796366]	Phase 1	40 participants (Actual)	Interventional	2013-02-21	Completed
A Phase III Clinical Trial to Study the Safety and Efficacy of MK-1293 Compared to Lantus™ in Subjects With Type 2 Diabetes Mellitus [NCT02059187]	Phase 3	531 participants (Actual)	Interventional	2014-02-11	Completed
A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events [NCT01959529]	Phase 3	7,637 participants (Actual)	Interventional	2013-10-29	Completed
A Randomized, Open-Label, Parallel-Arm Study Comparing the Effect of Once-weekly Dulaglutide With Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes and Moderate or Severe Chronic Kidney Disease [NCT01621178]	Phase 3	577 participants (Actual)	Interventional	2012-07-31	Completed
The Pharmacokinetic and Pharmacodynamic Intra-subject Variability of LY2605541 and the Effect of Exercise on LY2605541 Pharmacokinetics in Patients With Type 1 Diabetes Mellitus [NCT01784211]	Phase 1	76 participants (Actual)	Interventional	2013-02-28	Completed
A Phase 3, Open Label, Randomized, Parallel, 26 Week Treatment Study Comparing LY2605541 With Insulin Glargine as Basal Insulin Treatment in Combination With Oral Anti Hyperglycemia Medications in Asian Insulin Naïve Patients With Type 2 Diabetes Mellitus [NCT01894568]	Phase 3	388 participants (Actual)	Interventional	2013-07-31	Completed
Dapagliflozin Effect in Cognitive Impairment in Stroke Trial [NCT05565976]	Phase 2/Phase 3	270 participants (Anticipated)	Interventional	2020-08-01	Recruiting
Open Label Randomized Multicenter Clinical Trial to Compare Immunogenicity of Insulin Glargine Ezelin vs Lantus in Type 2 Diabetes Mellitus Patients [NCT03352674]	Phase 2	133 participants (Actual)	Interventional	2016-09-30	Completed
A Phase 3, Parallel-Design, Open-Label, Randomized Controlled Study to Evaluate the Efficacy and Safety of LY3209590 as a Weekly Basal Insulin Compared to Insulin Glargine in Adults With Type 2 Diabetes on Multiple Daily Injections [NCT05462756]	Phase 3	730 participants (Actual)	Interventional	2022-08-11	Active, not recruiting
A Randomized, Open-label, Active-controlled, 3-arm Parallel-group, 26-week Study Comparing the Efficacy and Safety of Lixisenatide to That of Insulin Glulisine Once Daily and Insulin Glulisine Three Times Daily in Patients With Type 2 Diabetes Insufficien [NCT01768559]	Phase 3	894 participants (Actual)	Interventional	2013-01-31	Completed
A Randomized, 24 Week, Active-controlled, Open-label, 3-arm, Parallel-group Multicenter Study Comparing the Efficacy and Safety of iGlarLixi to Insulin Glargine and Lixisenatide in Type 2 Diabetes Mellitus Patients Insufficiently Controlled With Oral Anti [NCT03798054]	Phase 3	878 participants (Actual)	Interventional	2019-02-15	Completed
Prospective Study Aim to Determine the Efficacy and Safety of a Glargine-based Hospital Discharge Algorithm in Cardiac Surgery Patients With Perioperative Hyperglycemia [NCT01792830]	Phase 3	175 participants (Actual)	Interventional	2012-10-31	Completed
A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Efficacy of the Addition of MK-3102 to Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy [NCT01755156]	Phase 3	402 participants (Actual)	Interventional	2013-01-11	Completed
Pharmacokinetics and Pharmacodynamics of LY2963016 Compared to Lantus® in Healthy Subjects Following Two Single Subcutaneous Doses [NCT01634165]	Phase 1	24 participants (Actual)	Interventional	2012-07-31	Completed
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of the Continuation of Sitagliptin Compared With the Withdrawal of Sitagliptin During Initiation and Titration of Insulin Glargine (LANT [NCT02738879]	Phase 3	746 participants (Actual)	Interventional	2016-05-09	Completed
Preserving Beta-cell Function in Type 2 Diabetes With Exenatide and Insulin (PREVAIL) [NCT02194595]	Phase 3	105 participants (Actual)	Interventional	2014-09-30	Completed
A Randomized, 24 Weeks, Active-controlled, Open-label, 2-arm Multicenter Study Comparing the Efficacy and Safety of iGlarLixi to IDegAsp in Chinese Type 2 Diabetes Mellitus Participants Insufficiently Controlled With Oral Antidiabetic Drug(s) [NCT05413369]	Phase 3	583 participants (Actual)	Interventional	2022-07-07	Completed
6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® in Insulin-Naïve Patients With Type 2 Diabetes Mellitus Not Adequately Controlled With Non-Insulin An [NCT01676220]	Phase 3	878 participants (Actual)	Interventional	2012-08-31	Completed
Intensive Glycemic Control For Diabetic Foot Ulcer Healing: A Multicenter Randomized Control Study (IN-GLOBE Study) [NCT04323462]	Phase 4	326 participants (Anticipated)	Interventional	2021-10-01	Recruiting
A Randomized, Double-Blind Trial Comparing the Effect of the Addition of Dulaglutide 1.5 mg Versus the Addition of Placebo to Titrated Basal Insulin on Glycemic Control in Chinese Patients With Type 2 Diabetes [NCT04591626]	Phase 3	291 participants (Actual)	Interventional	2020-12-07	Completed
A Randomized, Open-label, 2-treatment Crossover Study of a New Formulation of Insulin Glargine Comparing to Lantus® on 24-hour Glucose Profile in Japanese Patients With Type 1 Diabetes Mellitus on Treatment With Basal-bolus Insulin [NCT01676233]	Phase 1	20 participants (Actual)	Interventional	2012-09-30	Completed
An Individualized treatMent aPproach for oldER patIents: A Randomized, Controlled stUdy in Type 2 Diabetes Mellitus (IMPERIUM) [NCT02072096]	Phase 4	192 participants (Actual)	Interventional	2014-02-28	Terminated(stopped due to The trial was terminated per protocol because of lack of feasibility.)
Study 200977: Albiglutide + Insulin Glargine Versus Insulin Lispro + Insulin Glargine in the Treatment of Subjects With Type 2 Diabetes Mellitus: The Switch Study [NCT02229227]	Phase 3	814 participants (Actual)	Interventional	2014-11-21	Completed
Randomized Controlled Trial on the Safety and Efficacy of Sitagliptin Therapy for the Inpatient Management of General Medicine and Surgery Patients With Type 2 Diabetes [NCT01845831]	Phase 4	292 participants (Actual)	Interventional	2013-08-31	Completed
A Randomised, Double Blind, Cross-over Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, With or Without OADs in Subjects With Type 2 Diabetes (SWITCH 2) [NCT02030600]	Phase 3	721 participants (Actual)	Interventional	2014-01-06	Completed
A 26-Week, Multi-Center, Open-label, Randomized, Parallel-group Study to Evaluate the Efficacy and Safety of Two Treatment Regimens in Patients With Type 2 Diabetes After Short-Term Intensive Insulin Therapy: Basal Insulin Based Treatment (With Prandial O [NCT03359837]	Phase 4	384 participants (Actual)	Interventional	2018-01-20	Completed
Management of Diabetic Ketoacidosis in Children: Does Early Glargine Prevent Rebound Hyperglycemia? [NCT03107208]	Phase 4	61 participants (Actual)	Interventional	2017-07-21	Completed
Six-month, Randomized, Open-label, Parallel-group Comparison of the Insulin Analog SAR342434 to Humalog® in Adult Patients With Type 2 Diabetes Mellitus Also Using Insulin Glargine [NCT02294474]	Phase 3	505 participants (Actual)	Interventional	2015-01-31	Completed
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Glimepiride in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin [NCT01682759]	Phase 3	751 participants (Actual)	Interventional	2012-09-10	Completed
A Comparison of LY2605541 Versus Insulin Glargine Alone or in Combination With Pre-study Oral Antihyperglycemic Medications in Patients With Type 2 Diabetes Mellitus Previously Treated With Basal Insulin: An Open-Label, Randomized Study The IMAGINE 5 Stud [NCT01582451]	Phase 3	466 participants (Actual)	Interventional	2012-05-31	Completed
A Phase IV, Open Label, Randomized Trial on the Effect of Metformin Plus Lantus Insulin, Pioglitazone, or DPP4 Inhibitor on Fatty Liver in Patients With Type II Diabetes [NCT02365233]	Phase 4	5 participants (Actual)	Interventional	2013-05-01	Terminated(stopped due to IRB withheld the data due to inadequate supporting documentation)
A Clinical Trial Comparing Long Term Glycaemic Control of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine Therapy in Subjects With Type 2 Diabetes Mellitus [NCT02501161]	Phase 3	1,012 participants (Actual)	Interventional	2016-01-31	Completed
A Randomized, Double-Blind Trial Comparing the Effect of Dulaglutide 1.5 mg With Placebo on Glycemic Control in Patients With Type 2 Diabetes on Basal Insulin Glargine [NCT02152371]	Phase 3	300 participants (Actual)	Interventional	2014-05-31	Completed
A Phase III Clinical Trial to Study the Safety and Efficacy of MK-1293 Compared to Lantus™ in Subjects With Type 1 Diabetes Mellitus [NCT02059161]	Phase 3	508 participants (Actual)	Interventional	2013-10-17	Completed
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 26-Week Multicenter Study With a 78-Week Extension To Evaluate The Efficacy And Safety Of Ertugliflozin In Subjects With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monothe [NCT02033889]	Phase 3	621 participants (Actual)	Interventional	2013-12-13	Completed
Restoring Insulin Secretion Pediatric Medication Study [NCT01779375]	Phase 3	91 participants (Actual)	Interventional	2013-06-16	Completed
A Randomized, Open-label, 2-arm Parallel-group, Multicenter, 26-week Study Assessing the Safety and Efficacy of H0E901-U300 Versus Lantus in Older Patients With Type 2 Diabetes Inadequately Controlled on Antidiabetic Regimens Either Including no Insulin, [NCT02320721]	Phase 3	1,014 participants (Actual)	Interventional	2015-01-31	Completed
Six-Month, Randomized, Open-Label, Parallel-group Comparison of SAR342434 to Humalog® in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine, With a 6-month Safety Extension Period [NCT02273180]	Phase 3	507 participants (Actual)	Interventional	2014-10-31	Completed
Feasibility of Once-daily Administered GLP-1 Receptoragonist (Lixisenatide) in Combination With Basal Insulin in Patients With Type-2 Diabetes Mellitus Not Achieving Therapeutic Targets With Premixed Insulin [NCT02168491]	Phase 3	10 participants (Actual)	Interventional	2014-11-30	Completed
A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus (DUAL™ V - Basal Insulin Switch) [NCT01952145]	Phase 3	557 participants (Actual)	Interventional	2013-09-20	Completed
An Open-Label, Randomized, Multi-Center, Parallel-Group Clinical Trial Comparing the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 1 Diabetes Mellitus Patients [NCT02227862]	Phase 3	558 participants (Actual)	Interventional	2014-06-30	Completed
A Phase 3 Study of LY2189265 Compared to Insulin Glargine in Patients With Type 2 Diabetes Mellitus on a Sulfonylurea and/or Biguanide [NCT01584232]	Phase 3	361 participants (Actual)	Interventional	2012-04-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00000620 (6) [back to overview]	First Occurrence of MCE or Revascularization or Hospitalization for Congestive Heart Failure (CHF) in Lipid Trial.
NCT00000620 (6) [back to overview]	Stroke in the Blood Pressure Trial.
NCT00000620 (6) [back to overview]	First Occurrence of Major Cardiovascular Event (MCE) in the Lipid Trial.
NCT00000620 (6) [back to overview]	First Occurrence of Major Cardiovascular Event (MCE) in the Blood Pressure Trial.
NCT00000620 (6) [back to overview]	First Occurrence of a Major Cardiovascular Event (MCE); Specifically Nonfatal Heart Attack, Nonfatal Stroke, or Cardiovascular Death (Measured Throughout the Study) in the Glycemia Trial.
NCT00000620 (6) [back to overview]	Death From Any Cause in the Glycemia Trial.
NCT00069784 (7) [back to overview]	Incidence of Development of Type 2 Diabetes Mellitus in Participants With IGT and/or IFG
NCT00069784 (7) [back to overview]	Number of Patients With First Occurrence of Any Type of Cancer
NCT00069784 (7) [back to overview]	Total Mortality (All Causes)
NCT00069784 (7) [back to overview]	Composite Diabetic Microvascular Outcome (Kidney or Eye Disease)
NCT00069784 (7) [back to overview]	Composite of the First Occurrence of Cardiovascular (CV) Death, Nonfatal Myocardial Infarction (MI) or Nonfatal Stroke
NCT00069784 (7) [back to overview]	Composite of the First Occurrence of Cardiovascular (CV) Death, Nonfatal Myocardial Infarction (MI), Nonfatal Stroke, Revascularization Procedure or Hospitalization for Heart Failure (HF)
NCT00069784 (7) [back to overview]	Number of Patients With Various Types of Symptomatic Hypoglycemia Events
NCT00082381 (7) [back to overview]	Change in Rate of Hypoglycemic Events
NCT00082381 (7) [back to overview]	Change in Glycosylated Hemoglobin (HbA1c)
NCT00082381 (7) [back to overview]	Change in Fasting Serum Glucose
NCT00082381 (7) [back to overview]	Change in Body Weight
NCT00082381 (7) [back to overview]	Change in 7-point Self-monitored Blood Glucose (SMBG) Profile
NCT00082381 (7) [back to overview]	Percentage of Patients With Hypoglycemic Events
NCT00082381 (7) [back to overview]	Percentage of Patients Achieving HbA1c <=7%
NCT00097500 (9) [back to overview]	Change in Second Phase C-peptide Release
NCT00097500 (9) [back to overview]	Change in First Phase C-peptide Release
NCT00097500 (9) [back to overview]	M-value at Baseline, Week 52 and Week 56
NCT00097500 (9) [back to overview]	Seven Point Self Monitored Blood Glucose (SMBG) Measurements
NCT00097500 (9) [back to overview]	Change in Fasting Plasma Glucose
NCT00097500 (9) [back to overview]	Change in Glycosylated Hemoglobin (HbA1c)
NCT00097500 (9) [back to overview]	Change in Body Weight
NCT00097500 (9) [back to overview]	Beta-cell Function After 52 Weeks of Therapy
NCT00097500 (9) [back to overview]	Beta-cell Function 4 Weeks After Cessation of Therapy
NCT00147745 (5) [back to overview]	The Acute Effect of Colesevelam (Multiple Doses) on Oral Glucose Absorption From Baseline to 12 Weeks
NCT00147745 (5) [back to overview]	Acute Effect of a Single Dose of Colesevelam on Oral Glucose Absorption From Baseline to First Dose
NCT00147745 (5) [back to overview]	Change in Hemoglobin A1C Due to Effect of Colesevelam From Baseline to 12 Weeks
NCT00147745 (5) [back to overview]	Difference in Endogenous (Hepatic) Glucose Output During a High-dose Insulin Infusion From Baseline to After 12 Weeks of Treatment.
NCT00147745 (5) [back to overview]	Difference in Endogenous (Hepatic) Glucose Output During a Low-dose Insulin Infusion From Baseline to Week 12.
NCT00191282 (27) [back to overview]	Number of Participants Who Experienced Amputation for Peripheral Vascular Disease Planned After Randomization
NCT00191282 (27) [back to overview]	Number of Participants With Self-Reported Hypoglycemia During Month 18
NCT00191282 (27) [back to overview]	Number of Participants With Self-Reported Hypoglycemia During Month 12
NCT00191282 (27) [back to overview]	Number of Participants With Self-Reported Hypoglycemia During Month 9
NCT00191282 (27) [back to overview]	Number of Episodes of Self-Reported Hypoglycemia Reported by Participants With Self-Reported Hypoglycemia During Month 9
NCT00191282 (27) [back to overview]	Summary of Reasons for Deaths
NCT00191282 (27) [back to overview]	Number of Participants With Self-Reported Hypoglycemia During Month 6
NCT00191282 (27) [back to overview]	Number of Participants With Self-Reported Hypoglycemia During Month 3
NCT00191282 (27) [back to overview]	Number of Participants With Self-Reported Hypoglycemia During Month 1
NCT00191282 (27) [back to overview]	Number of Participants Who Experienced Stroke
NCT00191282 (27) [back to overview]	Number of Participants Who Experienced Revascularization Procedure for Peripheral Vascular Disease Planned After Randomization
NCT00191282 (27) [back to overview]	Number of Participants Who Experienced Primary Outcomes Adjusted for Metabolic Control and Major Cardiovascular (CV) Risk Factors
NCT00191282 (27) [back to overview]	Number of Participants Who Experienced Myocardial Infarction (MI)
NCT00191282 (27) [back to overview]	Number of Participants Who Experienced Hospitalization for Acute Coronary Syndromes (HACS)
NCT00191282 (27) [back to overview]	Number of Participants Who Experienced Death From Any Cause or Any One of the Primary Outcomes
NCT00191282 (27) [back to overview]	Number of Participants Who Experienced Death From Any Cause
NCT00191282 (27) [back to overview]	Number of Episodes of Self-Reported Hypoglycemia Reported by Participants With Self-Reported Hypoglycemia During Month 1
NCT00191282 (27) [back to overview]	Number of Episodes of Self-Reported Hypoglycemia Reported by Participants With Self-Reported Hypoglycemia During Month 12
NCT00191282 (27) [back to overview]	Number of Episodes of Self-Reported Hypoglycemia Reported by Participants With Self-Reported Hypoglycemia During Month 18
NCT00191282 (27) [back to overview]	Number of Participants Who Experienced Cardiovascular (CV) Death
NCT00191282 (27) [back to overview]	Number of Episodes of Self-Reported Hypoglycemia Reported by Participants With Self-Reported Hypoglycemia During Month 6
NCT00191282 (27) [back to overview]	Number of Participants Who Experienced a Primary Combined Outcome
NCT00191282 (27) [back to overview]	Number of Participants Who Experienced Coronary Revascularization Procedures
NCT00191282 (27) [back to overview]	Number of Participants Who Experienced Coronary Angiography Planned After Randomization
NCT00191282 (27) [back to overview]	Number of Participants Who Experienced Congestive Heart Failure
NCT00191282 (27) [back to overview]	Number of Participants Who Experienced Any One of the Primary Outcomes Adjusted for Indicators of Metabolic Control
NCT00191282 (27) [back to overview]	Number of Episodes of Self-Reported Hypoglycemia Reported by Participants With Self-Reported Hypoglycemia During Month 3
NCT00279201 (56) [back to overview]	ADDENDUM: Body Weight
NCT00279201 (56) [back to overview]	ADDENDUM: Change From Baseline in 1,5-Anhydroglucitol to Week 24
NCT00279201 (56) [back to overview]	ADDENDUM: Change in HbA1c From Point of Second Randomization (Addendum Baseline) to Endpoint
NCT00279201 (56) [back to overview]	ADDENDUM: HbA1c at Specified Visits and Endpoint
NCT00279201 (56) [back to overview]	ADDENDUM: Incremental Change From Baseline in Body Weight
NCT00279201 (56) [back to overview]	ADDENDUM: Insulin Dose
NCT00279201 (56) [back to overview]	ADDENDUM: Percentage of Participants With HbA1c < or = 7.0%, HbA1c < 7.0%, and < or = 6.5%
NCT00279201 (56) [back to overview]	ADDENDUM: Percentage of Participants With Self-reported Hypoglycemic Episodes
NCT00279201 (56) [back to overview]	ADDENDUM: Rate of Self-reported Hypoglycemic Episodes
NCT00279201 (56) [back to overview]	INITIATION: 7-point Self-monitored Plasma Glucose (SMPG) Profiles and Postprandial Excursions
NCT00279201 (56) [back to overview]	INITIATION: Body Weight
NCT00279201 (56) [back to overview]	INITIATION: HbA1c
NCT00279201 (56) [back to overview]	INITIATION: Incremental Change From Baseline in Body Weight
NCT00279201 (56) [back to overview]	INITIATION: Insulin Dose
NCT00279201 (56) [back to overview]	INITIATION: Participant Demographics of Participants Who Did Versus Did Not Achieve HbA1c Goal - Oral Diabetes Medication at Baseline
NCT00279201 (56) [back to overview]	INITIATION: Participant Demographics of Participants Who Did Versus Did Not Achieve HbA1c Goal at Week 24 - Baseline HbA1c Percentage Group
NCT00279201 (56) [back to overview]	INITIATION: Participant Demographics of Participants Who Did Versus Did Not Achieve HbA1c Goal at Week 24 - Origin
NCT00279201 (56) [back to overview]	INITIATION: Participant Demographics of Participants Who Did Versus Did Not Achieve HbA1c Goal at Week 24 - Pre Meals Blood Glucose, Post Meals Blood Glucose, Average of All Blood Glucose, and Fasting Blood Glucose
NCT00279201 (56) [back to overview]	INITIATION: Percentage of Participants With HbA1c < or = 7.0%, HbA1c <7.0%, and HbA1c < or = 6.5% at Endpoint
NCT00279201 (56) [back to overview]	INITIATION: Percentage of Participants With Self-reported Hypoglycemic Episodes
NCT00279201 (56) [back to overview]	INITIATION: Rate of Self-reported Hypoglycemic Episodes
NCT00279201 (56) [back to overview]	MAINTENANCE: 7-point SMPG Profiles and Postprandial Excursions
NCT00279201 (56) [back to overview]	MAINTENANCE: Body Weight
NCT00279201 (56) [back to overview]	MAINTENANCE: HbA1c at Specified Visits and Endpoint
NCT00279201 (56) [back to overview]	MAINTENANCE: Incremental Change From Baseline in Body Weight
NCT00279201 (56) [back to overview]	MAINTENANCE: Insulin Dose
NCT00279201 (56) [back to overview]	MAINTENANCE: Participant Demographics of Insulin Glargine Participants Who Did Versus Did Not Maintain HbA1c Goal - Baseline HbA1c Group
NCT00279201 (56) [back to overview]	MAINTENANCE: Participant Demographics of Insulin Glargine Participants Who Did Versus Did Not Maintain HbA1c Goal - Duration of Diabetes Group
NCT00279201 (56) [back to overview]	MAINTENANCE: Participant Demographics of Insulin Glargine Participants Who Did Versus Did Not Maintain HbA1c Goal - Mean of Post Meals Blood Glucose and Average of All Blood Glucose
NCT00279201 (56) [back to overview]	MAINTENANCE: Participant Demographics of Insulin Glargine Participants Who Did Versus Did Not Maintain HbA1c Goal - Oral Diabetes Medicine at Baseline
NCT00279201 (56) [back to overview]	MAINTENANCE: Participant Demographics of Lispro LM Participants Who Did Versus Did Not Maintain HbA1c Goal - Baseline HbA1c Group
NCT00279201 (56) [back to overview]	MAINTENANCE: Participant Demographics of Lispro LM Participants Who Did Versus Did Not Maintain HbA1c Goal - Duration of Diabetes Group
NCT00279201 (56) [back to overview]	MAINTENANCE: Participant Demographics of Lispro LM Participants Who Did Versus Did Not Maintain HbA1c Goal - Mean of Post Meals Blood Glucose and Average of All Blood Glucose
NCT00279201 (56) [back to overview]	MAINTENANCE: Participant Demographics of Lispro LM Participants Who Did Versus Did Not Maintain HbA1c Goal - Oral Diabetes Medicine at Baseline
NCT00279201 (56) [back to overview]	MAINTENANCE: Percentage of Participants With HbA1c < or = 7.0%, HbA1c <7.0, and HbA1c < or = 6.5%
NCT00279201 (56) [back to overview]	MAINTENANCE: Percentage of Participants With Self-reported Hypoglycemic Episodes
NCT00279201 (56) [back to overview]	MAINTENANCE: Change From Baseline to Endpoint in HbA1c
NCT00279201 (56) [back to overview]	MAINTENANCE: Rate of Self-reported Hypoglycemic Episodes
NCT00279201 (56) [back to overview]	MAINTENANCE: Change From Baseline in 1,5-Anhydroglucitol
NCT00279201 (56) [back to overview]	ADDENDUM: 24-Week Endpoint HbA1c
NCT00279201 (56) [back to overview]	INITIATION: 24-Week Endpoint Glycosylated Hemoglobin (HbA1c)
NCT00279201 (56) [back to overview]	INITIATION: Change From Baseline to Endpoint in 1,5 Anhydroglucitol (1,5 AG)
NCT00279201 (56) [back to overview]	INITIATION: Change in HbA1c From Baseline to 24 Weeks
NCT00279201 (56) [back to overview]	INITIATION: Participant Demographics of Participants Who Did Versus Did Not Achieve HbA1c Goal at Week 24 - 1,5 AG
NCT00279201 (56) [back to overview]	INITIATION: Participant Demographics of Participants Who Did Versus Did Not Achieve HbA1c Goal at Week 24 - Age
NCT00279201 (56) [back to overview]	INITIATION: Participant Demographics of Participants Who Did Versus Did Not Achieve HbA1c Goal at Week 24 - HbA1c
NCT00279201 (56) [back to overview]	INITIATION: Participant Demographics of Participants Who Did Versus Did Not Achieve HbA1c Goal at Week 24 - Homeostasis Model Assessment of Insulin Resistance (HOMA-IR)
NCT00279201 (56) [back to overview]	MAINTENANCE: Duration of Time HbA1c Maintained at Goal by Initiation Regimen (Insulin Glargine or Lispro Low Mix)
NCT00279201 (56) [back to overview]	MAINTENANCE: Participant Demographics of Insulin Glargine Participants Who Did Versus Did Not Maintain HbA1c Goal - 1,5 AG
NCT00279201 (56) [back to overview]	MAINTENANCE: Participant Demographics of Insulin Glargine Participants Who Did Versus Did Not Maintain HbA1c Goal - Baseline HbA1c
NCT00279201 (56) [back to overview]	MAINTENANCE: Participant Demographics of Insulin Glargine Participants Who Did Versus Did Not Maintain HbA1c Goal - Duration of Diabetes
NCT00279201 (56) [back to overview]	MAINTENANCE: Participant Demographics of Lispro LM Participants Who Did Versus Did Not Maintain HbA1c Goal - 1,5 AG
NCT00279201 (56) [back to overview]	MAINTENANCE: Participant Demographics of Lispro LM Participants Who Did Versus Did Not Maintain HbA1c Goal - Baseline HbA1c
NCT00279201 (56) [back to overview]	MAINTENANCE: Participant Demographics of Lispro LM Participants Who Did Versus Did Not Maintain HbA1c Goal - Duration of Diabetes
NCT00279201 (56) [back to overview]	MAINTENANCE: Rate of Increase in HbA1c
NCT00279201 (56) [back to overview]	ADDENDUM: 7-point SMPG Profiles
NCT00283049 (3) [back to overview]	Rate of Hypoglycemia, Symptomatic Hypoglycemia, Severe Hypoglycemia and Serious Hypoglycemia
NCT00283049 (3) [back to overview]	Change in Hemoglobin A1c (HbA1c) From Baseline to Week 12
NCT00283049 (3) [back to overview]	Occurrences of Hypoglycemia, Symptomatic Hypoglycemia, Severe Hypoglycemia, and Serious Hypoglycemia
NCT00309465 (1) [back to overview]	Primary: Preoperative Fasting Blood Sugar Upon Arrival at the Hospital Prior to Surgery
NCT00338104 (3) [back to overview]	Percentage of Glucose Levels > 180 mg/dL
NCT00338104 (3) [back to overview]	Percentage of Blood Glucose Values Between 80 - 140
NCT00338104 (3) [back to overview]	Percentage of Glucose Values < 50 mg/dL
NCT00353834 (2) [back to overview]	The Primary Endpoint Was the Change in FMD at the End of the Study Compared to Baseline Measurements in Subjects Treated With Exenatide Compared to Subjects Treated With Lantus.
NCT00353834 (2) [back to overview]	First Will be the Changes in TNG Stimulated Arterial Dilation (Endothelial-independent) in Subjects Treated With Exenatide Compared With Subjects Treated With Lantus at the End of the Study Compared to Baseline Measurements
NCT00357890 (4) [back to overview]	Beta Cell Function
NCT00357890 (4) [back to overview]	Hemoglobin A1c
NCT00357890 (4) [back to overview]	Insulin Sensitivity
NCT00357890 (4) [back to overview]	Percent Body Fat
NCT00360334 (28) [back to overview]	Hypoglycemic Rate Per 30 Days
NCT00360334 (28) [back to overview]	Incidence of Hypoglycemic Episodes
NCT00360334 (28) [back to overview]	Change in Low Density Lipoprotein (LDL) Cholesterol
NCT00360334 (28) [back to overview]	Change in TC to HDL Cholesterol Ratio
NCT00360334 (28) [back to overview]	Change in Waist Circumference
NCT00360334 (28) [back to overview]	Change in Systolic Blood Pressure
NCT00360334 (28) [back to overview]	Change in Diastolic Blood Pressure
NCT00360334 (28) [back to overview]	Change in Body Weight
NCT00360334 (28) [back to overview]	Change in Apolipoprotein-B
NCT00360334 (28) [back to overview]	Change in Fasting Serum Glucose
NCT00360334 (28) [back to overview]	Change in Fasting Serum Total Cholesterol (TC)
NCT00360334 (28) [back to overview]	Change in Waist-to-hip Ratio
NCT00360334 (28) [back to overview]	Change in Fasting Serum Triglycerides
NCT00360334 (28) [back to overview]	Change in Body Mass Index (BMI)
NCT00360334 (28) [back to overview]	Incidence of Severe Hypoglycemic Episodes
NCT00360334 (28) [back to overview]	Incidence of Nocturnal Hypoglycemic Episodes
NCT00360334 (28) [back to overview]	Change in High Density Lipoprotein (HDL) Cholesterol
NCT00360334 (28) [back to overview]	Change in 7 Point Self Monitored Blood Glucose Profile
NCT00360334 (28) [back to overview]	Severe Hypoglycemic Rate Per 30 Days
NCT00360334 (28) [back to overview]	Percent of Patients Who Achieved HbA1c ≤ 7.4% With Minimal Weight Gain (≤ 1kg)
NCT00360334 (28) [back to overview]	Percent of Patients Who Achieved HbA1c ≤ 7.4% and Weight Gain ≤ 0.5kg
NCT00360334 (28) [back to overview]	Percent of Patients Achieving HbA1c ≤ 7.4%
NCT00360334 (28) [back to overview]	Percent of Patients Achieving HbA1c < 7%
NCT00360334 (28) [back to overview]	Percent of Patients Achieving 5% Weight Loss
NCT00360334 (28) [back to overview]	Percent of Patients Achieving 10% Weight Loss
NCT00360334 (28) [back to overview]	Percent Change in Body Weight
NCT00360334 (28) [back to overview]	Percent of Patients Achieving HbA1c < 6.5%
NCT00360334 (28) [back to overview]	Nocturnal Hypoglycemic Rate Per 30 Days
NCT00360698 (11) [back to overview]	Daily Mean Plasma Glucose
NCT00360698 (11) [back to overview]	Patients With Glycosylated Haemoglobin (HbA1c) Value < 7%
NCT00360698 (11) [back to overview]	Rate of Nocturnal Symptomatic Hypoglycemia With Plasma Glucose < 70mg/dL
NCT00360698 (11) [back to overview]	Glycosylated Haemoglobin (HbA1c) Value
NCT00360698 (11) [back to overview]	Rate of Severe Symptomatic Hypoglycemia
NCT00360698 (11) [back to overview]	Rate of Symptomatic Hypoglycemia With Plasma Glucose < 70mg/dL
NCT00360698 (11) [back to overview]	Change in Daily Mean Plasma Glucose
NCT00360698 (11) [back to overview]	Change in Glycosylated Haemoglobin (HbA1c) Value
NCT00360698 (11) [back to overview]	Change in Weight
NCT00360698 (11) [back to overview]	Daily Dose of Insulin Glargine
NCT00360698 (11) [back to overview]	Daily Dose of Insulin Glulisine
NCT00366301 (1) [back to overview]	Percentage Reduction in C-reactive Protein (CRP)
NCT00377858 (12) [back to overview]	Hemoglobin A1c (HbA1c) at 36 Week Endpoint
NCT00377858 (12) [back to overview]	Hemoglobin A1c (HbA1c) at Interval Visits
NCT00377858 (12) [back to overview]	30-Day Adjusted Rates of Self-Reported Hypoglycemic Episodes (Including Nocturnal and Non-Nocturnal)
NCT00377858 (12) [back to overview]	7-point Self-monitored Blood Glucose Profiles
NCT00377858 (12) [back to overview]	Change From Baseline in Absolute Body Weight at 36 Week Endpoint
NCT00377858 (12) [back to overview]	Endpoint Insulin Dose Per Body Weight; Total, Basal, and Prandial
NCT00377858 (12) [back to overview]	Endpoint Insulin Dose; Total, Basal, and Prandial
NCT00377858 (12) [back to overview]	Glycemic Variability
NCT00377858 (12) [back to overview]	Number of Insulin Injections Per Day
NCT00377858 (12) [back to overview]	Number of Patients With at Least One Self-reported Hypoglycemic Episode, Including Nocturnal (and Non-nocturnal) Hypoglycemia
NCT00377858 (12) [back to overview]	Number of Patients With at Least One Severe Hypoglycemia Episode
NCT00377858 (12) [back to overview]	Percentage of Patients Who Achieved Hemoglobin A1c Less Than or Equal to 6.5%, Greater Than 6.5%, Less Than 7%, Greater Than or Equal to 7%, Less Than or Equal to 7%, and Greater Than 7% at Interval Visits and Endpoint
NCT00384085 (8) [back to overview]	Percentage of Patients Achieving Glycosylated Hemoglobin A1c (HbA1c) < 7.0% at Week 60 (Lantus/Apidra-3 Versus Novolog Mix 70/30 - ITT Population With All Sites) (Sensitivity Analysis)
NCT00384085 (8) [back to overview]	Percentage of Patients Achieving Glycosylated Hemoglobin A1c (HbA1c) < 7.0% at Week 60 (Lantus/Apidra-3 Versus Novolog Mix 70/30 - Intent To Treat (ITT) Population Without Good Clinical Practices (GCP) Noncompliant Sites)
NCT00384085 (8) [back to overview]	Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) at Week 60 (Lantus/Apidra-1 Versus Novolog Mix 70/30)Per Protocol Population
NCT00384085 (8) [back to overview]	Adjusted Incidence Rate of Hypoglycemia
NCT00384085 (8) [back to overview]	Adjusted Hypoglycemic Event Rates (Event/Patient-year)
NCT00384085 (8) [back to overview]	Percentage of Patients Achieving Glycosylated Hemoglobin A1c (HbA1c) <7.0% at Week 60 (Lantus/Apidra-1 Versus Novolog Mix 70/30)
NCT00384085 (8) [back to overview]	Percentage of Patients Achieving Glycosylated Hemoglobin A1c (HbA1c) <7.0% at Week 60 Without a Severe Hypoglycemic Event or a Symptomatic Hypoglycemic Event With an Self Monitoring Blood Glucose (SMBG) <50 mg/dl
NCT00384085 (8) [back to overview]	Absolute Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) at Week 60 (Lantus/Apidra-3 Versus Novolog Mix 70/30)
NCT00391027 (17) [back to overview]	Change From Baseline in Cardiovascular (CV) Biomarkers - High Sensitive C-reactive Protein (Hs-CRP)
NCT00391027 (17) [back to overview]	Change From Baseline in CV Biomarkers - Interleukin 6 (IL-6)
NCT00391027 (17) [back to overview]	Change From Baseline in CV Biomarkers - Soluble Tissue Factor (STF)
NCT00391027 (17) [back to overview]	Change From Baseline in CV Biomarkers - Thrombin-antithrombin Complexes (Tat-complexes)
NCT00391027 (17) [back to overview]	Change From Baseline in Fasting Plasma Glucose (FPG) Level
NCT00391027 (17) [back to overview]	Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26
NCT00391027 (17) [back to overview]	Number of Events of Nocturnal Hypoglycemia
NCT00391027 (17) [back to overview]	Number of Subjects Discontinued Due to Insufficient Clinical Response
NCT00391027 (17) [back to overview]	Number of Subjects With HbA1c < 6.5 %
NCT00391027 (17) [back to overview]	Number of Subjects With HbA1c < 7.0 %
NCT00391027 (17) [back to overview]	Analysis of Home Blood Glucose Monitoring (HBGM) (7 & 8 Point)
NCT00391027 (17) [back to overview]	Change From Baseline in Body Mass Index (BMI)
NCT00391027 (17) [back to overview]	Number of Subjects With HbA1c < 8.0 %
NCT00391027 (17) [back to overview]	Change From Baseline in HbA1c Prior to Week 26
NCT00391027 (17) [back to overview]	Continuous Glucose Monitoring System (CGMS) 24-hour Glucose Profile in a Subset of Patients
NCT00391027 (17) [back to overview]	Number of Subjects With Hypoglycemic Events by Severity
NCT00391027 (17) [back to overview]	Change From Baseline in Body Weight
NCT00418522 (20) [back to overview]	Percentage of Subjects Achieving Glycemic Control (HbA1c < 6.5%) at Week 26
NCT00418522 (20) [back to overview]	Percentage of Subjects Achieving Glycemic Control (HbA1c < 7.0%) at Week 26
NCT00418522 (20) [back to overview]	Percentage of Subjects Achieving Glycemic Control (HbA1c < 8.0%) at Week 26
NCT00418522 (20) [back to overview]	Change From Baseline in Lipids at Week 26
NCT00418522 (20) [back to overview]	Change From Baseline in Fasting and Postprandial Blood Glucose as Determined by Standardized Meal Tolerance Tests at Week 26
NCT00418522 (20) [back to overview]	Change From Baseline in 24-Hour Continuous Glucose Monitoring System (CGMS) Glucose Values at Week 26
NCT00418522 (20) [back to overview]	Change From Baseline in Body Weight at Week 26
NCT00418522 (20) [back to overview]	Change From Baseline in Fasting Plasma Glucose at Week 26
NCT00418522 (20) [back to overview]	Number of Total Subject Months of Treatment
NCT00418522 (20) [back to overview]	Number of Total Hypoglycemic Events
NCT00418522 (20) [back to overview]	Number of Subjects With Hypoglycemic Events
NCT00418522 (20) [back to overview]	Change From Baseline in Postprandial Blood Glucose as Measured by 8-Point Profiles at Week 26
NCT00418522 (20) [back to overview]	Change From Baseline in CV Biomarkers Adiponectin and Apolipoprotein B (ApoB) at Week 26
NCT00418522 (20) [back to overview]	Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) at Week 26 for the FAS
NCT00418522 (20) [back to overview]	Change From Baseline in Cardiovascular (CV) Biomarkers High Sensitivity C-reactive Protein (Hs-CRP), Leptin, and Spot Urine Microalbumin at Week 26
NCT00418522 (20) [back to overview]	Crude Hypoglycemic Event Rate
NCT00418522 (20) [back to overview]	Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) at Week 26 for the Per Protocol (PP) Population
NCT00418522 (20) [back to overview]	Change From Baseline in Mean Standard Deviation (SD) of 24-Hour Glucose Values Measured by CGMS at Week 26
NCT00418522 (20) [back to overview]	Number of Nocturnal Hypoglycemic Events
NCT00418522 (20) [back to overview]	Change From Baseline in Body Mass Index (BMI) at Week 26
NCT00467649 (12) [back to overview]	Phase 2: Change in Body Weight at Week 36
NCT00467649 (12) [back to overview]	Fasting Serum Lipids Change From Baseline to Week 24
NCT00467649 (12) [back to overview]	The Percentage of Patients Achieving HbA1c <=7% at Week 24 With no Gain in Body Weight From Baseline and no Incidence of Severe Hypoglycemia
NCT00467649 (12) [back to overview]	Percentage of Patients With no Weight Gain at Week 24
NCT00467649 (12) [back to overview]	Percentage of Patients With a Severe Hypoglycemia Adverse Event
NCT00467649 (12) [back to overview]	Percentage of Patients Achieving HbA1c <=7% at Week 24
NCT00467649 (12) [back to overview]	Change in Waist Circumference From Baseline at Week 24
NCT00467649 (12) [back to overview]	Change in HbA1c From Baseline at Week 24
NCT00467649 (12) [back to overview]	Change in Fasting Plasma Glucose From Baseline at Week 24
NCT00467649 (12) [back to overview]	Hypoglycemia Adverse Events
NCT00467649 (12) [back to overview]	Phase 2: Change in HbA1c at Week 36
NCT00467649 (12) [back to overview]	Change in Body Weight From Baseline at Week 24
NCT00469092 (6) [back to overview]	Number of Subjects Reporting Treatment Emergent Adverse Events
NCT00469092 (6) [back to overview]	Glycosylated Haemoglobin A1c (HbA1c)
NCT00469092 (6) [back to overview]	Number of Hypoglycaemic Episodes
NCT00469092 (6) [back to overview]	Number of Subjects Achieving the Treatment Target for Glycosylated Haemoglobin A1c (HbA1c)
NCT00469092 (6) [back to overview]	Treatment Satisfaction as Measured by the Diabetes Medication Satisfaction Questionnaire (Diab MedSat)
NCT00469092 (6) [back to overview]	9-point Self-measured Plasma Glucose Profiles
NCT00469833 (4) [back to overview]	C-peptide Concentration in Response to a Glucose Clamp and Oral Glucose Ingestion Before and After 2 Months of Insulin Treatment to Improve Average Glycemia.
NCT00469833 (4) [back to overview]	HbA1c Before and After 2 Months of Insulin Treatment to Improve Average Glycemia.
NCT00469833 (4) [back to overview]	Insulin Concentration in Response to a Glucose Clamp and Oral Glucose Ingestion Before and After 2 Months of Insulin Treatment to Improve Average Glycemia.
NCT00469833 (4) [back to overview]	ISR in Response to a Glucose Clamp and Oral Glucose Ingestion Before and After 2 Months of Insulin Treatment to Improve Average Glycemia.
NCT00500240 (3) [back to overview]	Overall Survival
NCT00500240 (3) [back to overview]	Progression Free Survival (PFS)
NCT00500240 (3) [back to overview]	1-Year Overall Survival Rate
NCT00510952 (11) [back to overview]	1-Year Adjusted Rates of Self-Reported Hypoglycemic Episodes (Including All, Nocturnal, and Severe) Overall
NCT00510952 (11) [back to overview]	Number of Participants With Self-Reported Hypoglycemic Episodes (Including All, Nocturnal, and Severe Hypoglycemia) Overall
NCT00510952 (11) [back to overview]	Total Daily Insulin Dose (Units) at Endpoint
NCT00510952 (11) [back to overview]	Total Daily Insulin Dose Per Body Weight (Units/Kilograms) at Endpoint
NCT00510952 (11) [back to overview]	Percentage of Patients With HbAlc Less Than 7.0 Percent and HbAlc Less Than or Equal to 6.5 Percent at Endpoint
NCT00510952 (11) [back to overview]	Change in Absolute Body Weight (kg) From Baseline to 24 Week Endpoint
NCT00510952 (11) [back to overview]	Change From Baseline to 24 Week Endpoint in Hemoglobin A1c (HbA1c)
NCT00510952 (11) [back to overview]	Actual and Change From Baseline to 12 Week and 24 Week Endpoint in HbAlc Value
NCT00510952 (11) [back to overview]	7-Point Self-Monitored Blood Glucose (SMBG) Profile at Endpoint
NCT00510952 (11) [back to overview]	30-Day Adjusted Rates of Self-Reported Hypoglycemic Episodes (Including All, Nocturnal, and Severe) Overall
NCT00510952 (11) [back to overview]	Glycemic Variability at Endpoint
NCT00511472 (5) [back to overview]	Number of Participants Who Experienced an Adverse Event During the Study
NCT00511472 (5) [back to overview]	Number of Participants Who Experienced an Adverse Event During the Outpatient Treatment Period
NCT00511472 (5) [back to overview]	Number of Participants Who Experienced an Adverse Event - Titration Scheme 2
NCT00511472 (5) [back to overview]	24-Hour Weighted Mean Blood Glucose Levels (mg/dL) by Treatment Group on Day 7
NCT00511472 (5) [back to overview]	Number of Participants Who Experienced an Adverse Event - Titration Scheme 1
NCT00548808 (9) [back to overview]	Safety: Number of Participants With Serious and Non-Serious Adverse Events
NCT00548808 (9) [back to overview]	Percentage of Patients Achieving HbA1c <6.5% and <7% Over Time
NCT00548808 (9) [back to overview]	Daily Total Insulin Dose Per Body Weight (U/kg/Day) at 16, 32, and 48 Weeks
NCT00548808 (9) [back to overview]	Daily Total Insulin Dose (U/Day) at 16, 32, and 48 Weeks
NCT00548808 (9) [back to overview]	Change in Hemoglobin A1c (HbA1c) Over Time
NCT00548808 (9) [back to overview]	Change From Baseline to 48 Week Endpoint in Lipid and Cholesterol Profiles
NCT00548808 (9) [back to overview]	Change From Baseline in Postprandial Blood Glucose Over Time
NCT00548808 (9) [back to overview]	7-point Self-monitored Blood Glucose Profiles
NCT00548808 (9) [back to overview]	Change From Baseline to 48 Week Endpoint in Hemoglobin A1c (HbA1c)
NCT00560417 (11) [back to overview]	Change From Baseline in Body Weight at Endpoint (LOCF)
NCT00560417 (11) [back to overview]	Total Daily Insulin Dose at Endpoint (LOCF)
NCT00560417 (11) [back to overview]	7-Point Self-Monitored Blood Glucose (SMBG) Profiles at Baseline and Endpoint (LOCF)
NCT00560417 (11) [back to overview]	Actual Hemoglobin A1C at 24 Weeks and Endpoint (LOCF)
NCT00560417 (11) [back to overview]	Change From Baseline in Hemoglobin A1C (HbA1c) at Endpoint (Last Observation Carried Forward [LOCF])
NCT00560417 (11) [back to overview]	Change From Baseline in Hemoglobin A1C at 24 Weeks and Endpoint (LOCF)
NCT00560417 (11) [back to overview]	Percentage of Participants With Hemoglobin A1C Less Than 7.0% and Hemoglobin A1C Less Than or Equal to 6.5%
NCT00560417 (11) [back to overview]	Glycemic Variability at Baseline and Endpoint (LOCF)
NCT00560417 (11) [back to overview]	Actual Body Weight at Baseline and Endpoint (LOCF)
NCT00560417 (11) [back to overview]	Incidence of Self-reported Hypoglycemic Episodes (All, Non-Nocturnal, Nocturnal, and Severe)
NCT00560417 (11) [back to overview]	Rate of All, Non-Nocturnal, and Nocturnal Self-Reported Hypoglycemic Episodes (Adjusted for One Year)
NCT00574912 (1) [back to overview]	Maximum Glucose Infusion Rate
NCT00590044 (4) [back to overview]	Mean Blood Glucose Concentration in mg/dL While on the Insulin Drip Among the 2 Groups
NCT00590044 (4) [back to overview]	Difference in Time in Hours to Resolution of DKA Between the 2 Groups
NCT00590044 (4) [back to overview]	Mean Daily Blood Glucose Concentration Between the Two Groups After the Resolution of Ketoacidosis and Transition to Subcutaneous Insulin
NCT00590044 (4) [back to overview]	Number of Hypoglycemia Episodes After the Transition Period From Intravenous Insulin to Subcutaneous Insulin Between 2 Treatment Groups
NCT00596687 (2) [back to overview]	# Participants With Hypoglycemic Events
NCT00596687 (2) [back to overview]	Mean Blood Glucose Concentration
NCT00609986 (4) [back to overview]	Severe Hypoglycemia
NCT00609986 (4) [back to overview]	Severe Hyperglycemia
NCT00609986 (4) [back to overview]	Delayed Graft Function
NCT00609986 (4) [back to overview]	Acute/Active Rejection
NCT00611884 (11) [back to overview]	Vital Signs: Pulse
NCT00611884 (11) [back to overview]	Vital Signs: Diastolic Blood Pressure (BP)
NCT00611884 (11) [back to overview]	Rate of Treatment Emergent Adverse Events (AEs)
NCT00611884 (11) [back to overview]	Rate of Nocturnal Major and Minor Hypoglycaemic Episodes
NCT00611884 (11) [back to overview]	Rate of Major and Minor Hypoglycaemic Episodes
NCT00611884 (11) [back to overview]	Laboratory Safety Parameters (Biochemistry): Serum Creatinine
NCT00611884 (11) [back to overview]	Laboratory Safety Parameters (Biochemistry): Alanine Aminotransferase (ALAT)
NCT00611884 (11) [back to overview]	Mean of 9-point Self Measured Plasma Glucose Profile (SMPG)
NCT00611884 (11) [back to overview]	Vital Signs: Systolic Blood Pressure (BP)
NCT00611884 (11) [back to overview]	Laboratory Safety Parameters (Biochemistry): Aspartate Aminotransferase (ASAT)
NCT00611884 (11) [back to overview]	Change in Glycosylated Haemoglobin (HbA1c)
NCT00612040 (12) [back to overview]	Vital Signs: Pulse
NCT00612040 (12) [back to overview]	Vital Signs: Systolic BP (Blood Pressure)
NCT00612040 (12) [back to overview]	Change in Glycosylated Haemoglobin (HbA1c)
NCT00612040 (12) [back to overview]	Change in Fasting Plasma Glucose (FPG)
NCT00612040 (12) [back to overview]	Mean of 9-point Self Measured Plasma Glucose Profile (SMPG)
NCT00612040 (12) [back to overview]	Laboratory Safety Parameters (Biochemistry): Alanine Aminotransferase (ALAT)
NCT00612040 (12) [back to overview]	Laboratory Safety Parameters (Biochemistry): Aspartate Aminotransferase (ASAT)
NCT00612040 (12) [back to overview]	Laboratory Safety Parameters (Biochemistry): Serum Creatinine
NCT00612040 (12) [back to overview]	Rate of Major and Minor Hypoglycaemic Episodes
NCT00612040 (12) [back to overview]	Rate of Nocturnal Major and Minor Hypoglycaemic Episodes
NCT00612040 (12) [back to overview]	Rate of Treatment Emergent Adverse Events (AEs)
NCT00612040 (12) [back to overview]	Vital Signs: Diastolic BP (Blood Pressure)
NCT00614055 (12) [back to overview]	Laboratory Safety Parameters (Biochemistry): Alanine Aminotransferase (ALAT)
NCT00614055 (12) [back to overview]	Laboratory Safety Parameters (Biochemistry): Aspartate Aminotransferase (ASAT)
NCT00614055 (12) [back to overview]	Rate of Treatment Emergent Adverse Events (AEs)
NCT00614055 (12) [back to overview]	Vital Signs: Systolic Blood Pressure (BP)
NCT00614055 (12) [back to overview]	Vital Signs: Pulse
NCT00614055 (12) [back to overview]	Vital Signs: Diastolic Blood Pressure (BP)
NCT00614055 (12) [back to overview]	Mean of 9-point Self Measured Plasma Glucose Profile (SMPG)
NCT00614055 (12) [back to overview]	Laboratory Safety Parameters (Biochemistry): Serum Creatinine
NCT00614055 (12) [back to overview]	Rate of Major and Minor Hypoglycaemic Episodes
NCT00614055 (12) [back to overview]	Rate of Nocturnal Major and Minor Hypoglycaemic Episodes
NCT00614055 (12) [back to overview]	Change in Fasting Plasma Glucose (FPG)
NCT00614055 (12) [back to overview]	Change in Glycosylated Haemoglobin (HbA1c)
NCT00641056 (10) [back to overview]	Percentage of Patients Achieving HbA1c <=6.5% at Week 26
NCT00641056 (10) [back to overview]	Change in Fasting Serum Glucose (FSG) From Baseline to Week 26
NCT00641056 (10) [back to overview]	Change in HbA1c From Baseline to Week 26
NCT00641056 (10) [back to overview]	Change in High-density Lipoprotein Cholesterol (HDL) From Baseline to Week 26
NCT00641056 (10) [back to overview]	Change in Total Cholesterol From Baseline to Week 26
NCT00641056 (10) [back to overview]	Change in Body Weight (BW) From Baseline to Week 26
NCT00641056 (10) [back to overview]	Percentage of Patients Achieving HbA1c <=7.0% at Week 26
NCT00641056 (10) [back to overview]	Change in Blood Pressure From Baseline to Week 26
NCT00641056 (10) [back to overview]	Ratio of Triglycerides at Week 26 to Baseline
NCT00641056 (10) [back to overview]	Assessment on Event Rate of Treatment-emergent Hypoglycemic Episodes
NCT00659165 (1) [back to overview]	Calories Consumed After Fast.
NCT00664534 (11) [back to overview]	Baseline Adjusted Glycosylated Hemoglobin (HbA1c) at Endpoint
NCT00664534 (11) [back to overview]	Rate Per 30 Days of All Self-reported Hypoglycemic Episodes
NCT00664534 (11) [back to overview]	7-point Self-monitored Blood Glucose Profiles
NCT00664534 (11) [back to overview]	HbA1c Over Time
NCT00664534 (11) [back to overview]	Mean Daily Total, Basal and Prandial Insulin Dose
NCT00664534 (11) [back to overview]	Mean Postprandial Blood Glucose Values
NCT00664534 (11) [back to overview]	Body Weight Change From Baseline to Endpoint
NCT00664534 (11) [back to overview]	Number of Participants With Adverse Events
NCT00664534 (11) [back to overview]	Percentage of Participants Using Each Possible Final Insulin Regimen
NCT00664534 (11) [back to overview]	Percentage of Patients Achieving HbA1c Less Than or Equal to 6.5% and Less Than or Equal to 7% Over Time
NCT00664534 (11) [back to overview]	Incidence of All Self-reported Hypoglycemic Episodes
NCT00666718 (11) [back to overview]	7-point Self-monitored Blood Glucose Profiles (SMBG) at Endpoint
NCT00666718 (11) [back to overview]	Change From Baseline in HbA1c at Week 12 and Week 24
NCT00666718 (11) [back to overview]	Glycemic Variability at Endpoint
NCT00666718 (11) [back to overview]	Number of Injections of Insulin at Week 24
NCT00666718 (11) [back to overview]	Number of Participants With Adverse Events (AE)
NCT00666718 (11) [back to overview]	Percentage of Participants With HbA1c Less Than 7.0% and Less Than or Equal to 6.5% at Endpoint
NCT00666718 (11) [back to overview]	Percentage of Participants With Self-Reported Hypoglycemic Episodes
NCT00666718 (11) [back to overview]	Rate Of All Self-reported Hypoglycemic Episodes
NCT00666718 (11) [back to overview]	Change in Body Weight From Baseline to Week 24
NCT00666718 (11) [back to overview]	Change From Baseline in Hemoglobin A1c (HbA1c) to Week 24
NCT00666718 (11) [back to overview]	Total Daily Insulin Dose at Endpoint
NCT00670228 (4) [back to overview]	Occurrence of the Major Adverse Cardiovascular Events (MACE)
NCT00670228 (4) [back to overview]	Left Ventricular (LV) Function Evaluated by Cardiac Magnetic Resonance Imaging (MRI)
NCT00670228 (4) [back to overview]	Infarct Size Absolute Change From Baseline at Day 60
NCT00670228 (4) [back to overview]	Biomarkers of Inflammation Measurement: CRP (C-Reactive Protein)
NCT00686712 (7) [back to overview]	Frequency of Glucose Readings < 130 mg/dL
NCT00686712 (7) [back to overview]	Frequency of Total Hypoglycemic Reactions
NCT00686712 (7) [back to overview]	Hemoglobin A1c Change From Baseline
NCT00686712 (7) [back to overview]	Total Daily Insulin Dose
NCT00686712 (7) [back to overview]	Body Mass Index Change From Baseline
NCT00686712 (7) [back to overview]	Frequency of Severe Hypoglycemic Reactions
NCT00686712 (7) [back to overview]	Any Adverse Event Other Than Hypoglycemia
NCT00687453 (7) [back to overview]	Hemoglobin A1c Change From Baseline
NCT00687453 (7) [back to overview]	Frequency of Severe Hypoglycemic Reactions
NCT00687453 (7) [back to overview]	Frequency of Pre-supper Glucose Readings 130 mg/dL or Less, Change From Baseline
NCT00687453 (7) [back to overview]	Total Daily Insulin Dose
NCT00687453 (7) [back to overview]	Body Mass Index Change From Baseline
NCT00687453 (7) [back to overview]	Frequency of Total Hypoglycemic Reactions
NCT00687453 (7) [back to overview]	Any Adverse Event Other Than Hypoglycemia
NCT00694122 (6) [back to overview]	Glucagon
NCT00694122 (6) [back to overview]	Cortisol
NCT00694122 (6) [back to overview]	Blood Glucose Area Under the Curve (AUC)
NCT00694122 (6) [back to overview]	Insulin Dose
NCT00694122 (6) [back to overview]	Blood Glucose
NCT00694122 (6) [back to overview]	Growth Hormone
NCT00700622 (1) [back to overview]	Change From Baseline in HbA1c to Week 16
NCT00751114 (10) [back to overview]	Lipid Profile: Change From Baseline to Study Endpoint
NCT00751114 (10) [back to overview]	Insulin Dose in the Insulin Glargine Group
NCT00751114 (10) [back to overview]	7-point Plasma Glucose Profile: Change From Baseline to Study Endpoint
NCT00751114 (10) [back to overview]	Change in Body Weight From Baseline to Study Endpoint
NCT00751114 (10) [back to overview]	HbA1c: Change From Baseline to Study Endpoint
NCT00751114 (10) [back to overview]	Self-monitored Fasting Plasma Glucose (SMFPG) Mean : Change From Baseline to Study Endpoint
NCT00751114 (10) [back to overview]	Number of Patients With at Least One Episode of Symptomatic Hypoglycemia
NCT00751114 (10) [back to overview]	Number of Patients With at Least One Episode of Severe Symptomatic Hypoglycemia
NCT00751114 (10) [back to overview]	HbA1c Response Rate: Percentage of Patients Who Reach the Target of HbA1c < 6.5% at Study Endpoint
NCT00751114 (10) [back to overview]	HbA1c Response Rate: Percentage of Patients Who Reach the Target of HbA1c < 7% at Study Endpoint
NCT00767000 (5) [back to overview]	Change in the Fasting Plasma Glucose Level
NCT00767000 (5) [back to overview]	Percentage of Participants Who Discontinued Study Medication Due to an Adverse Event
NCT00767000 (5) [back to overview]	Change in the Two-hour Post Meal Glucose Level
NCT00767000 (5) [back to overview]	Change in Hemoglobin A1c (HbA1c) Level
NCT00767000 (5) [back to overview]	Percentage of Participants Who Experienced at Least One Adverse Event
NCT00838916 (11) [back to overview]	Change From Baseline in Body Weight at Week 52
NCT00838916 (11) [back to overview]	Change From Baseline in Body Weight at Week 156
NCT00838916 (11) [back to overview]	Change From Baseline (BL) in Glycosylated Hemoglobin (HbA1c) at Week 52
NCT00838916 (11) [back to overview]	Number of Participants Who Achieved Clinically Meaningful HbA1c Response Levels of <6.5%, <7%, and <7.5% at Week 156
NCT00838916 (11) [back to overview]	Change From Baseline in Fasting Plasma Glucose (FPG) at Week 52
NCT00838916 (11) [back to overview]	Number of Participants Who Achieved Clinically Meaningful HbA1c Response Levels of <6.5%, <7%, and <7.5% at Week 52
NCT00838916 (11) [back to overview]	Change From Baseline in Fasting Plasma Glucose (FPG) at Week 156
NCT00838916 (11) [back to overview]	Albiglutide Plasma Concentrations at Week 8 and Week 24
NCT00838916 (11) [back to overview]	Time to Hyperglycemia Rescue
NCT00838916 (11) [back to overview]	Change From Baseline in HbA1c at Week 156
NCT00838916 (11) [back to overview]	Change From Baseline in Glucose Profile Measured by 24-hour Area Under Curve (AUC) at Week 52
NCT00851903 (7) [back to overview]	HbA1c: Change From Baseline to Study Endpoint
NCT00851903 (7) [back to overview]	Change in Body Weight From Baseline to Study Endpoint
NCT00851903 (7) [back to overview]	HbA1c Response Rate: Percentage of Patients Achieving Glycosylated Haemoglobin A1c (HbA1c) < 7% at Study Endpoint (End of Treatment Period)
NCT00851903 (7) [back to overview]	Number of Patients With at Least One Episode of Symptomatic Hypoglycemia
NCT00851903 (7) [back to overview]	Self-Monitored Fasting Plasma Glucose (SMFPG) Mean : Change From Baseline to Study Endpoint
NCT00851903 (7) [back to overview]	7-point Plasma Glucose Profile: Change From Baseline to Study Endpoint
NCT00851903 (7) [back to overview]	Insulin Dose
NCT00883558 (3) [back to overview]	Postprandial Glucose Excursion
NCT00883558 (3) [back to overview]	Time Spent With Blood Glucose Value Outside a 71-139 Milligrams Per Deciliter (mg/dL) Range During Continuous Glucose Monitoring
NCT00883558 (3) [back to overview]	Number of Participants With Hypoglycemic Events
NCT00909480 (14) [back to overview]	Glycaemic Control as Measured by Plasma Glucose (9-point Self-measured Profiles)
NCT00909480 (14) [back to overview]	Fasting Plasma Glucose (FPG)
NCT00909480 (14) [back to overview]	Hypoglycaemic Episodes, Nocturnal
NCT00909480 (14) [back to overview]	"Number of Subjects Having the Adverse Event Incorrect Dose Administered"
NCT00909480 (14) [back to overview]	Change in Body Weight From Baseline
NCT00909480 (14) [back to overview]	Change in HbA1c From Baseline
NCT00909480 (14) [back to overview]	Hypoglycaemic Episodes, Diurnal
NCT00909480 (14) [back to overview]	Hypoglycemic Episodes, Unclassifiable
NCT00909480 (14) [back to overview]	Incidence of Hypoglycaemic Episodes During the Trial
NCT00909480 (14) [back to overview]	Percentage of Subjects Achieving HbA1c Less Than or Equal to 6.5%
NCT00909480 (14) [back to overview]	Percentage of Subjects Achieving HbA1c Less Than or Equal to 7.0%
NCT00909480 (14) [back to overview]	Percentage of Subjects Achieving HbA1c of 6.5% or Less With no Hypoglycaemia
NCT00909480 (14) [back to overview]	Percentage of Subjects Achieving HbA1c of 7% or Less With no Hypoglycaemia
NCT00909480 (14) [back to overview]	Within-subject Variation of Self Measured Plasma Glucose (SMPG) Before Breakfast
NCT00911625 (1) [back to overview]	Average Blood Glucose Over 6 Days
NCT00935532 (11) [back to overview]	Assessment on Event Rate of Treatment-emergent Minor Hypoglycemic Events
NCT00935532 (11) [back to overview]	Change in Fasting Serum Glucose (FSG) From Baseline to Endpoint (Week 26)
NCT00935532 (11) [back to overview]	Change in HbA1c From Baseline to Endpoint (Week 26)
NCT00935532 (11) [back to overview]	Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Endpoint (Week 26)
NCT00935532 (11) [back to overview]	Change in Total Cholesterol From Baseline to Endpoint (Week 26)
NCT00935532 (11) [back to overview]	Percentage of Subjects Achieving HbA1c<=6.5%
NCT00935532 (11) [back to overview]	Percentage of Subjects Achieving HbA1c<=7%
NCT00935532 (11) [back to overview]	Change in Blood Pressure From Baseline to Endpoint (Week 26)
NCT00935532 (11) [back to overview]	Change in Body Weight From Baseline to Endpoint (Week 26)
NCT00935532 (11) [back to overview]	Ratio of Fasting Triglycerides at Endpoint (Week 26) to Baseline
NCT00935532 (11) [back to overview]	Assessment on Event Rate of Treatment-emergent Major Hypoglycemic Events
NCT00972283 (9) [back to overview]	Extension Trial (Primary Endpoint): Rate of Confirmed Hypoglycaemic Episodes
NCT00972283 (9) [back to overview]	Rate of Treatment Emergent Adverse Events (AEs)
NCT00972283 (9) [back to overview]	Extension Trial (Secondary Endpoint): Mean of 9-point Self Measured Plasma Glucose Profile (SMPG) at Week 78
NCT00972283 (9) [back to overview]	Main Trial (Secondary Endpoint): Rate of Confirmed Hypoglycaemic Episodes
NCT00972283 (9) [back to overview]	Extension Trial (Primary Endpoint): Rate of Nocturnal Confirmed Hypoglycaemic Episodes
NCT00972283 (9) [back to overview]	Main Trial (Primary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 52 Weeks of Treatment
NCT00972283 (9) [back to overview]	Main Trial (Secondary Endpoint): Mean of 9-point Self Measured Plasma Glucose Profile (SMPG) at Week 52
NCT00972283 (9) [back to overview]	Main Trial (Secondary Endpoint): Rate of Nocturnal Confirmed Hypoglycaemic Episodes
NCT00972283 (9) [back to overview]	Extension Trial (Secondary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 78 Weeks of Treatment
NCT00975286 (13) [back to overview]	Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24
NCT00975286 (13) [back to overview]	Change From Baseline in Body Weight at Week 24
NCT00975286 (13) [back to overview]	Change From Baseline in Average Insulin Glargine Daily Dose at Week 24
NCT00975286 (13) [back to overview]	Change From Baseline in Average 7-Point Self Monitored Plasma Glucose (SMPG) Profile at Week 24
NCT00975286 (13) [back to overview]	Change From Baseline in 2-Hour Postprandial Plasma Glucose (PPG) at Week 24
NCT00975286 (13) [back to overview]	Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24
NCT00975286 (13) [back to overview]	Number of Patients With Symptomatic Hypoglycemia and Severe Symptomatic Hypoglycemia
NCT00975286 (13) [back to overview]	Percentage of Patients With Glycosylated Hemoglobin (HbA1c) Level Less Than or Equal to 6.5% at Week 24
NCT00975286 (13) [back to overview]	Percentage of Patients With Glycosylated Hemoglobin (HbA1c) Level Less Than 7% at Week 24
NCT00975286 (13) [back to overview]	Percentage of Patients With at Least 5% Weight Loss From Baseline at Week 24
NCT00975286 (13) [back to overview]	Change From Baseline in Treatment Satisfaction Score (Sum of Items 1, 4, 5, 6, 7 and 8 of DTSQ) at Week 24
NCT00975286 (13) [back to overview]	Change From Baseline in Glucose Excursion at Week 24
NCT00975286 (13) [back to overview]	Percentage of Patients Requiring Rescue Therapy During the Double-blind Period
NCT00976391 (8) [back to overview]	Change From Baseline (BL) in Glycosylated Hemoglobin (HbA1c) at Week 26
NCT00976391 (8) [back to overview]	Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 36, 48 and 52
NCT00976391 (8) [back to overview]	Change From Baseline in Body Weight at Weeks 36, 48 and 52
NCT00976391 (8) [back to overview]	Time to Hyperglycemia Rescue
NCT00976391 (8) [back to overview]	Change From Baseline in Fasting Plasma Glucose (FPG) at Week 26
NCT00976391 (8) [back to overview]	Change From Baseline in Body Weight at Week 26
NCT00976391 (8) [back to overview]	Number of Participants Who Achieved HbA1c Response Level of <6.5% and <7.0% at Week 26
NCT00976391 (8) [back to overview]	Change From Baseline in HbA1c at Weeks 36, 48 and 52
NCT00979628 (2) [back to overview]	Number of Patients With Hypoglycemia Events (Blood Glucose Levels < 70 mg/dL) During Their Hospital Stay That Are Treated With Basal Plus, Basal-bolus and SSRI Treatments
NCT00979628 (2) [back to overview]	Mean Blood Glucose Levels (Measured in mg/dL) at Randomization Are Compared to Mean Blood Glucose Levels After First Day of Treatment Among Subjects Treated With Basal Plus, Basal -Bolus and SSRI Treatments
NCT00982228 (10) [back to overview]	Extension Trial (Primary Endpoint): Rate of Treatment Emergent Adverse Events (AEs)
NCT00982228 (10) [back to overview]	Main Trial (Secondary Endpoint): Rate of Nocturnal Confirmed Hypoglycaemic Episodes
NCT00982228 (10) [back to overview]	Main Trial (Secondary Endpoint): Rate of Confirmed Hypoglycaemic Episodes
NCT00982228 (10) [back to overview]	Main Trial (Secondary Endpoint): Mean of 9-point Self Measured Plasma Glucose Profile (SMPG) at Week 52
NCT00982228 (10) [back to overview]	Main Trial (Primary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 52 Weeks of Treatment
NCT00982228 (10) [back to overview]	Extension Trial (Secondary Endpoint): Mean of 9-point Self Measured Plasma Glucose Profile (SMPG) at Week 104 of Treatment
NCT00982228 (10) [back to overview]	Extension Trial (Secondary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 104 Weeks of Treatment
NCT00982228 (10) [back to overview]	Extension Trial (Primary Endpoint): Rate of Nocturnal Confirmed Hypoglycaemic Episodes
NCT00982228 (10) [back to overview]	Extension Trial (Primary Endpoint): Rate of Confirmed Hypoglycaemic Episodes
NCT00982228 (10) [back to overview]	Extension Trial (Primary Endpoint): Cross-reacting Antibodies to Human Insulin
NCT00982644 (9) [back to overview]	Main Trial (Secondary Endpoint): Rate of Nocturnal Confirmed Hypoglycaemic Episodes
NCT00982644 (9) [back to overview]	Main Trial (Secondary Endpoint): Rate of Confirmed Hypoglycaemic Episodes
NCT00982644 (9) [back to overview]	Main Trial (Secondary Endpoint): Mean of 9-point Self Measured Plasma Glucose Profile (SMPG) at Week 52
NCT00982644 (9) [back to overview]	Main Trial (Primary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 52 Weeks of Treatment
NCT00982644 (9) [back to overview]	Extension Trial (Secondary Endpoint): Mean of 9-point Self Measured Plasma Glucose Profile (SMPG) at Week 104
NCT00982644 (9) [back to overview]	Extension Trial (Secondary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 104 Weeks of Treatment
NCT00982644 (9) [back to overview]	Extension Trial (Primary Endpoint): Rate of Nocturnal Confirmed Hypoglycaemic Episodes
NCT00982644 (9) [back to overview]	Extension Trial (Primary Endpoint): Rate of Confirmed Hypoglycaemic Episodes
NCT00982644 (9) [back to overview]	Extension Trial (Primary Endpoint): Rate of Treatment Emergent Adverse Events (AEs)
NCT00993473 (16) [back to overview]	Percentage of Patients Reaching HbA1c Target of Less Than 7.5% at the End of Treatment Visit
NCT00993473 (16) [back to overview]	Average Daily Blood Glucose (BG) Based on CGMS Values: End of Treatment and Change From Baseline to End of Treatment
NCT00993473 (16) [back to overview]	Glycosylated Hemoglobin A1c (HbA1c): End of Treatment and Change From Baseline to End of Treatment
NCT00993473 (16) [back to overview]	Glycosylated Hemoglobin A1c (HbA1c): End of Treatment and Change From Baseline to End of Treatment (ANCOVA Estimates)
NCT00993473 (16) [back to overview]	Number of Patients With Different Types of Hypoglycemia Events
NCT00993473 (16) [back to overview]	"Event Rate of All Confirmed Low CGMS Excursions (Individual Component of Primary Endpoint) Defined as the Total Number of Episodes Divided by the Total Duration of the On-treatment Period in Years (Events Per Patient-year)"
NCT00993473 (16) [back to overview]	"Event Rate of All Confirmed Low FSBG (Individual Component of the Primary Endpoint) Defined as the Total Number of Episodes Divided by the Total Duration of the On-treatment Period in Years (Events Per Patient-year)"
NCT00993473 (16) [back to overview]	"Event Rate of All Hypoglycemia Defined as the Total Number of Episodes Divided by the Total Duration of the On-treatment Period in Years (Events Per Patient-year)"
NCT00993473 (16) [back to overview]	"Event Rate of Nocturnal Hypoglycemia Defined as the Total Number of All Hypoglycemia Episodes Divided by the Total Duration of the On-treatment Period in Years"
NCT00993473 (16) [back to overview]	Blood Glucose Variability Based on All On-treatment CGMS Values
NCT00993473 (16) [back to overview]	Event Rate of Nocturnal Symptomatic Hypoglycemia Defined as the Total Number of Episodes Divided by the Total Duration of the On-treatment Period in Years
NCT00993473 (16) [back to overview]	Event Rate of Severe Nocturnal Hypoglycemia Defined as the Total Number of Episodes Divided by the Total Duration of the On-treatment Period in Years
NCT00993473 (16) [back to overview]	Event Rate of Severe Symptomatic Hypoglycemia Defined as the Total Number of Episodes Divided by the Total Duration of the On-treatment Period in Years
NCT00993473 (16) [back to overview]	Event Rate of Symptomatic Hypoglycemia (Individual Component of Primary Endpoint) Defined as the Total Number of Episodes Divided by the Total Duration of the On-treatment Period in Years (Events Per Patient-year)
NCT00993473 (16) [back to overview]	Nocturnal Blood Glucose Variability Based on All On-treatment CGMS Values
NCT00993473 (16) [back to overview]	Percent of Blood Glucose (BG) Within the Range of 70 - 180 mg/dL (3.9-10 mmol/L)
NCT01006291 (4) [back to overview]	Rate of Nocturnal Confirmed Hypoglycaemic Episodes
NCT01006291 (4) [back to overview]	Rate of Confirmed Hypoglycaemic Episodes
NCT01006291 (4) [back to overview]	Change in Glycosylated Haemoglobin (HbA1c)
NCT01006291 (4) [back to overview]	Mean of 9-point Self Measured Plasma Glucose Profile (SMPG)
NCT01027871 (21) [back to overview]	Change From Baseline in Fasting Blood Glucose (FBG) at Week 12 Endpoint - Subgroup Analysis of LY2605541 Dosing Algorithms
NCT01027871 (21) [back to overview]	Change From Baseline in Fasting Blood Glucose (FBG) at Week 12 Endpoint
NCT01027871 (21) [back to overview]	Pharmacokinetics - Drug (LY2605541) Concentration at Steady State (Css) at Week 12 Endpoint
NCT01027871 (21) [back to overview]	Percentage of Participants Who Did Not Experience a Hypoglycemic Episode During Treatment With HbA1c <7.0% and HbA1c ≤6.5% at Week 12 Endpoint - Subgroup Analysis of LY2605541 Dosing Algorithms
NCT01027871 (21) [back to overview]	Percentage of Participants With Antibody Status Change From Baseline to Week 12 and Week 16
NCT01027871 (21) [back to overview]	Percentage of Participants With Hypoglycemia From Baseline Through Week 12 - Subgroup Analysis of LY2605541 Dosing Algorithms
NCT01027871 (21) [back to overview]	Percentage of Participants With Hypoglycemia From Baseline Through Week 12
NCT01027871 (21) [back to overview]	Fasting Blood Glucose (FBG) Level at Week 12 Endpoint as Measured by the 8-Point Self-Monitored Blood Glucose (SMBG) Profiles
NCT01027871 (21) [back to overview]	Change From Baseline in Hemoglobin A1c (HbA1c) at Week 12 Endpoint
NCT01027871 (21) [back to overview]	Change From Baseline in HbA1c at Week 12 Endpoint - Subgroup Analysis of LY2605541 Dosing Algorithms
NCT01027871 (21) [back to overview]	Glycemic Variability in Fasting Blood Glucose at Baseline and Week 12 - Subgroup Analysis of LY2605541 Dosing Algorithms
NCT01027871 (21) [back to overview]	Glycemic Variability in Fasting Blood Glucose at Baseline and Week 12
NCT01027871 (21) [back to overview]	Daily Basal Insulin Dose at Week 2 and Week 12 - Subgroup Analysis of LY2605541 Dosing Algorithms
NCT01027871 (21) [back to overview]	Daily Basal Insulin Dose at Week 2 and Week 12
NCT01027871 (21) [back to overview]	8-Point Self-Monitored Blood Glucose (SMBG) Measures at Week 12 Endpoint - Subgroup Analysis of LY2605541 Dosing Algorithms
NCT01027871 (21) [back to overview]	8-Point Self-Monitored Blood Glucose (SMBG) Measures at Week 12 Endpoint
NCT01027871 (21) [back to overview]	Rate of Hypoglycemia Per 30 Days From Baseline Through Week 12 - Subgroup Analysis of LY2605541 Dosing Algorithms
NCT01027871 (21) [back to overview]	Rate of Hypoglycemia Per 30 Days From Baseline Through Week 12
NCT01027871 (21) [back to overview]	Percentage of Participants With HbA1c <7.0% and ≤6.5% at Week 12 Endpoint
NCT01027871 (21) [back to overview]	Percentage of Participants With HbA1c <7.0% and ≤6.5% at Week 12 Endpoint - Subgroup Analysis of LY2605541 Dosing Algorithms
NCT01027871 (21) [back to overview]	Percentage of Participants With HbA1c <7.0% and HbA1c ≤6.5% at Week 12 Endpoint Who Did Not Experience a Hypoglycemic Episode During Treatment
NCT01045447 (2) [back to overview]	Mean of 9-point Self Measured Plasma Glucose Profile (SMPG)
NCT01045447 (2) [back to overview]	Change in Glycosylated Haemoglobin (HbA1c)
NCT01045707 (6) [back to overview]	Main Trial (Primary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 26 Weeks of Treatment
NCT01045707 (6) [back to overview]	Extension Trial (Secondary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 52 Weeks of Treatment
NCT01045707 (6) [back to overview]	Extension Trial (Primary Endpoint): Rate of Nocturnal Confirmed Hypoglycaemic Episodes
NCT01045707 (6) [back to overview]	Extension Trial (Primary Endpoint): Rate of Confirmed Hypoglycaemic Episodes
NCT01045707 (6) [back to overview]	Extension Trial (Primary Endpoint): Rate of Treatment Emergent Adverse Events (AEs)
NCT01045707 (6) [back to overview]	Main Trial (Secondary Endpoint): Mean of 9-point Self Measured Plasma Glucose Profile (SMPG) at Week 26
NCT01049412 (12) [back to overview]	Daily Basal Insulin Dose at Week 2 and Week 8 Endpoint
NCT01049412 (12) [back to overview]	Percentage of Participants With Antibody Status Change From Baseline to Week 8, Week 16 and Week 20
NCT01049412 (12) [back to overview]	Percentage of Participants With HbA1c <7.0% and HbA1c ≤6.5% at Week 8 Endpoint of Period I
NCT01049412 (12) [back to overview]	Change From Baseline in Daily Average Blood Glucose (Avg. BG) at Week 8 Endpoint as Measured by the 8-Point Self-Monitored Blood Glucose (SMBG) Profiles
NCT01049412 (12) [back to overview]	Daily Average Blood Glucose (Avg. BG) at Week 8 Endpoint as Measured by the 8-Point Self-Monitored Blood Glucose (SMBG) Profiles
NCT01049412 (12) [back to overview]	Glycemic Variability in Fasting Blood Glucose (FBG) at Week 8 Endpoint
NCT01049412 (12) [back to overview]	Percentage of Participants With Hypoglycemia Baseline Through Week 8
NCT01049412 (12) [back to overview]	Pharmacokinetics - Drug (LY2605541) Concentration at Steady State (Css) at Week 8 Endpoint
NCT01049412 (12) [back to overview]	Rate of Hypoglycemia Per 30 Days Baseline Through Week 8
NCT01049412 (12) [back to overview]	8-Point Self-Monitored Blood Glucose (SMBG) Measures at Week 8 Endpoint
NCT01049412 (12) [back to overview]	Percentage of Participants With HbA1c <7.0% and HbA1c ≤6.5% at Week 8 Endpoint Who Did Not Experience a Hypoglycemic Episode During Treatment (Period I)
NCT01049412 (12) [back to overview]	Change From Baseline in Hemoglobin (HbA1c) at Week 8 Endpoint of Period I
NCT01059799 (4) [back to overview]	Rate of Confirmed Hypoglycaemic Episodes
NCT01059799 (4) [back to overview]	Mean of 9-point Self Measured Plasma Glucose Profile (SMPG)
NCT01059799 (4) [back to overview]	Change in Glycosylated Haemoglobin (HbA1c)
NCT01059799 (4) [back to overview]	Rate of Nocturnal Confirmed Hypoglycaemic Episodes
NCT01068665 (2) [back to overview]	Change in Fasting Plasma Glucose (FPG)
NCT01068665 (2) [back to overview]	Change in Glycosylated Haemoglobin (HbA1c)
NCT01068678 (2) [back to overview]	Change in Glycosylated Haemoglobin (HbA1c)
NCT01068678 (2) [back to overview]	Change in Body Weight
NCT01075282 (26) [back to overview]	Change From Baseline to 26, 52 and 78 Weeks in the EuroQol 5 Dimension
NCT01075282 (26) [back to overview]	Change From Baseline to 26, 52 and 78 Weeks for Daily Mean Blood Glucose Values From the 8-point Self-monitored Blood Glucose (SMBG) Profiles
NCT01075282 (26) [back to overview]	Change From Baseline to 26, 52 and 78 Weeks on Electrocardiogram Parameters, Fridericia Corrected QT (QTcF) Interval and PR Interval
NCT01075282 (26) [back to overview]	Change From Baseline to 52 Weeks Endpoint in Glycosylated Hemoglobin (HbA1c)
NCT01075282 (26) [back to overview]	Change in Baseline to 26, 52 and 78 Weeks on Pulse Rate
NCT01075282 (26) [back to overview]	Change From Baseline to 52 and 78 Weeks in Updated Homeostasis Model Assessment of Beta-cell Function (HOMA2-%B) and Updated Homeostasis Model Assessment of Insulin Sensitivity (HOMA2-%S)
NCT01075282 (26) [back to overview]	Change From Baseline to 52 and 78 Weeks in Glucagon Concentration
NCT01075282 (26) [back to overview]	Change From Baseline to 26, 52, and 78 Weeks on Blood Pressure
NCT01075282 (26) [back to overview]	Change From Baseline to 26, 52 and 78 Weeks on Serum Calcitonin
NCT01075282 (26) [back to overview]	Change From Baseline to 26, 52 and 78 Weeks on Pancreatic Enzymes
NCT01075282 (26) [back to overview]	Change From Baseline to 26, 52 and 78 Weeks on Electrocardiogram Parameters, Heart Rate
NCT01075282 (26) [back to overview]	Change From Baseline to 26, 52 and 78 Weeks for Body Weight
NCT01075282 (26) [back to overview]	Change From Baseline to 26, 52 and 78 Weeks for Body Mass Index
NCT01075282 (26) [back to overview]	Number of Self-reported Hypoglycemic Events at 26, 52 and 78 Weeks
NCT01075282 (26) [back to overview]	Rate of Self-reported Hypoglycemic Events at 26, 52 and 78 Weeks
NCT01075282 (26) [back to overview]	Number of Participants Achieving Glycosylated Hemoglobin (HbA1c) Less Than 7% at 26, 52 and 78 Weeks
NCT01075282 (26) [back to overview]	Change From Baseline to 26 Weeks and 78 Weeks Endpoint in Glycosylated Hemoglobin (HbA1c)
NCT01075282 (26) [back to overview]	Number of Participants Requiring Additional Intervention Due to Hyperglycemia at 26, 52 and 78 Weeks
NCT01075282 (26) [back to overview]	Number of Participants Achieving Glycosylated Hemoglobin (HbA1c) Less Than or Equal to 6.5% at 26, 52 and 78 Weeks
NCT01075282 (26) [back to overview]	Number of Participants With Treatment Emergent Adverse Events at 26, 52 and 78 Weeks
NCT01075282 (26) [back to overview]	Number of Participants With LY2189265 Antibodies at 26, 52, 78 Weeks and 4 Weeks After Last Dose of Study Drug (83 Weeks Maximum)
NCT01075282 (26) [back to overview]	Number of Participants With Adjudicated Pancreatitis at 26, 52 and 78 Weeks
NCT01075282 (26) [back to overview]	Number of Participants With Adjudicated Cardiovascular Events at 26, 52 and 78 Weeks
NCT01075282 (26) [back to overview]	Change From Baseline to 26, 52 and 78 Weeks in the Low Blood Sugar Survey
NCT01075282 (26) [back to overview]	Change From Baseline to 26, 52 and 78 Weeks in the Impact of Weight on Self-Perception
NCT01075282 (26) [back to overview]	Change From Baseline to 26, 52 and 78 Weeks in the Impact of Weight on Activities of Daily Living
NCT01076647 (2) [back to overview]	Change in Body Weight
NCT01076647 (2) [back to overview]	Change in Glycosylated Haemoglobin (HbA1c)
NCT01079234 (6) [back to overview]	Main Trial (Primary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 26 Weeks of Treatment
NCT01079234 (6) [back to overview]	Main Trial (Secondary Endpoint): Change in Fasting Plasma Glucose (FPG) After 26 Weeks of Treatment
NCT01079234 (6) [back to overview]	Extension Trial (Primary Endpoint): Rate of Nocturnal Confirmed Hypoglycaemic Episodes
NCT01079234 (6) [back to overview]	Extension Trial (Secondary Endpoint): Change in Fasting Plasma Glucose (FPG) After 52 Weeks of Treatment
NCT01079234 (6) [back to overview]	Extension Trial (Primary Endpoint): Rate of Confirmed Hypoglycaemic Episodes
NCT01079234 (6) [back to overview]	Extension Trial (Secondary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 52 Weeks of Treatment
NCT01089569 (7) [back to overview]	Change From Baseline in Glucose Exposure (Area Under the Diurnal Median Curve or AUC)
NCT01089569 (7) [back to overview]	Change From Baseline in CGM Glucose Variability
NCT01089569 (7) [back to overview]	HbA1c Change
NCT01089569 (7) [back to overview]	Change From Baseline in Weight Changes
NCT01089569 (7) [back to overview]	Change From Baseline in Incidence of Hypoglycemia (Frequency)
NCT01089569 (7) [back to overview]	Change From Baseline in Incidence of Hypoglycemia (Degree)
NCT01089569 (7) [back to overview]	Change From Baseline in Glucose Stability (Absolute Hourly Rate of Change in Median Curve)
NCT01117350 (17) [back to overview]	Self-Monitored Fasting Plasma Glucose (SMFPG) Measurements: Change From Beginning to the End of the Extension Period
NCT01117350 (17) [back to overview]	Percentage of Patients Whose Glycosylated Haemoglobin (HbA1c) Has Decreased But Remains ≥7% at the End of the Comparative Period
NCT01117350 (17) [back to overview]	Body Weight: Change From Baseline to the End of the Comparative Period
NCT01117350 (17) [back to overview]	Body Weight: Change From Beginning to End of the Extension Period
NCT01117350 (17) [back to overview]	Daily Dose of Insulin Glargine Administered During the Extension Period
NCT01117350 (17) [back to overview]	Daily Dose of Insulin Glargine
NCT01117350 (17) [back to overview]	Self-Monitored 7-point Plasma Glucose (PG) Profile: Change From Beginning to the End of the Extension Period
NCT01117350 (17) [back to overview]	Self-Monitored Fasting Plasma Glucose (SMFPG) Measurements: Change From Baseline to the End of the Comparative Period
NCT01117350 (17) [back to overview]	Percentage of Patients Whose Glycosylated Haemoglobin (HbA1c) Has Increased at the End of the Comparative Period
NCT01117350 (17) [back to overview]	Daily Dose of Liraglutide
NCT01117350 (17) [back to overview]	Hypoglycemia Occurence: Number of Patients With at Least One Episode of Symptomatic / Severe Symptomatic Hypoglycemia During the Comparative Period
NCT01117350 (17) [back to overview]	Hypoglycemia Occurence: Number of Patients With at Least One Episode of Symptomatic / Severe Symptomatic Hypoglycemia During the Extension Period
NCT01117350 (17) [back to overview]	Self-Monitored 7-point Plasma Glucose (PG) Profile: Change From Baseline to the End of the Comparative Period
NCT01117350 (17) [back to overview]	Glycosylated Haemoglobin (HbA1c): Change From Baseline to the End of Comparative Period
NCT01117350 (17) [back to overview]	Glycosylated Haemoglobin (HbA1c): Change From Beginning to the End of the Extension Period
NCT01117350 (17) [back to overview]	Percentage of Patients Whose Glycosylated Haemoglobin (HbA1c) <7% at the End of the Comparative Period
NCT01117350 (17) [back to overview]	Percentage of Patients Whose Glycosylated Haemoglobin (HbA1c) <7% at the End of the Extension Period
NCT01123980 (7) [back to overview]	Number of Hypoglycaemic Episodes - Severe and Minor
NCT01123980 (7) [back to overview]	9-point Plasma Glucose Profiles
NCT01123980 (7) [back to overview]	Change in Glycosylated Haemoglobin (HbA1c)
NCT01123980 (7) [back to overview]	Number of Hypoglycaemic Episodes
NCT01123980 (7) [back to overview]	Number of Hypoglycaemic Episodes - All
NCT01123980 (7) [back to overview]	Percentage of Subjects Achieving HbA1c Below 7.0%
NCT01123980 (7) [back to overview]	Percentage of Subjects Achieving HbA1c Below or Equal to 6.5%
NCT01131052 (8) [back to overview]	Mean of Glycosylated Hemoglobin (hbA1c)
NCT01131052 (8) [back to overview]	Mean of Glycosylated Hemoglobin (hbA1c)
NCT01131052 (8) [back to overview]	Percent of Participants With a Mean Blood Glucose Concentration of Less Than 70 mg/dL
NCT01131052 (8) [back to overview]	Mean of Glycosylated Hemoglobin (hbA1c)
NCT01131052 (8) [back to overview]	Mean of Weekly Fasting Blood Glucose Concentration
NCT01131052 (8) [back to overview]	Percent of Participants With a Mean Blood Glucose Concentration of Less Than 40 mg/dL
NCT01131052 (8) [back to overview]	Mean Blood Glucose Concentration
NCT01131052 (8) [back to overview]	Mean of Daily Blood Glucose Concentration
NCT01135992 (6) [back to overview]	Rate of Confirmed Hypoglycaemic Episodes
NCT01135992 (6) [back to overview]	HbA1c (Glycosylated Haemoglobin)
NCT01135992 (6) [back to overview]	Fasting Plasma Glucose (FPG)
NCT01135992 (6) [back to overview]	Rate of Treatment Emergent Adverse Events (AEs)
NCT01135992 (6) [back to overview]	Change in Body Weight
NCT01135992 (6) [back to overview]	Rate of Nocturnal Confirmed Hypoglycaemic Episodes
NCT01136746 (5) [back to overview]	Number of Participants With Treatment-emergent Adverse Events Throughout Hospital Study Period
NCT01136746 (5) [back to overview]	Number (Incidence) of Hypoglycemia and Severe Hypoglycemia Episodes, Throughout Hospital Study Period
NCT01136746 (5) [back to overview]	Mean Plasma Glucose (MPG) by Hospital Day
NCT01136746 (5) [back to overview]	Percentage of Capillary Plasma Glucose Measurements Within the Range of 71 to 179 mg/dL Throughout the Hospital Study Period
NCT01136746 (5) [back to overview]	Mean Plasma Glucose (MPG) Throughout Hospital Study Period
NCT01175811 (10) [back to overview]	The Rate of Hypoglycemic Episodes
NCT01175811 (10) [back to overview]	Percentage of Participants With Hypoglycemic Episodes (Incidence)
NCT01175811 (10) [back to overview]	Percentage of Participants Experiencing a Severe Hypoglycemic Episode
NCT01175811 (10) [back to overview]	Change in Haemoglobin A1c (HbA1c) From Baseline to 24 Week Endpoint
NCT01175811 (10) [back to overview]	Change in HbA1c From Baseline to 12 Week Endpoint
NCT01175811 (10) [back to overview]	Daily Dose of Insulin: Total, Basal, and Prandial
NCT01175811 (10) [back to overview]	Change in Body Mass Index (BMI) From Baseline to 12 and 24 Weeks
NCT01175811 (10) [back to overview]	The Percentage of Participants Who Achieved Haemoglobin A1c (HbA1c) Less Than or Equal to 6.5% and Less Than or Equal to 7% at 12 Weeks and 24 Weeks
NCT01175811 (10) [back to overview]	The 7-point Self-monitored Blood Glucose (SMBG) Profiles at Baseline, 12 Weeks and 24 Weeks.
NCT01175811 (10) [back to overview]	Daily Dose of Insulin Per Kilogram of Body Weight: Total, Basal and Prandial
NCT01175824 (14) [back to overview]	Perceptions About Medications-Diabetes 21 (PAM-D21) Questionnaire Score at 24 Weeks
NCT01175824 (14) [back to overview]	The Number of Participants With a Hypoglycemic Episodes (Incidence)
NCT01175824 (14) [back to overview]	Change in HbA1c From Baseline to 24 Weeks Endpoint (Per Protocol Population)
NCT01175824 (14) [back to overview]	Change in the HbA1c Concentration From Baseline to 12 Weeks Endpoint
NCT01175824 (14) [back to overview]	Insulin Treatment Satisfaction Questionnaire (ITSQ) Score at 24 Weeks
NCT01175824 (14) [back to overview]	The Number of Participants With Severe Hypoglycemic Episodes
NCT01175824 (14) [back to overview]	Change in HbA1c From Baseline to 24 Weeks Endpoint (Intention-to-Treat Population)
NCT01175824 (14) [back to overview]	Daily Insulin Dose: Total, Basal, and Prandial at 12 Weeks and 24 Weeks
NCT01175824 (14) [back to overview]	The Rate of Hypoglycemic Episodes
NCT01175824 (14) [back to overview]	Glycemic Variability From the 7-point Self-Monitored Blood Glucose (SMBG) Profiles at 12 Weeks and 24 Weeks
NCT01175824 (14) [back to overview]	7-point Self-Monitored Blood Glucose (SMBG) Profiles at 12 Weeks and 24 Weeks
NCT01175824 (14) [back to overview]	Change in the Fasting Plasma Glucose Concentration From Baseline to 12 Weeks and 24 Weeks
NCT01175824 (14) [back to overview]	Change in Weight From Baseline to 12 Weeks and 24 Weeks
NCT01175824 (14) [back to overview]	Number of Participants Who Achieve a Target HbA1c Concentration of Less Than 7% or Less Than or Equal to 6.5% at 24 Weeks
NCT01181674 (12) [back to overview]	1) Percentage of Participants With Normal Glucose Tolerance in the Experimental Group 1 Compared to the Control Group. 2) Percentage of Participants With Normal Glucose Tolerance in the Experimental Group 2 Compared to the Control Group.
NCT01181674 (12) [back to overview]	1) Percentage of Participants With Normal Glucose Tolerance in the Experimental Group 1 Compared to the Control Group. 2) Percentage of Participants With Normal Glucose Tolerance in the Experimental Group 2 Compared to the Control Group.
NCT01181674 (12) [back to overview]	Change in Weight From Baseline
NCT01181674 (12) [back to overview]	HbA1C
NCT01181674 (12) [back to overview]	1) Percentage of Participants With Normal Glucose Tolerance in the Experimental Group 1 Compared to the Control Group. 2) Percentage of Participants With Normal Glucose Tolerance in the Experimental Group 2 Compared to the Control Group.
NCT01181674 (12) [back to overview]	Change in Fasting Plasma Glucose From Baseline
NCT01181674 (12) [back to overview]	Number of Participants With Severe Hypoglycemic Episodes
NCT01181674 (12) [back to overview]	Number of Participants With Symptomatic Hypoglycemic Episodes
NCT01181674 (12) [back to overview]	Percentage of Participants With Normal Fasting Plasma Glucose
NCT01181674 (12) [back to overview]	Normoglycemia on Therapy
NCT01181674 (12) [back to overview]	Normoglycemia on Therapy
NCT01181674 (12) [back to overview]	Normoglycemia on Therapy
NCT01184014 (1) [back to overview]	Mean Blood Glucose of All Readings
NCT01191268 (30) [back to overview]	Total Daily Insulin Dose Overall and by Components (Insulin Lispro and Insulin Glargine)
NCT01191268 (30) [back to overview]	Change From Baseline to 26 and 52 Weeks in Electrocardiogram Parameters, Fridericia Corrected QT (QTcF) Interval and PR Interval
NCT01191268 (30) [back to overview]	Change From Baseline to 26 and 52 Weeks in Body Weight
NCT01191268 (30) [back to overview]	Change From Baseline to 26 and 52 Weeks in Blood Pressure
NCT01191268 (30) [back to overview]	Change From Baseline to 26 and 52 Weeks in Blood Glucose Values From the 8-point Self-monitored Plasma Glucose (SMPG) Profiles
NCT01191268 (30) [back to overview]	Body Weight at Baseline, 52 Weeks, and 4 Weeks After Last Dose
NCT01191268 (30) [back to overview]	Blood Pressure at Baseline, 52 Weeks, and 4 Weeks After Last Dose
NCT01191268 (30) [back to overview]	Change From Baseline to 52-week Endpoint in Glycosylated Hemoglobin (HbA1c)
NCT01191268 (30) [back to overview]	Change From Baseline to 26-week Endpoint in Glycosylated Hemoglobin (HbA1c)
NCT01191268 (30) [back to overview]	Change From Baseline to 26 and 52 Weeks in Electrocardiogram Parameters, Heart Rate
NCT01191268 (30) [back to overview]	Change From Baseline to 26 and 52 Weeks in Serum Calcitonin
NCT01191268 (30) [back to overview]	Change From Baseline to 26 Weeks, 52 Weeks, and 4 Weeks After Last Dose in Body Mass Index (BMI)
NCT01191268 (30) [back to overview]	Change From Baseline to 26 and 52 Weeks in Pulse Rate
NCT01191268 (30) [back to overview]	Change From Baseline to 26 and 52 Weeks in Pancreatic Enzymes
NCT01191268 (30) [back to overview]	Number of Participants With Adjudicated Cardiovascular Events up to 52 Weeks
NCT01191268 (30) [back to overview]	Pancreatic Enzymes at Baseline, 52 Weeks, and 4 Weeks After Last Dose
NCT01191268 (30) [back to overview]	Change From Baseline to 26 and 52 Weeks in Fasting Serum Glucose
NCT01191268 (30) [back to overview]	Number of Participants With Self-reported Hypoglycemic Events up to 26 Weeks, 52 Weeks, and 4 Weeks After Last Dose
NCT01191268 (30) [back to overview]	Number of Participants With Treatment Emergent Adverse Events up to 26 Weeks, 52 Weeks, and 4 Weeks After Last Dose
NCT01191268 (30) [back to overview]	Number of Participants With Treatment Emergent LY2189265 Antibodies up to 26 Weeks, 52 Weeks, and 4 Weeks After Last Dose
NCT01191268 (30) [back to overview]	Percentage of Participants Attaining Glycosylated Hemoglobin (HbA1c) Less Than 7% and Less Than or Equal to 6.5% at Weeks 26 and 52
NCT01191268 (30) [back to overview]	Number of Events of Adjudicated Pancreatitis up to 26 Weeks, 52 Weeks, and 4 Weeks After Last Dose
NCT01191268 (30) [back to overview]	Change From Baseline to 26 and 52 Weeks in the Percentage of Participants Achieving Glycosylated Hemoglobin (HbA1c) Less Than 7% Without Nocturnal or Severe Hypoglycemia
NCT01191268 (30) [back to overview]	Pulse Rate at Baseline, 52 Weeks, and 4 Weeks After Last Dose
NCT01191268 (30) [back to overview]	Rate of Self-reported Hypoglycemic Events up to 52 Weeks
NCT01191268 (30) [back to overview]	Serum Calcitonin at Baseline, 52 Weeks, and 4 Weeks After Last Dose
NCT01191268 (30) [back to overview]	Change From Baseline to 26 and 52 Weeks in the EQ-5D
NCT01191268 (30) [back to overview]	Change From Baseline to 26 and 52 Weeks in the Low Blood Sugar Survey (LBSS)
NCT01191268 (30) [back to overview]	Change From Baseline to 26 and 52 Weeks in the Impact of Weight on Self-Perception (IW-SP)
NCT01191268 (30) [back to overview]	Change From Baseline to 26 and 52 Weeks in the Impact of Weight on Activities of Daily Living (IW-ADL)
NCT01194245 (6) [back to overview]	Mean Daily Insulin Dose
NCT01194245 (6) [back to overview]	Change From Baseline in Body Weight at the End of Each Treatment Period
NCT01194245 (6) [back to overview]	Change From Baseline in Glycosylated Hemoglobin A1C (HbA1c) at the End of Each Treatment Period
NCT01194245 (6) [back to overview]	Percentage of Participants Meeting Glucose Targets
NCT01194245 (6) [back to overview]	Rates of Hypoglycemia at the End of Each Treatment Period
NCT01194245 (6) [back to overview]	Mean Daily Postprandial Glucose (PPG) Excursions
NCT01194258 (6) [back to overview]	Rates of Hypoglycemia at the End of Each Treatment Period
NCT01194258 (6) [back to overview]	Change From Baseline in Glycosylated Hemoglobin A1C (HbA1C) at the End of Each Treatment Period
NCT01194258 (6) [back to overview]	Mean Daily Insulin Dose as Recorded During 10-Point Glucose Monitoring
NCT01194258 (6) [back to overview]	Percentage of Participants Meeting Glucose Targets at Least 2/3 of the Time
NCT01194258 (6) [back to overview]	Change From Baseline in Body Weight at the End of Each Treatment Period
NCT01194258 (6) [back to overview]	Mean Daily PPG Excursions
NCT01196104 (18) [back to overview]	Number of Subjects Reporting Cough Episodes
NCT01196104 (18) [back to overview]	Number of Cough Episodes Occuring Within 10 Minutes of Drug Inhalation
NCT01196104 (18) [back to overview]	Mild or Moderate Hypoglycemic Event Rate
NCT01196104 (18) [back to overview]	Change in HbA1c (%) From Baseline to Week 16
NCT01196104 (18) [back to overview]	Baseline Forced Vital Capacity (FVC)
NCT01196104 (18) [back to overview]	Baseline Forced Expiratory Volume in 1 Second (FEV1)
NCT01196104 (18) [back to overview]	Number of Single Coughing Episodes
NCT01196104 (18) [back to overview]	Week 20 (Follow-up) Forced Vital Capacity
NCT01196104 (18) [back to overview]	Week 20 (Follow-up) Forced Expiratory Volume in 1 Second
NCT01196104 (18) [back to overview]	Week 20 (Follow-up) Change From Baseline in Forced Vital Capacity
NCT01196104 (18) [back to overview]	Week 20 (Follow-up) Change From Baseline in Forced Expiratory Volume in 1 Second
NCT01196104 (18) [back to overview]	Week 16 Forced Vital Capacity
NCT01196104 (18) [back to overview]	Week 16 Forced Expiratory Volume in 1 Second
NCT01196104 (18) [back to overview]	Week 16 Change From Baseline in Forced Expiratory Volume in 1 Second
NCT01196104 (18) [back to overview]	Week 16 Change From Baseline Forced Vital Capacity
NCT01196104 (18) [back to overview]	Total Number of Cough Episodes
NCT01196104 (18) [back to overview]	Severe Hypoglycemic Event Rate
NCT01196104 (18) [back to overview]	Number of Subjects Reporting Intermittent Coughing Episodes
NCT01203774 (1) [back to overview]	HbA1c at Three Months of Each Period of Treatment
NCT01226043 (12) [back to overview]	Patient Overall Preference
NCT01226043 (12) [back to overview]	Percentage of Patients Who Discontinued Investigational Product (IP) During the Crossover Phase
NCT01226043 (12) [back to overview]	Percentage of Patients Achieving Fasting Plasma Glucose (FPG) <110 mg/dL
NCT01226043 (12) [back to overview]	Patient Preference Composite Score
NCT01226043 (12) [back to overview]	Percentage of Patients Who Discontinued Investigational Product During the Re-randomization Phase
NCT01226043 (12) [back to overview]	Change in Lantus Dose Injected Per Day
NCT01226043 (12) [back to overview]	Time to First Observation of HbA1c <7%
NCT01226043 (12) [back to overview]	Number of Patients With Hypoglycemic Events
NCT01226043 (12) [back to overview]	Percentage of Patients Who Discontinued Investigational Product During the Observational Phase
NCT01226043 (12) [back to overview]	Change in Fasting Plasma Glucose (FPG)
NCT01226043 (12) [back to overview]	Healthcare Professional's (HCP) Recommendation
NCT01226043 (12) [back to overview]	Percentage of Patients Achieving HbA1c Goal
NCT01240200 (6) [back to overview]	Diabetes Treatment Satisfaction Questionnaire: Status (DTSQs) Score
NCT01240200 (6) [back to overview]	Fasting Blood Glucose
NCT01240200 (6) [back to overview]	Hemoglobin A1c (HbA1c)
NCT01240200 (6) [back to overview]	Diabetes Treatment Satisfaction Questionnaire: Change (DTSQc) Score
NCT01240200 (6) [back to overview]	Number of Hypoglycemic Events
NCT01240200 (6) [back to overview]	Percent of Participants With Dosing Errors
NCT01257087 (3) [back to overview]	Percentage of Type 2 Diabetes Mellitus Patients With a Reduction in the Doses/Number of Diabetes Medications Used Preoperatively
NCT01257087 (3) [back to overview]	Percentage of Patients With Type 2 Diabetes Mellitus Who Achieve Fasting Blood Glucose of Less Than 5.6 mmol/l and/or HbA1c of Less Than 6%
NCT01257087 (3) [back to overview]	Number of Participants With Microvascular Events
NCT01272193 (6) [back to overview]	Change in Body Weight
NCT01272193 (6) [back to overview]	Rate of Nocturnal Confirmed Hypoglycaemic Episodes
NCT01272193 (6) [back to overview]	Rate of Confirmed Hypoglycaemic Episodes
NCT01272193 (6) [back to overview]	Mean Increment of 9-point Self Measured Plasma Glucose Profile (SMPG) at the Main Evening Meal
NCT01272193 (6) [back to overview]	Change in Glycosylated Haemoglobin (HbA1c)
NCT01272193 (6) [back to overview]	Rate of Treatment Emergent Adverse Events (AEs)
NCT01374178 (6) [back to overview]	Maximum Glucose Infusion Rate (Rmax)
NCT01374178 (6) [back to overview]	Pharmacokinetics: Area Under the Concentration-Time Curve (AUC)
NCT01374178 (6) [back to overview]	Pharmacokinetics: Maximum Concentration (Cmax)
NCT01374178 (6) [back to overview]	Total Glucose Infused (Gtot)
NCT01374178 (6) [back to overview]	Number of Participants With Clinically Significant Effects
NCT01374178 (6) [back to overview]	Time of Maximum Glucose Infusion Rate (tRmax)
NCT01378117 (9) [back to overview]	Number of Patients With Severe Hypoglycemic Episodes Among the 3 Treatment Groups
NCT01378117 (9) [back to overview]	Mean Total Daily Dose of Insulin in Units/Day Given During Hospitalization Among the Three Groups
NCT01378117 (9) [back to overview]	Number of Deaths Among the Subjects in Different Groups
NCT01378117 (9) [back to overview]	Number of Patients With a Mean Daily BG > 240 mg/dL After the 1st Day of Treatment Among the Treatment Groups
NCT01378117 (9) [back to overview]	Number of Patients With Hypoglycemic Events Among the Treatment Groups
NCT01378117 (9) [back to overview]	Mean Length of Stay in Days in the Hospital Among Different Groups
NCT01378117 (9) [back to overview]	Number of Subjects With Acute Renal Failure Among the Three Randomized Groups During Hospitalization
NCT01378117 (9) [back to overview]	Mean Blood Glucose Levels Among the Three Groups at the Time of Hospitalization to 1st Day After Therapy
NCT01378117 (9) [back to overview]	Percent of Blood Glucose Readings Within Target Range Between 70 and 140 mg/dL Among the Three Groups After 24 Hrs of Randomized Treatment
NCT01421459 (15) [back to overview]	Incidence of Hypoglycemic Events
NCT01421459 (15) [back to overview]	Insulin Treatment Satisfaction Questionnaire (ITSQ)
NCT01421459 (15) [back to overview]	Percentage of Participants With Detectable Insulin Antibody Levels
NCT01421459 (15) [back to overview]	Percentage of Participants With HbA1c <7 % and HbA1c ≤6.5%
NCT01421459 (15) [back to overview]	7-Point Self-Monitored Blood Glucose (SMBG) Profiles
NCT01421459 (15) [back to overview]	Percentage of Participants With Treatment Emergent Antibody Response (TEAR)
NCT01421459 (15) [back to overview]	Change From Baseline up to 24 Weeks in Hemoglobin A1c (HbA1c)
NCT01421459 (15) [back to overview]	Insulin Dose Per Body Weight (U/kg) Per Day
NCT01421459 (15) [back to overview]	Rate Per 30 Days of Hypoglycemic Events
NCT01421459 (15) [back to overview]	Insulin Dose (Units)
NCT01421459 (15) [back to overview]	Adult Low Blood Sugar Survey (ALBSS)
NCT01421459 (15) [back to overview]	Change From Baseline in Body Weight
NCT01421459 (15) [back to overview]	Change From Baseline in Hemoglobin A1c (HbA1c)
NCT01421459 (15) [back to overview]	Change From Baseline in Insulin Antibody Levels
NCT01421459 (15) [back to overview]	Glycemic Variability of Fasting Blood Glucose
NCT01435616 (20) [back to overview]	European Quality of Life-5 Dimension (EQ-5D)
NCT01435616 (20) [back to overview]	Change From Baseline to 52 Week Endpoint in Hemoglobin A1c (HbA1c)
NCT01435616 (20) [back to overview]	Adult Low Blood Sugar Survey
NCT01435616 (20) [back to overview]	Percentage of Participants With Equal or Above 2- and 3-fold ULN for Alanine Transaminase/Serum Glutamic Pyruvic Transaminase (ALT/SGPT) and Aspartate Transaminase/Serum Glutamic Oxaloacetic Transaminase (AST/SGOT)
NCT01435616 (20) [back to overview]	Percentage of Participants With Equal or Above 2-, and 3-fold Upper Limits of Normal (ULN) for Total Bilirubin
NCT01435616 (20) [back to overview]	Change From Baseline to 52 Weeks in Triglycerides, Low Density Lipoprotein Cholesterol (LDL-C), and High Density Lipoprotein Cholesterol (HDL-C)
NCT01435616 (20) [back to overview]	Insulin Dose Per Body Weight
NCT01435616 (20) [back to overview]	6 Point Self-monitored Blood Glucose (SMBG)
NCT01435616 (20) [back to overview]	Overall Treatment-Emergent Anti-LY2065541 Antibody Response (TEAR)
NCT01435616 (20) [back to overview]	Insulin Treatment Satisfaction Questionnaire
NCT01435616 (20) [back to overview]	Change From Baseline to 52 Weeks in Body Weight
NCT01435616 (20) [back to overview]	Intra-participant Variability of the Fasting Blood Glucose (FBG)
NCT01435616 (20) [back to overview]	Number of Insulin Dose Adjustments to Steady-State
NCT01435616 (20) [back to overview]	Fasting Blood Glucose (By Participant Self-monitored Blood Glucose Readings)
NCT01435616 (20) [back to overview]	Rate of Total and Nocturnal Hypoglycemia Events
NCT01435616 (20) [back to overview]	Percentage of Participants With Total and Nocturnal Hypoglycemic Events
NCT01435616 (20) [back to overview]	Percentage of Participants With Hemoglobin A1c Equal or Less Than 6.5% and Less Than 7.0 %
NCT01435616 (20) [back to overview]	Percentage of Participants With HbA1C Equal or Less Than 6.5% and Less Than 7.0 % and Without Nocturnal Hypoglycemia
NCT01435616 (20) [back to overview]	Hemoglobin A1c
NCT01435616 (20) [back to overview]	Fasting Serum Glucose (By Laboratory Measurement)
NCT01462266 (5) [back to overview]	Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24
NCT01462266 (5) [back to overview]	Change From Baseline in Hemoglobin A1c (A1C) at Week 24
NCT01462266 (5) [back to overview]	Percent of Participants Achieving Fasting Glucose Target at Any Time During the Study
NCT01462266 (5) [back to overview]	Time to Achieve the Fasting Glucose Target
NCT01462266 (5) [back to overview]	Change From Baseline in Daily Insulin Dose at Week 24
NCT01468987 (20) [back to overview]	Total Hypoglycemia Rates (Adjusted for 30 Days)
NCT01468987 (20) [back to overview]	Basal, Bolus, and Total Insulin Dose by Weight at 26 Weeks
NCT01468987 (20) [back to overview]	Lipid Profile at 26 Weeks
NCT01468987 (20) [back to overview]	Change From Baseline in Hemoglobin A1c (HbA1c) at 26 Weeks
NCT01468987 (20) [back to overview]	0300-hour Blood Glucose to FBG Excursion at 26 Weeks
NCT01468987 (20) [back to overview]	Body Weight Change From Baseline to 26 Weeks
NCT01468987 (20) [back to overview]	EuroQoL-5D (EQ-5D) at 26 Weeks
NCT01468987 (20) [back to overview]	Fasting Serum Glucose (FSG) From Laboratory at 26 Weeks
NCT01468987 (20) [back to overview]	Percentage of Participants With HbA1c <7.0% and ≤6.5% at 26 Weeks
NCT01468987 (20) [back to overview]	Rapid Assessment of Physical Activity (RAPA) at 26 Weeks
NCT01468987 (20) [back to overview]	Self-Monitored Blood Glucose (SMBG) 9-point Profiles at 26 Weeks
NCT01468987 (20) [back to overview]	Insulin Treatment Satisfaction Questionnaire (ITSQ) at 26 Weeks
NCT01468987 (20) [back to overview]	Low Blood Sugar Survey (LBSS) at 26 Weeks
NCT01468987 (20) [back to overview]	Nocturnal Hypoglycemia Rates (Adjusted for 30 Days)
NCT01468987 (20) [back to overview]	Number of Participants With Change in Anti-LY2605541 Antibodies From Baseline to 26 Weeks
NCT01468987 (20) [back to overview]	Percentage of Participants With HbA1c <7.0% Without Nocturnal Hypoglycemia at 26 Weeks
NCT01468987 (20) [back to overview]	Percentage of Participants With Nocturnal Hypoglycemia Episodes
NCT01468987 (20) [back to overview]	HbA1c at 26 Weeks
NCT01468987 (20) [back to overview]	Percentage of Participants With Total Hypoglycemia Episodes
NCT01468987 (20) [back to overview]	Fasting Blood Glucose (FBG) (by SMBG) Intra-participant Variability at 26 Weeks
NCT01476345 (4) [back to overview]	Pharmacokinetics: Area Under the Concentration-Time Curve From Time Zero to 24 Hours [AUC(0-24)] of LY2963016 and Lantus
NCT01476345 (4) [back to overview]	Total Amount of Glucose Infused (Gtot) Over the Duration of Clamp Procedure
NCT01476345 (4) [back to overview]	Pharmacokinetics: Maximum Plasma Concentration (Cmax) of LY2963016 and Lantus
NCT01476345 (4) [back to overview]	Maximum Glucose Infusion Rate (Rmax)
NCT01476475 (14) [back to overview]	Percentage of Participants With Documented Symptomatic and Severe Symptomatic Hypoglycemia
NCT01476475 (14) [back to overview]	Change in 30-minute and 1-hour PPG From Baseline to Week 24
NCT01476475 (14) [back to overview]	Change in Body Weight From Baseline to Week 24
NCT01476475 (14) [back to overview]	Change in Average 7-Point Self-Monitored Plasma Glucose (SMPG) Profiles From Baseline to Week 24
NCT01476475 (14) [back to overview]	Change in 2-hour Postprandial Plasma Glucose (PPG) From Baseline to Week 24
NCT01476475 (14) [back to overview]	Average Daily Insulin Glargine Dose at Week 24
NCT01476475 (14) [back to overview]	Percentage of Participants Requiring Rescue Therapy During 24-week Treatment Period
NCT01476475 (14) [back to overview]	Change in 30 Minute and 1-hour Plasma Glucose Excursion From Baseline to Week 24
NCT01476475 (14) [back to overview]	Percentage of Participants Reaching HbA1c <7% With no Body Weight Gain at Week 24
NCT01476475 (14) [back to overview]	Percentage of Participants Reaching HbA1c <7% at Week 24 With no Documented Symptomatic Hypoglycemia During 24-week Treatment Period
NCT01476475 (14) [back to overview]	Change in HbA1c From Baseline to Week 24
NCT01476475 (14) [back to overview]	Change in FPG From Baseline to Week 24
NCT01476475 (14) [back to overview]	Change in 2-hour Plasma Glucose Excursion From Baseline to Week 24
NCT01476475 (14) [back to overview]	Percentage of Participants With HbA1c ≤6.5 % or <7.0 % at Week 24
NCT01480843 (2) [back to overview]	Change in Duration of Hypoglycemia Episodes
NCT01480843 (2) [back to overview]	Change in Frequency of Hypoglycemia Episodes From Baseline, 5 Months, 8 Months
NCT01499082 (12) [back to overview]	Change in 8-Point SMPG Profiles Per Time Point From Baseline to Month 6 Endpoint
NCT01499082 (12) [back to overview]	Percentage of Participants With HbA1c <7% at Month 6 Endpoint
NCT01499082 (12) [back to overview]	Percentage of Participants With FPG <5.6 mmol/L (<100 mg/dL) at Month 6 Endpoint
NCT01499082 (12) [back to overview]	Percentage of Participants With At Least One Severe and/or Confirmed Nocturnal Hypoglycemia From Start of Week 9 to Month 6 Endpoint
NCT01499082 (12) [back to overview]	Change in Variability of Preinjection SMPG From Baseline to Month 6 Endpoint
NCT01499082 (12) [back to overview]	Change in Treatment Satisfaction Score Using The Diabetes Treatment Satisfaction Questionnaire (DTSQs) From Baseline to Month 6 Endpoint
NCT01499082 (12) [back to overview]	Change in HbA1c From Baseline to Month 6 Endpoint
NCT01499082 (12) [back to overview]	Change in Fasting Plasma Glucose (FPG) From Baseline to Month 6 Endpoint
NCT01499082 (12) [back to overview]	Change in Daily Basal Insulin Dose From Baseline to Month 6 Endpoint
NCT01499082 (12) [back to overview]	Change in Average Preinjection Self-Monitored Plasma Glucose (SMPG) From Baseline to Month 6 Endpoint
NCT01499082 (12) [back to overview]	Change in HbA1c From Month 6 to Month 9
NCT01499082 (12) [back to overview]	Percentage of Participants With Hypoglycemia (All and Nocturnal) Events From Baseline up to Month 12
NCT01499095 (12) [back to overview]	Change in HbA1c From Month 6 to Month 9
NCT01499095 (12) [back to overview]	Change in HbA1c From Baseline to Month 6 Endpoint
NCT01499095 (12) [back to overview]	Change in Fasting Plasma Glucose (FPG) From Baseline to Month 6 Endpoint
NCT01499095 (12) [back to overview]	Change in Daily Basal Insulin Dose From Baseline to Month 6 Endpoint
NCT01499095 (12) [back to overview]	Percentage of Participants With HbA1c <7% at Month 6 Endpoint
NCT01499095 (12) [back to overview]	Change in Average Preinjection Self-Monitored Plasma Glucose (SMPG) From Baseline to Month 6 Endpoint
NCT01499095 (12) [back to overview]	Percentage of Participants With Hypoglycemia (All and Nocturnal) Events From Baseline to Month 12
NCT01499095 (12) [back to overview]	Change in 8-Point SMPG Profiles Per Time Point From Baseline to Month 6 Endpoint
NCT01499095 (12) [back to overview]	Percentage of Participants With FPG <5.6 mmol/L (<100 mg/dL) at Month 6 Endpoint
NCT01499095 (12) [back to overview]	Percentage of Participants With At Least One Severe and/or Confirmed Nocturnal Hypoglycemia From Start of Week 9 to Month 6 Endpoint
NCT01499095 (12) [back to overview]	Change in Variability of Preinjection SMPG From Baseline to Month 6 Endpoint
NCT01499095 (12) [back to overview]	Change in Treatment Satisfaction Score Using The Diabetes Treatment Satisfaction Questionnaire (DTSQs) From Baseline to Month 6 Endpoint
NCT01524705 (4) [back to overview]	HbA1C Levels
NCT01524705 (4) [back to overview]	Coefficient of Variation at 26 Weeks Minus Coefficient of Variation at Baseline
NCT01524705 (4) [back to overview]	Weight Change During Trial
NCT01524705 (4) [back to overview]	Number of Participants With Hypoglycemia
NCT01569841 (6) [back to overview]	Glycosylated Haemoglobin (HbA1c)
NCT01569841 (6) [back to overview]	Fasting Plasma Glucose (FPG)
NCT01569841 (6) [back to overview]	Number of Treatment Emergent Confirmed Hypoglycaemic Episodes
NCT01569841 (6) [back to overview]	Mean Interstitial Glucose (IG) Based on 14 Days of CGM
NCT01569841 (6) [back to overview]	Average Time Within Glycaemic Target Range (Above 70 mg/dL and Below 130 mg/dL)
NCT01569841 (6) [back to overview]	Number of Treatment Emergent Adverse Events (AEs)
NCT01570751 (6) [back to overview]	Change in FPG From the End of Treatment Period A Until After 4 Weeks of Treatment in Treatment Period B
NCT01570751 (6) [back to overview]	Change From Baseline (Visit 18) in Glycosylated Haemoglobin (HbA1c) at the End of Each 16 Week Treatment Period
NCT01570751 (6) [back to overview]	Change From Baseline in Central Laboratory Measured Fasting Plasma Glucose (FPG) at the End of Each 16 Week Treatment Period
NCT01570751 (6) [back to overview]	Number of Adverse Events (AEs)
NCT01570751 (6) [back to overview]	Change in Patient Reported Outcome (PRO) Scores From Baseline to the End of Each 16 Week Treatment Period
NCT01570751 (6) [back to overview]	Change in PRO Scores From the End of Treatment Period A Until After 4 Weeks of Treatment in Treatment Period B
NCT01582451 (19) [back to overview]	Fasting Blood Glucose (FBG) (by Self Monitoring)
NCT01582451 (19) [back to overview]	Change From Baseline in Lipid Profile
NCT01582451 (19) [back to overview]	Insulin Dose Per Kilogram of Body Weight
NCT01582451 (19) [back to overview]	Rate of Total and Nocturnal Hypoglycemia Events (Adjusted by 30 Days)
NCT01582451 (19) [back to overview]	Percentage of Participants With HbA1c Equal to or Less Than (≤) 6.5% and Less Than (<) 7.0%
NCT01582451 (19) [back to overview]	Fasting Serum Glucose (FSG) (by Laboratory)
NCT01582451 (19) [back to overview]	HbA1c
NCT01582451 (19) [back to overview]	Percentage of Participants That Have Total and Nocturnal Hypoglycemic Events
NCT01582451 (19) [back to overview]	Intra-participant Variability in Fasting Blood Glucose (FBG)
NCT01582451 (19) [back to overview]	Insulin Treatment Satisfaction Questionnaire (ITSQ) Score
NCT01582451 (19) [back to overview]	Percentage of Participants With HbA1c <7.0% and Without Nocturnal Hypoglycemia
NCT01582451 (19) [back to overview]	Adult Low Blood Sugar Survey (LBSS) Score
NCT01582451 (19) [back to overview]	Change From Baseline to 26-week Endpoint in Hemoglobin A1c (HbA1c)
NCT01582451 (19) [back to overview]	Change From Baseline to 52 Weeks in HbA1c
NCT01582451 (19) [back to overview]	European Quality of Life - 5 Dimension (EuroQol-5D) Score
NCT01582451 (19) [back to overview]	Number of Insulin Dose Adjustments to Steady-state
NCT01582451 (19) [back to overview]	Number of Participants With Change in Anti-LY2605541 Antibodies
NCT01582451 (19) [back to overview]	6-point Self-monitored Blood Glucose (SMBG)
NCT01582451 (19) [back to overview]	Change From Baseline in Body Weight
NCT01584232 (6) [back to overview]	Change From Baseline in Fasting Blood Glucose (FBG) at 26 Weeks
NCT01584232 (6) [back to overview]	Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 26 Weeks
NCT01584232 (6) [back to overview]	Percentage of Participants With Hypoglycemic Episodes
NCT01584232 (6) [back to overview]	Change From Baseline in 8-Point Self-Monitored Blood Glucose (SMBG) at 26 Weeks
NCT01584232 (6) [back to overview]	Percentage of Participants Who Achieved Glycosylated Hemoglobin (HbA1c) <=6.5% or <7% at 26 Weeks
NCT01584232 (6) [back to overview]	Change From Baseline in Body Weight at 26 Weeks
NCT01596504 (17) [back to overview]	Change From Baseline to Day 57 in Waist Circumference
NCT01596504 (17) [back to overview]	Change From Baseline to Day 55 in Gastric Emptying Coefficient
NCT01596504 (17) [back to overview]	Change From Baseline to Day 56 in Plasma Glucose Corrected AUC From Time 0.5 Hours to 5.5 Hours
NCT01596504 (17) [back to overview]	Change From Baseline to Day 56 in PPG Excursion
NCT01596504 (17) [back to overview]	Change From Baseline to Day 57 in Body Weight
NCT01596504 (17) [back to overview]	Change From Baseline to Day 55 in Gastric Emptying Half Life (t1/2)
NCT01596504 (17) [back to overview]	Change From Baseline to Day 57/58 in 24-Hour Mean Heart Rate
NCT01596504 (17) [back to overview]	Change From Baseline to Day 56 in Average Daily Insulin Glargine Dose
NCT01596504 (17) [back to overview]	Number of Participants With 2-Hour Post-prandial Plasma Glucose (PPG) <7.77 (mmol/L) at Day 56
NCT01596504 (17) [back to overview]	Change From Baseline to Day 56 in the Cumulative Score Mean on the Appetite Perception Using a Visual Analogue Scale After Standardized Solid Breakfast
NCT01596504 (17) [back to overview]	Change From Baseline to Day 57/58 in 24-Hour Mean Systolic Blood Pressure and Diastolic Blood Pressure
NCT01596504 (17) [back to overview]	Change From Baseline to Day 56 in Average 7-Point Self-Monitored Plasma Glucose (SMPG)
NCT01596504 (17) [back to overview]	Change From Baseline to Day 56 in Corrected C-Peptide AUC From Time 0.5 Hours to 5.5 Hours
NCT01596504 (17) [back to overview]	Change From Baseline to Day 56 in Corrected Glucagon AUC From Time 0.5 Hours to 5.5 Hours
NCT01596504 (17) [back to overview]	Change From Baseline to Day 56 in Fasting Plasma Glucose (FPG)
NCT01596504 (17) [back to overview]	Change From Baseline to Day 56 in HbA1c
NCT01596504 (17) [back to overview]	Change From Baseline to Day 56 in Plasma Glucose Corrected Area Under The Plasma Concentration-Time Curve (AUC) From Time 0.5 Hours to 4.5 Hours
NCT01600950 (4) [back to overview]	Total Glucose Infused (Gtot)
NCT01600950 (4) [back to overview]	Time of Maximum Glucose Infusion Rate (tRmax)
NCT01600950 (4) [back to overview]	Pharmacodynamics: Duration of Action of LY2963016 and Lantus
NCT01600950 (4) [back to overview]	Maximum Glucose Infusion Rate (Rmax)
NCT01621178 (29) [back to overview]	Rate of Hypoglycemic Events (HE)
NCT01621178 (29) [back to overview]	Change From Baseline in FG
NCT01621178 (29) [back to overview]	Change From Baseline in HbA1c
NCT01621178 (29) [back to overview]	Change From Baseline in Hemoglobin A1c (HbA1c)
NCT01621178 (29) [back to overview]	Change From Baseline in Mean Daily Insulin Lispro Dose
NCT01621178 (29) [back to overview]	Change From Baseline in sCr
NCT01621178 (29) [back to overview]	Change From Baseline in Serum Creatinine (sCr)
NCT01621178 (29) [back to overview]	Change From Baseline in UACR
NCT01621178 (29) [back to overview]	Percentage of Participants With Self-Reported Hypoglycemic Events (HE)
NCT01621178 (29) [back to overview]	Rate of Hypoglycemic Events
NCT01621178 (29) [back to overview]	Percentage of Participants Whose HbA1c is <8.0%
NCT01621178 (29) [back to overview]	Change From Baseline in 8-Point Self-Monitored Plasma Glucose (SMPG)
NCT01621178 (29) [back to overview]	Change From Baseline in 8-Point SMPG
NCT01621178 (29) [back to overview]	Change From Baseline in Body Weight
NCT01621178 (29) [back to overview]	Change From Baseline in Body Weight
NCT01621178 (29) [back to overview]	Change From Baseline in eCrCl
NCT01621178 (29) [back to overview]	Change From Baseline in eGFR
NCT01621178 (29) [back to overview]	Change From Baseline in Estimated Creatinine Clearance (eCrCl)
NCT01621178 (29) [back to overview]	Change From Baseline in Estimated Glomerular Filtration Rate (eGFR)
NCT01621178 (29) [back to overview]	Change From Baseline in Fasting Glucose (FG)
NCT01621178 (29) [back to overview]	Change From Baseline in Urinary Albumin to Creatinine Ratio (UACR)
NCT01621178 (29) [back to overview]	Change in Mean Daily Insulin Lispro Dose
NCT01621178 (29) [back to overview]	Percentage of Participants Whose HbA1c is <7.0%
NCT01621178 (29) [back to overview]	Percentage of Participants Whose HbA1c Was <7.0%
NCT01621178 (29) [back to overview]	Percentage of Participants Whose HbA1c Was <8.0%
NCT01621178 (29) [back to overview]	Percentage of Participants With Estimated Average Glucose <154 mg/dL
NCT01621178 (29) [back to overview]	Percentage of Participants With Estimated Average Glucose <154 mg/dL
NCT01621178 (29) [back to overview]	Participants With Events of Allergic/Hypersensitivity Reactions
NCT01621178 (29) [back to overview]	Percentage of Participants With Self-Reported Hypoglycemic Events (HE)
NCT01634165 (6) [back to overview]	Pharmacokinetics: Maximum Serum LY2963016 or Lantus Concentration (Cmax)
NCT01634165 (6) [back to overview]	Pharmacokinetics: Area Under the Serum Concentration-Time Curve (AUC) From Time Zero to Last Measured Concentration Value [AUC(0-tlast)] of LY2963016 or Lantus
NCT01634165 (6) [back to overview]	Maximum Glucose Infusion Rate (Rmax)
NCT01634165 (6) [back to overview]	Total Amount of Glucose Infused (Gtot)
NCT01634165 (6) [back to overview]	Pharmacokinetics: Area Under the Serum LY2963016 or Lantus Concentration-Time Curve (AUC) From Zero to Infinity [AUC(0-∞)]
NCT01634165 (6) [back to overview]	Pharmacokinetics: Area Under the Serum Concentration-Time Curve From Time Zero to 24 Hours [AUC(0-24)] of LY2963016 or Lantus
NCT01648582 (22) [back to overview]	Change in Body Mass Index
NCT01648582 (22) [back to overview]	EQ-5D Health State Score Responses
NCT01648582 (22) [back to overview]	Percentages of Participants Developing Treatment-Emergent Dulaglutide Anti-drug Antibody (ADA)
NCT01648582 (22) [back to overview]	Percentage of Participants Attaining HbA1c of <7% or ≤6.5% at 26 Weeks and 52 Weeks
NCT01648582 (22) [back to overview]	Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 26 Weeks
NCT01648582 (22) [back to overview]	Change From Baseline to 26 Weeks and 52 Weeks on Blood Pressure (BP)
NCT01648582 (22) [back to overview]	Number of Participants With Adjudicated Cardiovascular (CV) Events
NCT01648582 (22) [back to overview]	Number of Participants With Adjudicated Pancreatitis
NCT01648582 (22) [back to overview]	Change From Baseline at 26 Weeks and 52 Weeks on Pulse Rate
NCT01648582 (22) [back to overview]	Change From Baseline in 7-point Self-monitored Blood Glucose (SMBG) Profiles at 26 Weeks and 52 Weeks
NCT01648582 (22) [back to overview]	Number of Self-reported Hypoglycemic Events
NCT01648582 (22) [back to overview]	Change From Baseline in HbA1c at 52 Weeks
NCT01648582 (22) [back to overview]	Change From Baseline in Electrocardiogram Parameters, Heart Rate (HR)
NCT01648582 (22) [back to overview]	Change From Baseline in Electrocardiogram Parameters, Fridericia Corrected QT (QTcF) Interval and PR Interval
NCT01648582 (22) [back to overview]	Change From Baseline in Body Weight
NCT01648582 (22) [back to overview]	Change From Baseline in EQ-5D Visual Analog Scale Score
NCT01648582 (22) [back to overview]	Change From Baseline in Homeostasis Model Assessment 2 Steady-state Beta (β)- Cell Function (HOMA2-%B) at 26 Weeks and 52 Weeks
NCT01648582 (22) [back to overview]	Change From Baseline in Pancreatic Enzymes
NCT01648582 (22) [back to overview]	Change From Baseline in Fasting Blood Glucose (FBG) at 26 Weeks and 52 Weeks
NCT01648582 (22) [back to overview]	Rate of Hypoglycemic Events
NCT01648582 (22) [back to overview]	Change From Baseline in Homeostasis Model Assessment 2 Insulin Sensitivity - Cell Function (HOMA2-%S) at 26 Weeks and 52 Weeks
NCT01648582 (22) [back to overview]	Change From Baseline in Serum Calcitonin
NCT01654380 (3) [back to overview]	Part B: Glycodynamics: Maximum Rate of Glucose Disposal
NCT01654380 (3) [back to overview]	Part B: Glucodynamics: Endogenous Glucose Output
NCT01654380 (3) [back to overview]	Part B: Glycodynamics: Glucose Disposal
NCT01658579 (10) [back to overview]	Percentage of Time Above the Upper Limit of Glycemic Range (Greater Than [>] 7.8 mmol/L [(140 mg/dL])
NCT01658579 (10) [back to overview]	Percentage of Time Below The Lower Limit of Glycemic Range (<4.4 mmol/L [80 mg/dL])
NCT01658579 (10) [back to overview]	Evaluation of Diurnal Glucose Exposure, Variability, and Stability
NCT01658579 (10) [back to overview]	Percentage of Time in Target Plasma Glucose Range (4.4-7.8 mmol/L [80-140 mg/dL])
NCT01658579 (10) [back to overview]	Change in HbA1c From Baseline to Week 8 and 16
NCT01658579 (10) [back to overview]	Change in Fasting Plasma Glucose (FPG) From Baseline to Week 8 and 16
NCT01658579 (10) [back to overview]	Percentage of Participants With Hypoglycemia (All and Nocturnal) Events From Baseline Up to Week 16
NCT01658579 (10) [back to overview]	Change in Basal Insulin Daily Dose From Baseline to Week 8 and 16
NCT01658579 (10) [back to overview]	Percentage of Time in Target Plasma Glucose Range (4.4-7.8 mmol/L [80-140 mg/dL]) in the Last Four Hours of Each Dosing Interval at Weeks 7 and 8 in Period A and Weeks 15 and 16 in Period B
NCT01658579 (10) [back to overview]	Change in Average 7-Point Self-Monitored Plasma Glucose (SMPG) Profile From Baseline to Week 8 and 16
NCT01676220 (13) [back to overview]	Change in 24-hour Average 8-point SMPG Profile From Baseline to Month 6 Endpoint
NCT01676220 (13) [back to overview]	Change in Daily Basal Insulin Dose From Baseline to Month 6
NCT01676220 (13) [back to overview]	Change in Fasting Plasma Glucose (FPG) From Baseline to Month 6 Endpoint
NCT01676220 (13) [back to overview]	Change in HbA1c From Baseline to Month 6 Endpoint
NCT01676220 (13) [back to overview]	Change in Preinjection Self-Monitored Plasma Glucose (SMPG) From Baseline to Month 6 Endpoint
NCT01676220 (13) [back to overview]	Change in Total Treatment Satisfaction Score Using The Diabetes Treatment Satisfaction Questionnaire (DTSQs) From Baseline to Month 6 Endpoint
NCT01676220 (13) [back to overview]	Change in Variability of 24 Hour Average 8-point SMPG Profiles From Baseline to Month 6 Endpoint
NCT01676220 (13) [back to overview]	Percentage of Participants With FPG <5.6 mmol/L (100 mg/dL) at Month 6
NCT01676220 (13) [back to overview]	Percentage of Participants With At Least One Severe and/or Confirmed Nocturnal Hypoglycemia From Start of Week 9 to Month 6
NCT01676220 (13) [back to overview]	Percentage of Participants With Hypoglycemia (All and Nocturnal) Events From Baseline up to Month 12
NCT01676220 (13) [back to overview]	Change in 8-Point SMPG Profiles Per Time Point From Baseline to Month 6
NCT01676220 (13) [back to overview]	Variability of Preinjection SMPG at Month 6 Endpoint
NCT01676220 (13) [back to overview]	Percentage of Participants With HbA1c <7% at Month 6
NCT01682759 (8) [back to overview]	Percentage of Participants Who Experienced at Least One Adverse Event Excluding Data After Glycemic Rescue
NCT01682759 (8) [back to overview]	Percentage of Participants Who Discontinued From the Study Due to an Adverse Event Excluding Data After Glycemic Rescue
NCT01682759 (8) [back to overview]	Percentage of Participants Achieving a Hemoglobin A1C of <7.0% at Week 54
NCT01682759 (8) [back to overview]	Percentage of Participants Achieving a Hemoglobin A1C of <6.5% at Week 54
NCT01682759 (8) [back to overview]	Change From Baseline in Hemoglobin A1C at Week 54
NCT01682759 (8) [back to overview]	Change From Baseline in Fasting Plasma Glucose at Week 54
NCT01682759 (8) [back to overview]	Change From Baseline in Body Weight at Week 54 Excluding Data After Gylcemic Rescue
NCT01682759 (8) [back to overview]	Percentage of Participants With an Adverse Event of Symptomatic Hypoglycemia Excluding Data After Glycemic Rescue
NCT01683266 (12) [back to overview]	Percentage of Participants With Fasting Plasma Glucose (FPG) <5.6 mmol/L (100 mg/dL) At Month 6
NCT01683266 (12) [back to overview]	Percentage of Participants With HbA1c Less Than or Equal to 6.5% at Month 6 Endpoint
NCT01683266 (12) [back to overview]	Percentage of Participants With HbA1c <7% at Month 6 Endpoint
NCT01683266 (12) [back to overview]	Percentage of Participants With FPG <7.2 mmol/L (130 mg/dL) at Month 6 Endpoint
NCT01683266 (12) [back to overview]	Change in Variability of Pre-injection SMPG From Baseline to Month 6 Endpoint
NCT01683266 (12) [back to overview]	Change in Total Treatment Satisfaction Score Using The Diabetes Treatment Satisfaction Questionnaire (DTSQs) From Baseline to Month 6 Endpoint
NCT01683266 (12) [back to overview]	Change In HbA1c From Baseline to Month 6 Endpoint
NCT01683266 (12) [back to overview]	Change in Fasting Plasma Glucose From Baseline to Month 6 Endpoint
NCT01683266 (12) [back to overview]	Change in Daily Average Total Insulin Dose From Baseline to Month 6 Endpoint
NCT01683266 (12) [back to overview]	Percentage of Participants With Hypoglycemia (All and Nocturnal) Events From Baseline to Month 12
NCT01683266 (12) [back to overview]	Change In Average Pre-Injection Self-Monitored Plasma Glucose (SMPG) From Baseline Month 6 Endpoint
NCT01683266 (12) [back to overview]	Change in 8--Point SMPG Profiles Per Time Point From Baseline to Month 6 Endpoint
NCT01688635 (4) [back to overview]	Total Amount of Glucose Infused (Gtot) Over the Duration of Clamp Procedure
NCT01688635 (4) [back to overview]	Pharmacokinetics (PK): Maximum Plasma Concentration (Cmax) of LY2963016 and US-Approved Lantus
NCT01688635 (4) [back to overview]	Pharmacokinetics (PK): Area Under the Concentration Time Curve (AUC) of LY2963016 and US-Approved Lantus
NCT01688635 (4) [back to overview]	Maximum Glucose Infusion Rate (Rmax)
NCT01755156 (19) [back to overview]	Percentage of Participants Who Experienced an Adverse Event Which Were Included Under the System Order Class of Investigations (Phase A+B)
NCT01755156 (19) [back to overview]	Percentage of Participants Who Discontinued Study Drug Due to an Adverse Event (Phase A+B)
NCT01755156 (19) [back to overview]	Kaplan-Meier Estimate of Cumulative Incidence of Participants Requiring Glycemic Rescue Therapy by 24 Weeks (Phase A)
NCT01755156 (19) [back to overview]	Kaplan-Meier Estimate of Cumulative Incidence of Participants Requiring Glycemic Rescue Therapy by 104 Weeks (Phase A+B)
NCT01755156 (19) [back to overview]	Change From Baseline in PMG Total Area Under the Plasma Concentration Time Curve (AUC) at Week 24 (Phase A)
NCT01755156 (19) [back to overview]	Percentage of Participants Attaining A1C Glycemic Goals of <7.0% After 24 Weeks of Treatment (Phase A)
NCT01755156 (19) [back to overview]	Change From Baseline in 2-hour Post-meal Glucose (PMG) at Week 24 (Phase A)
NCT01755156 (19) [back to overview]	Change From Baseline in A1C at Week 104 (Phase A+B)
NCT01755156 (19) [back to overview]	Change From Baseline in Fasting Insulin at Week 104 (Phase A+B)
NCT01755156 (19) [back to overview]	Change From Baseline in Glycosylated Hemoglobin (A1C) at Week 24 (Phase A)
NCT01755156 (19) [back to overview]	Change From Baseline in Fasting Insulin at Week 24 (Phase A)
NCT01755156 (19) [back to overview]	Percentage of Participants Attaining A1C Glycemic Goals of <7% After 104 Weeks of Treatment (Phase A+B)
NCT01755156 (19) [back to overview]	Percentage of Participants Attaining A1C Glycemic Goals of <6.5% After 104 Weeks of Treatment (Phase A+B)
NCT01755156 (19) [back to overview]	Percentage of Participants Requiring Glycemic Rescue Therapy at or Before Week 104 (Phase A+B)
NCT01755156 (19) [back to overview]	Percentage of Participants Requiring Glycemic Rescue Therapy at or Before Week 24 (Phase A)
NCT01755156 (19) [back to overview]	Percentage of Participants Who Experienced at Least One Adverse Event (Phase A+B)
NCT01755156 (19) [back to overview]	Change From Baseline in FPG at Week 104 (Phase A+B)
NCT01755156 (19) [back to overview]	Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24 (Phase A)
NCT01755156 (19) [back to overview]	Percentage of Participants Attaining A1C Glycemic Goals of <6.5% After 24 Weeks of Treatment (Phase A)
NCT01768559 (15) [back to overview]	Change in Body Weight From Baseline to Week 26
NCT01768559 (15) [back to overview]	Change in Average 7-point SMPG Profiles From Baseline to Week 26
NCT01768559 (15) [back to overview]	Change in FPG From Baseline to Week 26
NCT01768559 (15) [back to overview]	Change in Glucose Excursions From Baseline to Week 26 (in Participants Who Had an Injection of IMP Before Breakfast)
NCT01768559 (15) [back to overview]	Change in Insulin Glargine Dose From Baseline to Week 26
NCT01768559 (15) [back to overview]	Change in PPG From Baseline to Week 26 (in Participants Who Had an Injection of Investigational Medicinal Product [IMP] Before Breakfast)
NCT01768559 (15) [back to overview]	Insulin Glulisine Dose at Week 26
NCT01768559 (15) [back to overview]	Percentage of Participants Who Reached the Target of HbA1c <7% at Week 26 and Did Not Experienced Documented (Plasma Glucose <60 mg/dL) Symptomatic Hypoglycemia During 26 Week Treatment Period
NCT01768559 (15) [back to overview]	Percentage of Participants Who Reached the Target of HbA1c <7%, Had no Weight Gain at Week 26, and Did Not Experience Documented (Plasma Glucose <60 mg/dL) Symptomatic Hypoglycemia During 26-Week Treatment Period
NCT01768559 (15) [back to overview]	Percentage of Participants With no Weight Gain at Week 26
NCT01768559 (15) [back to overview]	Total Insulin Dose at Week 26
NCT01768559 (15) [back to overview]	Percentage of Participants With Documented Symptomatic and Severe Symptomatic Hypoglycemia
NCT01768559 (15) [back to overview]	Percentage of Participants With HbA1c Level <7% and ≤6.5% at Week 26
NCT01768559 (15) [back to overview]	Change in HbA1c From Baseline to Week 26
NCT01768559 (15) [back to overview]	Percentage of Participants Who Reached the Target of HbA1c <7% and Had no Weight Gain at Week 26
NCT01769404 (7) [back to overview]	Amount of Glucose Required to Reach Blood Glucose (BG) of 72 mg/dL
NCT01769404 (7) [back to overview]	Concentration of Cortisol
NCT01769404 (7) [back to overview]	Concentration of Epinephrine
NCT01769404 (7) [back to overview]	Concentration of Glucagon
NCT01769404 (7) [back to overview]	Amount of Glucose Required to Maintain BG of 72 mg/dL
NCT01769404 (7) [back to overview]	Concentration of Growth Hormone
NCT01769404 (7) [back to overview]	Concentration of Norepinephrine
NCT01771250 (4) [back to overview]	VLDL-TG Secretion Rate
NCT01771250 (4) [back to overview]	Very Low Density Lipoprotein-Triglyceride (VLDL-TG) Concentrations
NCT01771250 (4) [back to overview]	VLDL-TG Clearance Rate
NCT01771250 (4) [back to overview]	VLDL-TG Oxidation Rate
NCT01779362 (4) [back to overview]	ACPRg
NCT01779362 (4) [back to overview]	Insulin Sensitivity, M/I
NCT01779362 (4) [back to overview]	ß-cell Function Measured by Hyperglycemic Clamp Techniques at M12
NCT01779362 (4) [back to overview]	ß-cell Response Measured by Hyperglycemic Clamp
NCT01779375 (5) [back to overview]	Clamp Measure of Insulin Sensitivity
NCT01779375 (5) [back to overview]	M/I
NCT01779375 (5) [back to overview]	ß-cell Function Measured by Hyperglycemic Clamp Techniques at M12
NCT01779375 (5) [back to overview]	ß-cell Response Measured by Hyperglycemic Clamp
NCT01779375 (5) [back to overview]	ACPRg
NCT01784211 (5) [back to overview]	Part B: Pharmacokinetics: AUCτ of LY2605541 and Insulin Glargine: Exercise Versus Non-Exercise
NCT01784211 (5) [back to overview]	Part A: Pharmacokinetics: Maximum Drug Concentration (Cmax) of LY2605541 and Insulin Glargine: Intra-Participant Variability
NCT01784211 (5) [back to overview]	Part A: Pharmacodynamics: Total Amount of Glucose Infused Over the Duration of the Clamp (Gtot): Intra-Participant Variability
NCT01784211 (5) [back to overview]	Part A: Pharmacokinetics: Area Under the Concentration Versus Time Curve Over the Dosing Interval (AUCτ) of LY2605541 and Insulin Glargine: Intra-Participant Variability
NCT01784211 (5) [back to overview]	Part B: Pharmacokinetics: Cmax of LY2605541 and Insulin Glargine: Exercise Versus Non-Exercise
NCT01792830 (5) [back to overview]	Number of Participants Experiencing a Hyperglycemic Event
NCT01792830 (5) [back to overview]	Efficacy, Measured by a Change in HbA1c Levels
NCT01792830 (5) [back to overview]	The Number of Participants Experiencing a Severe Hypoglycemic Event
NCT01792830 (5) [back to overview]	The Number of Participants Experiencing a Hypoglycemic Event
NCT01792830 (5) [back to overview]	Number of Participants Readmitted to the Hospital
NCT01810952 (5) [back to overview]	Daily Insulin Dose/Kg Body Weight
NCT01810952 (5) [back to overview]	Average Daily Glucose Levels on Days 1-5 After the Initiation of the Treatment Protocol.
NCT01810952 (5) [back to overview]	Percent of Participants With Average Glucose >70 and <180 mg/dL
NCT01810952 (5) [back to overview]	Percent of Glucose Determinations >180 mg/dL
NCT01810952 (5) [back to overview]	Glucose Values <70 mg/dL.
NCT01819129 (4) [back to overview]	Number of Treatment Emergent Confirmed Hypoglycaemic Episodes
NCT01819129 (4) [back to overview]	Change From Baseline in 2-hour PPG Increment (Meal Test)
NCT01819129 (4) [back to overview]	Change From Baseline in Body Weight
NCT01819129 (4) [back to overview]	Change From Baseline in HbA1c
NCT01845831 (11) [back to overview]	Change in HbA1C
NCT01845831 (11) [back to overview]	Total Daily Insulin Dose
NCT01845831 (11) [back to overview]	Mean Percentage of Blood Glucose Readings Greater Than 13.3 mmol/L
NCT01845831 (11) [back to overview]	Mean Percentage of Blood Glucose Readings Between 5.6 - 7.8 mmol/L
NCT01845831 (11) [back to overview]	Mean Percentage of Blood Glucose Readings Between 3.9 - 7.8 mmol/L
NCT01845831 (11) [back to overview]	Length of Hospital Stay
NCT01845831 (11) [back to overview]	Acute Renal Failure Rate
NCT01845831 (11) [back to overview]	Mean Blood Glucose Concentration After First Day of Treatment
NCT01845831 (11) [back to overview]	Hospital Mortality Rate
NCT01845831 (11) [back to overview]	Number of Participants With a Hypoglycemic Event
NCT01845831 (11) [back to overview]	Mean Percentage of Blood Glucose Readings Between 3.9 - 10.0 mmol/L
NCT01849289 (6) [back to overview]	Within-subject Variability as Measured by Coefficient of Variation (CV%) in Pre-breakfast SMPG (Self-measured Plasma Glucose)
NCT01849289 (6) [back to overview]	Change From Baseline in FPG (Fasting Plasma Glucose) (Analysed by Central Laboratory)
NCT01849289 (6) [back to overview]	Change From Baseline in HbA1c (%) (Analysed by Central Laboratory)
NCT01849289 (6) [back to overview]	Number of Severe and Minor Treatment Emergent Hypoglycaemic Episodes
NCT01849289 (6) [back to overview]	Number of Treatment Emergent AEs (Adverse Events)
NCT01849289 (6) [back to overview]	Responder for HbA1c (Below 7.0%) at End of Trial Without Severe and Minor Hypoglycaemic Episodes
NCT01894568 (18) [back to overview]	Percentage of Participants With Total and Nocturnal Hypoglycemic Events (HE)
NCT01894568 (18) [back to overview]	Change From Baseline of European Quality of Life-5 Dimensions - 3 Levels (EuroQoL-5D-3L ) Index Score and Visual Analog Scale (VAS) Health State Score at Week 26
NCT01894568 (18) [back to overview]	Concentration of Triglycerides, Total Cholesterol, Low-Density Lipoprotein (LDL-C), and High-Density Lipoprotein Cholesterol (HDL-C) at Week 26
NCT01894568 (18) [back to overview]	Fasting Blood Glucose (FBG)
NCT01894568 (18) [back to overview]	Fasting Serum Glucose (FSG)
NCT01894568 (18) [back to overview]	Change From Baseline to 12 Weeks in Hemoglobin A1c (HbA1c)
NCT01894568 (18) [back to overview]	Change From Baseline to 26 Weeks in Adult Low Blood Sugar Survey (LBSS) Scores
NCT01894568 (18) [back to overview]	Change From Baseline to Week 26 in Body Weight
NCT01894568 (18) [back to overview]	Change From Baseline to Week 26 in Hemoglobin A1c (HbA1c)
NCT01894568 (18) [back to overview]	Percent Hemoglobin A1c at Week 26
NCT01894568 (18) [back to overview]	Intra-Participant Variability of the Fasting Blood Glucose (FBG)
NCT01894568 (18) [back to overview]	Percentage of Participants With Detectable Anti-Insulin Peglispro Antibodies at Week 26
NCT01894568 (18) [back to overview]	Percentage of Participants With HbA1c ≤6.5%
NCT01894568 (18) [back to overview]	Insulin Dose Per Kilogram (kg) of Body Weight
NCT01894568 (18) [back to overview]	30-Day Adjusted Rate of Total and Nocturnal Hypoglycemic Events
NCT01894568 (18) [back to overview]	9-Point Self-Monitored Blood Glucose (SMBG)
NCT01894568 (18) [back to overview]	Percentage of Participants Achieving Steady-State of Basal Insulin Dose at 26 Weeks (Time to Steady State for Basal Insulin [Stable Maximum Dose])
NCT01894568 (18) [back to overview]	Insulin Treatment Satisfaction Questionnaire (ITSQ) Score
NCT01919489 (15) [back to overview]	Change in Body Weight From Baseline
NCT01919489 (15) [back to overview]	HbA1c <7.0% and no Hypoglycemia
NCT01919489 (15) [back to overview]	Hypoglycemic Episodes
NCT01919489 (15) [back to overview]	Glycemic Control at Hospital Discharge and 6 Months Follow up
NCT01919489 (15) [back to overview]	Fasting and Postprandial Blood Glucose (BG) Concentration After Follow up of 26 Weeks
NCT01919489 (15) [back to overview]	Emergency Room Visits and Readmissions
NCT01919489 (15) [back to overview]	Change in Cardiovascular Risk Factors: Blood Pressure
NCT01919489 (15) [back to overview]	Change in BMI
NCT01919489 (15) [back to overview]	Cardiovascular Risk Factor: Heart Rate
NCT01919489 (15) [back to overview]	Total Daily Dose of Insulin
NCT01919489 (15) [back to overview]	Self-measured Blood Glucose (SMBG) 7-point Profiles at 26 Weeks Follow up
NCT01919489 (15) [back to overview]	HbA1c <7.0% and no Weight Gain
NCT01919489 (15) [back to overview]	HbA1c <7.0% and no Hypoglycemia
NCT01919489 (15) [back to overview]	Cardiovascular Risk Factor: Lipid Profile
NCT01919489 (15) [back to overview]	Acute Renal Failure
NCT01925989 (6) [back to overview]	Change in RQ, Pre-breakfast to Post-breakfast Meal, in T1DM
NCT01925989 (6) [back to overview]	Basal Metabolic Rate (BMR) for T1DM
NCT01925989 (6) [back to overview]	Total Number of Minutes of Lipid Oxidation (RQ Below 7.6) in T1DM and Healthy Participants
NCT01925989 (6) [back to overview]	Sleep Respiratory Quotient (RQ) of Untreated Healthy Participants
NCT01925989 (6) [back to overview]	Sleep Respiratory Quotient (RQ) in Type 1 Diabetes Mellitus (T1DM)
NCT01925989 (6) [back to overview]	Lipid Oxidation in T1DM and Healthy Participants
NCT01952145 (3) [back to overview]	Number of Treatment Emergent Confirmed Hypoglycaemic Episodes
NCT01952145 (3) [back to overview]	Change From Baseline in Body Weight
NCT01952145 (3) [back to overview]	Change From Baseline in HbA1c (Glycosylated Haemoglobin)
NCT01959529 (4) [back to overview]	Change in Glycosylated Haemoglobin (HbA1c)
NCT01959529 (4) [back to overview]	Occurrence of at Least One EAC Confirmed Severe Hypoglycaemic Episode Within a Subject (Yes/no)
NCT01959529 (4) [back to overview]	Number of EAC-confirmed Severe Hypoglycaemic Episodes
NCT01959529 (4) [back to overview]	Time From Randomisation to First Occurrence of a Major Adverse Cardiovascular Event (MACE): Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke
NCT02004366 (16) [back to overview]	Subjects With Wound and Other Infections
NCT02004366 (16) [back to overview]	Hospital Mortality
NCT02004366 (16) [back to overview]	Length of Hospital Stay
NCT02004366 (16) [back to overview]	Hypoglycemia <70 mg/dl
NCT02004366 (16) [back to overview]	Hypoglycemia < 40 mg/dl
NCT02004366 (16) [back to overview]	Hyperglycemia
NCT02004366 (16) [back to overview]	Number of Participants Requiring ICU Care During Hospitalization
NCT02004366 (16) [back to overview]	Hospital Complications
NCT02004366 (16) [back to overview]	Outpatient Mortality
NCT02004366 (16) [back to overview]	HbA1c Level
NCT02004366 (16) [back to overview]	Fasting BG Concentration
NCT02004366 (16) [back to overview]	Emergency Room Visits
NCT02004366 (16) [back to overview]	Differences in Glycemic Control
NCT02004366 (16) [back to overview]	Daily Dose of Insulin
NCT02004366 (16) [back to overview]	Subjects With Surgical Reinterventions
NCT02004366 (16) [back to overview]	Acute Renal Failure During Hospitalization
NCT02006342 (5) [back to overview]	Number of Participants Admitted to the ICU
NCT02006342 (5) [back to overview]	Intensive Care Unit Length of Stay
NCT02006342 (5) [back to overview]	Time to Anion Gap Closure
NCT02006342 (5) [back to overview]	Number of Participants Who Developed Hypoglycemia
NCT02006342 (5) [back to overview]	Hospital Length of Stay
NCT02030600 (6) [back to overview]	Number of Treatment Emergent Severe or BG Confirmed Symptomatic Nocturnal Hypoglycaemic Episode During the Maintenance Period
NCT02030600 (6) [back to overview]	Proportion of Subjects With One or More Severe Hypoglycaemic Episodes During the Maintenance Period
NCT02030600 (6) [back to overview]	FPG (Fasting Plasma Glucose)
NCT02030600 (6) [back to overview]	Change From Baseline in HbA1c (Glycosylated Haemoglobin)
NCT02030600 (6) [back to overview]	Number of Treatment Emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes During the Maintenance Period
NCT02030600 (6) [back to overview]	Incidence of Treatment Emergent Adverse Events
NCT02033889 (49) [back to overview]	Percentage of Participants With an A1C of <6.5% (48 mmol/Mol) at Week 104 (Excluding Rescue Approach)
NCT02033889 (49) [back to overview]	Percentage of Participants With an A1C of <6.5% (48 mmol/Mol) at Week 26 (Logistic Regression Using Multiple Imputation: Excluding Rescue Approach)
NCT02033889 (49) [back to overview]	Percentage of Participants With an A1C of <6.5% (48 mmol/Mol) at Week 52 (Excluding Rescue Approach)
NCT02033889 (49) [back to overview]	Percentage of Participants With an A1C of <7% (53 mmol/Mol) at Week 104 (Excluding Rescue Approach)
NCT02033889 (49) [back to overview]	Percentage of Participants With an A1C of <7% (53 mmol/Mol) at Week 26 (Logistic Regression Using Multiple Imputation: Excluding Rescue Approach)
NCT02033889 (49) [back to overview]	Percentage of Participants With an A1C of <7% (53 mmol/Mol) at Week 52 (Excluding Rescue Approach)
NCT02033889 (49) [back to overview]	Time to Glycemic Rescue Therapy at Week 26
NCT02033889 (49) [back to overview]	Ertugliflozin Plasma Concentrations (ng/mL): Summary Statistics Over Time (Excluding Rescue Approach)
NCT02033889 (49) [back to overview]	Change From Baseline in A1C at Week 52 (Excluding Rescue Approach)
NCT02033889 (49) [back to overview]	Change From Baseline in Body Weight at Week 104 (Excluding Rescue Approach)
NCT02033889 (49) [back to overview]	Change From Baseline in Body Weight at Week 26 (Excluding Rescue Approach)
NCT02033889 (49) [back to overview]	Change From Baseline in Body Weight at Week 52 (Excluding Rescue Approach)
NCT02033889 (49) [back to overview]	Change From Baseline in Fasting Plasma Glucose at Week 104 (Excluding Rescue Approach)
NCT02033889 (49) [back to overview]	Change From Baseline in Fasting Plasma Glucose at Week 26 (Excluding Rescue Approach)
NCT02033889 (49) [back to overview]	Change From Baseline in Fasting Plasma Glucose at Week 52 (Excluding Rescue Therapy)
NCT02033889 (49) [back to overview]	Change From Baseline in Sitting Systolic Blood Pressure at Week 52 (Excluding Rescue Approach)
NCT02033889 (49) [back to overview]	Change From Baseline in Sitting Diastolic Blood Pressure at Week 104 (Excluding Rescue Approach)
NCT02033889 (49) [back to overview]	Change From Baseline in Sitting Diastolic Blood Pressure at Week 26 (Excluding Rescue Approach)
NCT02033889 (49) [back to overview]	Change From Baseline in Sitting Diastolic Blood Pressure at Week 52 (Excluding Rescue Approach)
NCT02033889 (49) [back to overview]	Change From Baseline in Sitting Systolic Blood Pressure at Week 104 (Excluding Rescue Approach)
NCT02033889 (49) [back to overview]	Change From Baseline in Sitting Systolic Blood Pressure at Week 26 (Excluding Rescue Approach)
NCT02033889 (49) [back to overview]	Percentage of Participants Receiving Glycemic Rescue Therapy up to Week 26
NCT02033889 (49) [back to overview]	Percentage of Participants Receiving Glycemic Rescue Therapy up to Week 52
NCT02033889 (49) [back to overview]	Percentage of Participants Receiving Glycemic Rescue Therapy up to Week 104
NCT02033889 (49) [back to overview]	Percentage of Participants Experiencing An Adverse Event (AE) (Including Rescue Approach)
NCT02033889 (49) [back to overview]	Percentage of Participants Discontinuing Study Treatment Due to an AE (Including Rescue Approach)
NCT02033889 (49) [back to overview]	Percent Change From BMD at Week 104 as Measured by DXA at the Distal Forearm Using Raw Data (Excluding Bone Rescue Approach)
NCT02033889 (49) [back to overview]	Percent Change From Baseline in Bone Biomarker PTH at Week 52 (Excluding Bone Rescue Approach)
NCT02033889 (49) [back to overview]	Percent Change From Baseline in Bone Biomarker PTH at Week 104 (Excluding Bone Rescue Approach)
NCT02033889 (49) [back to overview]	Percent Change From Baseline in Bone Biomarker Procollagen Type I N-terminal Propeptide (P1NP) at Week 26 (Excluding Bone Rescue Approach)
NCT02033889 (49) [back to overview]	Percent Change From Baseline in Bone Biomarker Parathyroid Hormone (PTH) at Week 26 (Excluding Bone Rescue Approach)
NCT02033889 (49) [back to overview]	Percent Change From Baseline in Bone Biomarker P1NP at Week 52 (Excluding Bone Rescue Approach)
NCT02033889 (49) [back to overview]	Percent Change From Baseline in Bone Biomarker P1NP at Week 104 (Excluding Bone Rescue Approach)
NCT02033889 (49) [back to overview]	Percent Change From Baseline in Bone Biomarker CTX at Week 52 (Excluding Bone Rescue Approach)
NCT02033889 (49) [back to overview]	Percent Change From Baseline in Bone Biomarker CTX at Week 104 (Excluding Bone Rescue Approach)
NCT02033889 (49) [back to overview]	Percent Change From Baseline in Bone Biomarker Carboxy-Terminal Cross-Linking Telopeptides of Type I Collagen (CTX) at Week 26 (Excluding Bone Rescue Approach)
NCT02033889 (49) [back to overview]	Percent Change From Baseline in BMD at Week 52 as Measured by DXA at the Total Hip Using Raw Data (Excluding Bone Rescue Approach)
NCT02033889 (49) [back to overview]	Percent Change From Baseline in BMD at Week 52 as Measured by DXA at the Lumbar Spine (L1-L4) Using Raw Data (Excluding Bone Rescue Approach)
NCT02033889 (49) [back to overview]	Percent Change From Baseline in BMD at Week 52 as Measured by DXA at the Femoral Neck Using Raw Data (Excluding Bone Rescue Approach)
NCT02033889 (49) [back to overview]	Percent Change From Baseline in BMD at Week 52 as Measured by DXA at the Distal Forearm Using Raw Data (Excluding Bone Rescue Approach)
NCT02033889 (49) [back to overview]	Percent Change From Baseline in BMD at Week 26 as Measured by DXA at the Total Hip Using Raw Data (Excluding Bone Rescue Approach)
NCT02033889 (49) [back to overview]	Percent Change From Baseline in BMD at Week 26 as Measured by DXA at the Lumbar Spine (L1-L4) Using Raw Data (Excluding Bone Rescue Approach)
NCT02033889 (49) [back to overview]	Percent Change From Baseline in BMD at Week 26 as Measured by DXA at the Femoral Neck Using Raw Data (Excluding Bone Rescue Approach)
NCT02033889 (49) [back to overview]	Percent Change From Baseline in BMD at Week 26 as Measured by DXA at the Distal Forearm Using Raw Data (Excluding Bone Rescue Approach)
NCT02033889 (49) [back to overview]	Percent Change From Baseline in BMD at Week 104 as Measured by DXA at the Total Hip Using Raw Data (Excluding Bone Rescue Approach)
NCT02033889 (49) [back to overview]	Percent Change From Baseline in BMD at Week 104 as Measured by DXA at the Lumbar Spine (L1-L4) Using Raw Data (Excluding Bone Rescue Approach)
NCT02033889 (49) [back to overview]	Percent Change From Baseline in BMD at Week 104 as Measured by DXA at the Femoral Neck Using Raw Data (Excluding Bone Rescue Approach)
NCT02033889 (49) [back to overview]	Change From Baseline in A1C at Week 104 (Excluding Rescue Approach)
NCT02033889 (49) [back to overview]	Change From Baseline in A1C at Week 26 (Excluding Rescue Approach)
NCT02034513 (6) [back to overview]	Number of Treatment Emergent Severe or BG (Blood Glucose) Confirmed Symptomatic Hypoglycaemic Episodes During the Maintenance Period
NCT02034513 (6) [back to overview]	Incidence of Treatment Emergent Adverse Events
NCT02034513 (6) [back to overview]	FPG (Fasting Plasma Glucose)
NCT02034513 (6) [back to overview]	Change From Baseline in HbA1c (Glycosylated Haemoglobin)
NCT02034513 (6) [back to overview]	Proportion of Subjects With One or More Severe Hypoglycaemic Episodes During the Maintenance Period
NCT02034513 (6) [back to overview]	Number of Treatment Emergent Severe or BG Confirmed Symptomatic Nocturnal Hypoglycaemic Episodes During the Maintenance Period
NCT02058147 (15) [back to overview]	Percentage of Participants With Severe Symptomatic Hypoglycemia
NCT02058147 (15) [back to overview]	Average Daily Insulin Glargine Dose at Week 30
NCT02058147 (15) [back to overview]	Change in 2-Hour Postprandial Plasma Glucose (PPG) From Baseline to Week 30
NCT02058147 (15) [back to overview]	Change in Body Weight From Baseline to Week 30
NCT02058147 (15) [back to overview]	Change in Fasting Plasma Glucose (FPG) From Baseline to Week 30
NCT02058147 (15) [back to overview]	Change in HbA1c From Baseline to Week 30
NCT02058147 (15) [back to overview]	Change in Plasma Glucose Excursion From Baseline to Week 30
NCT02058147 (15) [back to overview]	Number of Documented Symptomatic Hypoglycemia Events Per Subject-Year
NCT02058147 (15) [back to overview]	Percentage of Participants Reaching HbA1c <7.0% at Week 30 With No Documented Symptomatic Hypoglycemia (PG ≤ 70 mg/dL [3.9 mmol/L]) During 30-Week Treatment Period
NCT02058147 (15) [back to overview]	Percentage of Participants Reaching HbA1c <7.0% With No Body Weight Gain at Week 30
NCT02058147 (15) [back to overview]	Percentage of Participants Reaching HbA1c <7.0% With No Body Weight Gain at Week 30 and No Documented Symptomatic Hypoglycemia (Plasma Glucose [PG] ≤ 70 mg/dL [3.9 mmol/L]) During 30-Week Treatment Period
NCT02058147 (15) [back to overview]	Percentage of Participants Requiring Rescue Therapy During 30-Week Treatment Period
NCT02058147 (15) [back to overview]	Percentage of Participants With Documented Symptomatic Hypoglycemia
NCT02058147 (15) [back to overview]	Percentage of Participants With HbA1c <7.0% or ≤6.5% at Week 30
NCT02058147 (15) [back to overview]	Mean Change in 7-point Self-monitored Plasma Glucose (SMPG) Profile From Baseline to Week 30
NCT02058160 (15) [back to overview]	Change in FPG From Baseline to Week 30
NCT02058160 (15) [back to overview]	Change in 2-hour PPG From Baseline to Week 30
NCT02058160 (15) [back to overview]	Change in 2-hour Plasma Blood Glucose Excursion From Baseline to Week 30
NCT02058160 (15) [back to overview]	Number of Documented Symptomatic Hypoglycemia Events Per Subject-Year
NCT02058160 (15) [back to overview]	Mean Change in 7-point Self-monitored Plasma Glucose (SMPG) Profile From Baseline to Week 30
NCT02058160 (15) [back to overview]	Change in Glycated Hemoglobin (HbA1c) From Baseline to Week 30
NCT02058160 (15) [back to overview]	Percentage of Participants With Severe Symptomatic Hypoglycemia
NCT02058160 (15) [back to overview]	Percentage of Participants With HbA1c <7.0% or ≤6.5% at Week 30
NCT02058160 (15) [back to overview]	Change in Daily Insulin Glargine Dose From Baseline to Week 30
NCT02058160 (15) [back to overview]	Change in Body Weight From Baseline to Week 30
NCT02058160 (15) [back to overview]	Percentage of Participants With Documented Symptomatic Hypoglycemia
NCT02058160 (15) [back to overview]	Percentage of Participants Requiring Rescue Therapy During 30-Week Treatment Period
NCT02058160 (15) [back to overview]	Percentage of Participants Reaching HbA1c <7.0% With No Documented Symptomatic Hypoglycemia (PG ≤ 70 mg/dL [3.9 mmol/L]) During 30-Week Treatment Period
NCT02058160 (15) [back to overview]	Percentage of Participants Reaching HbA1c <7.0% With No Body Weight Gain at Week 30 and No Documented Symptomatic Hypoglycemia (Plasma Glucose [PG] ≤ 70 mg/dL [3.9 mmol/L]) During 30-Week Treatment Period
NCT02058160 (15) [back to overview]	Percentage of Participants Reaching HbA1c <7.0% With No Body Weight Gain at Week 30
NCT02059161 (28) [back to overview]	Percentage of Participants With Negative AIA at Baseline Who Develop Confirmed Positive AIA at Any Time Up Through Week 52
NCT02059161 (28) [back to overview]	Percentage of Participants With Negative AIA at Baseline Who Develop Confirmed Positive AIA at Any Time Up Through Week 24
NCT02059161 (28) [back to overview]	Percentage of Participants With Confirmed Positive AIA Up Through Week 52
NCT02059161 (28) [back to overview]	Percentage of Participants With Any Confirmed Positive Anti-insulin Antibody (AIA) at Any Time Up Through Week 24
NCT02059161 (28) [back to overview]	Basal Insulin Dose at Week 24
NCT02059161 (28) [back to overview]	Percentage of Participants Who Develop Insulin Neutralizing Antibodies Up Through Week 52
NCT02059161 (28) [back to overview]	Percentage of Participants Who Develop Insulin Neutralizing Antibodies Up Through Week 24
NCT02059161 (28) [back to overview]	Basal Insulin Dose at Week 52
NCT02059161 (28) [back to overview]	Basal Insulin Dose Per kg of Body Weight at Week 24
NCT02059161 (28) [back to overview]	Basal Insulin Dose Per kg of Body Weight at Week 52
NCT02059161 (28) [back to overview]	Bolus Insulin Dose at Week 24
NCT02059161 (28) [back to overview]	Bolus Insulin Dose at Week 52
NCT02059161 (28) [back to overview]	Bolus Insulin Dose Per kg of Body Weight at Week 24
NCT02059161 (28) [back to overview]	Bolus Insulin Dose Per kg of Body Weight at Week 52
NCT02059161 (28) [back to overview]	Change From Baseline in 7-point Self-monitored Blood Glucose (SMBG) at Week 24
NCT02059161 (28) [back to overview]	Change From Baseline in A1C at Week 52
NCT02059161 (28) [back to overview]	Change From Baseline in AIA Titer After 24 Weeks of Treatment
NCT02059161 (28) [back to overview]	Change From Baseline in AIA Titer After 52 Weeks of Treatment
NCT02059161 (28) [back to overview]	Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24
NCT02059161 (28) [back to overview]	Change From Baseline in 7-point SMBG at Week 52
NCT02059161 (28) [back to overview]	Percentage of Participants Attaining A1C Glycemic Goals of <7% and <6.5% After 52 Weeks of Treatment.
NCT02059161 (28) [back to overview]	Change From Baseline in FPG at Week 52
NCT02059161 (28) [back to overview]	Percentage of Participants Attaining A1C Glycemic Goals of <7% and <6.5% After 24 Weeks of Treatment.
NCT02059161 (28) [back to overview]	Total Insulin Dose Per Kilogram (kg) of Body Weight (Unit/kg) at Week 52
NCT02059161 (28) [back to overview]	Total Insulin Dose Per Kilogram (kg) of Body Weight (Unit/kg) at Week 24
NCT02059161 (28) [back to overview]	Total Insulin Dose at Week 52
NCT02059161 (28) [back to overview]	Total Insulin Dose at Week 24
NCT02059161 (28) [back to overview]	Primary: Change From Baseline in Hemoglobin A1c (A1C) at Week 24
NCT02059187 (11) [back to overview]	Daily Basal Insulin Dose (Units) at Week 24
NCT02059187 (11) [back to overview]	Daily Basal Insulin Dose Per Body Weight (Units/kg) at Week 24
NCT02059187 (11) [back to overview]	Change From Baseline in Participant 7-Point Average of Self-Monitored Blood Glucose (SMBG) at Week 24
NCT02059187 (11) [back to overview]	Percentage of Participants Experiencing an Adverse Event (AE) of Hypoglycemia Up to Week 24
NCT02059187 (11) [back to overview]	Percentage of Participants Experiencing an AE Over the 24-week Treatment Period
NCT02059187 (11) [back to overview]	Percentage of Participants With Confirmed Anti-Insulin Antibodies (AIA) up to Week 24
NCT02059187 (11) [back to overview]	Change From Baseline in Participant Body Weight at Week 24
NCT02059187 (11) [back to overview]	Percentage of Participants With Hemoglobin A1C <6.5% at Week 24
NCT02059187 (11) [back to overview]	Percentage of Participants With Hemoglobin A1C <7% at Week 24
NCT02059187 (11) [back to overview]	Change From Baseline in Participant Fasting Plasma Glucose (FPG) at Week 24
NCT02059187 (11) [back to overview]	Change From Baseline in Participant Hemoglobin A1C Level at Week 24
NCT02061969 (11) [back to overview]	Mean Fasting Blood Glucose Level
NCT02061969 (11) [back to overview]	Mortality
NCT02061969 (11) [back to overview]	Number of Hypoglycemic Events < 40mg/dl
NCT02061969 (11) [back to overview]	Number of Hypoglycemic Events < 70mg/dl
NCT02061969 (11) [back to overview]	Number of Participants With Acute Complications
NCT02061969 (11) [back to overview]	Total Daily Dose of Insulin
NCT02061969 (11) [back to overview]	Total Number of Emergency Room Visits
NCT02061969 (11) [back to overview]	Total Number of Hospital Visits
NCT02061969 (11) [back to overview]	Total Number of Complications
NCT02061969 (11) [back to overview]	HbA1c
NCT02061969 (11) [back to overview]	Incidence of Acute Kidney Injury
NCT02072096 (6) [back to overview]	Change From Baseline in Body Mass Index (BMI)
NCT02072096 (6) [back to overview]	Change From Baseline of Estimated Glomerular Filtration Rate (eGFR)
NCT02072096 (6) [back to overview]	Change From Baseline of Urinary Albumin to Creatinine Ratio
NCT02072096 (6) [back to overview]	Percentage of Participants Achieving and Maintaining Individualized Glycated Hemoglobin A1c (HbA1c) Targets Without Clinically Significant Hypoglycemia
NCT02072096 (6) [back to overview]	Percentage of Participants Requiring Alternative Treatment Due to Glycemic Failure of First Line Injectable Therapy
NCT02072096 (6) [back to overview]	Number of Participants With Total Hypoglycemia and Other Categories of Hypoglycemia
NCT02099110 (8) [back to overview]	Percentage of Participants Who Experienced an Adverse Event (AE): Including Rescue Approach
NCT02099110 (8) [back to overview]	Percentage of Participants Who Discontinued Study Treatment Due to an AE: Including Rescue Approach
NCT02099110 (8) [back to overview]	Change From Baseline in Fasting Plasma Glucose (FPG) at Week 26 - Excluding Rescue Approach
NCT02099110 (8) [back to overview]	Change From Baseline in Sitting Systolic Blood Pressure at Week 26: Excluding Rescue Approach
NCT02099110 (8) [back to overview]	Change From Baseline in Static Beta-Cell Sensitivity to Glucose Index at Week 26; Excluding Rescue Approach
NCT02099110 (8) [back to overview]	Percentage of Participants Achieving a Hemoglobin A1C of <7% (<53 mmol/Mol) (Raw Proportions): Excluding Rescue Approach
NCT02099110 (8) [back to overview]	Change From Baseline in Body Weight at Week 26: Excluding Rescue Approach
NCT02099110 (8) [back to overview]	Change From Baseline in A1C at Week 26: Excluding Rescue Approach
NCT02128932 (8) [back to overview]	Change in Patient Reported Outcome Questionnaires. (PROs), Diabetes Treatment Satisfaction Questionnaire (DTSQs)
NCT02128932 (8) [back to overview]	Change in Systolic Blood Pressure.
NCT02128932 (8) [back to overview]	Change in Patient Reported Outcome (PRO) Questionnaire, Questionnaire SF-36v2™
NCT02128932 (8) [back to overview]	Subjects Who Achieve HbA1c ≤6.5% (48 mmol/Mol), American Association of Clinical Endocrinologists (AACE)
NCT02128932 (8) [back to overview]	Change in HbA1c From Baseline
NCT02128932 (8) [back to overview]	Change in Fasting Plasma Glucose From Baseline
NCT02128932 (8) [back to overview]	Change in Body Weight From Baseline
NCT02128932 (8) [back to overview]	Change in Diastolic Blood Pressure.
NCT02132637 (10) [back to overview]	Pharmacodynamics: Three-Hour Postprandial Glucose Area Under the Concentration Time Curve (AUC)
NCT02132637 (10) [back to overview]	Percentage of Participants With Hypoglycemia
NCT02132637 (10) [back to overview]	Fasting Blood Glucose
NCT02132637 (10) [back to overview]	Time to the Nadir Glucose
NCT02132637 (10) [back to overview]	Percentage of Participants With Clinically Significant Hypoglycemia 12 Hours Post Double Dose
NCT02132637 (10) [back to overview]	Percentage of Participants With Clinically Significant Hypoglycemia
NCT02132637 (10) [back to overview]	Nadir Glucose
NCT02132637 (10) [back to overview]	Duration of Glucose ≤70 mg/dL
NCT02132637 (10) [back to overview]	Beta Cell Function
NCT02132637 (10) [back to overview]	Pharmacodynamics: Three-Hour Postprandial Glucose Area Under the Concentration Time Curve (AUC) Excursion
NCT02152371 (16) [back to overview]	Percentage of Participants With Self-Reported Events of Hypoglycemia
NCT02152371 (16) [back to overview]	Number of Participants With Thyroid Tumors/Neoplasms (Including C-Cell Hyperplasia)
NCT02152371 (16) [back to overview]	Number of Participants With Investigator Reported and Adjudicated Cardiovascular Events
NCT02152371 (16) [back to overview]	Number of Participants With Dulaglutide Anti-Drug Antibodies
NCT02152371 (16) [back to overview]	Number of Participants With Adjudicated Acute Pancreatitis Events
NCT02152371 (16) [back to overview]	Change From Baseline to 28 Weeks in Hemoglobin A1c (HbA1c)
NCT02152371 (16) [back to overview]	Change From Baseline to 28 Weeks in Fasting Serum Glucose (FSG)
NCT02152371 (16) [back to overview]	Percentage of Participants Achieving HbA1c Target of <7.0% and Without Weight Gain (<0.1 Kilograms [kg]) at 28 Weeks and Without Documented Symptomatic Hypoglycemia During the Maintenance Period (Weeks 12-28)
NCT02152371 (16) [back to overview]	Change From Baseline to 28 Weeks in Daily Mean Insulin Glargine Dose
NCT02152371 (16) [back to overview]	Change From Baseline to 28 Weeks in Body Weight
NCT02152371 (16) [back to overview]	Percentage of Participants Achieving HbA1c Target of <7.0% and Without Weight Gain (<0.1 kg)
NCT02152371 (16) [back to overview]	Percentage of Participants Achieving HbA1c Target of <7.0% at 28 Weeks and Without Documented Symptomatic Hypoglycemia During the Maintenance Period (Weeks 12-28)
NCT02152371 (16) [back to overview]	Percentage of Participants Discontinuing the Study Due to Severe, Persistent Hyperglycemia
NCT02152371 (16) [back to overview]	Rate of Hypoglycemic Events up to 28 Weeks
NCT02152371 (16) [back to overview]	Change From Baseline to 28 Weeks in 7-Point Self Monitored Plasma Glucose (SMPG)
NCT02152371 (16) [back to overview]	Percentage of Participants Achieving HbA1c Targets of <7.0% or ≤6.5%
NCT02152384 (7) [back to overview]	Pharmacokinetics (PK): Area Under the Concentration Curve (AUC) for Insulin Lispro During Clamp
NCT02152384 (7) [back to overview]	Pharmacodynamics (PD): Area Under the Concentration Zero Through 5 Hours (AUC 0-5h) for Triglycerides
NCT02152384 (7) [back to overview]	Pharmacokinetics (PK): Area Under the Concentration Curve From Time Zero to Last Time (AUC [0 Tlast]) for Paracetamol
NCT02152384 (7) [back to overview]	Pharmacokinetics (PK): Under the Concentration Curve Zero Through 5 Hours (AUC 0-5h) for Prandial Insulin Lispro
NCT02152384 (7) [back to overview]	Appetite and Satiety Ratings, as Measured Using Visual Analog Scale (VAS) on Day 29
NCT02152384 (7) [back to overview]	Pharmacodynamics (PD): Average Glucose Infusion Rate From Euglycemic 2-step Hyperinsulinemic Clamp (M-value)
NCT02152384 (7) [back to overview]	Pharmacodynamics (PD): Plasma Glucose Area Under the Concentration Curve Zero Through 5 Hours (AUC 0-5h), Above Pre Meal Baseline for Insulin Lispro
NCT02168491 (3) [back to overview]	Change in Body Weight From Baseline to End of Study
NCT02168491 (3) [back to overview]	Change in Fasting Plasma Glucose (FPG, Mean Over 2 Weeks)
NCT02168491 (3) [back to overview]	Change in HbA1c From Baseline to End
NCT02197520 (5) [back to overview]	Pharmacokinetics (PK): Area Under the Concentration Curve Concentration Curve Zero Through 5 Hours (AUC 0-5h) for Prandial Insulin Lispro
NCT02197520 (5) [back to overview]	Pharmacodynamics (PD): Plasma Glucose Area Under the Concentration Curve Zero Through 5 Hours (AUC 0-5h), Above Pre Meal Baseline for Insulin Lispro
NCT02197520 (5) [back to overview]	Pharmacodynamics (PD): Average Glucose Infusion Rate From Euglycemic 2-step Hyperinsulinemic Clamp (M-value)
NCT02197520 (5) [back to overview]	Pharmacokinetics (PK): Area Under the Concentration Curve Zero Through 5 Hours (AUC 0-5h) for Acetaminophen
NCT02197520 (5) [back to overview]	Appetite and Satiety Ratings, as Measured Using Visual Analog Scale (VAS) on Day 29
NCT02227862 (13) [back to overview]	Change in Cross-reactive Insulin Antibody Percent Binding for Mylan's Insulin Glargine Assay Over Time
NCT02227862 (13) [back to overview]	Change in Cross-reactive Insulin Antibody Percent Binding for Lantus Assay Over Time
NCT02227862 (13) [back to overview]	Change From Baseline in FPG Over Time
NCT02227862 (13) [back to overview]	Change From Baseline in 8-point SMBG Profile Over Time
NCT02227862 (13) [back to overview]	Change in HbA1c From Baseline to 24 Weeks
NCT02227862 (13) [back to overview]	Summary of Actual and Change From Baseline in HbA1c
NCT02227862 (13) [back to overview]	Hypoglycemia Occurrence
NCT02227862 (13) [back to overview]	Change in Total Insulin Antibody Percent Binding for Mylan's Insulin Glargine Assay Over Time
NCT02227862 (13) [back to overview]	Change in Total Insulin Antibody Percent Binding for Lantus Assay Over Time
NCT02227862 (13) [back to overview]	Change in Total Daily Insulin Dose Per Unit Body Weight From Baseline Over Time
NCT02227862 (13) [back to overview]	Occurrence of Local and Systematic Reactions
NCT02227862 (13) [back to overview]	Proportion of Patients With HbA1c < 7%
NCT02227862 (13) [back to overview]	Rate of Hypoglycemic Events Per 30 Days Over Time
NCT02227875 (7) [back to overview]	Change in Cross-Reactive Insulin Antibody Percent Binding for Lantus Assay Over Time
NCT02227875 (7) [back to overview]	Change in Cross-Reactive Insulin Antibody Percent Binding for Mylan's Insulin Glargine Assay Over Time
NCT02227875 (7) [back to overview]	Hypoglycemia Occurrence
NCT02227875 (7) [back to overview]	Change in Total Insulin Antibody Percent Binding for Lantus Assay Over Time
NCT02227875 (7) [back to overview]	Rate of Hypoglycemic Events Per 30 Days
NCT02227875 (7) [back to overview]	Change in Total Insulin Antibody Percent Binding for Mylan's Insulin Glargine Assay Over Time
NCT02227875 (7) [back to overview]	Change in HbA1c From Baseline to 24 Weeks
NCT02229227 (40) [back to overview]	Number of Participants With Daytime and Nocturnal Hypoglycemia
NCT02229227 (40) [back to overview]	Number of Participants With Different Number of Erythrocytes in Urine at Week 0 and Week 26
NCT02229227 (40) [back to overview]	Number of Participants With Different Number of Leukocytes in Urine at Week 0 and Week 26
NCT02229227 (40) [back to overview]	Number of Participants With Different Values of Potential of Hydrogen (pH) at Week 0 and Week 26
NCT02229227 (40) [back to overview]	Number of Participants With Hematology Values of Clinical Concern
NCT02229227 (40) [back to overview]	Number of Participants With Hypoglycemic Events (in Total and by Each Category as Defined by the American Diabetes Association Criteria)
NCT02229227 (40) [back to overview]	Number of Participants With On-therapy Adverse Events (AE) and Serious AE (SAE), and AE Leading to Discontinuation of Randomized Study Medication
NCT02229227 (40) [back to overview]	Number of Participants With Other AE of Special Interest
NCT02229227 (40) [back to overview]	Number of Participants With Vital Signs of Clinical Concern
NCT02229227 (40) [back to overview]	Percentage of Participants With Events of Hypoglycemia With Confirmed Home Blood Glucose Monitoring and/or Third-party Intervention Through Week 26
NCT02229227 (40) [back to overview]	Total Daily Basal Insulin (Insulin Glargine) at Week 4, 10, 18, and 26 Visits
NCT02229227 (40) [back to overview]	Total Daily Bolus Insulin (Insulin Lispro) at Week 4, 10, 18, and 26 Visits
NCT02229227 (40) [back to overview]	Total Daily Insulin Dose at Week 4, Week 10 and Week 18
NCT02229227 (40) [back to overview]	Total Number of Weekly Insulin Injections to Achieve Glycemic Control at Baseline/Randomization and Week 4, 10, 18, and 26
NCT02229227 (40) [back to overview]	Number of Participants Achieving HbA1c <7.0% up to Week 26
NCT02229227 (40) [back to overview]	Mean Albumin at Week 0 and Week 26
NCT02229227 (40) [back to overview]	Change From Baseline in Body Weight at Week 26
NCT02229227 (40) [back to overview]	Change From Baseline in Fasting Plasma Glucose (FPG) at Week 26
NCT02229227 (40) [back to overview]	Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26
NCT02229227 (40) [back to overview]	Number of Participants Achieving a HbA1c <6.5% at Week 26
NCT02229227 (40) [back to overview]	Number of Participants Achieving HbA1c <7.0% at Week 26
NCT02229227 (40) [back to overview]	Number of Participants Treated With Once-weekly Albiglutide That Were Able to Discontinue Insulin Lispro at Week 4 and Did Not Meet Prespecified Criteria for Severe, Persistent Hyperglycemia Through Week 26
NCT02229227 (40) [back to overview]	Number of Participants Who Met Prespecified Criteria for Severe, Persistent Hyperglycemia at Week 26
NCT02229227 (40) [back to overview]	Number of Participants With Hypoglycemia With Blood Glucose <56 Milligrams Per Deciliter (mg/dL) (<3.1 Millimoles Per Liter [mmol/L]), Regardless of Symptoms
NCT02229227 (40) [back to overview]	Percentage of Participants Achieving HbA1c <7.0% Without Severe or Documented Symptomatic Hypoglycemia at Week 26
NCT02229227 (40) [back to overview]	Percentage of Participants Achieving HbA1c <7.0% Without Weight Gain and Without Severe or Documented Hypoglycemia at Week 26
NCT02229227 (40) [back to overview]	Percentage of Participants Achieving HbA1c <7.0% Without Weight Gain at Week 26
NCT02229227 (40) [back to overview]	Percentage of Participants With Severe or Documented Symptomatic Hypoglycemia Through Week 26
NCT02229227 (40) [back to overview]	Total Daily Insulin Dose at Week 26
NCT02229227 (40) [back to overview]	Change From Baseline in Total Cholesterol (TC), Low-density Lipoprotein Cholesterol (LDL-c), High Density Lipoprotein (HDL-c), Triglycerides (TG) and Free Fatty Acids (FFA) at Week 10 and Week 26
NCT02229227 (40) [back to overview]	Change From Baseline to Week 26 in Body Weight
NCT02229227 (40) [back to overview]	Change From Baseline to Week 26 in FPG
NCT02229227 (40) [back to overview]	Change From Baseline to Week 26 in HbA1c
NCT02229227 (40) [back to overview]	Mean Creatinine at Week 0 and Week 26
NCT02229227 (40) [back to overview]	Mean Specific Gravity at Week 0 and Week 26
NCT02229227 (40) [back to overview]	Mean Urine Albumin/Creatinine Ratio at Week 0 and Week 26
NCT02229227 (40) [back to overview]	Number of Participants Achieving a HbA1c <6.5% up to Week 26
NCT02229227 (40) [back to overview]	Number of Participants Meeting Prespecified Criteria for Severe, Persistent Hyperglycemia up to Week 26
NCT02229227 (40) [back to overview]	Number of Participants With Clinical Chemistry Values of Clinical Concern
NCT02229227 (40) [back to overview]	Number of Participants With Clinically Significant Change in Electrocardiogram (ECG) Parameters
NCT02273180 (9) [back to overview]	Percentage of Participants With Hypersensitivity Reactions and Injection Site Reactions
NCT02273180 (9) [back to overview]	Number of Hypoglycemia Events (Any Hypoglycemia, Documented Symptomatic Hypoglycemia and Severe Hypoglycemia) Per Participant-Year
NCT02273180 (9) [back to overview]	Change in Post Prandial Plasma Glucose (PPG) Excursion From Baseline to Week 26
NCT02273180 (9) [back to overview]	Change in Daily Insulin Dose From Baseline to Week 26 and Week 52
NCT02273180 (9) [back to overview]	Percentage of Participants With Treatment Emergent Anti-insulin Antibodies (AIAs)
NCT02273180 (9) [back to overview]	Percentage of Participants With HbA1c <7.0% at Week 26
NCT02273180 (9) [back to overview]	Change in Mean 24-Hour Plasma Glucose Concentration From Baseline to Week 26
NCT02273180 (9) [back to overview]	Change in Fasting Plasma Glucose (FPG) From Baseline to Week 26
NCT02273180 (9) [back to overview]	Change in HbA1c From Baseline to Week 26
NCT02294474 (9) [back to overview]	Percentage of Participants With HbA1c <7.0% and <=6.5% at Week 26
NCT02294474 (9) [back to overview]	Change in Daily Insulin Dose From Baseline to Week 26
NCT02294474 (9) [back to overview]	Change in Post Prandial Glucose (PPG) Excursion From Baseline to Week 26
NCT02294474 (9) [back to overview]	Change in Mean 24-Hour Plasma Glucose Concentration From Baseline to Week 26
NCT02294474 (9) [back to overview]	Percentage of Participants With Hypersensitivity Reactions and Injection Site Reactions
NCT02294474 (9) [back to overview]	Percentage of Participants With Hypoglycemia (Any Hypoglycemia, Documented Symptomatic Hypoglycemia and Severe Hypoglycemia)
NCT02294474 (9) [back to overview]	Change in Fasting Plasma Glucose (FPG) From Baseline to Week 26
NCT02294474 (9) [back to overview]	Percentage of Participants With Treatment-Emergent Anti-insulin Antibodies (AIAs)
NCT02294474 (9) [back to overview]	Change in HbA1c From Baseline to Week 26
NCT02320721 (12) [back to overview]	Percentage of Participants With Hypoglycemia (Any Hypoglycemia, Documented Symptomatic Hypoglycemia, Severe and/or Confirmed Hypoglycemia) During the 26 Weeks of Treatment
NCT02320721 (12) [back to overview]	Percentage of Participants With HbA1c <7.5% or HbA1c <7% During 26-Week Randomized Period
NCT02320721 (12) [back to overview]	Percentage of Participants With HbA1c <7.5% or <7.0% at Week 26 and No Severe and/or Confirmed (≤3.9 mmol/L [70 mg/dL]) Hypoglycemia During 26-Week Randomized Period
NCT02320721 (12) [back to overview]	Hypoglycemia (Any Hypoglycemia, Documented Symptomatic Hypoglycemia, Severe and/or Confirmed Hypoglycemia) Event Rate Per Participant Year During the 26 Weeks of Treatment
NCT02320721 (12) [back to overview]	Percentage of Participants With At Least One Severe and/ or Confirmed (≤3.9 mmol/L [70 mg/dL]) Nocturnal Hypoglycemia (22:00 to 08:59 Hours Next Morning) During 26-Week Randomized Period
NCT02320721 (12) [back to overview]	Percentage of Participants With At Least One Severe and/ or Confirmed (≤3.9 mmol/L [70 mg/dL]) Nocturnal Hypoglycemia (00:00 to 05:59 Hours) During 26-Week Randomized Period
NCT02320721 (12) [back to overview]	Percentage of Participants With At Least One Severe and/ or Confirmed (≤3.9 mmol/L [70 mg/dL]) Hypoglycemia Occurring at Any Time of the Day During 26-Week Randomized Period
NCT02320721 (12) [back to overview]	Percentage of Participants Requiring Rescue Therapy Over the 26 Weeks of Treatment
NCT02320721 (12) [back to overview]	Change in World Health Organization-5 (WHO-5) Well-Being Questionnaire Percentage Score From Baseline to Week 26
NCT02320721 (12) [back to overview]	Change in HbA1c From Baseline to Week 26
NCT02320721 (12) [back to overview]	Change in Fasting Plasma Glucose (FPG) From Baseline to Week 26
NCT02320721 (12) [back to overview]	Hypoglycemia (Any Hypoglycemia, Documented Symptomatic Hypoglycemia, Severe and/or Confirmed Hypoglycemia) Event Rate Per Participant Year: By Age Categorical Data During the 26 Weeks of Treatment
NCT02408120 (11) [back to overview]	Mean Blood Glucose Levels at Bedtime
NCT02408120 (11) [back to overview]	Mean Blood Glucose Levels Before Dinner
NCT02408120 (11) [back to overview]	Mean Blood Glucose Levels Before Lunch
NCT02408120 (11) [back to overview]	Mean Daily BG Levels
NCT02408120 (11) [back to overview]	Mortality
NCT02408120 (11) [back to overview]	Number of Blood Glucose Readings Within 100-140 mg/dL Range
NCT02408120 (11) [back to overview]	Number of Hypoglycemia Events
NCT02408120 (11) [back to overview]	Number of Subjects That Experienced Hospital Complications
NCT02408120 (11) [back to overview]	Mean Daily Dose of Insulin
NCT02408120 (11) [back to overview]	Average Number of Days of Hospital Stay
NCT02408120 (11) [back to overview]	Incidence of Hyperglycemia
NCT02420262 (5) [back to overview]	Responder for HbA1c Below or Equal to 6.5 %
NCT02420262 (5) [back to overview]	Responder for HbA1c Below 7.0%
NCT02420262 (5) [back to overview]	Number of Treatment Emergent Severe or Blood Glucose Confirmed Symptomatic Hypoglycaemic Episodes.
NCT02420262 (5) [back to overview]	Change in Body Weight
NCT02420262 (5) [back to overview]	Change in HbA1c (Glycosylated Haemoglobin)
NCT02443402 (28) [back to overview]	Number of Subjects Requiring Re-intubation Within 24 Hours
NCT02443402 (28) [back to overview]	Number of Subjects Requiring Re-intubation
NCT02443402 (28) [back to overview]	Number of Subject Requiring Surgical Re-Intervention
NCT02443402 (28) [back to overview]	Number of Participants With Stress Hyperglycemic Events in the Intensive Care Unit (ICU)
NCT02443402 (28) [back to overview]	Number of Participants With Severe Hyperglycemic Events During Continuous Insulin Infusion (CII)
NCT02443402 (28) [back to overview]	Number of Participants With Infections Not Requiring Hospital Re-admission
NCT02443402 (28) [back to overview]	Number of Participants With Hypoglycemia During Intensive Care Unit (ICU) Stay
NCT02443402 (28) [back to overview]	Number of Participants With Hypoglycemia After Transition From Intensive Care Unit (ICU)
NCT02443402 (28) [back to overview]	Number of Participants With Hyperglycemia After Transition From Intensive Care Unit (ICU)
NCT02443402 (28) [back to overview]	Number of Participants With Emergency Room (ER) Visits
NCT02443402 (28) [back to overview]	Hospital Complication Rate
NCT02443402 (28) [back to overview]	Total Insulin Therapy in the Intensive Care Unit (ICU)
NCT02443402 (28) [back to overview]	Duration of Continuous Intravenous Insulin (CII)
NCT02443402 (28) [back to overview]	Hospital Mortality Rate
NCT02443402 (28) [back to overview]	Intensive Care Unit (ICU) Mortality Rate
NCT02443402 (28) [back to overview]	Length of Hospital Stay After Study Randomization
NCT02443402 (28) [back to overview]	Length of Stay: Intensive Care Unit (ICU)
NCT02443402 (28) [back to overview]	Mean Amount of Insulin Therapy in the Intensive Care Unit (ICU)
NCT02443402 (28) [back to overview]	Number of Participants Re-admitted to the Hospital Due to Wound Infections
NCT02443402 (28) [back to overview]	Mean Blood Glucose (BG) Concentration After Transition From Intensive Care Unit (ICU)
NCT02443402 (28) [back to overview]	Mean Daily Intensive Care Unit (ICU) Blood Glucose (BG) Concentration
NCT02443402 (28) [back to overview]	Mean Units Subcutaneous (SQ) Insulin Required
NCT02443402 (28) [back to overview]	Need for Continuous Intravenous Insulin (CII) for Treatment of Hyperglycemia
NCT02443402 (28) [back to overview]	Number of Subjects With Persistent Hyperglycemia
NCT02443402 (28) [back to overview]	Number of Participants With Blood Glucose Less Than 40 mg/dl
NCT02443402 (28) [back to overview]	Number of Participants Re-admitted to the Hospital Not Due to Wound Infections
NCT02443402 (28) [back to overview]	Number of Subjects Requiring the Use of Inotropes for Greater Than 24 Hours
NCT02443402 (28) [back to overview]	Number of Participants With Cerebrovascular Events
NCT02451137 (13) [back to overview]	Change From Baseline in Body Weight at Month 6 and Month 12
NCT02451137 (13) [back to overview]	Change From Baseline in Fasting Plasma Glucose (FPG) at Month 6 and Month 12
NCT02451137 (13) [back to overview]	Change From Baseline in HbA1c at Month 6 and Month 12
NCT02451137 (13) [back to overview]	Percentage of Participants Reaching Individualized HbA1c Target Without Documented Symptomatic <=3.9 mmol/L (<= 70 mg/dL) and <3.0 mmol/L (< 54 mg/dL) and/or Severe Hypoglycemia During the 12-Month Randomized Period
NCT02451137 (13) [back to overview]	Percentage of Participants With at Least One Treatment-Emergent Hypoglycemia Event (Any Time of the Day, Nocturnal) Per Type of Hypoglycaemia During the Month 6 and Month 12 on Treatment Period
NCT02451137 (13) [back to overview]	Percentage of Participants With Hospitalizations, Emergency Rooms and Specialty Visits From Baseline to Month 6 and Month 12
NCT02451137 (13) [back to overview]	Scores of Total Treatment Satisfaction, Hyperglycemia Perception, and Hypoglycemia Perception From Diabetes Treatment Satisfaction Questionnaire Change Version (DTSQc) at Month 12
NCT02451137 (13) [back to overview]	Scores of Total Treatment Satisfaction, Hyperglycemia Perception, and Hypoglycemia Perception From Diabetes Treatment Satisfaction Questionnaire Status Version (DTSQs) at Baseline, Month 6, Month 12
NCT02451137 (13) [back to overview]	Treatment Persistence Measured by Medication Possession Ratio (MPR)
NCT02451137 (13) [back to overview]	Percentage of Participants Reaching Individualized HbA1c Target Without Documented Symptomatic <3.0 mmol/L (<54 mg/dL) and/or Severe Hypoglycemia During the 6-Month Randomized Period
NCT02451137 (13) [back to overview]	Percentage of Participants With Individualized Glycated Hemoglobin Target Attainment Per Healthcare Effectiveness Data and Information Set (HEDIS) Criteria Without Documented Symptomatic(Blood Glucose <=70 mg/dL [<=3.9 mmol/L]) and/or Severe Hypoglycemia
NCT02451137 (13) [back to overview]	"Percentage of Responders (Participants and Provider) Who Reported Excellent or Good Responses to Global Effectiveness Scale (GES) Question at Month 6, and Month 12"
NCT02451137 (13) [back to overview]	Change From Baseline in Basal Insulin Dose at Month 6 and Month 12
NCT02451917 (7) [back to overview]	Estimated Glomerular Filtration Rate (eGFR) Calculated by CKD-EPI
NCT02451917 (7) [back to overview]	Difference in A1c Levels
NCT02451917 (7) [back to overview]	Body Mass Index (BMI)
NCT02451917 (7) [back to overview]	Total Daily Insulin Dose
NCT02451917 (7) [back to overview]	Serum Creatinine
NCT02451917 (7) [back to overview]	Number of Hypoglycemic Events
NCT02451917 (7) [back to overview]	Glycemic Variability
NCT02453685 (4) [back to overview]	HbA1c Below 7.0% Without Severe Hypoglycaemic Episodes
NCT02453685 (4) [back to overview]	Change in HbA1c (Glycosylated Haemoglobin)
NCT02453685 (4) [back to overview]	Total Daily Insulin Dose
NCT02453685 (4) [back to overview]	Number of Treatment Emergent Hypoglycaemic Episodes Classified According to the American Diabetes Association (ADA) and the Novo Nordisk Definitions
NCT02501161 (54) [back to overview]	Insulin Dose
NCT02501161 (54) [back to overview]	Change in Body Weight
NCT02501161 (54) [back to overview]	Change in Blood Pressure (Systolic and Diastolic)
NCT02501161 (54) [back to overview]	Change in Biochemistry Parameters- ALP, ALT, AST, Lipase and Amylase
NCT02501161 (54) [back to overview]	Change in Biochemistry Parameter- Sodium, Potassium and Calcium
NCT02501161 (54) [back to overview]	Change in Biochemistry Parameter- Creatinine, Total Bilirubin
NCT02501161 (54) [back to overview]	Change in Biochemistry Parameter- Albumin
NCT02501161 (54) [back to overview]	Number of Treatment-emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes During 26 Weeks of Treatment
NCT02501161 (54) [back to overview]	Participants Who Achieved (Yes/no): HbA1c ≤6.5%
NCT02501161 (54) [back to overview]	Participants Who Achieved (Yes/no): HbA1c <7.0% Without Weight Gain
NCT02501161 (54) [back to overview]	Participants Who Achieved (Yes/no): HbA1c <7.0% Without Treatment-emergent Severe or Blood Glucose (BG) Confirmed Symptomatic Hypoglycaemic Episodes
NCT02501161 (54) [back to overview]	Participants Who Achieved (Yes/no): HbA1c <7.0%
NCT02501161 (54) [back to overview]	Participants Who Achieved (Yes/no): HbA1c < 7.0% Without Treatment-emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes and Without Weight Gain
NCT02501161 (54) [back to overview]	Eye Examination Category
NCT02501161 (54) [back to overview]	ECG Evaluation
NCT02501161 (54) [back to overview]	Change in TRIM-D
NCT02501161 (54) [back to overview]	Change in SMPG-mean Postprandial Increment Over All Meals
NCT02501161 (54) [back to overview]	Change in SMPG-mean 9-point Profile
NCT02501161 (54) [back to overview]	Change in Short Form Health Survey Version 2.0 (SF-36v2™, Acute Version) Health Survey: Scores From the 8 Domains and Summaries of the Physical Component Score (PCS) and the Mental Component Score (MCS)
NCT02501161 (54) [back to overview]	Change in Pulse Rate
NCT02501161 (54) [back to overview]	Change in Haematological Parameter- Thrombocytes and Leukocytes
NCT02501161 (54) [back to overview]	Number of TEAEs During 104 Weeks of Treatment
NCT02501161 (54) [back to overview]	Number of TEAEs During 26 Weeks of Treatment
NCT02501161 (54) [back to overview]	Number of Treatment Emergent Hypoglycaemic Episodes During 104 Weeks of Treatment
NCT02501161 (54) [back to overview]	Number of Treatment Emergent Hypoglycaemic Episodes During 26 Weeks of Treatment
NCT02501161 (54) [back to overview]	Number of Treatment-emergent Nocturnal Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes During 104 Weeks of Treatment
NCT02501161 (54) [back to overview]	Number of Treatment-emergent Nocturnal Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes During 26 Weeks of Treatment
NCT02501161 (54) [back to overview]	Number of Treatment-emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes During 104 Weeks of Treatment
NCT02501161 (54) [back to overview]	Change in Haematological Parameter- Neutrophils
NCT02501161 (54) [back to overview]	Change in Haematological Parameter- Monocytes
NCT02501161 (54) [back to overview]	Change in Haematological Parameter- Lymphocytes
NCT02501161 (54) [back to overview]	Change in Haematological Parameter- Haemoglobin
NCT02501161 (54) [back to overview]	Change in Haematological Parameter- Haematocrit
NCT02501161 (54) [back to overview]	Change in Haematological Parameter- Erythrocytes
NCT02501161 (54) [back to overview]	Change in Haematological Parameter- Eosinophils
NCT02501161 (54) [back to overview]	Change in Haematological Parameter- Basophils
NCT02501161 (54) [back to overview]	Participants Who Achieved (Yes/no): HbA1c ≤6.5% Without Treatment-emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes and Without Weight Gain
NCT02501161 (54) [back to overview]	Participants Who Achieved (Yes/no): HbA1c ≤6.5% Without Weight Gain
NCT02501161 (54) [back to overview]	SMPG-9-point Profile (Individual Points in the Profile)
NCT02501161 (54) [back to overview]	Time From Randomisation to HbA1c >6.5% at 2 Consecutive Visits
NCT02501161 (54) [back to overview]	Time From Randomisation to Inadequate Glycaemic Control and Need for Treatment Intensification
NCT02501161 (54) [back to overview]	Change in Fasting HDL-cholesterol
NCT02501161 (54) [back to overview]	Change in Fasting Free Fatty Acids
NCT02501161 (54) [back to overview]	Change in Fasting C-peptide
NCT02501161 (54) [back to overview]	Change in Calcitonin
NCT02501161 (54) [back to overview]	Participants Who Achieved (Yes/no): HbA1c ≤6.5% Without Treatment-emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes
NCT02501161 (54) [back to overview]	Change in Fasting Human Insulin
NCT02501161 (54) [back to overview]	Change in HbA1c
NCT02501161 (54) [back to overview]	Change in FPG
NCT02501161 (54) [back to overview]	Change in Urine Albumin/Creatinine Ratio
NCT02501161 (54) [back to overview]	Change in Fasting VLDL-cholesterol
NCT02501161 (54) [back to overview]	Change in Fasting Triglycerides
NCT02501161 (54) [back to overview]	Change in Fasting Total Cholesterol
NCT02501161 (54) [back to overview]	Change in Fasting LDL-cholesterol
NCT02551874 (6) [back to overview]	Percentage of Subjects Achieving a Therapeutic Glycemic Response at Week 24
NCT02551874 (6) [back to overview]	Percentage of Subjects Achieving a Therapeutic Glycemic Response, Without Hypoglycaemia, at Week 24
NCT02551874 (6) [back to overview]	Change From Baseline in the Mean Value of 24-hour Glucose at Week 2
NCT02551874 (6) [back to overview]	Mean Change From Baseline in HbA1c at Week 24
NCT02551874 (6) [back to overview]	Mean Change From Baseline in Total Body Weight at Week 24
NCT02551874 (6) [back to overview]	Percentage of Subjects With Confirmed Hypoglycaemia at Week 24
NCT02556918 (26) [back to overview]	Total IV Insulin in ICU
NCT02556918 (26) [back to overview]	Number of Subjects With Hyperglycemia in Intensive Care Unit (ICU)
NCT02556918 (26) [back to overview]	Number of Subjects With Hyperglycemia (Blood Glucose Greater Than or Equal to 300 mg/dL) in Non-ICU
NCT02556918 (26) [back to overview]	Number of Subjects Returning to the ER Within 30 Days
NCT02556918 (26) [back to overview]	Number of Subjects Readmitted to the Hospital
NCT02556918 (26) [back to overview]	Number of Patients With Severe Hypoglycemic Events in Non-intensive Care Unit (ICU)
NCT02556918 (26) [back to overview]	Number of Patients With Severe Hypoglycemic Events in Intensive Care Unit (ICU)
NCT02556918 (26) [back to overview]	Number of Patients With Hypoglycemic Events in Non-intensive Care Unit (ICU)
NCT02556918 (26) [back to overview]	Number of Patients With Hyperglycemia in the Intensive Care Unit (ICU)
NCT02556918 (26) [back to overview]	Number of Patients Requiring Subcutaneous (SQ) Insulin After Discontinuation of Continuous Intravenous Insulin Infusion (CII)
NCT02556918 (26) [back to overview]	Number of Patients Requiring Continuous Intravenous Insulin Infusion (CII)
NCT02556918 (26) [back to overview]	Number of Intensive Care Unit (ICU) Readmission
NCT02556918 (26) [back to overview]	Number of Cerebrovascular Events
NCT02556918 (26) [back to overview]	Median Number of Days of Subcutaneous (SC) Insulin After Discontinuation of Continuous Intravenous Insulin Infusion (CII)
NCT02556918 (26) [back to overview]	Mean Post-operative Blood Glucose (BG) Concentration
NCT02556918 (26) [back to overview]	Mean Insulin Dose Per Day During Intensive Care Unit (ICU) Recovery
NCT02556918 (26) [back to overview]	Mean Blood Glucose (BG) Concentration in the Intensive Care Unit (ICU)
NCT02556918 (26) [back to overview]	Length of Intensive Care Unit (ICU) Stay
NCT02556918 (26) [back to overview]	Duration of Intubation
NCT02556918 (26) [back to overview]	Duration of Continuous Intravenous Insulin Infusion (CII)
NCT02556918 (26) [back to overview]	Composite of Perioperative Complications
NCT02556918 (26) [back to overview]	Amount of Subcutaneous (SC) Insulin Taken in Intensive Care Unit (ICU)
NCT02556918 (26) [back to overview]	Amount of Subcutaneous (SC) Insulin in Intensive Care Unit (ICU) 48 Hours
NCT02556918 (26) [back to overview]	Number of Patients With Hypoglycemic Events in Intensive Care Unit (ICU)
NCT02556918 (26) [back to overview]	Number of Patients With Persistent Hyperglycemia
NCT02556918 (26) [back to overview]	Total Length of Hospital Stay
NCT02561130 (9) [back to overview]	Glycated Hemoglobin (HbA1C)
NCT02561130 (9) [back to overview]	Percentage of Weight Loss From Baseline
NCT02561130 (9) [back to overview]	Change in Waist Circumference From Baseline
NCT02561130 (9) [back to overview]	Number of Participants With Severe Hypoglycemic Episodes
NCT02561130 (9) [back to overview]	Number of Participants With Non-severe Symptomatic Hypoglycemic Episodes
NCT02561130 (9) [back to overview]	Number of Participants Achieving Drug-free HbA1C < 6.0%
NCT02561130 (9) [back to overview]	Number of Participants Achieving Drug-free Diabetes Remission in the Experimental Group Compared to the Control Group
NCT02561130 (9) [back to overview]	Number of Participants Achieving Drug-free Diabetes Remission
NCT02561130 (9) [back to overview]	Number of Participants Achieving Diabetes Relapse Without Overt Hyperglycemia Off Diabetes Drugs
NCT02623998 (6) [back to overview]	Number of Participants With Severe Hypoglycemic Episodes
NCT02623998 (6) [back to overview]	Number of Participants With Hyperglycemia Relapse in the Experimental Group Compared to the Control Group
NCT02623998 (6) [back to overview]	Number of Participants With Drug-free Normal Glucose Tolerance
NCT02623998 (6) [back to overview]	Number of Participants Achieving Drug-free Diabetes Remission
NCT02623998 (6) [back to overview]	Change in Waist Circumference
NCT02623998 (6) [back to overview]	Percent Change in Weight
NCT02666430 (11) [back to overview]	Local and Systemic Allergic Reactions
NCT02666430 (11) [back to overview]	Change From Baseline in Cross-Reactive Insulin Antibody - Lantus Assay
NCT02666430 (11) [back to overview]	Change From Baseline in Cross-Reactive Insulin Antibody - Mylan Insulin Glargine Assay
NCT02666430 (11) [back to overview]	Change From Baseline in Fasting Plasma Glucose
NCT02666430 (11) [back to overview]	Change From Baseline in Total Insulin Antibodies - Lantus Assay
NCT02666430 (11) [back to overview]	Change From Baseline in Total Insulin Antibodies - Mylan Insulin Glargine Assay
NCT02666430 (11) [back to overview]	Change From Baseline Total Daily Insulin Dose
NCT02666430 (11) [back to overview]	Change in Hemoglobin A1c (HbA1c) From Baseline
NCT02666430 (11) [back to overview]	Hypoglycemic Incidence
NCT02666430 (11) [back to overview]	Hypoglycemic Rate
NCT02666430 (11) [back to overview]	Overall Average of Self-monitoring Blood Glucose (SMBG) Change From Baseline
NCT02680457 (2) [back to overview]	Glycemic Variability: Mean Amplitude of Glucose Excursion (MAGE)
NCT02680457 (2) [back to overview]	Glycemic Variability: Area Under the Curve of Glucose
NCT02688933 (8) [back to overview]	Coefficient of Variation (CV%) in Mean CGM Glucose
NCT02688933 (8) [back to overview]	Change From Baseline in Daily Insulin Dose at Week 16
NCT02688933 (8) [back to overview]	Percentage of Time of Mean Glucose Concentration Within the Target Range of 70-180 mg/dL as Obtained From CGM
NCT02688933 (8) [back to overview]	Percentage of Time Glucose Concentrations Within the Target Range of 70 to 140 mg/dL During Last 4 Hours of CGM Data Collection Prior to Next Day Basal Insulin Injection
NCT02688933 (8) [back to overview]	Mean Change From Baseline in Glucose Level During Last 4 Hours of CGM Data Collection Prior to the Next Day Basal Insulin Injection During Week 15 and/or Week 16
NCT02688933 (8) [back to overview]	Change From Baseline in Time (Min) of Mean Glucose Concentration Within the Target Range of 70 to 180 mg/dL, by End of Study hbA1c Levels During Week 15 and/or Week 16
NCT02688933 (8) [back to overview]	Percentage of Participants With Documented Symptomatic Nocturnal Hypoglycemia
NCT02688933 (8) [back to overview]	Documented Symptomatic Nocturnal Hypoglycemia Event Rate Per Participant-Year
NCT02735044 (11) [back to overview]	Percentage of Participants With FPG of <=130 mg/dL (7.2 mmol/L) at Month 6
NCT02735044 (11) [back to overview]	Percentage of Participants With HbA1c Values of <7.5% Without Any Episode of Severe and/or Documented Self-Monitored Plasma Glucose ([SMPG] <54 mg/dL [3.0 mmol/L]) Symptomatic Hypoglycemia During the Last 3 Months of the Main 6-month Randomized Period
NCT02735044 (11) [back to overview]	Change From Baseline in 24-Hour Mean Plasma Glucose Based on 8-point SMPG Profiles to Month 6
NCT02735044 (11) [back to overview]	Percentage of Participants With Any Hyperglycemia With Ketosis at Month 12
NCT02735044 (11) [back to overview]	Change From Baseline in Variability of 24-Hour Mean Plasma Glucose Based on 8-point SMPG Profiles at Month 6
NCT02735044 (11) [back to overview]	Change From Baseline in HbA1c to Month 6
NCT02735044 (11) [back to overview]	Change From Baseline to Month 6 in 8-Point SMPG Profile Per Time Point
NCT02735044 (11) [back to overview]	Percentage of Participants With at Least One Hypoglycemic Events (Any Hypoglycemia, Severe Hypoglycemia, Documented Symptomatic, Probable Symptomatic, Asymptomatic Hypoglycemia, Pseudo-hypoglycemia and Severe and/or Confirmed Hypoglycemia) at Month 12
NCT02735044 (11) [back to overview]	Percentage of Participants With HbA1c Values of <7.5% at Month 6
NCT02735044 (11) [back to overview]	Change From Baseline in Fasting Plasma Glucose (FPG) to Month 6
NCT02735044 (11) [back to overview]	Percentage of Participants With FPG of <=130 mg/dL (7.2 mmol/L) Without Any Episode of Severe and/or Documented (SMPG <54 mg/dL [3.0 mmol/L]) Symptomatic Hypoglycemia During the Last 3 Months of the Main 6-month Randomized Period
NCT02738151 (19) [back to overview]	Change From Baseline in 8 Point SMPG Profile to Week 12 and Week 24 Per Time Point
NCT02738151 (19) [back to overview]	Change From Baseline in Total Diabetes Treatment Satisfaction Questionnaire (DTSQ) Status at Week 12 and Week 24
NCT02738151 (19) [back to overview]	Change From Baseline in Fasting Self-Monitoring Plasma Glucose (SMPG) to Week 12 and Week 24
NCT02738151 (19) [back to overview]	Change From Baseline in Fasting Plasma Glucose (FPG) to Week 12 and Week 24
NCT02738151 (19) [back to overview]	Change From Baseline in 24-hour Average 8-point SMPG Profile to Week 12 and Week 24
NCT02738151 (19) [back to overview]	Percentage of Participants With At Least One Hypoglycemic Events (Any, Severe and/or Confirmed Hypoglycemia: Any Time of the Day) by Study Period
NCT02738151 (19) [back to overview]	Percentage of Participants Reaching Target HbA1c of < 7% and =<6.5% at Week 12 and Week 24
NCT02738151 (19) [back to overview]	Percentage of Participants With At Least One Hypoglycemic Events (Any, Severe and/or Confirmed Hypoglycemia: Nocturnal) by Study Period
NCT02738151 (19) [back to overview]	Change From Baseline in HbA1c to Week 12
NCT02738151 (19) [back to overview]	Change From Baseline in HbA1c to Week 24
NCT02738151 (19) [back to overview]	Percentage of Participants Requiring a Rescue Therapy During 24 Weeks Treatment Period
NCT02738151 (19) [back to overview]	Percentage of Participants With Sulphonylurea or Meglitinide Dose Reduction/ Discontinuation Due to Hypoglycemia During 24 Weeks Treatment Period
NCT02738151 (19) [back to overview]	Change From Baseline in Basal Insulin Dose (U/kg Body Weight) to Week 12 and Week 24
NCT02738151 (19) [back to overview]	Change From Baseline in 4-point SMPG Profile to Week 12 and Week 24 Per Time Point
NCT02738151 (19) [back to overview]	Percentage of Participants Reaching Target HbA1c <7% and =<6.5% at Week 12 and Week 24 Without Severe and/or Confirmed Hypoglycemia (70 mg/dL) Event
NCT02738151 (19) [back to overview]	Hypoglycemia (Any, Severe and/or Confirmed Hypoglycemia: Nocturnal ) Event Rate Per Participant Year During Study Period
NCT02738151 (19) [back to overview]	Hypoglycemia (Any, Severe and/or Confirmed Hypoglycemia: Any Time of the Day) Event Rate Per Participant Year During Study Period
NCT02738151 (19) [back to overview]	Change From Baseline in Variability of Fasting SMPG to Week 12 and Week 24
NCT02738151 (19) [back to overview]	Change From Baseline in Variability of 24-Hour 8-Point SMPG Profiles at Week 12 and Week 24
NCT02738879 (15) [back to overview]	Change From Baseline in Total Daily Insulin Dose (Units) at Week 30
NCT02738879 (15) [back to overview]	Event Rate of Documented Hypoglycemia With Blood Glucose <56 mg/dL (≤3.1 mmol/L)
NCT02738879 (15) [back to overview]	Event Rate of Documented Hypoglycemia With Blood Glucose ≤70 mg/dL (≤3.9 mmol/L)
NCT02738879 (15) [back to overview]	Event Rate of Documented Symptomatic Hypoglycemia With Blood Glucose <56 mg/dL (≤3.1 mmol/L)
NCT02738879 (15) [back to overview]	Percentage of Participants With Documented Symptomatic Hypoglycemia With Blood Glucose <56 mg/dL (≤3.1 mmol/L)
NCT02738879 (15) [back to overview]	Percentage of Participants Who Experienced One or More Adverse Events (AEs)
NCT02738879 (15) [back to overview]	Percentage of Participants With A1C Goal <7.0% (<53 mmol/Mol at Week 30 and No Documented Hypoglycemia With Blood Glucose ≤70 mg/dL (≤3.9 mmol/L) up to Week 30
NCT02738879 (15) [back to overview]	Percentage of Participants With A1C Goal <7.0% (<53 mmol/Mol) at Week 30
NCT02738879 (15) [back to overview]	Percentage of Participants With Documented Hypoglycemia With Blood Glucose <56 mg/dL (≤3.1 mmol/L)
NCT02738879 (15) [back to overview]	Percentage of Participants With Documented Hypoglycemia With Blood Glucose ≤70 mg/dL (≤3.9 mmol/L)
NCT02738879 (15) [back to overview]	Percentage of Participants With Events of Documented Symptomatic Hypoglycemia With Blood Glucose ≤70 mg/dL (≤3.9 mmol/L)
NCT02738879 (15) [back to overview]	Event Rate of Documented Symptomatic Hypoglycemia With Blood Glucose ≤70 mg/dL (≤3.9 mmol/L)
NCT02738879 (15) [back to overview]	Change From Baseline in A1C at Week 30
NCT02738879 (15) [back to overview]	Change From Baseline in Fasting Plasma Glucose (FPG) at Week 30
NCT02738879 (15) [back to overview]	Percentage of Participants Who Discontinued Study Drug Due to an AE
NCT02741687 (10) [back to overview]	Number of Patients Transferred to the ICU Immediately After Surgery or During Hospitalization
NCT02741687 (10) [back to overview]	Number of Participants With Hypoglycemic Events
NCT02741687 (10) [back to overview]	Number of Participants Experiencing Complications
NCT02741687 (10) [back to overview]	Length of Hospital Stay
NCT02741687 (10) [back to overview]	Total Daily Dose of Insulin for Patients Requiring Supplemental Insulin
NCT02741687 (10) [back to overview]	Number of Patients Requiring Supplemental, Subcutaneous Insulin
NCT02741687 (10) [back to overview]	Number of Participants With Hospital Readmissions After Discharge
NCT02741687 (10) [back to overview]	Number of Days in the ICU
NCT02741687 (10) [back to overview]	Number of Participants With Emergency Room Visits After Discharge
NCT02741687 (10) [back to overview]	Number of Participants Experiencing Stress Hyperglycemia
NCT02773368 (33) [back to overview]	Responder After 26 Weeks (Yes/No) for: HbA1c ≤ 6.5%
NCT02773368 (33) [back to overview]	Responder After 26 Weeks (Yes/No) for: HbA1c < 7.0% Without Weight Gain
NCT02773368 (33) [back to overview]	Responder After 26 Weeks (Yes/No) for: HbA1c < 7.0% Without Treatment-emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes During the Last 12 Weeks of Treatment and Without Weight Gain
NCT02773368 (33) [back to overview]	Responder After 26 Weeks (Yes/No) for: HbA1c < 7.0% Without Treatment-emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes During the Last 12 Weeks of Treatment
NCT02773368 (33) [back to overview]	Responder (Yes/No) for HbA1c Below 7.0%
NCT02773368 (33) [back to overview]	Number of Treatment-emergent Hypoglycaemic Episodes According to ADA Definition During 26 Weeks
NCT02773368 (33) [back to overview]	Change in HbA1c (Glycosylated Haemoglobin)
NCT02773368 (33) [back to overview]	Change in Fasting Plasma Glucose (FPG)
NCT02773368 (33) [back to overview]	Change in Body Weight
NCT02773368 (33) [back to overview]	Change From Baseline in the 9-point Self-measured Plasma Glucose (SMPG) Profile
NCT02773368 (33) [back to overview]	Change From Baseline in Systolic Blood Pressure
NCT02773368 (33) [back to overview]	Change From Baseline in SMPG 9-point Profile: Prandial Plasma Glucose Increments (From Before Meal to 90 Min After Breakfast, Lunch and Dinner). The Mean Increment Over All Meals Will be Derived as the Mean of All Available Meal Increments
NCT02773368 (33) [back to overview]	Change From Baseline in Self-measured Plasma Glucose (SMPG) 9-point Profile: Mean of the 9-point Profile
NCT02773368 (33) [back to overview]	Change From Baseline in Patient Reported Outcomes (PROs) After 26 Weeks: Summary Scores of Treatment Related Impact Measure for Diabetes (TRIM-D)
NCT02773368 (33) [back to overview]	Change From Baseline in Patient Reported Outcomes (PROs) After 26 Weeks: Summary Scores of Medical Outcomes Study 36-item Short Form (SF-36v2)
NCT02773368 (33) [back to overview]	Change From Baseline in Fasting Lipid Profile: Very-low-density Lipoprotein Cholesterol (VLDL Cholesterol)
NCT02773368 (33) [back to overview]	Change From Baseline in Fasting Lipid Profile: Low-density Lipoprotein Cholesterol (LDL Cholesterol)
NCT02773368 (33) [back to overview]	Change From Baseline in Fasting Lipid Profile: High-density Lipoprotein Cholesterol (HDL Cholesterol)
NCT02773368 (33) [back to overview]	Change From Baseline in Fasting Lipid Profile: Free Fatty Acids
NCT02773368 (33) [back to overview]	Change From Baseline in Fasting Lipid Profile: Cholesterol
NCT02773368 (33) [back to overview]	Change From Baseline in Diastolic Blood Pressure
NCT02773368 (33) [back to overview]	Change From Baseline in Clinical Evaluation After 26 Weeks: Pulse Rate
NCT02773368 (33) [back to overview]	Change From Baseline in Clinical Evaluation After 26 Weeks: Eye Examination: Fundoscopy/Fundus Photography
NCT02773368 (33) [back to overview]	Change From Baseline in Clinical Evaluation After 26 Weeks: Electrocardiogram (ECG)
NCT02773368 (33) [back to overview]	Change From Baseline After 26 Weeks in Waist Circumference
NCT02773368 (33) [back to overview]	Number of Treatment-emergent Severe or BG (Blood Glucose) Confirmed Symptomatic Hypoglycaemic Episodes
NCT02773368 (33) [back to overview]	Number of Treatment-emergent Nocturnal Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes During 26 Weeks
NCT02773368 (33) [back to overview]	Number of Treatment-emergent Adverse Events
NCT02773368 (33) [back to overview]	Insulin Dose, Total Daily Dose (U)
NCT02773368 (33) [back to overview]	Change From Baseline in Fasting Lipid Profile: Triglycerides
NCT02773368 (33) [back to overview]	Responder After 26 Weeks (Yes/No) for: HbA1c ≤ 6.5% Without Weight Gain
NCT02773368 (33) [back to overview]	Responder After 26 Weeks (Yes/No) for: HbA1c ≤ 6.5% Without Treatment-emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes During the Last 12 Weeks of Treatment and Without Weight Gain
NCT02773368 (33) [back to overview]	Responder After 26 Weeks (Yes/No) for: HbA1c ≤ 6.5% Without Treatment-emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes During the Last 12 Weeks of Treatment
NCT02787551 (18) [back to overview]	Change From Baseline in the Daily Average of the 7-point Self-monitored Plasma Glucose (SMPG) to Week 26: Core Period
NCT02787551 (18) [back to overview]	Change From Baseline in Body Weight at Week 26: Core Period
NCT02787551 (18) [back to overview]	Change From Baseline in 2-Hour Postprandial Plasma Glucose (PPG) During Standardized Meal Test to Week 52: Single Arm Extension Period
NCT02787551 (18) [back to overview]	Change From Baseline in 2-Hour Postprandial Plasma Glucose (PPG) During Standardized Meal Test to Week 26: Core Period
NCT02787551 (18) [back to overview]	Change From Baseline in 2-Hour Blood Glucose Excursion During Standardized Meal Test to Week 52: Single Arm Extension Period
NCT02787551 (18) [back to overview]	Change From Baseline in 2-Hour Blood Glucose Excursion During Standardized Meal Test to Week 26: Core Period
NCT02787551 (18) [back to overview]	Percentage of Participants Reaching HbA1c <7% or <=6.5% at Week 26: Core Period
NCT02787551 (18) [back to overview]	Number of Documented Symptomatic Hypoglycemia Events Per Participant-Year: Single Arm Extension Period
NCT02787551 (18) [back to overview]	Number of Documented Symptomatic Hypoglycemia Events Per Participant-Year: Core Period
NCT02787551 (18) [back to overview]	Percentage of Participants Requiring Rescue Therapy During the 52 Week Treatment Period: Single Arm Extension Period
NCT02787551 (18) [back to overview]	Percentage of Participants Requiring Rescue Therapy During the 26 Week Treatment Period: Core Period
NCT02787551 (18) [back to overview]	Change From Baseline in the Daily Average of the 7-point Self-monitored Plasma Glucose (SMPG) to Week 52: Single Arm Extension Period
NCT02787551 (18) [back to overview]	Change From Baseline in Glycated Hemoglobin (HbA1c) to Week 52: Single Arm Extension Period
NCT02787551 (18) [back to overview]	Change From Baseline in Glycated Hemoglobin (HbA1c) to Week 26: Core Period
NCT02787551 (18) [back to overview]	Change From Baseline in Fasting Plasma Glucose (FPG) to Week 52: Single Arm Extension Period
NCT02787551 (18) [back to overview]	Change From Baseline in Fasting Plasma Glucose (FPG) to Week 26: Core Period
NCT02787551 (18) [back to overview]	Change From Baseline in Body Weight to Week 52: Single Arm Extension Period
NCT02787551 (18) [back to overview]	Percentage of Participants Reaching HbA1c <7 % or <=6.5% at Week 52: Single Arm Extension Period
NCT02906917 (12) [back to overview]	Number of Treatment Emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes
NCT02906917 (12) [back to overview]	Number of Nocturnal, Treatment Emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes
NCT02906917 (12) [back to overview]	Incidence of TEAEs
NCT02906917 (12) [back to overview]	Change in Pre-breakfast SMPG (Used for Titration)
NCT02906917 (12) [back to overview]	Change in Postprandial SMPG Increment (From 9-point Profile)
NCT02906917 (12) [back to overview]	Change in HbA1c (%) - Week 38
NCT02906917 (12) [back to overview]	Change in HbA1c (%) - Week 26
NCT02906917 (12) [back to overview]	Change in FPG
NCT02906917 (12) [back to overview]	Change in Body Weight
NCT02906917 (12) [back to overview]	Total Insulin Dose
NCT02906917 (12) [back to overview]	Responder (Yes/No) for HbA1c <7% Without Severe or BG Confirmed Symptomatic Hypoglycaemia
NCT02906917 (12) [back to overview]	Responder (Yes/No) for HbA1c < 7%
NCT03013985 (14) [back to overview]	Number of Days of Hospital Stay
NCT03013985 (14) [back to overview]	Mean Daily Glucose in Patients With Admission HbA1c Lower Than 8%
NCT03013985 (14) [back to overview]	Mean Daily Glucose in Patients With Admission HbA1c Higher Than 8%
NCT03013985 (14) [back to overview]	Mean Daily Blood Glucose Concentration Inpatient
NCT03013985 (14) [back to overview]	Mean Daily Glucose in Patients With Length of Stay Shorter Than 5 Days
NCT03013985 (14) [back to overview]	Hospital Mortality
NCT03013985 (14) [back to overview]	Percent of Subjects With Severe Hypoglycemia
NCT03013985 (14) [back to overview]	Percent of Subjects With Hypoglycemic Events
NCT03013985 (14) [back to overview]	Mean Daily Blood Glucose Concentration After Hospital Discharge
NCT03013985 (14) [back to overview]	Mean Daily Glucose in Patients With Length of Stay Shorter Than 3 Days
NCT03013985 (14) [back to overview]	Mean Daily Glucose in Patients With Length of Stay Longer Than 5 Days
NCT03013985 (14) [back to overview]	Percent of Blood Glucose 70-180 Measured by Point of Care Test
NCT03013985 (14) [back to overview]	Number Subjects With Cardiac Complications
NCT03013985 (14) [back to overview]	Number of Patients With Acute Renal Failure
NCT03078478 (16) [back to overview]	Percentage of Participants With FPG ≤ 7.2 mmol/L (130 mg/dL) at End of Treatment (up to 88 Weeks) (Yes/no)
NCT03078478 (16) [back to overview]	Number of Nocturnal, Severe or BG-confirmed Symptomatic Hypoglycaemic Episodes During Treatment (up to 88 Weeks)
NCT03078478 (16) [back to overview]	Number of Severe Hypoglycaemic Episodes During Treatment (up to 88 Weeks)
NCT03078478 (16) [back to overview]	Number of Severe Hypoglycaemic Episodes During Maintenance 2 (36 Weeks)
NCT03078478 (16) [back to overview]	Number of Nocturnal, Severe or BG-confirmed Symptomatic Hypoglycaemic Episodes During Maintenance 2 (36 Weeks)
NCT03078478 (16) [back to overview]	Number of Adverse Events From Randomisation to End of Maintenance Period 2 (up to 88 Weeks)
NCT03078478 (16) [back to overview]	Change in HbA1c From Baseline to End of Treatment (up to 88 Weeks)
NCT03078478 (16) [back to overview]	Change in Fasting Plasma Glucose (FPG) From Baseline to End of Treatment (up to 88 Weeks)
NCT03078478 (16) [back to overview]	Number of Severe or BG-confirmed Symptomatic Hypoglycaemic Episodes During Maintenance 2 (36 Weeks)
NCT03078478 (16) [back to overview]	Change in Body Weight From Baseline to End of Treatment (up to 88 Weeks)
NCT03078478 (16) [back to overview]	Percentage of Participants With HbA1c < 7.0% (53 mmol/Mol) at End of Treatment (up to 88 Weeks) and no Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes During Maintenance 2 (36 Weeks) (Yes/no)
NCT03078478 (16) [back to overview]	Percentage of Participants With HbA1c < 7.0% (53 mmol/Mol) at End of Treatment (up to 88 Weeks) and no Nocturnal, Severe or BG-confirmed Symptomatic Hypoglycaemic Episodes During Maintenance 2 (36 Weeks) (Yes/no)
NCT03078478 (16) [back to overview]	Basal Insulin Dose (U) at End of Treatment (up to 88 Weeks)
NCT03078478 (16) [back to overview]	Percentage of Participants With FPG ≤ 5.0 mmol/L (90 mg/dL) at End of Treatment (up to 88 Weeks) (Yes/no)
NCT03078478 (16) [back to overview]	Change in Mean Pre-breakfast Self-measured Plasma Glucose Used for Titration From Baseline to End of Treatment (up to 88 Weeks)
NCT03078478 (16) [back to overview]	Number of Severe or BG-confirmed Symptomatic Hypoglycaemic Episodes During Treatment (up to 88 Weeks)
NCT03095651 (14) [back to overview]	Plasma Concentration/Time (AUC0-24) of MK-5160
NCT03095651 (14) [back to overview]	Time to Maximum Plasma Concentration
NCT03095651 (14) [back to overview]	Steady State Plasma Concentration (Css) of MK-5160
NCT03095651 (14) [back to overview]	Apparent Terminal Half-life
NCT03095651 (14) [back to overview]	Day 12 to Day 1 Accumulation Ratio of AUC0-24.
NCT03095651 (14) [back to overview]	Day 12 to Day 1 Accumulation Ratio of Cmax
NCT03095651 (14) [back to overview]	Maximal Glucose Infusion Rate
NCT03095651 (14) [back to overview]	Number of Participants Discontinuing Study Drug Due to an AE
NCT03095651 (14) [back to overview]	Number of Participants Experiencing an Adverse Event (AE)
NCT03095651 (14) [back to overview]	Plasma Clearance
NCT03095651 (14) [back to overview]	Steady State Plasma Concentration (Css) of Glargine
NCT03095651 (14) [back to overview]	Maximum Plasma Concentration (Cmax) of Glargine
NCT03095651 (14) [back to overview]	Maximum Plasma Concentration (Cmax) of MK-5160
NCT03095651 (14) [back to overview]	Plasma Concentration/Time (AUC0-24) of Glargine
NCT03107208 (4) [back to overview]	Evaluation of CGM and POC Glucose Monitoring During DKA Treatment in Children.
NCT03107208 (4) [back to overview]	Rate of Recurrent Ketogenesis
NCT03107208 (4) [back to overview]	Risk of Hypoglycemia Between Those Given Early Administration of Glargine Versus Those Given Standard-of-care Management.
NCT03107208 (4) [back to overview]	Rate of Rebound Hyperglycemia
NCT03170544 (26) [back to overview]	Time to Reach a 50% Decrease In Plasma MK-1092 Concentration (t1/2) Parts 1 and 3
NCT03170544 (26) [back to overview]	Time to Reach a 50% Decrease In Plasma MK-1092 Concentration (t1/2) Part 4
NCT03170544 (26) [back to overview]	Time to Reach a 50% Decrease In Plasma Insulin Glargine Concentration (t1/2) Parts 1 and 3
NCT03170544 (26) [back to overview]	Time to Reach a 50% Decrease In Plasma Insulin Glargine Concentration (t1/2) Part 4
NCT03170544 (26) [back to overview]	Rate of Plasma Drug Removal (CL/F) MK-1092 Parts 1 and 3
NCT03170544 (26) [back to overview]	Rate of Plasma Drug Removal (CL/F) MK-1092 Part 4
NCT03170544 (26) [back to overview]	GIRmax After a Single Dose Administration of Subcutaneous MK-1092 or Glargine to Adult Participants With Type 2 Diabetes Mellitus (T2DM) (Part 4)
NCT03170544 (26) [back to overview]	GIRmax After a Single Dose Administration of Subcutaneous MK-1092 or Glargine to Healthy Adult Participants (Part 1)
NCT03170544 (26) [back to overview]	Maximal Plasma Insulin Glargine Concentration (Cmax) Part 4
NCT03170544 (26) [back to overview]	Maximal Plasma Insulin Glargine Concentration (Cmax) Parts 1 and 3
NCT03170544 (26) [back to overview]	Maximal Plasma MK-1092 Concentration (Cmax) Part 4
NCT03170544 (26) [back to overview]	Maximal Plasma MK-1092 Concentration (Cmax) Parts 1 and 3
NCT03170544 (26) [back to overview]	Number of Participants Who Discontinued the Study Due to an AE
NCT03170544 (26) [back to overview]	GIRmax After a Single Dose Administration of Subcutaneous MK-1092 or Glargine to Adult Participants With Type 1 Diabetes Mellitus (T1DM) (Part 3)
NCT03170544 (26) [back to overview]	Area Under the Plasma Drug Curve From 0 to Infinity (AUC0-inf) MK-1092 Parts 1 and 3
NCT03170544 (26) [back to overview]	Number of Participants Who Experienced an Adverse Event (AE)
NCT03170544 (26) [back to overview]	Time-Weighted Average GIR (TWA[GIR]) After a Single Dose Administration of Subcutaneous MK-1092 or Glargine to Healthy Adult Participants (Part 1)
NCT03170544 (26) [back to overview]	Time-Weighted Average GIR (TWA[GIR]) After a Single Dose Administration of Subcutaneous MK-1092 or Glargine to Adult Participants With T2DM (Part 4)
NCT03170544 (26) [back to overview]	Time-Weighted Average GIR (TWA[GIR]) After a Single Dose Administration of Subcutaneous MK-1092 or Glargine to Adult Participants With T1DM (Part 3)
NCT03170544 (26) [back to overview]	Time to Reach Maximum Plasma MK-1092 Concentration (Tmax) Parts 1 and 3
NCT03170544 (26) [back to overview]	Time to Reach Maximum Plasma MK-1092 Concentration (Tmax) Part 4
NCT03170544 (26) [back to overview]	Time to Reach Maximum Plasma Insulin Glargine Concentration (Tmax) Parts 1 and 3
NCT03170544 (26) [back to overview]	Time to Reach Maximum Plasma Insulin Glargine Concentration (Tmax) Part 4
NCT03170544 (26) [back to overview]	Area Under the Plasma Drug Curve From 0 to Infinity (AUC0-inf) Insulin Glargine Part 4
NCT03170544 (26) [back to overview]	Area Under the Plasma Drug Curve From 0 to Infinity (AUC0-inf) Insulin Glargine Parts 1 and 3
NCT03170544 (26) [back to overview]	Area Under the Plasma Drug Curve From 0 to Infinity (AUC0-inf) MK-1092 Part 4
NCT03211858 (18) [back to overview]	Number of Participants With at Least One Hypoglycemic Event: Subgroup Analysis by Prior Use of NovoLog/NovoRapid or Humalog/Liprolog
NCT03211858 (18) [back to overview]	Number of Participants With at Least One Hypoglycemic Event
NCT03211858 (18) [back to overview]	Number of Participants With Adverse Events: Subgroup Analysis by Prior Use of NovoLog/NovoRapid or Humalog/Liprolog
NCT03211858 (18) [back to overview]	Number of Hypoglycemia Events Per Participant-Year
NCT03211858 (18) [back to overview]	Percentage of Participants With Hypersensitivity Reactions and Injection Site Reactions
NCT03211858 (18) [back to overview]	Change in the Mean 24-hour Plasma Glucose Concentration From Baseline to Week 26 and Week 52
NCT03211858 (18) [back to overview]	Change in Postprandial Plasma Glucose (PPG) Excursion From Baseline to Week 26 and Week 52
NCT03211858 (18) [back to overview]	Change in Glycated Hemoglobin A1c (HbA1c) From Baseline to Week 26
NCT03211858 (18) [back to overview]	Change in Glycated Hemoglobin A1c From Baseline to Week 26 and Week 52: Subgroup Analysis by Prior Use of NovoLog/NovoRapid or Humalog/Liprolog
NCT03211858 (18) [back to overview]	Change in Fasting Plasma Glucose (FPG) From Baseline to Week 26 and Week 52
NCT03211858 (18) [back to overview]	Change in Daily Insulin Dose From Baseline to Day 1, Week 26 and Week 52: Subgroup Analysis by Prior Use of NovoLog/NovoRapid or Humalog/Liprolog
NCT03211858 (18) [back to overview]	Change in Daily Insulin Dose From Baseline to Day 1, Week 26 and Week 52
NCT03211858 (18) [back to overview]	Change in 7-Point SMPG Profiles From Baseline to Week 26 and Week 52 Per Time Point
NCT03211858 (18) [back to overview]	Percentage of Participants With Treatment-Induced, Treatment-Boosted and Treatment-Emergent Anti-insulin Aspart Antibodies (AIAs)
NCT03211858 (18) [back to overview]	Change in HbA1c From Baseline to Week 52
NCT03211858 (18) [back to overview]	Percentage of Participants With Treatment-Induced, Treatment-Boosted and Treatment-Emergent Anti-insulin Aspart Antibodies (AIAs): Subgroup Analysis by Prior Use of NovoLog/NovoRapid or Humalog/Liprolog
NCT03211858 (18) [back to overview]	Percentage of Participants With HbA1c <7% at Week 26 and Week 52
NCT03211858 (18) [back to overview]	Percentage of Participants With at Least One Positive Anti-Insulin Aspart Antibodies (AIA) Sample
NCT03214367 (12) [back to overview]	Rate of Documented Symptomatic Hypoglycemia at Week 26
NCT03214367 (12) [back to overview]	Percentage of Participants With HbA1c <7%
NCT03214367 (12) [back to overview]	Change From Baseline in ITSQ Lifestyle Flexibility Domain Score at Week 26
NCT03214367 (12) [back to overview]	Change From Baseline in Insulin Treatment Satisfaction Questionnaire (ITSQ) Regimen Inconvenience Domain Score at Week 26
NCT03214367 (12) [back to overview]	Change From Baseline in Hemoglobin A1c (HbA1c) Efficacy Estimand at Week 26
NCT03214367 (12) [back to overview]	Change From Baseline in HbA1c at Week 52
NCT03214367 (12) [back to overview]	Change From Baseline in 2-hour PPG Excursion During MMTT Efficacy Estimand at Week 26
NCT03214367 (12) [back to overview]	Change From Baseline in 1,5-Anhydroglucitol (1,5-AG) at Week 26
NCT03214367 (12) [back to overview]	Change From Baseline in 1-hour Postprandial Glucose (PPG) Excursion During Mixed-Meal Tolerance Test (MMTT) Efficacy Estimand at Week 26
NCT03214367 (12) [back to overview]	Rate of Severe Hypoglycemia at Week 26
NCT03214367 (12) [back to overview]	Change From Baseline in Insulin Dose at Week 26
NCT03214367 (12) [back to overview]	Change From Baseline in 10-Point Self-Monitoring Blood Glucose (SMBG) Values at Week 26
NCT03214380 (11) [back to overview]	Change From Baseline in 10-Point Self-Monitoring Blood Glucose (SMBG) Values at Week 26
NCT03214380 (11) [back to overview]	Change From Baseline in Insulin Dose at Week 26
NCT03214380 (11) [back to overview]	2-hour PPG Excursion During MMTT Efficacy Estimand
NCT03214380 (11) [back to overview]	Change From Baseline in 1,5-Anhydroglucitol (1,5-AG) at Week 26
NCT03214380 (11) [back to overview]	Change From Baseline in Hemoglobin A1c (HbA1c) Efficacy Estimand at Week 26
NCT03214380 (11) [back to overview]	Change From Baseline in Insulin Treatment Satisfaction Questionnaire (ITSQ) Regimen Inconvenience Domain Score at Week 26
NCT03214380 (11) [back to overview]	Rate of Severe Hypoglycemia
NCT03214380 (11) [back to overview]	Rate of Documented Symptomatic Hypoglycemia
NCT03214380 (11) [back to overview]	Number of Participants With HbA1c <7%
NCT03214380 (11) [back to overview]	Change From Baseline in ITSQ Lifestyle Flexibility Domain Score at Week 26
NCT03214380 (11) [back to overview]	1-hour Postprandial Glucose (PPG) Excursion During Mixed-Meal Tolerance Test (MMTT) Efficacy Estimand
NCT03260868 (4) [back to overview]	Number of Participants With At Least One Hypoglycemic Events (Any, Severe Documented Symptomatic, Probable Symptomatic, Asymptomatic, Pseudo-hypoglycemia: Any Time of the Day) During 24 Week Treatment Period
NCT03260868 (4) [back to overview]	Change From Baseline in Glycated Hemoglobin A1c (HbA1c) to Week 24
NCT03260868 (4) [back to overview]	Change From Baseline in Glycated Hemoglobin A1c to Week 16
NCT03260868 (4) [back to overview]	Change From Baseline in Fasting Plasma Glucose (FPG) to Week 16 and Week 24
NCT03285594 (9) [back to overview]	Change From Baseline in Body Weight at Week 18
NCT03285594 (9) [back to overview]	Percentage of Participants With Adverse Events (AEs)
NCT03285594 (9) [back to overview]	Change From Baseline in Body Weight at Week 52
NCT03285594 (9) [back to overview]	Change From Baseline in Fasting Plasma Glucose (FPG) at Week 18
NCT03285594 (9) [back to overview]	Change From Baseline in HbA1c at Week 52
NCT03285594 (9) [back to overview]	Change From Baseline in Hemoglobin A1c (HbA1c) at Week 18
NCT03285594 (9) [back to overview]	Change From Baseline in SBP at Week 12 for All Participants
NCT03285594 (9) [back to overview]	Change From Baseline in Systolic Blood Pressure (SBP) for Participants With Baseline SBP ≥130 mmHg at Week 12
NCT03285594 (9) [back to overview]	Percentage of Participants With Hypoglycemic Events
NCT03336528 (17) [back to overview]	Number of Participants With an Episode of Severe Hypoglycemia While Hospitalized
NCT03336528 (17) [back to overview]	Daily Dose of Insulin in Hospitalized Patients
NCT03336528 (17) [back to overview]	Hemoglobin A1c (HbA1c) in Discharged Patients
NCT03336528 (17) [back to overview]	Mean Daily Blood Glucose Concentration in Hospitalized Patients
NCT03336528 (17) [back to overview]	Mean Daily Blood Glucose Concentration in Discharged Patients.
NCT03336528 (17) [back to overview]	Length of Hospital Stay
NCT03336528 (17) [back to overview]	Number of Blood Glucose Point-of-care Test Results Between 70 and 180 mg/dL in Hospitalized Patients
NCT03336528 (17) [back to overview]	Number of Clinically Significant Hypoglycemia Episodes in Discharged Patients
NCT03336528 (17) [back to overview]	Number of Episodes of Severe Hyperglycemia in Discharged Patients
NCT03336528 (17) [back to overview]	Number of Hypoglycemia Episodes in Discharged Patients
NCT03336528 (17) [back to overview]	Number of Participants Experiencing Acute Kidney Injury in Discharged Patients
NCT03336528 (17) [back to overview]	Number of Participants Experiencing Cardiac Complications During Hospitalization
NCT03336528 (17) [back to overview]	Number of Participants Who Died During Hospitalization
NCT03336528 (17) [back to overview]	Number of Participants With Acute Kidney Injury During Hospitalization
NCT03336528 (17) [back to overview]	Number of Participants With an Episode of Clinically Significant Hypoglycemia While Hospitalized
NCT03336528 (17) [back to overview]	Number of Participants With an Episode of Hypoglycemia While Hospitalized
NCT03336528 (17) [back to overview]	Number of Participants With an Episode of Severe Hyperglycemia While Hospitalized
NCT03338010 (12) [back to overview]	Rate of Total Symptomatic and Nocturnal Hypoglycemia Events (Adjusted by 1 Year)
NCT03338010 (12) [back to overview]	Insulin Treatment Satisfaction Questionnaire (ITSQ)
NCT03338010 (12) [back to overview]	Change From Baseline in Glycemic Variability of Fasting Blood Glucose
NCT03338010 (12) [back to overview]	Change From Baseline in 7-Point Self-Monitored Blood Glucose (SMBG) Values
NCT03338010 (12) [back to overview]	Basal Insulin Dose Units Per Day
NCT03338010 (12) [back to overview]	Change From Baseline in Basal Insulin Dose Units Per Day
NCT03338010 (12) [back to overview]	Change From Baseline in Body Weight
NCT03338010 (12) [back to overview]	Change From Baseline in HbA1c (Lantus® to LY2963016)
NCT03338010 (12) [back to overview]	Change From Baseline in Hemoglobin A1c (HbA1c) (LY2963016 to Lantus®)
NCT03338010 (12) [back to overview]	Number of Participants With Detectable Anti-Glargine Antibodies
NCT03338010 (12) [back to overview]	Percentage of Participants With HbA1c <7% at Week 24
NCT03338010 (12) [back to overview]	Percentage of Participants With HbA1c ≤6.5% at Week 24
NCT03350984 (3) [back to overview]	Differences in the Mean Daily Blood Glucose Between a Basal-bolus Scheme and NPH Schemes of Insulin.
NCT03350984 (3) [back to overview]	Number of Participants With Sustained Glycemic Control During Hospital Stay
NCT03350984 (3) [back to overview]	the Number of Participants With Mild and Severe Hypoglycemic Events
NCT03371108 (9) [back to overview]	Immunogenicity - Percentage of Subjects With Confirmed Positive AIA After Baseline
NCT03371108 (9) [back to overview]	Treatment-induced Anti-Insulin Antibody (TI-AIA) is the Primary Endpoint
NCT03371108 (9) [back to overview]	CFB in HbA1c to Week 26
NCT03371108 (9) [back to overview]	Immunogenicity - Mean Change From Baseline in Each Treatment Group in AIA Titers After Baseline
NCT03371108 (9) [back to overview]	Immunogenicity - Percentage of Subjects in Each Treatment Group With Confirmed Positive AIA at Baseline Who Developed at Least a 4-fold Increase in Titers After Baseline
NCT03371108 (9) [back to overview]	Immunogenicity - Percentage of Subjects in Each Treatment Group With Negative AIA at Baseline Who Develop Confirmed Positive AIA After Baseline
NCT03371108 (9) [back to overview]	Immunogenicity - Percentage of Subjects With Confirmed Positive AIA After Baseline Who Develop Any Anti-insulin Neutralizing Antibodies After Baseline
NCT03371108 (9) [back to overview]	Efficacy - HbA1c Control
NCT03371108 (9) [back to overview]	Efficacy - Postbaseline FBG Control
NCT03434119 (5) [back to overview]	Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 26
NCT03434119 (5) [back to overview]	Percentage of Participants Achieving HbA1c Target of <7% at Week 26
NCT03434119 (5) [back to overview]	Percentage of Participants With Hypoglycemic Events (Any Hypoglycemia, Severe Hypoglycemia, Documented Hypoglycemia) During the On-Treatment Period
NCT03434119 (5) [back to overview]	Change From Baseline in Body Weight at Week 26
NCT03434119 (5) [back to overview]	Change From Baseline in Daily Insulin Glargine Dose at Week 26
NCT03555305 (4) [back to overview]	Pharmacodynamics (PD): Total Amount of Glucose Infused (Gtot)
NCT03555305 (4) [back to overview]	PK: Area Under the Concentration Versus Time Curve From Time Zero to 24 Hours (AUC[0-24]) of Insulin Glargine and Lantus
NCT03555305 (4) [back to overview]	PD: Maximum Glucose Infusion Rate (Rmax)
NCT03555305 (4) [back to overview]	Pharmacokinetics (PK): Maximum Serum Concentration (Cmax) of Insulin Glargine and Lantus
NCT03660553 (3) [back to overview]	Hemoglobin A1c (HbA1c)
NCT03660553 (3) [back to overview]	Incidence of Any Hypoglycemia
NCT03660553 (3) [back to overview]	Incidence of Severe Hypoglycemia
NCT03668808 (11) [back to overview]	Continuous Glucose Monitoring - Time in Range (70-180 mg/dl)
NCT03668808 (11) [back to overview]	Continuous Glucose Monitoring - Time in Range (70-140 mg/dl)
NCT03668808 (11) [back to overview]	CGM Fasting Blood Glucose (FBG)
NCT03668808 (11) [back to overview]	CGM % Time 70-180 mg/dl
NCT03668808 (11) [back to overview]	CGM % Time >180 mg/dl
NCT03668808 (11) [back to overview]	CGM - Coefficient of Variation (CV)
NCT03668808 (11) [back to overview]	CGM % Time <70 mg/dl
NCT03668808 (11) [back to overview]	Liverpool Jet-Lag Questionnaire
NCT03668808 (11) [back to overview]	Sleep Quantity Measured by ActiGraph
NCT03668808 (11) [back to overview]	Sleep Efficiency Measured by ActiGraph
NCT03668808 (11) [back to overview]	Mean ± SD CGM Glucose (mg/dl)
NCT03670641 (6) [back to overview]	Number of Participants With A1C of <6.5% After CGM-guided Insulin Therapy Intervention
NCT03670641 (6) [back to overview]	Percent Time Glucose Values Remain in Range While Wearing CGM During Insulin Intervention
NCT03670641 (6) [back to overview]	Number of Patients With Glucose Values <55 mg/dL During 4 Week of Insulin and CGM Intervention
NCT03670641 (6) [back to overview]	Number of Participants Achieving Euglycemic Glucose Targets Within a 4 Week Period
NCT03670641 (6) [back to overview]	See if Diabetes Distress is Affected With Intervention Via Problem Areas In Diabetes (PAID) - 5 Questionnaire Scale
NCT03670641 (6) [back to overview]	Change in Baseline A1C and A1C Measured at 3 Month Intervals up to 12 Months
NCT03687827 (6) [back to overview]	Level of Glycated Haemoglobin (HbA1c) - Percentage
NCT03687827 (6) [back to overview]	Level of Glycated Haemoglobin (HbA1c) - mmol/Mol
NCT03687827 (6) [back to overview]	Time Spent in Tight Glycaemic Target Range 70-140 mg/dL (3.9-7.8 mmol/L) Both Inclusive, Using Flash Glucose Monitoring
NCT03687827 (6) [back to overview]	Time Spent in Nocturnal Glycaemic Target Range 70-140 mg/dL (3.9-7.8 mmol/L) Both Inclusive, in the Nocturnal Period (00:01 am - 05:59 am Both Inclusive) Using Flash Glucose Monitoring
NCT03687827 (6) [back to overview]	Percentage of Time Spent in Glycaemic Target Range 70-180 mg/dL (3.9-10.0 mmol/L) Both Inclusive, Using Flash Glucose Monitoring (FGM)
NCT03687827 (6) [back to overview]	Mean Glucose Levels Using Flash Glucose Monitoring (FGM)
NCT03689374 (25) [back to overview]	Change From Baseline to Week 52 in Body Weight (Kilogram (kg))
NCT03689374 (25) [back to overview]	Change From Baseline to Week 52 in Body Weight (Percentage): Ratio to Baseline
NCT03689374 (25) [back to overview]	Change From Baseline to Week 52 in Fasting Blood Lipids: High-density Lipoprotein (HDL) Cholesterol (Ratio to Baseline)
NCT03689374 (25) [back to overview]	Change From Baseline to Week 52 in Fasting Blood Lipids: Low-density Lipoprotein (LDL) Cholesterol (Ratio to Baseline)
NCT03689374 (25) [back to overview]	Change From Baseline to Week 52 in Fasting Blood Lipids: Total Cholesterol (Ratio to Baseline)
NCT03689374 (25) [back to overview]	Number of Event Adjudication Committee-confirmed Severe (ADA) or Clinically Significant Hypoglycaemic Episodes (Plasma Glucose < 3.0 mmol/L (54 mg/dL)) From Randomization to Week 52
NCT03689374 (25) [back to overview]	Total Daily Insulin Dose at Week 52
NCT03689374 (25) [back to overview]	Number of Event Adjudication Committee-confirmed Severe Hypoglycaemic Episodes (ADA) From Randomization to Week 52
NCT03689374 (25) [back to overview]	Number of Event Adjudication Committee-confirmed Severe Hypoglycaemic Episodes (ADA) Requiring Hospitalization, Documented Medical Help, or is Life-threatening From Randomization to Week 52
NCT03689374 (25) [back to overview]	Time to First Event Adjudication Committee-confirmed Severe Hypoglycaemic Episode (ADA) Requiring Hospitalization, Documented Medical Help, or is Life-threatening Randomization up to Week 52
NCT03689374 (25) [back to overview]	Change From Baseline to Week 52 in Diabetes Quality of Life Clinical Trial Questionnaire (DQLCTQ-R): Scores From the 8 Domains
NCT03689374 (25) [back to overview]	Change From Baseline to Week 52 in 36-item Short Form Health Survey Version 2 (SF-36v2): Total Summary Scores (Physical Component and Mental Component) and Scores From the 8 Domains
NCT03689374 (25) [back to overview]	Change From Baseline to Week 52 in Waist Circumference
NCT03689374 (25) [back to overview]	Daily Basal Insulin Dose at Week 52
NCT03689374 (25) [back to overview]	Number of Event Adjudication Committee-confirmed Severe (ADA) or Blood Glucose (BG) Confirmed, Symptomatic Hypoglycaemic Episodes (Plasma Glucose Less Than (<) 3.1 mmol/L (56 mg/dL)) From Randomization to Week 52
NCT03689374 (25) [back to overview]	Number of Event Adjudication Committee-confirmed Severe (ADA) or Blood Glucose Confirmed, Symptomatic Hypoglycaemic Episodes (Plasma Glucose <= 3.9 mmol/L (70 mg/dL)) From Randomization to Week 52
NCT03689374 (25) [back to overview]	Change From Baseline to Week 52 in Systolic and Diastolic Blood Pressure
NCT03689374 (25) [back to overview]	Time to First Event Adjudication Committee (EAC)-Confirmed Severe Hypoglycaemic Episode American Diabetes Association (ADA) From Randomization up to Week 52
NCT03689374 (25) [back to overview]	Change From Baseline to Week 52 in Fasting Plasma Glucose (FPG)
NCT03689374 (25) [back to overview]	Change From Baseline to Week 52 in Fasting Blood Lipids: Triglycerides (Ratio to Baseline)
NCT03689374 (25) [back to overview]	Change From Baseline in Glycated Haemoglobin (HbA1c)
NCT03689374 (25) [back to overview]	Change From Baseline to Week 52 in 7-point Self-measured Plasma Glucose Profile (SMPG ): Mean 7-point Profile (7-PP)
NCT03689374 (25) [back to overview]	Change From Baseline to Week 52 in 7-point Self-measured Plasma Glucose Profile: Mean Post-prandial Increment (Over All Meals)
NCT03689374 (25) [back to overview]	Change From Baseline to Week 52 in Body Mass Index (BMI)
NCT03689374 (25) [back to overview]	Change From Baseline to Week 52 in Pulse Rate
NCT03730662 (8) [back to overview]	Rate of Hypoglycemia With Blood Glucose <54 Milligram/Deciliter (mg/dL) [<3.0 (Millimole/Liter (mmol/L))] or Severe Hypoglycemia
NCT03730662 (8) [back to overview]	Pharmacokinetics (PK): Steady State Area Under the Concentration Time Curve From Zero to Tau (AUC 0-Tau) of Tirzepatide
NCT03730662 (8) [back to overview]	Percentage of Participants With HbA1c of <7.0%
NCT03730662 (8) [back to overview]	Mean Change From Baseline in Daily Average 7-Point Self-Monitored Blood Glucose (SMBG) Values
NCT03730662 (8) [back to overview]	Change From Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg)
NCT03730662 (8) [back to overview]	Change From Baseline in HbA1c (5 mg)
NCT03730662 (8) [back to overview]	Change From Baseline in Body Weight
NCT03730662 (8) [back to overview]	Change From Baseline in Fasting Serum Glucose
NCT03740919 (10) [back to overview]	Rate of Documented Post-dose Hypoglycemic Events Within 1 and 2 Hours After the Prandial Dose
NCT03740919 (10) [back to overview]	Rate of Severe Hypoglycemia
NCT03740919 (10) [back to overview]	Percentage of Participants With Documented Hypoglycemic Events
NCT03740919 (10) [back to overview]	Percentage of Participants With Documented Post-dose Hypoglycemic Events Within 1 and 2 Hours After the Prandial Dose
NCT03740919 (10) [back to overview]	Change From Baseline in 7-Point Self-Monitored Blood Glucose (SMBG) Values at Week 26
NCT03740919 (10) [back to overview]	Change From Baseline in Hemoglobin A1c (HbA1c) Efficacy Estimand at Week 26
NCT03740919 (10) [back to overview]	Percentage of Participants With HbA1c < 7.0% and <7.5%
NCT03740919 (10) [back to overview]	Rate of Documented Hypoglycemia Events
NCT03740919 (10) [back to overview]	Change From Baseline in Insulin Dose at Week 26
NCT03740919 (10) [back to overview]	Change From Baseline in HbA1c (Postprandial) at Week 26
NCT03751657 (15) [back to overview]	Fasting C-peptide
NCT03751657 (15) [back to overview]	Fluctuations of the 9-point Profile (Defined as the Integrated Absolute Distance From the Mean Profile Value Divided by Measurement Time).
NCT03751657 (15) [back to overview]	Change in Cross-reactive Anti-human Insulin Antibody Status (Positive/Negative)
NCT03751657 (15) [back to overview]	9-point Profile (Individual SMPG Values)
NCT03751657 (15) [back to overview]	Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (<3.0 mmol/L (54 mg/dL), Confirmed by BG Meter) or Severe Hypoglycaemic Episodes (Level 3)
NCT03751657 (15) [back to overview]	Number of Hypoglycaemic Alert Episodes (Level 1) (≥3.0 and <3.9 mmol/L (≥54 and <70 mg/dL), Confirmed by BG Meter)
NCT03751657 (15) [back to overview]	Number of Severe Hypoglycaemic Episodes (Level 3)
NCT03751657 (15) [back to overview]	Change in Fasting Plasma Glucose
NCT03751657 (15) [back to overview]	Change in Glycated Haemoglobin (HbA1c) [Percentage Point (%-Point)]
NCT03751657 (15) [back to overview]	Number of Treatment Emergent Adverse Events (TEAEs)
NCT03751657 (15) [back to overview]	Change in HbA1c [Millimoles/Mole (mmol/Mol)]
NCT03751657 (15) [back to overview]	Change in Body Weight
NCT03751657 (15) [back to overview]	Change in Anti-insulin 287 Antibody Titres
NCT03751657 (15) [back to overview]	Weekly Dose of Insulin 287 and Weekly Dose of Insulin Glargine
NCT03751657 (15) [back to overview]	Change in Mean of the 9-point Profile, Defined as the Area Under the Profile Divided by Measurement Time
NCT03874715 (8) [back to overview]	Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)
NCT03874715 (8) [back to overview]	Number of Participants With at Least One Hypoglycemic Event
NCT03874715 (8) [back to overview]	Number of Hypoglycemic Events Per Participant-year
NCT03874715 (8) [back to overview]	Pharmacokinetics: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Insulin Aspart Following Administration of Either SAR341402 (Switching Arm) or NovoLog (Non-switching Arm)
NCT03874715 (8) [back to overview]	Pharmacokinetics: Maximum Observed Plasma Concentration (Cmax) of Insulin Aspart Following Administration of Either SAR341402 (Switching Arm) or NovoLog (Non-switching Arm)
NCT03874715 (8) [back to overview]	Pharmacokinetics (PK): Area Under the Plasma Concentration Versus Time Curve From Time Zero to Last Measurable Timepoint (AUClast) of Insulin Aspart Following Administration of Either SAR341402 (Switching Arm) or NovoLog (Non-switching Arm)
NCT03874715 (8) [back to overview]	Number of Participants With Treatment-emergent Anti-Insulin Aspart Antibodies (AIAs)
NCT03874715 (8) [back to overview]	Pharmacokinetics: Area Under the Plasma Concentration Versus Time Curve (AUC) of Insulin Aspart Following Administration of Either SAR341402 (Switching Arm) or NovoLog (Non-switching Arm)
NCT03922750 (9) [back to overview]	Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (Below 3.0 mmol/L (54 mg/dL), Confirmed by BG Meter) or Severe Hypoglycaemic Episodes (Level 3)
NCT03922750 (9) [back to overview]	Number of Hypoglycaemic Alert Episodes(Level 1) (Greater Than or Equal to 3.0 and Below 3.9 mmol/L (Greater Than or Equal to 54 and Below 70 mg/dL), Confirmed by BG Meter)
NCT03922750 (9) [back to overview]	Change in Body Weight
NCT03922750 (9) [back to overview]	Number of Treatment-emergent Adverse Events (TEAEs)
NCT03922750 (9) [back to overview]	Number of Severe Hypoglycaemic Episodes (Level 3)
NCT03922750 (9) [back to overview]	Percentage of Time in Target Range 3.9-10.0 mmol/L (70-180 Milligrams Per Deciliter (mg/dL)) Measured Using CGM (Continuous Glucose Monitoring)
NCT03922750 (9) [back to overview]	Weekly Insulin Dose
NCT03922750 (9) [back to overview]	Change in Fasting Plasma Glucose (FPG)
NCT03922750 (9) [back to overview]	Change in Glycosylated Haemoglobin (HbA1c)
NCT03951805 (9) [back to overview]	Percentage of Time in Target Range (TIR) 3.9-10.0 Millimoles Per Liter (mmol/L) (70-180 Milligrams Per Deciliter (mg/dL) Measured Using CGM (Continuous Glucose Monitoring)
NCT03951805 (9) [back to overview]	Number of Treatment Emergent Adverse Events (TEAEs)
NCT03951805 (9) [back to overview]	Number of Severe Hypoglycaemic Episodes (Level 3)
NCT03951805 (9) [back to overview]	Number of Hypoglycaemic Alert Episodes (Level 1) (Greater Than or Equal to 3.0 and Below 3.9 mmol/L (Greater Than or Equal to 54 and Below 70 mg/dL), Confirmed by Blood Glucose (BG) Meter)
NCT03951805 (9) [back to overview]	Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (Below 3.0 mmol/L (54 Milligrams Per Deciliter [mg/dL]), Confirmed by Blood Glucose (BG) Meter) or Severe Hypoglycaemic Episodes (Level 3)
NCT03951805 (9) [back to overview]	Change in HbA1c (Glycated Haemoglobin)
NCT03951805 (9) [back to overview]	Change in Fasting Plasma Glucose (FPG)
NCT03951805 (9) [back to overview]	Weekly Insulin Dose
NCT03951805 (9) [back to overview]	Change in Body Weight
NCT03952130 (9) [back to overview]	Change From Baseline in Hemoglobin A1c (HbA1c)
NCT03952130 (9) [back to overview]	2-hour PPG Excursion During MMTT
NCT03952130 (9) [back to overview]	1-hour Postprandial Glucose (PPG) Excursion During Mixed-Meal Tolerance Test (MMTT)
NCT03952130 (9) [back to overview]	Change From Baseline in 10-Point Self-Monitoring Blood Glucose (SMBG) Values
NCT03952130 (9) [back to overview]	Change From Baseline in 1,5-Anhydroglucitol (1,5-AG)
NCT03952130 (9) [back to overview]	Change From Baseline in Daily Insulin Dose
NCT03952130 (9) [back to overview]	Percentage of Participants With HbA1c <7% and ≤6.5%
NCT03952130 (9) [back to overview]	Rate of Severe Hypoglycemia
NCT03952130 (9) [back to overview]	Rate of Documented Symptomatic Post Meal Hypoglycemia
NCT03952143 (9) [back to overview]	1-hour Postprandial Glucose (PPG) Excursion During Mixed-Meal Tolerance Test (MMTT)
NCT03952143 (9) [back to overview]	2-hour PPG Excursion During MMTT
NCT03952143 (9) [back to overview]	Change From Baseline in 1,5-Anhydroglucitol (1,5-AG)
NCT03952143 (9) [back to overview]	Change From Baseline in Hemoglobin A1c (HbA1c)
NCT03952143 (9) [back to overview]	Rate of Severe Hypoglycemia
NCT03952143 (9) [back to overview]	Change From Baseline in 10-Point Self-Monitoring Blood Glucose (SMBG) Values
NCT03952143 (9) [back to overview]	Change From Baseline in Insulin Dose
NCT03952143 (9) [back to overview]	Percentage of Participants With HbA1c <7% and ≤6.5%
NCT03952143 (9) [back to overview]	Rate of Documented Symptomatic Postmeal Hypoglycemia
NCT04075513 (12) [back to overview]	Glucose Total Coefficient of Variation (CV%)
NCT04075513 (12) [back to overview]	Change From Baseline in Fasting Plasma Glucose (FPG) at Week 12
NCT04075513 (12) [back to overview]	Change From Baseline in Glycated Hemoglobin A1c (HbA1c) at Week 12
NCT04075513 (12) [back to overview]	Percentage of Time of Glucose Concentration Within the Target Range of Greater Than or Equal to (>=) 70 to Less Than or Equal to (<=) 180 Milligrams Per Deciliter: Non-inferiority Analysis
NCT04075513 (12) [back to overview]	Percentage of Time With Glucose Level <70 Milligrams Per Deciliter (All Time and During the Night)
NCT04075513 (12) [back to overview]	Number of Participants With at Least One Hypoglycemic Event During the On-treatment Period
NCT04075513 (12) [back to overview]	Number of Hypoglycemic Events Per Participant Year During the On-treatment Period
NCT04075513 (12) [back to overview]	Mean Hours Per Day With Glucose Level <70 Milligrams Per Deciliter (All Time and During the Night)
NCT04075513 (12) [back to overview]	Glucose Within-day CV% and Between-day CV%
NCT04075513 (12) [back to overview]	Percentage of Time With Glucose Level >180 Milligrams Per Deciliter
NCT04075513 (12) [back to overview]	Percentage of Time of Glucose Concentration Within the Target Range of >=70 to <=180 Milligrams Per Deciliter: Superiority Analysis
NCT04075513 (12) [back to overview]	Mean Hours Per Day With Glucose Level >180 Milligrams Per Deciliter
NCT04093752 (10) [back to overview]	Percentage of Participants Who Achieved Weight Loss ≥5%
NCT04093752 (10) [back to overview]	Percentage of Participants Achieving an HbA1c Target Value of <7.0%
NCT04093752 (10) [back to overview]	Mean Change From Baseline in HbA1c (5 mg)
NCT04093752 (10) [back to overview]	Mean Change From Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg)
NCT04093752 (10) [back to overview]	Mean Change in Daily Glucose Average From Baseline in 7-Point Self-Monitored Blood Glucose (SMBG) Values
NCT04093752 (10) [back to overview]	Diabetes Treatment Satisfaction as Measured by the Diabetes Treatment Satisfaction Questionnaire, Change Version (DTSQc) Hyperglycemia, Hypoglycemia and Treatment Satisfaction Score
NCT04093752 (10) [back to overview]	Percentage of Participants Achieving an HbA1c Target Value of <5.7%
NCT04093752 (10) [back to overview]	Rate of Hypoglycemia With Blood Glucose < 54 mg/dL or Severe Hypoglycemia
NCT04093752 (10) [back to overview]	Mean Change From Baseline in Fasting Serum Glucose
NCT04093752 (10) [back to overview]	Mean Change From Baseline in Body Weight
NCT04591626 (9) [back to overview]	Change From Baseline in Hemoglobin A1c (HbA1c)
NCT04591626 (9) [back to overview]	Percentage of Participants Achieving HbA1c <7.0%
NCT04591626 (9) [back to overview]	Percentage of Participants Achieving HbA1c <7.0% With no Weight Gain (<0.1 kg) and Without Documented Symptomatic Hypoglycemia (Blood Glucose <3.0 mmol/L)
NCT04591626 (9) [back to overview]	Percentage of Participants Achieving HbA1c <7.0% Without Weight Gain (<0.1 kg)
NCT04591626 (9) [back to overview]	Percentage of Participants Achieving HbA1c <7.0% Without Documented Symptomatic Hypoglycemia (Blood Glucose <3.0 mmol/L)
NCT04591626 (9) [back to overview]	Change From Baseline in Fasting Serum Glucose (FSG)
NCT04591626 (9) [back to overview]	Change From Baseline in Blood Glucose From Daily Self-Monitored Blood Glucose (SMBG) Profile
NCT04591626 (9) [back to overview]	Change From Baseline in Body Weight
NCT04591626 (9) [back to overview]	Change From Baseline in Daily Mean Insulin Glargine Doses
NCT04605991 (12) [back to overview]	Change From Baseline in Insulin Treatment Satisfaction Questionnaire (ITSQ) - Glycemic Control Domain Score at Week 12
NCT04605991 (12) [back to overview]	Change From Baseline in Daily Insulin Dose at Week 12
NCT04605991 (12) [back to overview]	Change From Baseline in Bolus/Total Insulin Dose Percentage at Week 12
NCT04605991 (12) [back to overview]	Change From Baseline in Percentage of Time With CGM Sensor Glucose Value >250 mg/dL (>13.9 mmol/L) During Daytime and 24-hour Period at Week 12
NCT04605991 (12) [back to overview]	Percentage of Participants With HbA1c <7% and ≤6.5%
NCT04605991 (12) [back to overview]	Change From Baseline in Hemoglobin A1c (HbA1c) at Week 12
NCT04605991 (12) [back to overview]	Change From Baseline in Percentage of Time With CGM Sensor Glucose Values Between 70-180 mg/dL (3.9-10.0 mmol/L) (Both Inclusive) During the 24-hour Period at Week 12
NCT04605991 (12) [back to overview]	Change From Baseline in Percentage of Time With Continuous Glucose Monitoring (CGM) Sensor Glucose Values Between 70-180 Milligrams/Deciliter (mg/dL) (3.9-10.0 Millimoles/Liter [mmol/L]) (Both Inclusive) During Daytime Period at Week 12
NCT04605991 (12) [back to overview]	Change From Baseline in Percentage of Time With CGM Sensor Glucose Values <54 mg/dL (<3.0 mmol/L) During Daytime and 24-hour Periods at Week 12
NCT04605991 (12) [back to overview]	Change From Baseline in Percentage of Time With CGM Sensor Glucose Values >180 mg/dL (>10.0 mmol/L) During Daytime and 24-hour Period at Week 12
NCT04605991 (12) [back to overview]	Change From Baseline in Postprandial Incremental Area Under the Glucose Curve (iAUC) 0-1 Hour at Week 12
NCT04605991 (12) [back to overview]	Change From Baseline in Postprandial Incremental Area Under the Glucose Curve (iAUC) 0-2 Hour at Week 12
NCT04834362 (4) [back to overview]	Length of Hospital Stay
NCT04834362 (4) [back to overview]	Mortality
NCT04834362 (4) [back to overview]	Total Daily Dose of Insulin
NCT04834362 (4) [back to overview]	Glycemic Control

First Occurrence of MCE or Revascularization or Hospitalization for Congestive Heart Failure (CHF) in Lipid Trial.

Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, cardiovascular death, revascularization procedure or hospitalization for CHF in Lipid Trial participants. (NCT00000620)
Timeframe: 4.7 years

Intervention	participants (Number)
Lipid Trial: Fenofibrate	641
Lipid Trial: Placebo	667

Intervention	participants (Number)
Glycemia Trial: Intensive Control	503
Glycemia Trial: Standard Control	543

Intervention	participants (Number)
	Participants with a composite endpoint	Endpoint's composition: vitrectomy	Endpoint's composition: laser therapy for DR	Endpoint's composition: dialysis	Endpoint's composition: renal transplant	Endpoint's composition: serum creatinine doubled	Endpoint's composition: death due to renal failure	Endpoint's composition: albuminuria progression
Insulin Glargine	1323	24	57	18	0	82	4	1153
Standard Care	1363	25	67	28	0	88	3	1171

Intervention	participants (Number)
	Participants with a composite endpoint	Endpoint's composition: CV death	Endpoint's composition: nonfatal MI	Endpoint's composition: nonfatal stroke
Insulin Glargine	1041	484	297	261
Standard Care	1013	476	282	256

Intervention	participants (Number)
	Patients with hypoglycemia events	Patients with non-severe hypoglycemia	Patients with confirmed non-severe hypoglycemia	Patients with severe hypoglycemia
Insulin Glargine	3597	3533	2581	352
Standard Care	1624	1582	904	113

Intervention	events per 30 days per patient (Least Squares Mean)
	Baseline event rate	Change in event rate at week 26
Exenatide Arm	0.09	0.23
Insulin Glargine Arm	0.11	0.29

Intervention	percentage (Least Squares Mean)
	Baseline HbA1c	Change in HbA1c at week 26
Exenatide Arm	8.13	-1.00
Insulin Glargine Arm	8.19	-1.05

Intervention	mmol/L (Least Squares Mean)
	Baseline fasting serum glucose	Change in fasting serum glucose at week 26
Exenatide Arm	10.27	-1.22
Insulin Glargine Arm	10.46	-2.86

Intervention	kg (Least Squares Mean)
	Baseline body weight	Change in body weight at week 26
Exenatide Arm	88.42	-2.32
Insulin Glargine Arm	89.25	1.75

Intervention	mmol/L (Least Squares Mean)
	Pre-breakfast: Baseline SMBG	Pre-breakfast: Change in SMBG at week 26	2hr post breatfast: Baseline SMBG	2hr post breakfast: Change in SMBG at week 26	Pre-lunch: Baseline SMBG	Pre-lunch: Change in SMBG at week 26	2hr post lunch: Baseline SMBG	2hr post lunch: Change in SMBG at week 26	Pre-dinner: Baseline SMBG	Pre-dinner: Change in SMBG at week 26	2hr post dinner: Baseline SMBG	2hr post dinner: Change in SMBG at week 26	3:00 AM: Baseline SMBG	3:00 AM: Change in SMBG at week 26
Exenatide Arm	9.47	-1.25	12.51	-3.77	9.61	-1.50	11.15	-1.68	9.46	-1.15	11.17	-3.06	9.02	-1.05
Insulin Glargine Arm	9.50	-2.56	12.36	-2.86	9.47	-1.93	10.96	-1.69	9.35	-1.72	11.49	-1.65	9.36	-1.97

Intervention	ratio (Least Squares Mean)
	52 weeks	56 weeks
Exenatide Arm	2.88	1.00
Insulin Glargine Arm	1.01	1.08

Intervention	mg/min/kg (Mean)
	baseline (week -2)	week 52	week 56
Exenatide Arm	2.24	3.18	3.19
Insulin Glargine Arm	2.79	3.85	2.81

Intervention	mmol/L (Mean)
	Pre-breakfast measurement (week 0)	Pre-breakfast measurement (week 52)	2-hour post-breakfast measurement (week 0)	2-hour post-breakfast measurement (week 52)	Pre-lunch measurement (week 0)	Pre-lunch measurement (week 52)	2-hour post-lunch measurement (week 0)	2-hour post-lunch measurement (week 52)	Pre-dinner measurement (week 0)	Pre-dinner measurement (week 52)	2-hour post-dinner measurement (week 0)	2-hour post-dinner measurement (week 52)	Bedtime measurement (week 0)	Bedtime measurement (week 52)
Exenatide Arm	8.92	7.27	11.00	6.98	8.14	6.52	9.90	7.97	8.38	7.53	10.42	6.98	9.76	7.61
Insulin Glargine Arm	8.38	5.63	11.17	7.53	8.54	6.24	10.52	8.15	8.07	6.98	10.26	8.81	9.85	8.03

Intervention	mg*hr/dL (Least Squares Mean)
Colesevelam 3.8g	-49.1
Colesevelam Matching Placebo	-4.7
Open-label Insulin Glargine	-59.3

Intervention	percent (Least Squares Mean)
Colesevelam 3.8g	-0.29
Colesevelam Matching Placebo	0.16
Open-label Insulin Glargine	-0.81

Intervention	mg/kg/min (Least Squares Mean)
Colesevelam 3.8g	-0.06
Colesevelam Matching Placebo	-0.011
Open-label Insulin Glargine	-0.01

Intervention	mg/kg/min (Least Squares Mean)
Colesevelam 3.8g	-0.08
Colesevelam Matching Placebo	-0.16
Open-label Insulin Glargine	-0.04

Intervention	participants (Number)
	Fatal MI	Fatal Stroke	CV Death other than Stroke/MI	Non-CV Death	Unknown
Fasting	12	2	28	8	1
Postprandial	12	3	29	7	0

Intervention	kilograms (Mean)
	Baseline (n=170,173,198,200)	Week 6 (n=162,163,184,193)	Week 12 (n=151,158,174,187)	Week 24 (n=145,151,164,176)	Endpoint (n=164,170,192,198)
Basal Bolus Prior Glargine Addendum	89.25	89.66	89.62	89.80	90.09
Basal Bolus Prior Lispro LM Addendum	91.85	91.53	91.59	91.92	92.40
Lispro Low Mix Prior Glargine Addendum	90.09	89.85	91.19	91.22	91.45
Lispro Mid Mix Prior Lispro Low Mix Addendum	93.63	93.71	94.60	94.18	94.09

Intervention	ug/mL (Mean)
	Baseline (n=166,172,197,199)	Endpoint (n=142,150,165,171)	Change (n=142,150,165,171)
Basal Bolus Prior Glargine Addendum	7.31	8.43	0.90
Basal Bolus Prior Lispro LM Addendum	7.84	8.18	0.26
Lispro Low Mix Prior Glargine Addendum	7.37	8.14	0.53
Lispro Mid Mix Prior Lispro Low Mix Addendum	7.77	7.73	-0.18

Intervention	percent (Mean)
	Baseline (n=174,200,171,199)	Endpoint (n=160,187,159,176)
Basal Bolus Prior Glargine Addendum	7.98	0.18
Basal Bolus Prior Lispro Low Mix Addendum	8.00	0.19
Lispro LM Prior Glargine Addendum	8.03	0.04
Lispro Mid Mix Prior Lispro Low Mix Addendum	8.01	0.19

insulin glargine

Description

Cross-References

Synonyms (24)

Research Excerpts

Overview

Effects

Actions

Treatment

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Research

Studies (2,081)

Market Indicators

Research Demand Index: 104.54

Study Types

Clinical Trials (511)

Trial Overview

Trial Outcomes

First Occurrence of MCE or Revascularization or Hospitalization for Congestive Heart Failure (CHF) in Lipid Trial.

Stroke in the Blood Pressure Trial.

First Occurrence of Major Cardiovascular Event (MCE) in the Lipid Trial.

First Occurrence of Major Cardiovascular Event (MCE) in the Blood Pressure Trial.

First Occurrence of a Major Cardiovascular Event (MCE); Specifically Nonfatal Heart Attack, Nonfatal Stroke, or Cardiovascular Death (Measured Throughout the Study) in the Glycemia Trial.

Death From Any Cause in the Glycemia Trial.

Incidence of Development of Type 2 Diabetes Mellitus in Participants With IGT and/or IFG

Number of Patients With First Occurrence of Any Type of Cancer

Total Mortality (All Causes)

Composite Diabetic Microvascular Outcome (Kidney or Eye Disease)

Composite of the First Occurrence of Cardiovascular (CV) Death, Nonfatal Myocardial Infarction (MI) or Nonfatal Stroke

Composite of the First Occurrence of Cardiovascular (CV) Death, Nonfatal Myocardial Infarction (MI), Nonfatal Stroke, Revascularization Procedure or Hospitalization for Heart Failure (HF)

Number of Patients With Various Types of Symptomatic Hypoglycemia Events

Change in Rate of Hypoglycemic Events

Change in Glycosylated Hemoglobin (HbA1c)

Change in Fasting Serum Glucose

Change in Body Weight

Change in 7-point Self-monitored Blood Glucose (SMBG) Profile

Percentage of Patients With Hypoglycemic Events

Percentage of Patients Achieving HbA1c <=7%

Change in Second Phase C-peptide Release

Change in First Phase C-peptide Release

M-value at Baseline, Week 52 and Week 56

Seven Point Self Monitored Blood Glucose (SMBG) Measurements

Change in Fasting Plasma Glucose

Change in Glycosylated Hemoglobin (HbA1c)

Change in Body Weight

Beta-cell Function After 52 Weeks of Therapy

Beta-cell Function 4 Weeks After Cessation of Therapy

The Acute Effect of Colesevelam (Multiple Doses) on Oral Glucose Absorption From Baseline to 12 Weeks

Acute Effect of a Single Dose of Colesevelam on Oral Glucose Absorption From Baseline to First Dose

Change in Hemoglobin A1C Due to Effect of Colesevelam From Baseline to 12 Weeks

Difference in Endogenous (Hepatic) Glucose Output During a High-dose Insulin Infusion From Baseline to After 12 Weeks of Treatment.

Difference in Endogenous (Hepatic) Glucose Output During a Low-dose Insulin Infusion From Baseline to Week 12.

Number of Participants Who Experienced Amputation for Peripheral Vascular Disease Planned After Randomization

Number of Participants With Self-Reported Hypoglycemia During Month 18

Number of Participants With Self-Reported Hypoglycemia During Month 12

Number of Participants With Self-Reported Hypoglycemia During Month 9

Number of Episodes of Self-Reported Hypoglycemia Reported by Participants With Self-Reported Hypoglycemia During Month 9

Summary of Reasons for Deaths

Number of Participants With Self-Reported Hypoglycemia During Month 6

Number of Participants With Self-Reported Hypoglycemia During Month 3

Number of Participants With Self-Reported Hypoglycemia During Month 1

Number of Participants Who Experienced Stroke

Number of Participants Who Experienced Revascularization Procedure for Peripheral Vascular Disease Planned After Randomization

Number of Participants Who Experienced Primary Outcomes Adjusted for Metabolic Control and Major Cardiovascular (CV) Risk Factors

Number of Participants Who Experienced Myocardial Infarction (MI)

Number of Participants Who Experienced Hospitalization for Acute Coronary Syndromes (HACS)

Number of Participants Who Experienced Death From Any Cause or Any One of the Primary Outcomes

Number of Participants Who Experienced Death From Any Cause

Number of Episodes of Self-Reported Hypoglycemia Reported by Participants With Self-Reported Hypoglycemia During Month 1

Number of Episodes of Self-Reported Hypoglycemia Reported by Participants With Self-Reported Hypoglycemia During Month 12

Number of Episodes of Self-Reported Hypoglycemia Reported by Participants With Self-Reported Hypoglycemia During Month 18

Number of Participants Who Experienced Cardiovascular (CV) Death

Number of Episodes of Self-Reported Hypoglycemia Reported by Participants With Self-Reported Hypoglycemia During Month 6

Number of Participants Who Experienced a Primary Combined Outcome

Number of Participants Who Experienced Coronary Revascularization Procedures

Number of Participants Who Experienced Coronary Angiography Planned After Randomization

Intervention	percent glycosylated hemoglobin (Mean)
	Baseline (n=174,200,171,199)	Week 12 (n=150,175,151,161)	Week 24 (n=145,171,144,159)	Endpoint (n=160, 187,159,176)
Basal Bolus Prior Glargine Addendum	7.98	8.19	8.14	8.14
Basal Bolus Prior Lispro Low Mix Addendum	8.00	8.13	8.19	8.16
Lispro LM Prior Glargine Addendum	8.03	8.07	8.05	8.03
Lispro Mid Mix Prior Lispro Low Mix Addendum	8.01	8.11	8.19	8.19

Intervention	kilograms (Mean)
	Baseline (n=170,173,198,200)	Week 6 change (n=161,162,183,193)	Week 12 change (n=150,158,173,187)	Week 24 change (n=144,151,163,176)	Endpoint change (n=163,169,191,198)
Basal Bolus Prior Glargine Addendum	89.25	0.32	0.27	1.03	0.86
Basal Bolus Prior Lispro LM Addendum	91.85	0.38	0.43	0.77	0.85
Lispro Low Mix Prior Glargine Addendum	90.09	0.64	0.83	1.51	1.42
Lispro Mid Mix Prior Lispro Low Mix Addendum	93.63	0.28	0.54	0.73	0.55

Intervention	units/kg/day (Mean)
	Baseline (n=171,174,199,200)	Week 1 (n=152,158,183,183)	Week 2 (n=147,159,180,187)	Week 3 (n=149,158,179,184)	Week 4 (n=145,157,178,178)	Week 5 (n=148,153,172,173)	Week 6 (n=162,168,190,196)	Week 8 (n=139,154,164,174)	Week 10 (n=141,152,158,174)	Week 12 (n=152,161,177,190)	Week 24 (n=147,151,166,179)	Endpoint (n=165,170,199,200)
Basal Bolus Prior Glargine Addendum	0.46	0.49	0.54	0.57	0.63	0.65	0.68	0.71	0.76	0.77	0.79	0.77
Basal Bolus Prior Lispro LM Addendum	0.55	0.58	0.63	0.65	0.69	0.73	0.73	0.76	0.78	0.80	0.82	0.81
Lispro Low Mix Prior Glargine Addendum	0.46	0.49	0.53	0.58	0.61	0.65	0.66	0.69	0.73	0.74	0.76	0.76
Lispro Mid Mix Prior Lispro Low Mix Addendum	0.55	0.57	0.59	0.64	0.67	0.70	0.72	0.75	0.77	0.79	0.80	0.79

Intervention	percent of participants (Number)
	<=7.0%	<7.0%	<=6.5%
Basal Bolus Prior Glargine Addendum	18.2	4.0	4.0
Basal Bolus Prior Lispro Low Mix Addendum	22.0	17.6	5.0
Lispro LM Prior Glargine Addendum	16.0	13.9	3.7
Lispro Mid Mix Prior Lispro Low Mix Addendum	12.5	8.8	4.4

Intervention	percentage of participants (Number)
	Hypoglycemia episodes endpoint	Overall hypoglycemia episodes	Severe episodes endpoint	Severe episodes overall	Nocturnal episodes endpoint	Nocturnal episodes overall
Basal Bolus Prior Glargine Addendum	34.9	47.9	0.0	0.0	19.3	27.1
Basal Bolus Prior Lispro LM Addendum	40.9	53.7	0.0	0.0	25.0	31.1
Lispro Low Mix Prior Glargine Addendum	40.9	56.1	0.0	1.0	23.7	36.9
Lispro Mid Mix Prior Lispro Low Mix Addendum	41.5	56.1	0.0	1.2	20.5	31.0

Intervention	episodes/participant/year (Mean)
	Hypoglycemia episodes Endpoint	Hypoglycemia episodes Overall	Nocturnal episodes Endpoint	Nocturnal episodes Overall	Severe episodes Endpoint	Severe episodes Overall
Basal Bolus Prior Glargine Addendum	11.18	9.04	3.01	2.15	0.00	0.00
Basal Bolus Prior Lispro Low Mix Addendum	12.11	11.39	2.37	2.09	0.00	0.00
Lispro LM Prior Glargine Addendum	10.11	10.73	2.51	3.14	0.00	0.02
Lispro Mid Mix Prior Lispro Low Mix Addendum	11.10	11.54	2.46	2.47	0.00	0.02

Intervention	milligrams per 100 Milliliters (mg/dL) (Mean)
	Baseline mean fasting blood glucose (n=986,993)	Mean fasting blood glucose (n=938,922)	Baseline AM 2-hour postprandial BG (n=977,989)	AM 2-hour postprandial blood glucose (n=932,920)	Baseline midday premeal BG (n=976,988)	Midday premeal blood glucose (BG) (n=934,919)	Baseline midday 2-hour postprandial BG (n=974,988)	Midday 2-hour postprandial BG (n=929,916)	Baseline evening pre-meal BG (n=983,993)	Evening pre-meal blood glucose (n=936,922)	Baseline evening 2hour postprandial BG (n=983,991)	Evening 2-hour postprandial BG (n=932,921)	Baseline 3 AM blood glucose (n=955,975)	3 AM blood glucose (n=912,899)	Baseline AM 2-hour BG excursion (n=975,987)	AM 2-hour blood glucose excursion (n=932,920)	Baseline midday 2-hour BG excursion (n=966,981)	Midday 2-hour blood glucose excursion (n=928,916)	Baseline PM 2-hour BG excursion (n=979,988)	PM 2-hour blood glucose excursion (n=929,921)	Baseline mean all meal time excursions (n=985,991)	Mean of all meal time excursions (n=935,921)	Baseline mean all 2hour PP BG (n=986,993)	Mean of all 2-hour postprandial BG (n=935,921)	Baseline AM/PM 2-hour postprandial BG (n=986,993)	AM/PM 2-hour postprandial BG (n=935,921)	Baseline mean all premeal BG (n=988,994)	Mean of all premeal blood glucose (n=938,922)	Baseline AM/PM 2-hour BG excursion (n=985,991)	AM/PM 2-hour blood glucose excursion (n=935,921)	Baseline mean of all BG values (n=989,995)	Mean of all blood glucose values (n=938,922)
Insulin Glargine	196.16	121.52	251.45	171.79	203.87	137.43	232.73	169.38	203.33	141.86	239.73	175.73	197.99	131.08	55.32	50.57	26.60	32.21	36.50	34.17	40.80	38.96	241.58	172.28	245.67	173.73	201.29	133.62	46.05	42.42	218.05	149.89
Lispro Low Mix	192.91	133.54	252.46	167.40	203.76	130.36	231.53	167.91	200.36	143.44	236.33	163.20	194.11	129.70	60.06	34.01	28.08	37.46	36.31	19.51	41.63	30.34	240.08	166.17	244.36	165.19	198.97	135.80	48.11	26.74	216.12	147.96

Intervention	kilograms (Mean)
	Actual weight at Baseline (n=1046,1044)	Actual weight at Week 6 (n=1008,995)	Actual weight at Week 12 (n=970,960)	Actual weight at Week 18 (n=943,927)	Actual weight at Week 24 (n=925,911)	Actual weight Endpoint (n=1016,1008)
Insulin Glargine	88.23	89.24	89.80	90.33	90.78	90.74
Lispro Low Mix	88.84	90.63	91.79	92.46	92.63	92.67

Intervention	percent glycosylated hemoglobin (Mean)
	Baseline (n=1030,1017)	Week 12 (n=952,953)	Week 24 (n=922,911)	Endpoint (LOCF) (n=990,986)
Insulin Glargine	9.02	7.42	7.28	7.33
Lispro Low Mix	9.06	7.27	7.19	7.23

Intervention	kilograms (kg) (Mean)
	Change from baseline at Week 6 (n=1008,995)	Change from baseline at Week 12 (n=970, 960)	Change from baseline at Week 18 (n=943,927)	Change from baseline at Week 24 (n=925,911)	Change from baseline at endpoint (n=1016,1008)
Insulin Gargine	0.97	1.60	2.24	2.59	2.45
Lispro Low Mix	1.66	2.63	3.44	3.76	3.60